Filed Pursuant to Rule 424(b)(3)
Registration No. 333-110504
CHANGE TECHNOLOGY PARTNERS, INC.
---------------------
537 STEAMBOAT ROAD
GREENWICH, CONNECTICUT 06830
(203) 661-5233
---------------------
January 13, 2004
Dear Stockholder:
You are cordially invited to attend the special meeting of the stockholders
of Change Technology Partners, Inc. ("Change") to be held at 537 Steamboat Road,
Greenwich, Connecticut 06830, on February 9, 2004 at 10:00 a.m., local time, and
any adjournment or postponement of the meeting. At the special meeting, you will
be asked to consider, approve and adopt resolutions relating to the merger of
CTP/N Merger Corp., a Delaware corporation and wholly-owned subsidiary of Change
("Subcorp"), with and into Neurologix, Inc., a Delaware corporation
("Neurologix"), with Neurologix as the surviving corporation (the "Merger"), and
amendments to Change's certificate of incorporation in connection with the
Merger to (i) increase the number of authorized shares of Change common stock to
750,000,000 shares, (ii) decrease the par value of Change common stock to $0.001
per share, (iii) change the name of Change to "Neurologix, Inc." and (iv)
increase the size of and divide Change's board of directors into three classes,
with staggered three-year terms for each class. The respective boards of
directors of Change, Subcorp and Neurologix have unanimously approved the
Merger. The approval of the Merger by the Change board of directors was based,
in part, on the opinion of BNY Capital Markets, Inc., Change's financial
advisor, as to the fairness, from a financial point of view, to Change's
stockholders of the Merger.
In connection with the Merger, Change common stockholders will continue to
hold their shares and Neurologix stockholders will be entitled to receive, based
upon the exchange ratio provided in the merger agreement, shares of Change
common stock for each share of Neurologix common stock or Neurologix Series B
convertible preferred stock that they own at the effective time of the Merger.
Following the Merger, Neurologix's current stockholders and noteholders
(including holders of Neurologix common stock issuable upon the conversion or
exchange, as applicable, of (i) Neurologix's initial series of convertible
preferred stock, (ii) Neurologix's Series B convertible preferred stock and
(iii) a promissory note in the aggregate principal amount of $2.0 million
payable by Neurologix (the "Existing Neurologix Note")) are expected to hold
approximately 68% of the outstanding common stock of the combined company, and
Change's current stockholders are expected to hold approximately 32% of the
outstanding common stock of the combined company.
Change common stock is traded on the over-the-counter market and prices are
quoted on the OTC electronic bulletin board under the symbol "CTPI."
THE CHANGE BOARD OF DIRECTORS HAS UNANIMOUSLY APPROVED THE MERGER AGREEMENT
AND THE TRANSACTIONS CONTEMPLATED BY IT AND UNANIMOUSLY RECOMMENDS THAT THE
HOLDERS OF CHANGE COMMON STOCK AND SERIES A CONVERTIBLE PREFERRED STOCK VOTE FOR
THE (I) APPROVAL AND ADOPTION OF THE MERGER AGREEMENT AND THE TRANSACTIONS
CONTEMPLATED BY IT AND (II) THE PROPOSED AMENDMENTS TO ITS CERTIFICATE OF
INCORPORATION.
THIS PROXY STATEMENT AND PROSPECTUS CONTAINS DETAILED INFORMATION ABOUT THE
PROPOSALS RELATING TO THE MERGER AND WE URGE YOU TO READ IT CAREFULLY. IN
PARTICULAR, YOU SHOULD READ THE "RISK FACTORS" SECTION BEGINNING ON PAGE 16 FOR
A DESCRIPTION OF VARIOUS RISKS YOU SHOULD CONSIDER IN EVALUATING THE PROPOSED
TRANSACTIONS. IN ADDITION, YOU MAY OBTAIN ADDITIONAL INFORMATION ABOUT CHANGE
FROM DOCUMENTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
YOUR VOTE IS VERY IMPORTANT. IF YOU DO NOT VOTE, IT WILL HAVE THE SAME
EFFECT AS IF YOU HAD VOTED AGAINST THE MERGER. PLEASE COMPLETE, SIGN AND DATE
THE ENCLOSED PROXY CARD AND RETURN IT PROMPTLY IN THE ACCOMPANYING ENVELOPE,
WHICH REQUIRES NO POSTAGE IF MAILED IN THE UNITED STATES, WHETHER OR NOT YOU
PLAN ON ATTENDING THE SPECIAL MEETING. IT IS IMPORTANT THAT YOU RETURN THE PROXY
CARD PROMPTLY, WHETHER OR NOT YOU PLAN TO ATTEND THE MEETING, SO THAT YOUR
SHARES ARE PROPERLY VOTED.
If you have any questions prior to the special meeting or need further
assistance, please call Change's proxy solicitors, MacKenzie Partners, Inc.,
toll-free at (800) 322-2885.
Thank you for your cooperation.
Very truly yours,
(Michael Gleason)
MICHAEL GLEASON
Chairman of the Board and Chief
Executive Officer
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED THE MERGER AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED BY IT OR DETERMINED THAT THIS PROXY STATEMENT AND PROSPECTUS IS
ACCURATE OR ADEQUATE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
This proxy statement and prospectus is dated January 13, 2004 and is first
being mailed to stockholders on or about January 13, 2004.
NEUROLOGIX, INC.
ONE BRIDGE PLAZA
FORT LEE, NEW JERSEY 07024
(201) 592-6451
JANUARY 13, 2004
Dear Stockholder:
The board of directors of Neurologix, Inc. ("Neurologix") has unanimously
approved the merger of CTP/N Merger Corp. ("Subcorp"), a Delaware corporation
and wholly-owned subsidiary of Change Technology Partners, Inc., a Delaware
corporation ("Change"), with and into Neurologix, with Neurologix as the
surviving corporation (the "Merger"). The respective boards of directors of
Subcorp and Change have also unanimously approved the Merger.
In connection with the Merger, Neurologix stockholders will be entitled to
receive, based upon the exchange ratio provided in the merger agreement, shares
of Change common stock for each share of Neurologix common stock or Neurologix
Series B convertible preferred stock that they own at the effective time of the
Merger. Following the Merger, Neurologix's current stockholders and noteholders
(including holders of Neurologix common stock issuable upon the conversion or
exchange, as applicable, of (i) Neurologix's initial series of convertible
preferred stock, (ii) Neurologix's Series B convertible preferred stock and
(iii) a promissory note in the aggregate principal amount of $2.0 million
payable by Neurologix (the "Existing Neurologix Note")) are expected to hold
approximately 68% of the outstanding common stock of the combined company and
Change's current stockholders are expected to hold approximately 32% of the
outstanding common stock of the combined company.
THE BOARD OF DIRECTORS OF NEUROLOGIX HAS DETERMINED THAT THE APPROVAL OF
THE MERGER IS ADVISABLE, AND IN THE BEST INTERESTS OF, NEUROLOGIX AND ITS
STOCKHOLDERS.
Pursuant to a voting agreement, the holders of (i) 100% of Neurologix's
outstanding initial series of convertible preferred stock, (ii) approximately
79.2% of Neurologix's outstanding Series B convertible preferred stock and (iii)
the Existing Neurologix Note have agreed to convert their securities into
Neurologix common stock immediately prior to the effective time of the Merger.
These holders, together with the holders of a majority of Neurologix's
outstanding common stock, have approved the Merger.
Neurologix stockholders who properly demand appraisal rights prior to
February 3, 2004, who do not consent to the approval and adoption of the merger
agreement and the Merger and who otherwise comply with the provisions of Section
262 of the General Corporation Law of the State of Delaware will be entitled, if
the Merger is completed, to statutory appraisal of the fair value of their
shares of common stock. Refer to the section entitled "Appraisal Rights" in the
accompanying proxy statement and prospectus and the full text of Section 262 of
the General Corporation Law of the State of Delaware, which is attached as
Appendix E to the accompanying proxy statement, for a description of the
procedures that Neurologix shareholders must follow in order to exercise their
appraisal rights.
THIS PROXY STATEMENT AND PROSPECTUS CONTAINS DETAILED INFORMATION ABOUT THE
MERGER AND WE URGE YOU TO READ IT CAREFULLY. IN PARTICULAR, YOU SHOULD READ THE
"RISK FACTORS" SECTION BEGINNING ON PAGE 16 FOR A DESCRIPTION OF VARIOUS RISKS
YOU SHOULD CONSIDER IN EVALUATING THE PROPOSED TRANSACTION. IN ADDITION, YOU MAY
OBTAIN ADDITIONAL INFORMATION ABOUT CHANGE FROM THE DOCUMENTS THAT IT HAS FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION.
If you have any questions or need further assistance, please call Mark
Hoffman at (201) 592-6451.
Sincerely,
MARK HOFFMAN
Secretary
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED THE MERGER AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED BY IT OR DETERMINED THAT THIS PROXY STATEMENT AND PROSPECTUS IS
ACCURATE OR ADEQUATE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
This proxy statement and prospectus is dated January 13, 2004, and is first
being mailed to stockholders on or about January 13, 2004.
CHANGE TECHNOLOGY PARTNERS, INC.
537 STEAMBOAT ROAD
GREENWICH, CONNECTICUT 06830
(203) 661-5233
---------------------
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD FEBRUARY 9, 2004
---------------------
To the Stockholders of Change Technology Partners, Inc.:
NOTICE IS GIVEN that a special meeting of the stockholders of Change
Technology Partners, Inc., a Delaware corporation ("Change"), will be held at
537 Steamboat Road, Greenwich, Connecticut 06830, on February 9, 2004, at 10:00
a.m., local time. The board of directors asks you to attend this meeting, in
person or by proxy, for the following purposes:
1. To consider, approve and adopt the merger agreement and the
transactions contemplated by it.
2. To consider, approve and adopt a proposal to amend the certificate
of incorporation of Change, as provided in the merger agreement, which
amendments provide for (i) increasing the number of authorized shares of
Change common stock from 500,000,000 shares to 750,000,000 shares, (ii)
decreasing the par value of Change common stock from $0.01 per share to
$0.001 per share, (iii) changing the name of Change to "Neurologix, Inc."
and (iv) increasing the size of and dividing Change's board of directors
into three classes, with staggered three-year terms for each class.
3. To transact any other business as may properly come before the
special meeting or any adjournment or postponement of the special meeting.
The approval of proposals 1 and 2 above requires the affirmative vote of the
holders of a majority of the outstanding shares of Change common stock and
Series A preferred stock voting together as a single class.
Approval of proposals 1 and 2 listed above is a condition to the closing of
the Merger. Therefore, if you vote against any one of these proposals, it would
have the effect of a vote against the other proposals and the Merger. Should
either of these proposals fail to be approved by the required vote of the
stockholders at the special meeting then both Change and Neurologix will be
entitled to terminate the merger agreement.
THE CHANGE BOARD OF DIRECTORS HAS UNANIMOUSLY APPROVED THE MERGER AGREEMENT
AND THE TRANSACTIONS CONTEMPLATED BY IT AND UNANIMOUSLY RECOMMENDS THAT THE
HOLDERS OF CHANGE COMMON STOCK AND SERIES A CONVERTIBLE PREFERRED STOCK VOTE FOR
THE APPROVAL AND ADOPTION OF THE MERGER AGREEMENT AND THE TRANSACTIONS
CONTEMPLATED BY IT AND THE AMENDMENTS TO CHANGE'S CERTIFICATE OF INCORPORATION.
If, for any reason, the Merger is not consummated, neither of proposals 1
or 2 will be effected.
Only stockholders of record at the close of business on January 12, 2004,
are entitled to notice of the special meeting and to vote at the meeting. A list
of stockholders entitled to vote as of the close of business on January 12, 2004
will be available at the special meeting for examination by any stockholder or
the stockholder's attorney or agent. Please note that, by delivering a proxy to
vote at the special meeting, you are also granting a proxy voting in favor of
any adjournments or postponements of the special meeting.
We cordially invite you to attend the special meeting in person because it
is important that your shares be represented at the meeting. However, to ensure
your representation at the special meeting, please sign, date and return the
enclosed proxy card in the accompanying postage-paid envelope as promptly as
possible. If you attend the meeting, you may vote in person, which will revoke a
signed proxy if you have already sent one in.
You may also revoke your proxy at any time before the meeting by filing a
written revocation with Change at the address set forth above or by filing a
duly executed proxy bearing a later date.
By the Order of the Board of Directors
of
Change Technology Partners, Inc.,
(Michael Gleason)
MICHAEL GLEASON
Chairman of the Board and Chief
Executive Officer
January 13, 2004
YOUR VOTE IS VERY IMPORTANT.
TO ASSURE YOUR REPRESENTATION AT THE MEETING, PLEASE COMPLETE, SIGN AND DATE THE
ENCLOSED PROXY CARD AND RETURN IT PROMPTLY IN THE ACCOMPANYING ENVELOPE, WHICH
REQUIRES NO POSTAGE IF MAILED IN THE UNITED STATES.
TABLE OF CONTENTS
PAGE
----
Questions and Answers About the Meeting.............................................. 1
Summary.............................................................................. 4
Risk Factors......................................................................... 16
Special Note Regarding Forward-Looking Statements.................................... 22
The Change Special Meeting........................................................... 23
The Merger........................................................................... 26
The Merger Agreement................................................................. 39
Description of Related Agreements.................................................... 50
Proposed Amendments to Change's Certificate of Incorporation in Connection with the
Merger............................................................................. 55
Material United States Federal Income Tax Consequences of the Merger................. 56
Market Price and Dividend Policy..................................................... 58
Unaudited Pro Forma Financial Statements............................................. 59
Management of the Combined Company After the Merger.................................. 65
Certain Relationships and Related-Party Transactions................................. 77
Selected Historical Financial Data of Change......................................... 78
Management's Discussion and Analysis of Financial Condition and Results of Operations
of Change.......................................................................... 81
Business of Change................................................................... 90
Selected Historical Consolidated Financial Data of Neurologix........................ 92
Management's Discussion and Analysis of Financial Condition and Results of Operations
of Neurologix...................................................................... 93
Business of Neurologix............................................................... 99
Comparison of the Rights of the Holders of Neurologix Common Stock or Series B
Convertible Preferred Stock and the Holders of Change Common Stock................. 104
Information Regarding Beneficial Ownership of Management and Principal Stockholders
of Change.......................................................................... 112
Information Regarding Beneficial Ownership of Management and Principal Stockholders
of Neurologix...................................................................... 114
Information Regarding Beneficial Ownership of Management and Principal Stockholders
of the Combined Company............................................................ 117
Legal Matters........................................................................ 121
Experts.............................................................................. 121
Stockholder Proposals................................................................ 121
Where You Can Find More Information.................................................. 121
Index to Financial Statements........................................................ F-1
Appendices
Appendix A Agreement and Plan of Merger
Appendix B Amendment No. 1 to Agreement and Plan of Merger
Appendix C Voting Agreement
Appendix D Opinion of BNY Capital Markets, Inc.
Appendix E Section 262 of the Delaware General Corporation Law
Appendix F Form of Proxy Card
i
QUESTIONS AND ANSWERS ABOUT THE MEETING
Q: WHAT IS THE PROPOSED TRANSACTION?
A: Change Technology Partners, Inc., a Delaware corporation ("Change"), is
proposing to acquire all of the outstanding securities of Neurologix, Inc., a
Delaware corporation ("Neurologix"). The acquisition will be effected by the
merger of a wholly-owned subsidiary of Change with and into Neurologix, with
Neurologix surviving as a wholly-owned subsidiary of Change (the "Merger"). Upon
completion of the Merger, Neurologix's corporate name will be Neurologix
Research, Inc. Upon completion of the Merger and as part of the amendment to its
certificate of incorporation, Change's corporate name will be "Neurologix, Inc."
We sometimes refer to Change following completion of the Merger and the change
of its corporate name as the "combined company."
Q: HOW MANY SHARES OF CHANGE COMMON STOCK WILL BE ISSUED IN THE MERGER?
A: The exact number of shares of common stock to be issued by Change will not
be determined until immediately prior to the effective time of the Merger.
Change currently expects to issue approximately 391,275,156 shares of Change
common stock in the Merger. Change will issue a press release approximately 48
hours prior to the special meeting announcing an updated estimate of the number
of shares to be issued, based on the value of Change's Net Cash Assets at that
time. No fractional shares will be issued. All fractional shares will be rounded
to the nearest whole number for each shareholder on an aggregate basis.
Q: WHAT WILL I RECEIVE IN THE MERGER?
A: Change Stockholders: You will continue to hold the Change securities you
currently own.
Neurologix Stockholders: You will be entitled to receive a number of shares of
the combined company's common stock, based upon the exchange ratio provided in
the merger agreement, for each share of Neurologix common stock or Series B
convertible preferred stock you own on the date of the closing of the Merger. If
you are an option holder, you will receive replacement options based on the
exchange ratio provided for in the merger agreement.
Q: WILL I HAVE APPRAISAL RIGHTS IN CONNECTION WITH THE MERGER?
A: Change Stockholders: Under Delaware law, Change stockholders do not have
appraisal rights with respect to the Merger.
Neurologix Stockholders: Yes. Under Section 262 of the Delaware General
Corporation Law, holders of Neurologix common stock and Series B convertible
preferred stock have appraisal rights with respect to the Merger. Record holders
of shares of Neurologix who follow the statutory procedures provided in Section
262 of the Delaware General Corporation Law, may have their shares appraised by
the Delaware Court of Chancery and may be entitled to receive the "fair value"
of those shares, which could be greater than, less than or the same as the value
of the consideration to be received in the Merger. A copy of Section 262 is
attached as Appendix E to this proxy statement and prospectus. Please also refer
to the section of this proxy statement and prospectus entitled "The Merger --
Appraisal Rights."
Q: WILL I BE ABLE TO FREELY RESELL THE SHARES OF CHANGE COMMON STOCK I RECEIVE
IN THE MERGER?
A: All shares of Change common stock received by Neurologix stockholders in
connection with the Merger will be freely transferable under federal securities
laws, except for shares received by persons who are deemed to be "affiliates" of
Change or Neurologix for purposes of Rule 145 under the Securities Act of 1933,
as amended (the "Securities Act"), prior to the completion of the Merger. These
shares may be resold only in transactions permitted by the resale provisions of
Rule 145 under the Securities Act, or Rule 144 under the Securities Act in the
case of persons who become affiliates of Neurologix, or as otherwise permitted
under the Securities Act.
Q: WHAT ARE THE TAX CONSEQUENCES OF THE TRANSACTIONS TO ME?
A: Change Stockholders: There will be no tax consequences to you as
stockholders as a result of the Merger.
Neurologix Stockholders: The Merger is structured as a tax free reorganization
under section 368(a) of the Internal Revenue Code. As a result, U.S. holders of
Neurologix common stock or Series B convertible preferred stock will not
recognize
1
any taxable gain or loss for U.S. federal income tax purposes on the receipt of
Change common stock in the Merger. Each Neurologix stockholder's aggregate tax
basis and holding period with respect to the shares of Change common stock it
will receive in the Merger will be the same as that for the shares of Neurologix
common stock or Series B convertible preferred stock that will be surrendered in
exchange for Change common stock.
Q: WHAT STOCKHOLDER APPROVALS ARE NEEDED?
A: Change Stockholders: The Merger proposal and the proposal relating to the
amendments to the certificate of incorporation must be approved by the
affirmative vote of a majority of the outstanding shares of Change common stock
and Series A convertible preferred stock voting together as a single class. A
broker non-vote or an abstention has the same effect as a vote against the
Merger and charter amendment proposals.
Neurologix Stockholders: The Merger has been approved by the affirmative vote
of holders of a majority of the outstanding shares of Neurologix's capital stock
voting together as a single class.
Q: WHAT PERCENTAGE OF THE COMBINED COMPANY'S COMMON STOCK WILL BE HELD BY
EXISTING HOLDERS OF CAPITAL STOCK AFTER THE MERGER?
A: It is anticipated that existing Change securityholders will hold
approximately 32% of the shares of the combined company's outstanding common
stock after the Merger. The exact percentage will be determined immediately
prior to the effective time of the Merger. Change will issue a press release
approximately 48 hours prior to the special meeting announcing an updated
estimate of the number of shares to be issued, based on the value of Change's
Net Cash Assets at that time.
Q: WHAT PERCENTAGE OF THE COMBINED COMPANY'S COMMON STOCK WILL BE HELD BY
FORMER NEUROLOGIX STOCKHOLDERS?
A: It is anticipated that existing Neurologix securityholders will hold
approximately 68% of the shares of the combined company's outstanding common
stock after the Merger. The exact percentage will be determined immediately
prior to the effective time of the Merger.
Q: HAS SOMEONE DETERMINED THAT THE TRANSACTIONS ARE IN MY BEST INTERESTS?
A: Change Stockholders: The Change board of directors has unanimously
determined that the Merger and the transactions relating to the Merger,
including the proposals described in this proxy statement and prospectus, are
advisable to, and in the best interests of, Change and its stockholders and
recommends that Change stockholders vote FOR approval and adoption of each of
the proposals relating to the Merger.
Neurologix Stockholders: The Neurologix board of directors has unanimously
determined that the Merger and transactions relating to the Merger, including
the proposals described in this proxy statement and prospectus, are advisable
and in the best interests of Neurologix and its stockholders.
The Merger and the transactions relating to the Merger have been approved by the
written consent of the holders of a majority of the outstanding shares of
Neurologix's capital stock voting together as a single class. This proxy
statement and prospectus is being provided to you for informational purposes
only. You do not need to take any further action to participate in the Merger.
Q: WHEN DO YOU EXPECT THE TRANSACTIONS TO BE COMPLETED?
A: Change and Neurologix plan to complete the transactions as soon as possible
after the Change special meeting, subject to the satisfaction or waiver of the
other conditions to the transactions. Although the companies cannot predict when
these conditions will be satisfied, Change and Neurologix expect to complete the
transactions during the first calendar quarter of 2004.
Q: WHAT DO I NEED TO DO NOW?
A: You should carefully read and consider the information contained in this
proxy statement and prospectus, including its appendices. It contains important
information about Change, Neurologix and the combined company. It also contains
important information about the respective factors that the boards of directors
of Change and Neurologix considered in evaluating the proposed transactions.
Change Stockholders: After reading and considering the information contained in
this proxy statement and prospectus, you should then complete and sign your
proxy card and return it in the enclosed return envelope as soon as possible, so
that your
2
shares will be represented at Change's special meeting. If you sign and send in
your proxy but do not indicate how you want to vote, your proxy will be counted
as a vote in favor of the Merger and the other proposals.
Neurologix Stockholders: After reading and considering the information
contained in this proxy and prospectus, you do not need to take any further
action to participate in the Merger.
Q: CAN I CHANGE MY VOTE AFTER I HAVE MAILED MY SIGNED PROXY CARD?
A: Change Stockholders: Yes. You can change your vote at any time before your
proxy is voted at Change's special meeting. You can do this in one of three
ways:
- First, you can send a written notice stating that you revoke your proxy to the
proxy solicitor for Change at the address listed below;
- Second, you can complete and submit a new proxy card, dated a later date than
the first proxy card, and send it to the proxy solicitor for Change at the
address listed below. The new proxy card will automatically replace any
earlier dated proxy card that you returned so long as it is received by the
proxy solicitor for Change at least 1 day prior to the Change special meeting;
or
- Third, you can attend Change's special meeting of stockholders AND vote in
person. Your attendance without voting at Change's special meeting of
stockholders will not, however, by itself revoke your proxy.
You should send any notice of revocation or your completed new proxy card to the
proxy solicitor for Change at the address provided below:
MacKenzie Partners, Inc.
105 Madison Ave.
New York, New York 10016
Attention: Dan Sullivan
Telephone: (800) 322-2885
Facsimile: (212) 929-0308
Neurologix Stockholders: You are not being asked to provide a signed proxy card
because the holders of a majority of the outstanding shares of Neurologix's
capital stock voting together as a single class have already approved by written
consent the Merger and the transactions related to the Merger. THIS PROXY
STATEMENT AND PROSPECTUS IS BEING PROVIDED TO YOU FOR INFORMATIONAL PURPOSES
ONLY.
Q: SHOULD I SEND IN MY STOCK CERTIFICATES NOW?
A: Change Stockholders: No. You will keep the certificates you own. Although
the name of the company will be changed, there is no need to exchange your
existing stock certificates.
Neurologix Stockholders: No. After the Merger is completed, the exchange agent
will send you written instructions for exchanging your stock certificates.
Q: WHOM SHOULD I CALL WITH QUESTIONS ABOUT THE PROPOSALS?
A: If you are a Change stockholder you should contact:
MacKenzie Partners, Inc.
105 Madison Ave.
New York, New York 10016
Attention: Dan Sullivan
Telephone: (800) 322-2885
Facsimile: (212) 929-0308
If you are a Neurologix stockholder you should contact:
Mark Hoffman
Treasurer and Secretary
Telephone: (201) 592-6451
Q: WHERE CAN I GET MORE INFORMATION?
A: You may obtain more information from the sources set forth under the section
of this proxy statement and prospectus entitled "Where You Can Find More
Information."
3
SUMMARY
This summary highlights selected information from this proxy statement and
prospectus and may not contain all of the information that is important to you.
To understand the Merger fully and for a more complete description of the legal
terms of the Merger, you should carefully read this entire proxy statement and
prospectus, including the appendices and the other documents to which we refer
you. See the section of this proxy statement and prospectus entitled, "Where You
Can Find More Information." Please note that the term "combined company" refers
to Change Technology Partners, Inc. after the Merger is completed and its name
has been changed to "Neurologix, Inc."
THE COMPANIES
CHANGE TECHNOLOGY PARTNERS, INC.
537 Steamboat Road
Greenwich, Connecticut 06830
(203) 661-5233
Arinco Computer Systems Inc., the predecessor to Change, was incorporated
on March 31, 1978. Arinco Computer Systems was organized principally to serve
its subsidiary operations, which included the sale of telecommunications
equipment and services and the retail sales of computers. From 1985 to March
2000, Arinco Computer Systems had no business operations. In March 2000, an
investor group acquired control of Arinco Computer Systems for the purpose of
using Arinco Computer Systems to sell business consulting services. In September
2000, Arinco Computer Systems Inc. merged with and into Change Technology
Partners, Inc. (f/k/a Pangea Internet, Inc.), a wholly owned subsidiary. All of
the stockholders of Arinco Computer Systems became stockholders of Change, and
Change redomesticated from New Mexico to Delaware.
Until approximately July 2001, Change provided a broad range of consulting
services, including e-services and technology strategy, online branding, web
architecture and design, systems integration, systems architecture and
outsourcing. The Change board of directors then voted to sell or wind down its
business operations, other than those conducted by its only operating
subsidiary, Canned Interactive, and use its assets to invest in and develop new
businesses. Canned Interactive designs and produces interactive media, primarily
for the entertainment industry. On September 30, 2002, the Change board of
directors announced the adoption of a plan of liquidation and dissolution but
continued to review suitable business opportunities.
On June 30, 2003, Change sold Canned Interactive. Currently, the assets of
Change primarily consist of cash and cash equivalents.
NEUROLOGIX, INC.
One Bridge Plaza
Fort Lee, New Jersey 07024
(201) 592-6451
Established in 1999, Neurologix, Inc. develops proprietary gene therapies
for the treatment of central nervous system disorders, with an initial clinical
focus on Parkinson's disease and epilepsy. Neurologix's scientific founders
recently became the first and only team to receive approval from the U.S. Food
and Drug Administration to conduct a Phase I human clinical trial using gene
therapy to treat Parkinson's disease. The clinical trial began in August 2003.
Neurologix owns or licenses 11 patents and patent applications in this field,
several of which support the treatment to be used in the ongoing clinical trial.
THE COMBINED COMPANY
The combined company will continue to develop proprietary gene therapies
for the treatment of central nervous system disorders, with an initial clinical
focus on Parkinson's disease and epilepsy. The combined company expects to
continue to devote most of its resources to the research and development of its
gene therapy products. The combined company will maintain its corporate offices
in Fort Lee, New Jersey and a
4
laboratory in New York, New York. Following the Merger, Neurologix's executive
officers will become the executive officers of the combined company.
BOARD RECOMMENDATIONS AND FINANCIAL OPINION RELATING TO THE MERGER
RECOMMENDATION OF THE CHANGE BOARD OF DIRECTORS
The Change board of directors has unanimously approved the merger
agreement, the transactions contemplated by the merger agreement and the
amendments to Change's certificate of incorporation, and unanimously recommends
that the holders of Change common stock and Change Series A preferred stock vote
FOR (i) the approval and adoption of the merger agreement and the transactions
contemplated by it and (ii) the amendments to Change's certificate of
incorporation. Please refer to the section of this proxy statement and
prospectus entitled "The Merger -- Recommendation of Change's Board of
Directors; Factors Considered by Change's Board of Directors in Relation to the
Merger."
FACTORS CONSIDERED BY THE CHANGE BOARD OF DIRECTORS
In making its determination, the Change board of directors considered a
number of factors including, but not limited to, the following:
- the Merger with Neurologix is a suitable business opportunity and may
provide more value to the stockholders of Change than they would receive
under the plan of liquidation and dissolution previously adopted by the
Change board of directors on September 30, 2002;
- the financial resources of the combined company will enhance Neurologix's
ability to conduct a Phase I clinical trial using gene therapy to treat
Parkinson's disease;
- the overall terms of the merger agreement and the other transaction
agreements;
- the opinion of BNY Capital Markets, Inc., Change's financial advisor; and
- the qualification of the Merger as a tax-free reorganization for U.S.
federal tax purposes.
Please refer to the section of this proxy statement and prospectus entitled "The
Merger -- Recommendation of Change's Board of Directors; Factors Considered by
Change's Board of Directors in Relation to the Merger."
OPINION OF THE FINANCIAL ADVISOR TO CHANGE
The Change board of directors received a written opinion from BNY Capital
Markets, Inc. as to the fairness, from a financial point of view, to Change's
stockholders, of the Merger. BNY Capital Markets' written opinion, dated August
11, 2003, is attached to this proxy statement and prospectus as Appendix D. You
should read this opinion carefully in its entirety for a description of the
assumptions made, procedures followed, matters considered and limitations on the
review undertaken. BNY CAPITAL MARKETS' OPINION IS ADDRESSED TO THE CHANGE BOARD
OF DIRECTORS AND DOES NOT CONSTITUTE A RECOMMENDATION TO ANY STOCKHOLDER WITH
RESPECT TO ANY MATTERS RELATING TO THE MERGER. Please refer to the section of
this proxy statement and prospectus entitled "The Merger -- Opinion of the
Financial Advisor to Change."
RECOMMENDATION OF THE NEUROLOGIX BOARD OF DIRECTORS
The Neurologix board of directors has unanimously determined that the
Merger and the transactions contemplated by it, as described in this proxy
statement and prospectus, are advisable and in the best interests of Neurologix
and its stockholders and recommended that Neurologix's stockholders vote FOR the
approval and adoption of the Merger on August 8, 2003. Based on the board's
recommendation, the holders of a majority of Neurologix's outstanding shares of
capital stock voting together as a single class executed a written consent
approving the Merger on August 13, 2003. Please refer to the section of this
proxy statement and
5
prospectus entitled "The Merger -- Recommendation of Neurologix's Board of
Directors; Factors Considered by Neurologix's Board of Directors in Relation to
the Merger."
FACTORS CONSIDERED BY THE NEUROLOGIX BOARD OF DIRECTORS
The Neurologix board of directors considered a number of factors in
approving the Merger and the other transactions contemplated by the merger
agreement and recommending them to Neurologix stockholders, including those
listed below:
- the financial resources of the combined company will enhance Neurologix's
ability to conduct a Phase I clinical trial of gene therapy for the
treatment of Parkinson's disease;
- becoming a company with publicly traded securities may enhance the
ability of Neurologix to raise additional capital in the future for its
research and development efforts;
- the overall terms of the merger agreement and the other transaction
agreements;
- the time and resources that would be required to obtain comparable
alternative financing, if available; and
- the qualification of the Merger as a tax-free reorganization for U.S.
federal tax purposes.
Please refer to the section of this proxy statement and prospectus entitled "The
Merger -- Recommendation of Neurologix's Board of Directors; Factors Considered
by Neurologix's Board of Directors in Relation to the Merger."
THE MERGER AND RELATED MATTERS
THE MERGER
In the Merger, Subcorp, a wholly-owned subsidiary of Change, will merge
with and into Neurologix, and Neurologix will survive as a wholly-owned
subsidiary of Change. All of Neurologix's stockholders will be entitled to
receive Change common stock in exchange for their Neurologix capital stock. Upon
completion of the Merger, Change will change its corporate name to "Neurologix,
Inc." and will decrease the par value of its common stock from $0.01 to $0.001
per share. The merger agreement is attached to this proxy statement and
prospectus as Appendix A. Amendment No. 1 to the merger agreement is attached to
this proxy statement and prospectus as Appendix B. References to the merger
agreement in this proxy statement and prospectus refer to the merger agreement
as amended by Amendment No. 1 unless the context otherwise requires. You should
carefully read the merger agreement in its entirety, as it is the legal document
that governs the Merger. Please also refer to the sections of this proxy
statement and prospectus entitled "The Merger" and "The Merger Agreement."
RESULTS OF THE MERGER AND RELATED TRANSACTIONS
At the effective time of the Merger and assuming the conversion of
Neurologix securities as set forth in the voting agreement, as described below,
each share of Neurologix common stock and Series B convertible preferred stock
that is issued and outstanding immediately prior to the effective time of the
Merger will be converted into the right to receive a proportionate number of
shares of Change common stock according to the exchange ratio in the merger
agreement. No fractional shares will be issued. Fractional shares will be
rounded to the nearest whole number for each shareholder on an aggregate basis.
The holders of Change securities will continue to hold their Change
securities.
It is anticipated that, upon the closing of the Merger, the existing Change
stockholders and the existing Neurologix stockholders will hold approximately
32% and 68% respectively of the combined company's outstanding common stock. The
exact percentages will be determined immediately prior to the effective time of
the Merger. Please refer to the section of this proxy statement and prospectus
entitled "The Merger Agreement -- Conversion of Securities."
6
VOTING AGREEMENT
In connection with the merger agreement, Change, Subcorp, Neurologix,
holders of approximately 86.1% of the outstanding shares of Neurologix common
stock, holders of 100% of the outstanding shares of Neurologix's initial series
of convertible preferred stock, holders of approximately 79.2% of the
outstanding shares of Neurologix Series B convertible preferred stock, and all
of the persons having an interest in the 6% secured promissory note of
Neurologix due in October 2007 (the "Existing Neurologix Note") entered into a
voting agreement, a copy of which is attached as Appendix C. Under the voting
agreement, these securityholders agreed to vote for the Merger and the
transactions related to the Merger, convert their shares of Neurologix's initial
series of convertible preferred stock and Series B convertible preferred stock
and interests in the Existing Neurologix Note into Neurologix common stock and
waive their appraisal rights with respect to such securities under Delaware law.
Please refer to the section of this proxy statement and prospectus entitled
"Description of Related Agreements -- Voting Agreement."
BOARD COMPOSITION
The board of directors of the combined company will consist initially of 6
directors divided into three classes of directors with the directors in each
class serving staggered three-year terms. Each class will consist, as nearly as
possible, of one-third of the directors constituting the entire board. Following
the Merger, the board of the combined company will be free to fix the number of
directors from time to time and to nominate, or have a nominating committee
nominate, those directors as the board or nominating committee may choose in its
sole discretion. Please refer to the section of this proxy statement and
prospectus entitled "The Merger Agreement -- Material Covenants -- Change Board
of Directors."
APPRAISAL RIGHTS
Change's stockholders do not have appraisal rights with respect to the
Merger.
Neurologix stockholders who properly demand appraisal rights prior to
February 3, 2004, who do not consent to the approval and adoption of the merger
agreement and the Merger and who otherwise comply with the provisions of Section
262 of the Delaware General Corporation Law will be entitled, if the Merger is
completed, to statutory appraisal of the fair value of their shares of
Neurologix common stock. See the section of this proxy statement and prospectus
entitled "The Merger -- Appraisal Rights" and the full text of Section 262 of
the Delaware General Corporation Law, which is attached as Appendix E, for a
description of the procedures that Neurologix stockholders must follow in order
to exercise their appraisal rights.
CONDITIONS TO THE MERGER
The respective obligations of Change, Subcorp and Neurologix to complete
the Merger are subject to the satisfaction or waiver of the following
conditions:
- obtaining the approval of all of the proposals that are described in this
proxy statement and prospectus by the requisite vote of Change's
stockholders;
- the representations and warranties of each of Change, Subcorp and
Neurologix contained in the merger agreement being accurate in all
material respects;
- the Merger and the transactions contemplated in the merger agreement
being consummated prior to February 15, 2004; and
- other conditions precedent that are customary for transactions of this
type.
Change's obligation to complete the Merger is subject to the satisfaction
or waiver by Change of the following additional conditions:
- the aggregate number of shares for which appraisal rights are sought by
Neurologix's stockholders does not exceed 5% of the aggregate number of
shares of Neurologix common stock and Series B convertible preferred
stock outstanding on the date of the closing of the Merger; and
7
- since December 31, 2002, no event shall have occurred which has had a
material adverse effect on Neurologix.
Neurologix's obligation to complete the Merger is subject to the
satisfaction or waiver by Neurologix of the following additional conditions:
- since December 31, 2002, no event shall have occurred which has had a
material adverse effect on Change and its subsidiaries, taken as a whole;
- the receipt by Neurologix of resignations from each of the directors of
Change and Subcorp, other than Austin M. Long, III and Craig J. Nickels
as directors of Change, effective as of the date of the closing of the
Merger;
- Change's Net Cash Assets, as defined in the merger agreement, as of the
date of the closing of the Merger is at least $6.5 million; and
- Change has terminated all of its employee benefit plans, except for its
2000 stock option plan.
Please refer to the section of this proxy statement and prospectus entitled
"The Merger Agreement -- Conditions to the Merger."
TERMINATION PROVISIONS
The merger agreement may be terminated by mutual written consent of Change
and Neurologix.
Either Change or Neurologix may terminate the merger agreement:
- if any law or regulation exists that makes consummation of the Merger
illegal or otherwise prohibits the Merger;
- if the Merger is not consummated on or before February 15, 2004;
- if at or before the completion of the closing of the Merger, Change,
Subcorp or Neurologix discovers that any representation or warranty made
in the merger agreement for its benefit is untrue in any material respect
under certain circumstances;
- if (i) at Change's special meeting the requisite vote of Change's
stockholders to approve the Merger, the merger agreement and the
transactions contemplated by it and the amendments to Change's
certificate of incorporation have not been obtained or (ii) the Change
board of directors withdraws its recommendation to its stockholders to
approve the Merger, the merger agreement and the transactions
contemplated by the merger agreement;
- if the other party defaults in the performance of any material obligation
under the merger agreement where the default would reasonably be expected
to prevent Change or Neurologix, as applicable, from obtaining a material
portion of the benefits intended by the parties to be derived by Change
or Neurologix, as applicable, from the merger agreement, with limited
exception; or
- in the event that any of the conditions to a respective party's
obligation to close the Merger have not been satisfied or waived by
February 15, 2004 or in the event that any such condition cannot possibly
be satisfied prior to February 15, 2004.
Please refer to the section of this proxy statement and prospectus entitled "The
Merger Agreement -- Termination of the Merger Agreement."
TERMINATION FEES
Under the merger agreement, if Neurologix or Change terminates the merger
agreement because, at Change's special meeting, the requisite vote of Change's
stockholders to approve the Merger, the merger agreement and the transactions
contemplated by the merger agreement and the amendments to Change's certificate
of incorporation is not obtained, then upon termination, Change will pay to
Neurologix $225,000 in cash. However, if within 120 days after such termination,
Change acquires or offers, or makes a proposal or
8
agrees to acquire in any manner, whether directly or indirectly, any business or
company (including, but not limited to, the assets, capital stock or ownership
interests thereof) then Neurologix shall be entitled to $1,100,000 in cash.
If Neurologix or Change terminates the merger agreement in connection with
Change's entry into a competing transaction, or if the Change board of directors
withdraws its recommendation to its stockholders to approve the Merger, the
merger agreement and the transactions contemplated by the merger agreement, then
upon such termination or withdrawal, Change will pay to Neurologix an amount
equal to $1,100,000 in cash. Change may offset the payment against the unpaid
principal of the $1,100,000 loan it provided to Neurologix under the merger
agreement.
In the event that the merger agreement is terminated such that Neurologix
would be entitled to receive from Change both of the payments described in the
preceding two paragraphs, Neurologix will only be entitled to the $1,100,000
payment described above. Please refer to the section of this proxy statement and
prospectus entitled "The Merger Agreement -- Expenses and Termination Fees."
NON-SOLICITATION PROVISIONS
Under the merger agreement, both Change and Neurologix are prohibited from
soliciting, entering into or providing non-public information with respect to a
competing acquisition proposal.
However, Change may consider any unsolicited third-party competing
transaction if the Change board of directors determines, after consultation with
its financial advisor and legal counsel, that (i) such third party has submitted
to Change a competing transaction which has a reasonable likelihood of resulting
in a superior proposal and (ii) the failure to participate in such process would
constitute a breach of the Change board of directors' fiduciary duties under
applicable law.
Additionally, the merger agreement permits Neurologix to raise up to $1.0
million from the sale of additional equity between August 13, 2003 and the date
of the closing of the Merger. Neurologix currently does not intend to exercise
this right to raise additional capital. Please refer to the section of this
proxy statement and prospectus entitled "The Merger Agreement -- Material
Covenants -- Non-Solicitation of Competing Transactions."
INTERIM OPERATIONS COVENANTS
Change and Neurologix have agreed to limitations on their operations
between the signing of the merger agreement and the effective time of the
Merger. Please refer to the section of this proxy statement and prospectus
entitled "The Merger Agreement -- Material Covenants -- Interim Operations of
Change, Subcorp and Neurologix."
LOAN BY CHANGE TO NEUROLOGIX
Under the merger agreement, Change agreed to loan to Neurologix the
principal amount of $1,100,000, secured by all of the assets of Neurologix. On
August 13, 2003, in connection with the execution of the merger agreement,
Change funded a loan of $750,000 to Neurologix. On November 14, 2003, Change,
Neurologix and Subcorp amended the merger agreement to, among other things,
increase the principal amount of the loan from $750,000 to $1,100,000. On
December 18, 2003, Change funded the additional $350,000. Interest on the unpaid
principal accrues at the rate of 4% per year. The outstanding principal under
the loan and the accrued interest will be due and payable on demand at any time
after June 30, 2004. Please refer to the section of this proxy statement and
prospectus entitled "The Merger Agreement -- Material Covenants -- Loan to
Neurologix."
INCOME TAX CONSEQUENCES OF THE MERGER
The Merger is intended to be free of U.S. federal income tax to holders of
Neurologix common stock or Series B convertible preferred stock who receive
Change common stock in exchange for Neurologix common stock
9
or Series B convertible preferred stock in connection with the Merger. Please
refer to the section of this proxy statement and prospectus entitled "Material
United States Federal Income Tax Consequences of the Merger."
STOCK EXCHANGE LISTING
Change's common stock is traded, and will continue to be traded, on the
over-the-counter market. Prices of Change's common stock are quoted on the OTC
electronic bulletin board under the symbol "CTPI." The combined company's common
stock will be quoted on the OTC electronic bulletin board under a new symbol.
Please refer to the section of this proxy statement and prospectus entitled
"Market Price and Dividend Policy -- Change."
ANTICIPATED ACCOUNTING TREATMENT
The acquisition is anticipated to be accounted for as a reverse
acquisition. The assets and liabilities of Neurologix will be recorded at their
historical carrying values and the assets and liabilities of Change will be
recorded at their fair values, which approximate historical values. The reported
financial condition and results of operations of Neurologix after the Merger
will reflect these values, but will not be retroactively restated to reflect the
historical financial position or results of operations of Change. Please refer
to the section of this proxy statement and prospectus entitled "The
Merger -- Accounting Treatment."
COMPARISON OF STOCKHOLDERS' RIGHTS
The certificates of incorporation and bylaws of Neurologix and Change
differ. As a result, Neurologix's stockholders will have different rights as
stockholders of Change from those they have now. Change's stockholders will have
substantially the same rights as they currently have, as modified by the
proposed amendments to Change's certificate of incorporation. Please refer to
the section of this proxy statement and prospectus entitled "Comparison of the
Rights of the Holders of Neurologix Common Stock or Series B Convertible
Preferred Stock and the Holders of Change Common Stock."
10
SUMMARY SELECTED HISTORICAL FINANCIAL DATA OF CHANGE
The table below presents Change's selected historical financial data for
the fiscal years ended December 31, 1998, 1999, 2000, 2001 and 2002 and for the
nine months ended September 30, 2002 and 2003. The selected historical financial
data for the fiscal years ended December 31, 1998 and 1999 have been derived
from audited financial statements not included in this proxy statement and
prospectus. The selected historical financial data for the fiscal years ended
December 31, 2000, 2001 and 2002 have been derived from audited financial
statements included elsewhere in this proxy statement and prospectus. The audit
opinion to these financial statements contains an explanatory paragraph that
states that Change adopted a plan of liquidation and dissolution which raises
substantial doubt about its ability to continue as a going concern. The
consolidated financial statements do not include any adjustments that might
result from the outcome of that uncertainty. The audit opinion also contains an
explanatory paragraph that refers to changes in Change's method of accounting
for goodwill and other intangibles. The selected historical financial data for
the nine months ended September 30, 2002 and 2003 have been derived from
unaudited condensed financial statements included elsewhere in this proxy
statement and prospectus. The unaudited condensed financial statements, in the
opinion of management, include all adjustments, consisting only of normal
recurring adjustments, necessary for a fair statement of the results for the
unaudited interim periods. The results for any interim period are not
necessarily indicative of the results that may be expected for a full year.
On June 30, 2003, Change sold all of the issued and outstanding shares of
its Canned Interactive subsidiary. Accordingly, the operations of Canned for all
periods presented have been reclassed into a one-line presentation and are
included in "Income (loss) from discontinued operations."
You should read this information in conjunction with the audited
consolidated financial statements, including the notes to those statements, and
"Management's Discussion and Analysis of Financial Condition and Results of
Operations of Change" included elsewhere in this report.
NINE MONTHS ENDED
FISCAL YEAR ENDED DECEMBER 31, SEPTEMBER 30,
----------------------------------------------- -----------------
2002 2001 2000 1999 1998 2003 2002
------- -------- -------- ------ ------ ------- -------
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)
STATEMENT OF OPERATIONS DATA:
Revenues.................................. $ -- $ 4,596 $ 1,370 $ -- $ -- $ -- $ --
Cost of Revenues.......................... -- 6,088 1,119 -- -- -- --
------- -------- -------- ------ ------ ------- -------
Gross (loss) profit....................... -- (1,492) 251 -- -- -- --
Operating expenses:
General and administrative................ 3,342 12,894 3,305 12 11 2,275 2,667
Equity based compensation................. 377 3,086 2,921 -- -- 358 394
Severance................................. -- 1,326 -- -- -- 140 --
Loss on disposal of subsidiaries.......... -- 377 -- -- -- -- --
Impairment losses......................... 69 7,263 -- -- -- -- --
------- -------- -------- ------ ------ ------- -------
Loss from operations...................... (3,788) (26,438) (5,975) (12) (11) (2,773) (3,061)
Other income (expense).................... 194 (4,687) (263) 20 (42) 271 24
------- -------- -------- ------ ------ ------- -------
(Loss) income from continuing operations
before extraordinary item............... (3,594) (31,125) (6,238) 8 (53) (2,502) (3,037)
Income (loss) from discontinued
operations.............................. 93 (1,075) -- -- -- (1,899) (26)
------- -------- -------- ------ ------ ------- -------
Loss before extraordinary item............ (3,501) (32,200) -- -- -- (4,401) (3,063)
Extraordinary item........................ -- -- -- -- 666 -- --
------- -------- -------- ------ ------ ------- -------
Net (loss) income......................... (3,501) (32,200) (6,238) 8 613 (4,401) (3,063)
Dividends................................. -- -- -- (14) (24) -- --
11
NINE MONTHS ENDED
FISCAL YEAR ENDED DECEMBER 31, SEPTEMBER 30,
----------------------------------------------- -----------------
2002 2001 2000 1999 1998 2003 2002
------- -------- -------- ------ ------ ------- -------
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)
Deemed dividend attributable to issuance
of convertible preferred stock.......... -- -- 40,000 -- -- -- --
------- -------- -------- ------ ------ ------- -------
Net (loss) income applicable to common
stockholders............................ (3,501) (32,200) (46,238) (6) 589 (4,401) (3,063)
Basic and diluted (loss) income per common
share from continuing operations........ (0.02) (0.23) (1.31) (0.00) (0.02) (0.01) (0.02)
Discontinued operations................... (0.00) (0.00) (0.00) (0.00) (0.00) (0.01) (0.00)
Extraordinary item........................ (0.00) (0.00) (0.00) (0.00) 0.15 (0.00) (0.00)
------- -------- -------- ------ ------ ------- -------
Basic and diluted net (loss) income per
common share............................ $ (0.02) $ (0.23) $ (1.31) $(0.00) $ 0.13 $ (0.02) $ (0.02)
BALANCE SHEET DATA:
Cash, cash equivalents and marketable
securities.............................. $ 2,944 $ 8,702 $ 30,333 $ 245 $ 173 $ 5,963 $ 1,533
Working capital........................... 8,413 10,660 30,012 245 236 7,249 8,551
Total assets.............................. 12,733 16,152 38,576 246 238 7,705 13,209
Total long-term obligations............... 8 74 15 -- -- -- 38
Stockholders' equity...................... 11,619 14,660 37,182 245 236 7,406 12,060
12
SUMMARY SELECTED HISTORICAL FINANCIAL DATA OF NEUROLOGIX
The following selected historical financial data as of December 31, 2002
and 2001, and for the fiscal years ended December 31, 2002, 2001, and 2000, has
been derived from the audited financial statements of Neurologix, which were
audited by J.H. Cohn LLP, Neurologix's current independent auditors. The audit
opinion to these financial statements includes an explanatory paragraph relating
to Neurologix's ability to continue as a going concern. The following selected
historical financial data as of December 31, 2000 and 1999, as of September 30,
2003 and 2002, for the period from February 12, 1999 (date of inception) through
December 31, 1999 and for the nine months ended September 30, 2003 and 2002 is
unaudited and has been derived from unaudited financial statements which, in the
opinion of management, include all adjustments, consisting only of normal
recurring adjustments, necessary for a fair statement of the results of
operations. You should read this information in conjunction with the audited
financial statements and "Management's Discussion and Analysis of Financial
Condition and Results of Operations of Neurologix" included elsewhere in this
proxy statement and prospectus.
NINE MONTHS ENDED
YEARS ENDED DECEMBER 31, SEPTEMBER 30,
--------------------------------------------------- -----------------------
2002 2001 2000 1999(1) 2003 2002
----------- --------- ----------- ----------- ----------- ---------
(UNAUDITED) (UNAUDITED)
STATEMENT OF OPERATIONS DATA:
Revenues(2)
Operating expenses:
Research and licensing......... $ 440,830 $ 326,000 $ 653,690 $ 180,000 $ 730,388 $ 329,285
Scientific consulting.......... 286,256 202,750 222,000 41,500 220,084 196,545
Administrative expenses........ 485,981 246,121 157,353 107,831 540,027 248,665
----------- --------- ----------- --------- ----------- ---------
Loss from operations............. (1,213,067) (774,871) (1,033,043) (329,331) (1,490,499) (774,495)
----------- --------- ----------- --------- ----------- ---------
Other income (expenses):
Dividend income................ 6,736 -- 2,902 984 662 --
Interest income................ 14,798 -- -- -- 13,055 --
Interest expense............... (118,098) (95,755) (24,438) -- (95,422) (88,097)
----------- --------- ----------- --------- ----------- ---------
Totals....................... (96,564) (95,755) (21,536) 984 (81,705) (88,097)
----------- --------- ----------- --------- ----------- ---------
Net loss......................... $(1,309,631) $(870,626) $(1,054,579) $(328,347) $(1,572,204) $(862,592)
=========== ========= =========== ========= =========== =========
Net income (loss) per
share -- basic and diluted..... $ (.55) $ (.38) $ (.48) $ (.15) $ (.63) $ (.38)
DECEMBER 31, SEPTEMBER 30,
---------------------------------------------------- ------------------------
2002 2001 2000 1999 2003 2002
---------- ----------- ----------- ----------- ----------- ----------
(UNAUDITED) (UNAUDITED) (UNAUDITED)
BALANCE SHEET DATA:
Total assets.................... $1,933,921 $ 288,496 $ 283,628 $ 241,565 $ 1,376,144 $2,266,914
Total long term obligations..... 2,238,251 1,925,153 1,100,038 -- 3,168,624 2,208,250
Mandatorily redeemable
convertible preferred stock... 500,000 500,000 500,000 500,000 500,000 500,000
Total stockholders'
deficiency.................... (889,330) (2,216,642) (1,378,516) (323,937) (2,292,470) (466,336)
---------------
(1) Results for the fiscal year ended December 31, 1999 are from February 12,
1999, the date of inception of Neurologix.
(2) Neurologix has never earned revenues nor declared or paid any cash dividends
on its capital stock.
13
SUMMARY PRO FORMA COMBINED FINANCIAL DATA
The following summary unaudited pro forma combined financial data of Change
and Neurologix has been derived from, and should be read together with, the
unaudited pro forma condensed combined financial statements and related notes
included elsewhere in this proxy statement and prospectus.
The unaudited pro forma combined financial data is provided for
illustrative purposes only and does not reflect what the results of operations
and financial position of the combined company would have been if the Merger and
the related transactions had actually occurred on the dates assumed. This data
also does not purport to indicate the combined company's future operating
results or consolidated financial position.
YEAR ENDED NINE MONTHS ENDED
DECEMBER 31, 2002 SEPTEMBER 30, 2003
PRO FORMA AS PRO FORMA AS
ADJUSTED ADJUSTED
------------------ -------------------
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)
COMBINED STATEMENT OF OPERATIONS DATA:
Operating expenses..........................................
General and administrative expenses......................... $ 4,205 $ 3,313
Research and licensing...................................... 441 730
Scientific consulting....................................... 286 220
Impairment charge........................................... 69 --
------------ ------------
Loss from operations........................................ (5,001) (4,263)
Other income (expense):
Interest and dividend income, net........................... 646 13
Equity in losses and impairment of investments in
unconsolidated subsidiaries............................... (549) (110)
Realized gain on sale of investment......................... -- 286
------------ ------------
Totals...................................................... 97 189
------------ ------------
Loss from continuing operations............................. (4,904) (4,074)
(Loss) gain from discontinued operations (including loss on
disposal), net............................................ 93 (1,899)
------------ ------------
Net loss.................................................... (4,811) (5,973)
------------ ------------
Basic and diluted net loss per common share................. $ (0.01) $ (0.01)
============ ============
Weighted average common shares outstanding, basic and
diluted................................................... 564,505,532 575,815,900
------------ ------------
SEPTEMBER 30, 2003
------------------
BALANCE SHEET DATA:
Total assets................................................ $8,676
Total stockholders' equity.................................. 7,637
14
UNAUDITED COMPARATIVE PER SHARE INFORMATION
The following table presents per common share information regarding the
income (loss) and book value of Change and Neurologix on both a historical and
unaudited pro forma combined basis. The unaudited pro forma combined per share
information has been derived from the unaudited pro forma combined financial
statements and related notes included elsewhere in this proxy statement and
prospectus. You should read the information below in conjunction with the
financial statements and accompanying notes of Change and Neurologix that are
included in this proxy statement and prospectus and with the unaudited pro forma
combined information included in the section of this proxy statement and
prospectus entitled "Unaudited Pro Forma Financial Statements."
The unaudited pro forma combined financial information is provided for
illustrative purposes only and does not reflect the results of operations and
the financial position of the combined company as if the Merger and the related
transactions had actually occurred on the dates assumed. This information also
does not indicate the combined company's future operating results or
consolidated financial position.
AS OF AND FOR THE AS OF AND FOR THE
YEAR ENDED NINE MONTHS ENDED
DECEMBER 31, 2002 SEPTEMBER 30, 2003
----------------- ------------------
NEUROLOGIX HISTORICAL:
Loss from continuing operations per share:
Basic and diluted......................................... $(0.54) $(0.63)
Book value per common share................................. (0.37) (0.92)
CHANGE HISTORICAL:
Loss from continuing operations per share:
Basic and diluted......................................... (0.02) (0.01)
Book value per common share................................. 0.01 0.01
COMBINED COMPANY -- UNAUDITED PRO FORMA COMBINED:
Basic and diluted loss per common share..................... (0.01) (0.01)
Book value per common share................................. 0.01 0.01
NEUROLOGIX PRO FORMA COMBINED PER NEUROLOGIX EQUIVALENT
COMMON SHARE DATA:(1)
Basic and diluted loss per common share..................... 0.00 0.00
Book value per common share................................. 0.00 0.00
---------------
(1) We calculated the Neurologix equivalent pro forma per share data by dividing
the applicable combined company pro forma per share data by 70.2127, the
estimate of the exchange ratio in the merger agreement, based on the value
of Change's Net Cash Assets and outstanding shares of common stock as of
July 31, 2003.
RISK FACTORS
The transactions described in this proxy statement and prospectus involve
substantial risks. Please refer to the section of this proxy statement and
prospectus entitled "Risk Factors" immediately following this summary for a
discussion of certain risks relating to the proposed transactions.
15
RISK FACTORS
Change stockholders voting in favor of the Merger and the proposals related
to the Merger effectively will be choosing to combine the businesses of the two
companies. If the Merger is consummated, Neurologix stockholders will become
investors in Change common stock. This combination and investment involve some
risks. You should carefully consider the information below as well as all other
information provided to you or incorporated by reference in this proxy statement
and prospectus in deciding whether to adopt the merger agreement and approve the
related proposals, including information in the section of this proxy statement
and prospectus entitled "Special Note Regarding Forward-Looking Statements."
RISK FACTORS RELATED TO THE COMBINED COMPANY'S BUSINESS
BECAUSE NEUROLOGIX IS A COMPANY WITH A LIMITED OPERATING HISTORY, IT IS
DIFFICULT TO PREDICT THE COMBINED COMPANY'S FUTURE GROWTH AND OPERATING RESULTS.
Neurologix's limited operating history makes predicting the combined company's
future growth and operating results extremely difficult. Neurologix was
incorporated in Delaware in 1999. You should consider the risks and
uncertainties that a company with a limited existence will face in the rapidly
evolving market for gene-based therapy technologies and products. In particular,
you should consider that Neurologix has not demonstrated that it can:
- discover gene therapies that will be effective in treating Parkinson's
disease or any other disease;
- obtain the regulatory approvals necessary to commercialize product
candidates that it may develop in the future;
- manufacture, or arrange for third-parties to manufacture, future product
candidates in a manner that will enable the company to be profitable;
- attract, retain and manage a large, diverse staff of physicians and
researchers;
- establish many of the business functions necessary to operate, including
sales, marketing, administrative and financial functions, and establish
appropriate financial controls;
- develop relationships with third-party collaborators to market and
exploit the technologies that Neurologix may develop;
- make, use and sell future product candidates without infringing upon
third party intellectual property rights;
- secure intellectual property protection of the company's future product
candidates; or
- respond effectively to competitive pressures.
In addition, if the pending Phase I clinical trial is unsuccessful, future
operations and profitability will be significantly adversely affected. If the
combined company cannot accomplish these goals, its business may not succeed.
NEUROLOGIX'S TECHNOLOGIES ARE IN EARLY STAGES OF DEVELOPMENT AND NO
REVENUES HAVE BEEN GENERATED FROM THE SALE OF ANY PRODUCT BASED ON ITS
TECHNOLOGIES. Neurologix's technologies are in early stages of development and,
to date, Neurologix has not generated any revenue from sales of products or
developed any future product candidates. Even if the combined company obtains
regulatory approval for a future product candidate, it may not be successful in
engaging collaborative partners to finance and manage the sales and marketing of
such a product. As a result of those and other factors, no assurance can be
provided that the combined company will be able to generate revenue from sales
of any future product candidates or otherwise successfully commercially exploit
its technologies.
THE COMBINED COMPANY PRESENTLY INTENDS TO RELY ON STRATEGIC RELATIONSHIPS
WITH THIRD PARTIES TO DEVELOP ITS TECHNOLOGIES AND TEST AND COMMERCIALIZE ANY
FUTURE PRODUCT CANDIDATE. The combined company intends to develop strategic
relationships with third parties to finance research and development costs,
manufacture (or assist with the manufacturing) and market any future product
candidates (including wholly or partially
16
financing the costs of marketing, sales and distribution). Given the high cost
of funding clinical trials, commercializing a proposed product and obtaining
governmental approval, Neurologix believes that successful development and
commercialization of its technologies and future product candidates will depend
in large part on the establishment of one or more of these strategic
relationships. There is no assurance that the combined company will be able to
negotiate any agreements with such third parties on terms that are acceptable to
it, or at all. In addition, the failure to raise additional capital in the
future could put the combined company at a disadvantage when negotiating such
agreements with other companies. Additionally, Neurologix cannot guarantee that
such third parties will not also independently develop competitive technologies
and products.
NEUROLOGIX HAS A HISTORY OF OPERATING LOSSES AND THE COMBINED COMPANY MAY
NEVER BE PROFITABLE. Neurologix has incurred operating losses since its
inception in 1999 as it has been engaged primarily in research and development
activities. Specifically, Neurologix reported a cumulative net loss of
approximately $5.1 million through September 30, 2003, and a net loss of
approximately $1.3 million for the twelve months ended December 31, 2002 and
$1.6 million for the nine months ended September 30, 2003. As of December 31,
2002 and September 30, 2003, Neurologix's accumulated deficit was approximately
$3.5 million and $5.1 million, respectively, with working capital of $1.6
million and $0.1 million, respectively. Because it may take years to develop,
test and obtain regulatory approval for a gene-based therapy product before it
can be sold, the combined company likely will continue to incur significant
losses for the foreseeable future. Accordingly, the combined company may never
be profitable and, if it becomes profitable, it may be unable to sustain
profitability.
PRE-CLINICAL TESTING AND CLINICAL TRIALS REQUIRED FOR FUTURE PRODUCT
CANDIDATES WILL BE EXPENSIVE AND TIME-CONSUMING AND THEIR OUTCOME IS UNCERTAIN.
The industry in which the combined company will compete is subject to stringent
regulation by a wide range of regulatory authorities. The combined company may
not obtain regulatory approval for any future product candidates it develops. To
market a pharmaceutical product in the United States rigorous preclinical
testing and clinical trials of the product must be completed and an extensive
regulatory approval process implemented by the Food and Drug Administration, or
FDA. To date, neither the FDA nor any other regulatory agency has approved a
gene therapy product for sale in the United States. Satisfaction of regulatory
requirements typically takes many years, is dependent upon the type, complexity
and novelty of the product and requires the expenditure of substantial
resources. The combined company may encounter delays or rejections in the
regulatory approval process resulting from additional governmental regulation or
changes in FDA policy during the period of product development, clinical trials
and FDA regulatory review. Failure to comply with applicable FDA or other
applicable regulatory requirements may result in criminal prosecution, civil
penalties, recall or seizure of products, total or partial suspension of
production or injunction, as well as other regulatory action against the
combined company's future product candidates or the combined company itself. If
regulatory approval of a future product candidate is granted, such approval will
be limited to those disease indications for which the future product candidate
has been demonstrated to be safe and effective through clinical trials. The FDA
also strictly regulates the promotion and labeling of pharmaceutical products
after approval. Outside the United States, the ability to market a product is
also contingent upon receiving clearances from appropriate foreign regulatory
authorities. The non-U.S. regulatory approval process includes all of the risks
associated with FDA clearance described above.
The combined company will face the risks of failure involved in developing
therapies based on new technologies. The estimated aggregate cost of completing
the pending Phase I clinical trial of Neurologix's initial product candidate for
treating Parkinson's disease is $1 million. This trial may not be successful.
The combined company will also need to conduct significant additional
research and animal testing, referred to as preclinical testing, before clinical
trials involving other future product candidates can be conducted. It may take
many years to complete preclinical testing and clinical trials and failure could
occur at any stage of testing. Acceptable results in early testing or trials may
not be repeated in later tests. Whether any products in preclinical testing or
early stage clinical trials will become approved products is unknown. Before
applications can be filed with the FDA for product approval, it must be
demonstrated that a particular future product candidate is safe and effective.
The combined company's failure to adequately demonstrate the safety and efficacy
of future product candidates would prevent the FDA from approving them. The
combined
17
company's product development costs will increase if it experiences delays in
testing or regulatory approvals or if it becomes necessary to perform more or
larger clinical trials than planned. If the delays are significant, they could
negatively affect the combined company's financial results and the commercial
prospects for future product candidates.
IF FUTURE PRODUCT CANDIDATES EMPLOYING THE COMBINED COMPANY'S TECHNOLOGIES
DO NOT ACHIEVE SIGNIFICANT MARKET ACCEPTANCE, ITS BUSINESS WILL SUFFER. The
combined company's future success depends upon health care administrators and
providers, patients and third-party payors' (including, without limitation,
health insurance companies, Medicaid and Medicare) acceptance of its products.
Market acceptance will depend on numerous factors, many of which are outside the
combined company's control, including:
- the safety and efficacy of future product candidates, as demonstrated in
clinical trials;
- favorable regulatory approval and product labeling;
- the frequency of product use;
- the availability, safety, efficacy and ease of use of alternative
therapies;
- the price of future product candidates relative to alternative therapies;
and
- the availability of third-party reimbursement.
Unanticipated side effects, patient discomfort, defects or unfavorable publicity
concerning any of the combined company's future product candidates, or any other
product incorporating technology similar to that used by future product
candidates, could have a material adverse effect on the combined company's
ability to commercialize its products or achieve market acceptance.
ADVERSE EVENTS IN THE FIELD OF GENE THERAPY MAY NEGATIVELY AFFECT PUBLIC
PERCEPTION OF, AND THE COMBINED COMPANY'S ABILITY TO OBTAIN REGULATORY APPROVAL
FOR, FUTURE PRODUCT CANDIDATES. Patient complications that may occur in
gene-based clinical trials conducted by the combined company and other companies
and the resulting publicity surrounding them, as well as any other serious
adverse events in the field of gene therapy that may occur in the future, may
result in greater governmental regulation of future product candidates and
potential regulatory delays relating to the testing or approval of them. Even
with the requisite approval, the commercial success of the combined company's
product candidates will depend in part on public acceptance of the use of gene
therapies for the prevention or treatment of human disease. Public attitudes may
be influenced by claims that gene therapy is unsafe, and gene therapy may not
gain the acceptance of the public or the medical community. Negative public
reaction to gene therapy could result in greater governmental regulation,
stricter clinical trial oversight and commercial product labeling requirements
of gene therapies and could negatively affect demand for any products the
combined company may develop.
NEUROLOGIX HAS NO MANUFACTURING CAPABILITIES OR EXPERIENCE. Neurologix does
not have any experience in manufacturing products for commercial sale and if the
combined company is not successful in engaging a third-party to manufacture its
products, no assurance can be provided that it will be able to:
- develop and implement large-scale manufacturing processes and purchase
needed equipment and machinery on favorable terms;
- hire and retain skilled personnel to oversee manufacturing operations;
- avoid design and manufacturing defects; or
- develop and maintain a manufacturing facility in compliance with
governmental regulations, including the FDA's good manufacturing
practices.
The combined company, or third-party manufacturers that it contracts with
to manufacture any future product candidate, must receive FDA approval before
producing clinical material or commercial products. The combined company's
future product candidates may compete with other products for access to
third-party manufacturing facilities and may be subject to delays in manufacture
if third party manufacturers give priority to products other than the combined
company's future product candidates. The combined company may be
18
unable to manufacture commercial-scale quantities of gene-based therapy
products, or any quantities at all. Failure to successfully manufacture products
in commercial-scale quantities, and on a timely basis, would prevent the
combined company from achieving its business objectives.
THE COMBINED COMPANY WILL BE DEPENDENT ON ITS KEY PHYSICIANS AND
RESEARCHERS. The combined company's future success depends, to a significant
degree, on the skills, experience and efforts of Neurologix's current key
physicians and researchers, including Dr. Matthew J. During and Dr. Michael G.
Kaplitt. If either Dr. During or Dr. Kaplitt were unable or unwilling to
continue in their present positions, it is likely that the combined company's
business, financial condition, operating results and future prospects would be
materially adversely affected.
THE COMBINED COMPANY'S SUCCESS DEPENDS ON ITS ABILITY TO PROTECT ITS
INTELLECTUAL PROPERTY. The combined company's ability to commercialize its
product candidates will depend, in large measure, on its ability to protect
those products and its technology through U.S. and foreign patents. There is no
assurance that any of the combined company's product candidates or technologies
will be patentable, that any pending patent applications will result in issued
patents, or that Neurologix's issued patents, if challenged, will be held to be
valid or enforceable or will be interpreted to provide the combined company with
meaningful protection. Consequently, there is no assurance that the combined
company's patents will prevent other companies from developing similar or
therapeutically equivalent products, or that other companies will not be issued
patents that may prevent the manufacture, use or sale of its products or require
it to pay significant licensing fees in order to market its products.
From time to time, the combined company may need to obtain licenses to
patents and other proprietary rights held by third parties in order to develop,
manufacture and market product candidates. If the combined company is unable to
obtain these licenses on commercially reasonable terms and in a timely manner,
then its ability to commercially exploit such future product candidates will be
inhibited or prevented.
Neurologix also relies on a combination of trade secret and copyright laws,
employee and third-party nondisclosure agreements, and other protective measures
to protect its intellectual property rights. The combined company cannot be
certain that these measures will provide meaningful protection of its trade
secrets, know-how or other proprietary information. The laws of foreign
countries may not protect the combined company's intellectual property rights to
the same extent as do the laws of the United States. The combined company cannot
assure you that it will be able to protect its intellectual property rights.
OTHER COMPANIES MAY CLAIM THAT THE COMBINED COMPANY'S TECHNOLOGIES INFRINGE
ON THEIR INTELLECTUAL PROPERTY OR PROPRIETARY RIGHTS. Because of the complex and
difficult legal and factual questions that relate to patent positions in the
combined company's industry, no assurance can be provided that its future
product candidates or technologies will not be found to infringe upon the
intellectual property or proprietary rights of others. Third parties may claim
that future product candidates or the combined company's technologies infringe
on their patents, copyrights, trademarks or other proprietary rights and demand
that it cease development or marketing of those products or technology or pay
license fees. The combined company may not be able to avoid costly patent
infringement litigation, which will divert the attention of management away from
the development of new products and the operation of its business. No assurance
can be provided that the combined company would prevail in any such litigation.
If the combined company is found to have infringed on a third party's
intellectual property rights it may be liable for money damages, encounter
significant delays in bringing products to market or be precluded from
manufacturing particular future product candidates or using particular
technology.
THE COMBINED COMPANY MAY FACE PRODUCT LIABILITY CLAIMS RELATED TO THE USE
OR MISUSE OF FUTURE PRODUCT CANDIDATES EMPLOYING ITS TECHNOLOGY. Clinical trials
of future product candidates, and any subsequent sales of products employing the
combined company's technology, may involve injuries to persons using those
products as a result of mislabeling, misuse or product failure. Product
liability insurance is expensive. Although Neurologix has purchased product
liability insurance to cover claims made during the expected duration of the
ongoing Phase I clinical trials, there can be no assurance that this insurance
will be available to the combined company in the future on satisfactory terms,
if at all. A successful product liability claim or series of claims brought
against
19
the combined company in excess of any insurance coverage that it may obtain in
the future could have a material adverse effect on its business, financial
condition, results of operations and future prospects.
THE COMBINED COMPANY WILL FACE INTENSE COMPETITION AND RAPID TECHNOLOGICAL
CHANGE. There is substantial competition to improve existing treatments and
develop new treatments for Parkinson's disease and other central nervous system
disorders, some of which involve gene-based therapies. For example, companies
such as Cell Genesys (through its Ceregene subsidiary) and Avigen have announced
research and development efforts involving gene-based therapies for Parkinson's
disease. Some of the companies conducting research and development in this area
are large pharmaceutical and medical device companies and other companies that
have far greater financial and other resources than those available to the
combined company. Further, the biotechnology industry is highly competitive and
rapidly evolving, significant developments in the combined company's industry
likely will continue at a rapid pace. There can be no assurance that any of the
combined company's future product candidates will have advantages over
alternative products and technologies that may be significant enough to cause
health care providers to purchase the combined company's future product
candidates or technologies.
THE COMBINED COMPANY WILL REQUIRE SUBSTANTIAL ADDITIONAL FUNDING TO
CONTINUE ITS BUSINESS, WHICH IT MAY NOT BE ABLE TO OBTAIN ON ACCEPTABLE TERMS,
OR AT ALL. The success of the combined company's business depends on a positive
outcome in the pending Phase I clinical trial and its ability to develop future
product candidates, put those future product candidates through rigorous and
time-consuming clinical testing, and obtain regulatory approval for and
manufacture those future product candidates. The combined company will require
substantial additional capital in the future to execute its business plan. The
exact amount of the combined company's future capital requirements will depend
on numerous factors, some of which are not within the combined company's
control, including the progress of its research and development efforts, the
costs of testing and manufacturing future product candidates, and changes in
governmental regulation. Additional capital may not be available on acceptable
terms, if at all. If the combined company is unable to raise adequate additional
capital on acceptable terms, it will be forced to curtail or cease its planned
product development.
THE COMBINED COMPANY'S OPERATIONS WILL INVOLVE HAZARDOUS MATERIALS AND WILL
BE SUBJECT TO ENVIRONMENTAL CONTROLS AND REGULATIONS. The combined company's
research and development processes may involve the use of hazardous materials,
including chemicals and radioactive and biological materials. The risk of
accidental contamination or discharge or any resultant injury from these
materials cannot be completely eliminated. Federal, state and local laws and
regulations govern the use, manufacture, storage, handling and disposal of these
materials. The combined company could be subject to civil damages in the event
of an improper or unauthorized release of, or exposure of individuals to, such
hazardous materials. In addition, claimants may sue the combined company for
injury or contamination that results from its use or the use by third parties of
these materials and the combined company's liability may exceed its total
assets. Compliance with environmental laws and regulations may be expensive and
current or future environmental regulations may impair the combined company's
research, development or production efforts.
RISKS RELATED TO THE MERGER
CHANGE MAY NOT OBTAIN THE REQUISITE STOCKHOLDER APPROVAL NECESSARY TO
CONSUMMATE THE MERGER. The Merger will not be consummated if Change fails to
obtain the required approval of its stockholders.
THE COMBINED COMPANY MAY BE UNABLE TO REALIZE THE BENEFITS ANTICIPATED BY
CHANGE AND NEUROLOGIX. The Merger involves the integration of two companies that
have previously operated independently. There can be no assurances that the
benefits expected from such integration will be realized. Unforeseen liabilities
in winding down Change's operations may result in a reduction in the capital
available for the ongoing operations of the combined company. Incurring
unexpected costs or delays in connection with such integration could have a
material adverse effect on the combined company's business, financial condition
or results of operations. In addition, if the combined company's future product
candidates and other business ventures do not provide adequate returns, Change
and its stockholders may have been better off liquidating Change rather than
participating in the Merger.
20
RISKS RELATED TO THE COMBINED COMPANY'S CAPITAL STRUCTURE
A SMALL NUMBER OF STOCKHOLDERS WILL EXERCISE SIGNIFICANT CONTROL OVER THE
COMBINED COMPANY'S AFFAIRS. Following the closing, (i) Palisade Private
Partnership, L.P. is expected to beneficially own approximately 172,519,415
shares, or 30.33%, of the combined company's outstanding common stock; (ii)
Auckland Technology Enabling Corporation is expected to beneficially own
approximately 92,154,169 shares, or 16.20%, of the combined company's
outstanding common stock; and (iii) Zenith Partners is expected to beneficially
own approximately 58,452,073 shares, or 10.28%, of the combined company's common
stock. These shareholders will be able to exert significant influence over
matters requiring approval by the combined company's stockholders, including the
election of directors and the approval of significant corporate transactions.
Such influence could delay or prevent an outside party from acquiring or merging
with the combined company.
Additionally, Medtronic International, Ltd. is expected to beneficially own
approximately 22,754,111 shares, or 4.00%, shares of the combined company's
outstanding common stock. Pursuant to certain agreements entered into in
connection with its investment in Neurologix, Medtronic (a) has a right of first
refusal with respect to new issuances of Neurologix securities, subject to
limited exceptions, (b) has the right to designate directors of Neurologix and
(c) has a right of first refusal with respect to one patent application owned by
Neurologix in the event that Neurologix intends to sell or license its rights in
the patent application. Following the Merger, Medtronic's right of first refusal
with respect to new issuances of Neurologix securities will terminate.
SHARES OF CHANGE'S COMMON STOCK HAVE BEEN THINLY TRADED IN THE PAST.
Although a trading market for Change common stock exists, the trading volume has
not been significant, and an active trading market for the common stock may not
continue. As a result of the thin trading market or "float" for Change's common
stock, the market price for the combined company's common stock may fluctuate
significantly more than the stock market as a whole. Without an active public
trading market, the combined company's common stock is less liquid than the
stock of companies with broader public ownership. As a result, the trading price
of the combined company's common stock may be more volatile, and an investor may
be unable to liquidate his investment in the combined company. Trading of a
relatively small volume of the combined company's common stock may have a
greater impact on the trading price for the combined company's stock than would
be the case if its trading volume were larger. Change cannot predict the prices
at which the combined company's common stock will trade in the future.
21
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Any statements in this proxy statement and prospectus about Change's,
Neurologix's or the combined company's expectations, beliefs, plans, objectives,
assumptions or future events or performance are not historical facts and are
forward-looking statements. These statements are often, but not always, made
through the use of words or phrases such as "will likely result," "expect,"
"will continue," "anticipate," "believe," "estimate," "intend," "plan,"
"projection," "would" and "outlook." Accordingly, these statements involve
estimates, assumptions and uncertainties which could cause actual results to
differ materially from those expressed in them. Any forward-looking statements
are qualified in their entirety by reference to the factors discussed throughout
this proxy statement and prospectus. In addition to the risks related to the
business of the combined company, Change and Neurologix and the risks relating
to the Merger described under "Risk Factors," factors that could cause actual
results to differ materially from those described in the forward-looking
statements include:
- the combined company may not be able to develop or commercialize
effective therapies for the treatment of central nervous system
disorders;
- the combined company may not be able to secure sufficient financing to
complete the clinical trial for treatment of Parkinson's disease or for
the development and commercialization of effective therapies;
- general economic conditions;
- adverse publicity and litigation; and
- the ability of the companies to complete the Merger and the combined
company's ability to manage its growth.
You should not place undue reliance on any of these forward-looking
statements, which speak only as of the date of this proxy statement and
prospectus. Neither of the companies undertakes any obligation to update any
forward-looking statement to reflect events or circumstances occurring after the
date of this proxy statement and prospectus. New factors emerge from time to
time and it is not possible to predict which will arise. In addition, neither of
the companies can assess the impact of each factor on its business or the extent
to which any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking statements.
22
THE CHANGE SPECIAL MEETING
THE MATTERS TO BE CONSIDERED AT THE CHANGE SPECIAL MEETING ARE OF GREAT
IMPORTANCE TO CHANGE STOCKHOLDERS. THE CHANGE BOARD URGES ALL CHANGE
STOCKHOLDERS TO READ AND CAREFULLY CONSIDER THE INFORMATION PRESENTED IN THIS
PROXY STATEMENT AND PROSPECTUS, AND TO COMPLETE, DATE, SIGN AND PROMPTLY RETURN
THE ENCLOSED PROXY CARD IN THE ENCLOSED POSTAGE-PAID ENVELOPE.
GENERAL
This proxy statement and prospectus is being furnished in connection with
the solicitation by the Change board of directors of proxies from the holders of
Change common stock and Change Series A convertible preferred stock for use at
the Change special meeting. The meeting will be held at 537 Steamboat Road,
Greenwich, Connecticut 06830, on February 9, 2004, at 10:00 a.m., local time.
Change is first mailing this document, the attached notice of special meeting of
stockholders and the enclosed proxy card to Change's stockholders on or about
January 13, 2004.
MATTERS TO BE CONSIDERED AT THE CHANGE SPECIAL MEETING
At the Change special meeting, Change stockholders will be asked:
1. to consider, approve and adopt the merger agreement and the
transactions contemplated by it;
2. to consider, approve and adopt a proposal to amend the certificate
of incorporation of Change, as provided in the merger agreement and
contingent upon the closing of the Merger, which amendments provide for (i)
increasing the number of authorized shares of Change common stock from
500,000,000 shares to 750,000,000 shares, (ii) decreasing the par value of
Change common stock from $0.01 per share to $0.001 per share, (iii)
changing the name of Change to "Neurologix, Inc." and (iv) increasing the
size of and dividing the Change board of directors into three classes, with
staggered three-year terms for each class; and
3. to transact any other business as may properly come before the
special meeting or any adjournment or postponement of the special meeting.
Change knows of no matter to be brought before the Change special meeting
other than the proposals described above. If any other business should properly
come before the special meeting, the persons named in the proxy card will vote
in their discretion.
THE CHANGE BOARD OF DIRECTORS HAS UNANIMOUSLY APPROVED THE MERGER AGREEMENT
AND THE TRANSACTIONS CONTEMPLATED BY IT AND UNANIMOUSLY RECOMMENDS THAT THE
HOLDERS OF BOTH CHANGE COMMON STOCK AND CHANGE SERIES A CONVERTIBLE PREFERRED
STOCK VOTE FOR THE (I) APPROVAL AND ADOPTION OF THE MERGER AGREEMENT AND THE
TRANSACTIONS CONTEMPLATED BY IT AND (II) AMENDMENTS TO CHANGE'S CERTIFICATE OF
INCORPORATION.
If, for any reason, the Merger is not consummated, nether proposal 1 nor
proposal 2 will be effected.
RECORD DATE; QUORUM; REQUIRED VOTE; SHARES OUTSTANDING AND ENTITLED TO VOTE
The Change board of directors has fixed the close of business on January
12, 2004 as the record date for the Change special meeting. Accordingly, only
holders of Change common stock or Series A convertible preferred stock on the
record date will be entitled to vote at the Change special meeting and any
adjournment or postponement of the special meeting. At the record date,
177,503,920 shares of Change common stock and 645 shares of Change Series A
convertible preferred stock were outstanding and entitled to vote.
The presence, in person or by proxy, of a majority of these outstanding
shares is necessary to constitute a quorum at the Change special meeting. Each
share of Change common stock or Series A convertible preferred stock is entitled
to one vote with respect to each matter to be voted on at the special meeting.
The vote required for the adoption of the merger agreement and the
transactions contemplated by it is the affirmative vote of the holders of a
majority of the outstanding shares of Change common stock and Series A
23
convertible preferred stock, voting together as a single class, entitled to vote
on such adoption, provided a quorum is present. FOR THIS PROPOSAL, AN ABSTENTION
OR A BROKER NON-VOTE WILL HAVE THE EFFECT OF A "NO" VOTE.
The vote required for the approval of the proposal to amend Change's
certificate of incorporation is the affirmative vote of the holders of a
majority of the outstanding shares of Change common stock and Series A
convertible preferred stock, voting together as a single class, entitled to vote
on such amendments, provided a quorum is present. FOR THIS PROPOSAL, AN
ABSTENTION OR A BROKER NON-VOTE WILL HAVE THE EFFECT OF A "NO" VOTE.
Both the merger proposal and the proposal to amend Change's certificate of
incorporation must be approved in order for the Merger to occur and for the
amendment of Change's certificate of incorporation to be given effect.
SECURITY OWNERSHIP OF MANAGEMENT
As of the record date, the directors and executive officers of Change and
their affiliates beneficially owned approximately 33.5 million of the
outstanding shares of Change common stock. Accordingly, Change directors,
executive officers and their affiliates hold shares representing approximately
18.71% of the outstanding shares of Change common stock and 18.71% of the shares
of Change common stock that will be eligible to vote at the special meeting.
VOTING OF PROXIES
PROPERLY EXECUTED PROXIES THAT HAVE NOT BEEN REVOKED WILL BE VOTED AT THE
SPECIAL MEETING IN ACCORDANCE WITH THE INSTRUCTIONS INDICATED IN THE PROXIES. IF
NO INSTRUCTIONS ARE INDICATED, SUCH PROXIES WILL BE VOTED FOR ALL OF THE
PROPOSALS DESCRIBED IN THIS PROXY STATEMENT AND PROSPECTUS.
Voting instructions are included on your proxy card. If you properly
complete your proxy card and submit it to Change in time to vote, one of the
individuals named as your proxy will vote your shares as you have directed.
Please note, however, that if your shares are held of record by a broker,
bank or other nominee and you wish to vote at the special meeting, you must
bring to the meeting a letter from the broker, bank or other nominee confirming
your beneficial ownership of the shares.
If any other matters are properly presented at the special meeting,
including consideration of a motion to adjourn the meeting to another time and
place for the purpose of soliciting additional proxies, the persons named in the
enclosed forms of proxy will have discretion to vote on those matters in
accordance with their best judgment.
REVOCATION OF PROXIES
Any proxy may be revoked by the person giving it at any time before it is
voted.
Proxies may be revoked by:
- sending a written notice of revocation to the proxy solicitor for Change
at the address below;
- completing and submitting a new proxy card, dated a later date than the
first proxy card, and sending it to the proxy solicitor for Change at the
address below; or
- attending the special meeting AND voting in person.
In order to vote in person at the special meeting, you must attend the
meeting and cast the votes in accordance with the voting procedures established
for the meeting. Attendance at the special meeting without voting in accordance
with the voting procedures will not in and of itself revoke a proxy. Any written
notice of
24
revocation either must be delivered at the special meeting or must be sent, in
time to be received before the day of the special meeting, to the proxy
solicitor:
MacKenzie Partners, Inc.
105 Madison Avenue
New York, NY 10016
Contact: Dan Sullivan
Phone: (800) 322-2885
Facsimile: (212) 929-0308
SOLICITATION OF PROXIES
Change will bear the cost of the solicitation of proxies from its
stockholders. Change will bear the expense of printing and mailing this document
and the material used in this solicitation of proxies. Brokerage houses,
fiduciaries, nominees and others will, upon request, be reimbursed for their
out-of-pocket expenses in forwarding proxy materials to the owners of Change
common stock or Series A convertible preferred stock held in their names. In
addition to the solicitation of proxies by use of the mails, proxies may be
solicited from Change stockholders by directors, officers and employees of
Change in person or by telephone, telegraph, facsimile or other appropriate
means of communication. No additional compensation, except for reimbursement of
reasonable out-of-pocket expenses, will be paid to these directors, officers and
employees of Change in connection with the solicitation. In addition, MacKenzie
Partners, Inc., a proxy solicitation firm has been engaged by Change to act as a
proxy solicitor and will receive fees estimated at $7,500, plus reimbursement of
out-of-pocket expenses. Any questions or requests for assistance regarding this
proxy statement and prospectus and related proxy materials may be directed to:
MacKenzie Partners, Inc.
105 Madison Avenue
New York, NY 10016
Contact: Dan Sullivan
Phone: (800) 322-2885
Facsimile: (212) 929-0308
STOCKHOLDER PROPOSALS
Under the SEC rules relating to when a company must include a stockholder's
proposal in its proxy statement, stockholders may present proper proposals for
inclusion in Change's proxy statement for consideration at the next annual
meeting of its stockholders by submitting their proposals to Change in a timely
manner.
APPRAISAL RIGHTS
Under Delaware law, Change stockholders will not be entitled to dissenters'
rights of appraisal in connection with the Merger or with respect to any other
proposal to be voted on at the special meeting.
STOCKHOLDER LIST
As required by Delaware law, Change will make available for inspection by
any Change stockholder for any purposes germane to the special meeting a
complete list of stockholders eligible to vote at the special meeting, during
ordinary business hours, at the principal offices of Change for the 10 days
prior to the special meeting. The stockholder list will also be available for
inspection at the special meeting.
25
THE MERGER
In the proposed transaction, Subcorp will merge with and into Neurologix,
and Neurologix will survive the Merger as a wholly-owned subsidiary of Change.
Upon completion of the Merger, Change will change its corporate name to
"Neurologix, Inc." For more information regarding the terms of the Merger,
please refer to the section of this proxy statement and prospectus entitled "The
Merger Agreement."
BACKGROUND OF THE MERGER
On September 30, 2002, the Change board of directors announced the adoption
of a plan of liquidation and dissolution but continued to review suitable
business opportunities. In early April 2003, Michael Gleason contacted Steven
Berman and Martin Berman of Palisade Private Partnership, L.P. in connection
with a proposed transaction with Neurologix Inc.
On April 28, 2003, Michael Gleason met with Steven Berman, Martin Berman
and Mark Hoffman of Palisade Private Partnership, L.P. and Drs. Martin Kaplitt
and Mathew During of Neurologix, to discuss a proposed transaction with
Neurologix. Michael Gleason agreed to discuss with William Avery, the then chief
executive officer and a member of the board of directors of Change, a proposed
transaction with Neurologix.
In May 2003, Michael Gleason and William Avery made several trips to the
offices of Neurologix and participated in conference calls with representatives
of Neurologix to discuss the principal business terms of the proposed
transaction.
On May 27, 2003, a meeting of the Neurologix board of directors was held to
review the principal terms of the letter of intent for the proposed transaction
with Change. Following a discussion of the proposed terms of the transaction,
the board adopted and approved the letter of intent subject to due diligence and
other conditions contained in the letter of intent.
On June 10, 2003, Change and Neurologix entered into a letter of intent
reflecting the principal business terms of the proposed transaction. During the
next several weeks, both companies conducted legal and financial diligence and
were afforded opportunities to discuss any issue with management and legal
counsel. Change and Neurologix also began negotiations of the transaction
agreements.
On June 10, 2003, the members of Neurologix board of directors executed
written consents approving a modification of the letter of intent.
On July 30, 2003, Change engaged BNY Capital Markets, Inc. to act as the
financial advisor to the board of directors of Change in connection with the
proposed transaction.
On August 8, 2003, a meeting of the Change board of directors was held. BNY
Capital Markets, Inc. rendered to the board its oral opinion that the Merger is
fair from a financial point of view to Change stockholders. On August 8, 2003,
representatives of Change and Neurologix and their respective legal counsel held
a conference call to finalize outstanding issues.
On August 8, 2003, a meeting of the Neurologix board of directors was held
to review the terms of the merger agreement and the transactions contemplated
therein. Following a discussion of the principal terms of the transactions, the
board adopted and approved the merger agreement and the ancillary agreements and
determined to recommend that the merger agreement be approved and adopted by
Neurologix's stockholders.
On August 11, 2003, BNY Capital Markets, Inc. rendered its written opinion
that the Merger is fair from a financial point of view to Change stockholders.
The Change board of directors then approved the merger agreement and the
transactions contemplated therein and determined that it is advisable to, and in
the best interest of, Change stockholders.
On August 13, 2003, Neurologix's stockholders holding 86.1% of the
outstanding shares of Neurologix common stock, 100% of the outstanding shares of
Neurologix's initial series of convertible preferred stock, and 79.2% of the
outstanding shares of Neurologix Series B convertible preferred stock and 91.4%
of the outstanding shares of Neurologix common stock, initial series of
convertible preferred stock and Series B
26
convertible preferred stock voting together as a single class delivered written
consents to Neurologix approving and adopting the merger agreement and the
transactions contemplated by the merger agreement.
On August 13, 2003, the parties to the merger agreement, voting agreement
and loan documents executed and delivered all relevant agreements and Change
funded a $750,000 secured loan to Neurologix. That same day, Change issued a
press release announcing the execution of the merger agreement and the related
agreements.
On October 21, 2003, a meeting of the Change board of directors was held to
review the terms of the amendment to the merger agreement and the transactions
contemplated therein. Following a discussion of the principal terms of the
transactions, the board adopted and approved the amendment to the merger
agreement.
On October 23, 2003, a meeting of the Neurologix board of directors was
held to review the terms of the amendment to the merger agreement and the
transactions contemplated therein. Following a discussion of the principal terms
of the transactions, the board adopted and approved the amendment to the merger
agreement.
On November 14, 2003, Change, Subcorp and Neurologix amended the merger
agreement to extend the termination date of the merger agreement and increase
the amount of the secured loan from Change to Neurologix from $750,000 to
$1,100,000. In addition, the definition of Net Cash Assets was modified to
increase from $500,000 to $600,000 the amount of expenses permitted to be
incurred by Change and not be counted against its total net cash assets for
purposes of computing the merger exchange ratio.
On December 18, 2003, Change funded the additional $350,000 loan to
Neurologix.
RECOMMENDATION OF CHANGE'S BOARD OF DIRECTORS; FACTORS CONSIDERED BY CHANGE'S
BOARD OF DIRECTORS IN RELATION TO THE MERGER
THE CHANGE BOARD OF DIRECTORS HAS UNANIMOUSLY DETERMINED THAT THE MERGER
AND THE TRANSACTIONS RELATING TO THE MERGER, INCLUDING THE PROPOSALS RELATING TO
THE MERGER DESCRIBED IN THIS PROXY STATEMENT AND PROSPECTUS, ARE ADVISABLE TO,
AND IN THE BEST INTERESTS OF, CHANGE AND ITS STOCKHOLDERS AND RECOMMENDS THAT
YOU VOTE FOR APPROVAL AND ADOPTION OF EACH OF THE PROPOSALS RELATING TO THE
MERGER.
In reaching the above determination, the Change board of directors gave
significant consideration to a variety of factors, including those described
below. In view of the wide variety of factors bearing on its decision, the
Change board did not consider it practicable to, nor did it attempt to, quantify
or assign relative specific weight to the factors it considered in reaching its
decision. In addition, individual directors may have given different weight to
different factors. The Change board consulted with its legal and financial
advisors in connection with its consideration of the Merger. The Change board
does not intend the following discussion of the information and factors to be
exhaustive but believes the discussion includes the material factors it
considered.
In making its determination, the Change board of directors considered the
following potentially material factors:
- Suitable Business Opportunity. On September 30, 2002, the Change board
of directors announced the adoption of a plan of liquidation and
dissolution. However, the board continued to review suitable business
opportunities. The directors of Change believe the proposed transaction
with Neurologix is a suitable business opportunity and may provide more
value to the stockholders of Change than they would receive under the
plan of liquidation and dissolution.
- Financial Resources of the Combined Company Will Enhance Its Ability to
Conduct the Phase I Clinical Trial of Gene Therapy for the Treatment of
Parkinson's disease. Neurologix's scientific founders recently became
the first and only team to receive FDA approval to conduct a Phase I
human clinical trial of gene therapy for the treatment of Parkinson's
disease. The Change board believes that the financial resources of the
combined company will greatly enhance its ability to conduct the Phase I
clinical trial.
27
- Terms of the Merger Agreement and other Transaction Agreements. The
Change board evaluated the overall terms of the merger agreement and the
other transaction agreements, including, but not limited to, the exchange
ratio and the adjustments to the exchange ratio, the non-solicitation
provisions and related fiduciary out, voting commitments, the termination
fee provisions, the representations and warranties of the parties, the
interim covenants, the closing conditions and the $1,100,000 secured loan
provided by Change to Neurologix.
- Opinion of Change's Financial Advisor. The Change board also considered
the favorable opinion of BNY Capital Markets, Inc. described in this
proxy statement and prospectus.
- Tax Treatment. The qualification of the Merger as a tax-free
reorganization for federal tax purposes.
In considering the recommendation of the Change board of directors to approve
and adopt the Merger proposals described in this proxy statement and prospectus,
Change stockholders should be aware that some officers and directors of Change
have interests in the proposed Merger that are different from and in addition to
the interests of Change stockholders generally. The Change board of directors
was aware of these interests and considered them in approving the merger
agreement and the Merger. Please refer to the section of this proxy statement
and prospectus entitled "The Merger -- Interests of Certain Persons in the
Merger."
RECOMMENDATION OF NEUROLOGIX'S BOARD OF DIRECTORS; FACTORS CONSIDERED BY
NEUROLOGIX'S BOARD OF DIRECTORS IN RELATION TO THE MERGER
THE NEUROLOGIX BOARD OF DIRECTORS HAS UNANIMOUSLY DETERMINED THAT THE
MERGER AND THE TRANSACTIONS RELATING TO THE MERGER, AS DESCRIBED IN THIS PROXY
STATEMENT AND PROSPECTUS, ARE ADVISABLE TO, AND IN THE BEST INTERESTS OF,
NEUROLOGIX AND ITS STOCKHOLDERS. BASED UPON SUCH RECOMMENDATION, THE HOLDERS OF
A MAJORITY OF NEUROLOGIX'S CAPITAL STOCK ENTERED INTO THE VOTING AGREEMENT AND
EXECUTED A WRITTEN CONSENT APPROVING THE MERGER AGREEMENT AND THE TRANSACTIONS
CONTEMPLATED BY THE MERGER AGREEMENT.
In making the above determination, the Neurologix board of directors gave
significant consideration to a variety of factors, including those described
below. In view of the wide variety of factors bearing on its decision, the
Neurologix board did not consider it practicable to, nor did it attempt to,
quantify or assign relative specific weight to the factors it considered in
reaching its decision. In addition, individual directors may have given
different weights to different factors. The Neurologix board does not intend for
the following discussion of the information and factors considered by it to be
exhaustive but believes such discussion includes the material factors it
considered in making its determination.
In making its determination, the Neurologix board of directors considered
the following potentially material factors:
- Financial Resources of the Combined Company Will Enhance Its Ability to
Conduct the Phase I Clinical Trial of Gene Therapy for the Treatment of
Parkinson's Disease. Neurologix's scientific founders recently became
the first and only team to receive FDA approval to conduct a Phase I
human clinical trial using gene therapy to treat Parkinson's disease. The
trial began in August 2003. The Neurologix board of directors believes
that the $1,100,000 secured loan provided by Change to Neurologix upon
the execution of the merger agreement and the financial resources of the
combined company will greatly enhance its ability to conduct its clinical
trial for the treatment of Parkinson's disease.
- Neurologix Will Require Additional Financing. The combined company will
need significant additional financing to fund its research and
development efforts. The combined company will have securities that are
publicly traded. Although trading is currently only on the
over-the-counter market and liquidity is not significant, the Neurologix
board of directors believes that the Merger may provide it with greater
access to financing to be able to satisfy its future capital needs.
- Terms of the Merger Agreement and Other Transaction Agreements. The
Neurologix board of directors evaluated the overall terms of the merger
agreement and the other transaction agreements, including, but not
limited to, the exchange ratio and the adjustments to the exchange ratio,
the
28
termination fee provisions, the representations of the parties, the
interim covenants, the closing conditions and the immediate availability
of the $1,100,000 secured loan provided by Change to Neurologix upon the
execution of the merger agreement.
- Availability of Alternative Financing. The Neurologix board of directors
also considered the difficulty of obtaining venture capital or other
financing in the current market, the time needed to obtain alternative
financing, even if available, and the terms that would likely be required
if such financing could be obtained, including liquidation preferences
and other protective provisions.
- Tax Treatment. The qualification of the Merger as a tax-free
reorganization for U.S. federal tax purposes.
Neurologix stockholders should be aware that some officers and directors of
Neurologix have interests in the proposed Merger that are different from and in
addition to the interests of Neurologix stockholders generally. The Neurologix
board of directors was aware of these interests and considered them in approving
the merger agreement and the Merger. Please refer to the section of this proxy
statement and prospectus entitled "The Merger -- Interests of Certain Persons in
the Merger."
OPINION OF THE FINANCIAL ADVISOR TO CHANGE
The Change board of directors evaluated several potential financial
advisors in connection with the Merger on the basis of reputation, experience
with comparable deals and cost, and selected BNY Capital Markets, Inc. to act as
its exclusive financial advisor in connection with the Merger. On August 8,
2003, at a meeting of the Change board of directors held to evaluate the
proposed Merger, BNY Capital Markets, Inc. rendered to the Change board an oral
opinion to the effect that the Merger was fair from a financial point of view to
stockholders of Change, based on and subject to the matters described in the
opinion and finalizing of all relevant agreements. On August 11, 2003, BNY
Capital Markets, Inc. confirmed its oral opinion by delivery of its written
opinion dated the same date.
In arriving at its opinion, BNY Capital Markets, Inc.:
- reviewed the merger agreement, the voting agreement and the agreements
relating to the loan provided by Change to Neurologix;
- reviewed and analyzed certain internal financial statements, including
audited historical and unaudited interim statements, and other financial
and operating data concerning Change and Neurologix, as well as
projections prepared by the management of Neurologix;
- discussed the past and current operations and financial condition as well
as the prospects of Change and Neurologix with senior executives and
consultants of Change and Neurologix;
- reviewed Change's Annual Reports on Form 10-K for the years ended
December 31, 2000 through 2002, its Quarterly Report on Form 10-Q for the
quarter ended March 31, 2003, its Reports on Form 8-K, dated June 18,
2003, and June 30, 2003, and its certificate of incorporation;
- reviewed the reported prices and trading activity of Change common stock
from March 28, 2000 to August 11, 2003;
- reviewed publicly available information for certain publicly-traded
companies selected for comparative purposes;
- considered traditional valuation methodologies, including but not limited
to publicly-traded companies selected for comparative purposes, recent
industry merger and acquisition transactions, recent industry venture
capital transactions and discounted cash flow analyses; and
- performed such other analyses and considered such other factors deemed
relevant and appropriate.
In rendering its opinion, BNY Capital Markets, Inc. assumed and relied,
without independent verification, on the accuracy and completeness of all
financial and other information and data publicly available or furnished to or
otherwise reviewed by or discussed with BNY Capital Markets, Inc. and relied
upon the
29
assurances of management of Change and Neurologix that they were not aware of
any facts or circumstances that would make such information inaccurate or
misleading in any material respect. With respect to financial forecasts and
other information and data relating to Change and Neurologix provided to or
otherwise discussed with BNY Capital Markets, Inc., the management teams of
Change and Neurologix advised BNY Capital Markets, Inc. that such forecasts and
other information and data were reasonably prepared on bases reflecting the best
currently available estimates and judgments of the management teams of Change
and Neurologix as to the future financial performance of Change and Neurologix.
BNY Capital Markets, Inc. assumed that the Merger and related transactions would
be consummated in accordance with their terms, without waiver, modification or
amendment of any material term, condition or agreement and that, in the course
of obtaining the necessary third-party approvals and consents for the Merger and
related transactions, no delay, limitation, restriction or condition would be
imposed that would have an adverse effect on Change or Neurologix. BNY Capital
Markets, Inc. also assumed that the Merger would be treated as a tax-free
reorganization for U.S. federal income tax purposes.
BNY Capital Markets, Inc. did not express an opinion as to the price or
range of prices at which the shares of Change common stock may trade subsequent
to the announcement of the Merger or as to the price or range of prices at which
the shares of Change common stock may trade subsequent to the consummation of
the Merger.
BNY Capital Markets, Inc. expressed no view as to, and its opinion does not
address, the underlying business decision of Change to proceed with or effect
the Merger. The opinion of BNY Capital Markets, Inc. was necessarily based on
information available, and financial, stock market and other conditions and
circumstances existing and disclosed, to BNY Capital Markets, Inc. as of the
date of its opinion.
THE FULL TEXT OF THE WRITTEN OPINION OF BNY CAPITAL MARKETS, INC., DATED
AUGUST 11, 2003, WHICH DESCRIBES THE ASSUMPTIONS MADE, PROCEDURES FOLLOWED,
MATTERS CONSIDERED AND LIMITATIONS ON THE REVIEW UNDERTAKEN, IS ATTACHED TO THIS
PROXY STATEMENT AND PROSPECTUS AS APPENDIX D AND IS INCORPORATED BY REFERENCE.
THE OPINION OF BNY CAPITAL MARKETS, INC. IS ADDRESSED TO THE CHANGE BOARD OF
DIRECTORS AND RELATES ONLY TO THE FAIRNESS, FROM A FINANCIAL POINT OF VIEW, OF
THE MERGER TO THE STOCKHOLDERS OF CHANGE AND DOES NOT CONSTITUTE A
RECOMMENDATION TO ANY STOCKHOLDER OF CHANGE OR NEUROLOGIX WITH RESPECT TO ANY
MATTERS RELATING TO THE MERGER.
Pursuant to a letter agreement dated July 30, 2003, BNY Capital Markets,
Inc. was engaged to provide financial advisory services, including a financial
opinion letter (the Opinion), in connection with the Merger. At the August 11,
2003 meeting of the Change board of directors, BNY Capital Markets, Inc.
rendered its oral opinion, subsequently confirmed in writing, that, as of such
date and based upon and subject to the various considerations set forth in its
opinion, the valuation of Neurologix associated with the Merger was fair from a
financial point of view to the holders of shares of Change common stock.
The summary set forth below is not a complete description of the analyses
underlying the Opinion. The preparation of a financial opinion is a complex
process involving various determinations and as such is not readily susceptible
to summary description. Accordingly, BNY Capital Markets, Inc. believes that its
analyses must be considered as a whole and that selecting portions of its
analyses and factors or focusing on information presented in tabular format,
without considering all factors, could create a misleading or incomplete view of
the processes underlying its analyses and opinion.
BNY Capital Markets, Inc. considered industry performance, general
business, economic, market and financial conditions and other matters existing
as of the date of its opinion, many of which are beyond the control of Change
and Neurologix. No company, transaction or business used in those analyses as a
comparison is identical to Change, Neurologix or the Merger, and an evaluation
of those analyses is not entirely mathematical. Rather, the analyses involve
complex considerations and judgments concerning financial and operating
characteristics and other factors that could affect the acquisition, public
trading or other values of the companies, business segments or transactions
analyzed.
The estimates contained in BNY Capital Markets, Inc.'s analyses and the
valuation ranges resulting from any particular analysis are not necessarily
indicative of actual values or predictive of future results or values,
30
which may be significantly more or less favorable than those suggested by its
analyses. In addition, analyses relating to the value of businesses or
securities do not necessarily purport to be appraisals or to reflect the prices
at which businesses or securities actually may be sold. Accordingly, BNY Capital
Markets, Inc.'s analyses and estimates are inherently subject to substantial
uncertainty.
BNY Capital Markets, Inc.'s opinion and analyses were only one of many
factors considered by Change's board of directors in its evaluation of the
Merger and should not be viewed as determinative of the views of the Change
board of directors or management with respect to the Merger.
The following is a summary of the material financial analyses performed by
BNY Capital Markets, Inc. in connection with the rendering of its opinion dated
August 11, 2003. THE FINANCIAL ANALYSES SUMMARIZED BELOW INCLUDE INFORMATION
PRESENTED IN TABULAR FORMAT. IN ORDER TO FULLY UNDERSTAND BNY CAPITAL MARKETS,
INC.'S FINANCIAL ANALYSES, THE TABLES MUST BE READ TOGETHER WITH THE TEXT OF
EACH SUMMARY. THE TABLES ALONE DO NOT CONSTITUTE A COMPLETE DESCRIPTION OF THE
FINANCIAL ANALYSES. CONSIDERING THE DATA BELOW WITHOUT CONSIDERING THE FULL
NARRATIVE DESCRIPTION OF THE FINANCIAL ANALYSES, INCLUDING THE METHODOLOGIES AND
ASSUMPTIONS UNDERLYING THE ANALYSES, COULD CREATE A MISLEADING OR INCOMPLETE
VIEW OF BNY CAPITAL MARKETS, INC.'S FINANCIAL ANALYSES.
Merger Overview. For purposes of the financial analyses, BNY Capital
Markets, Inc. assumed that the Merger would result in existing Change
Stockholders owning approximately 33.3% of the fully diluted shares of the pro
forma company, which would imply a pre-money equity value for Neurologix of
$15.0 million (assuming Net Cash Assets are at least $7.5 million). This
pre-money equity value was compared against the valuation determined by the
financial analyses summarized below.
Selected Comparative Mergers and Acquisitions Analysis. Using publicly
available information, BNY Capital Markets, Inc. reviewed the purchase prices,
including net debt, and implied transaction value multiples paid or proposed to
be paid in the following seven selected merger and acquisition transactions with
biotechnology targets that are focused on gene therapy:
DATE
EFFECTIVE ACQUIROR TARGET
7/30/03 - Boston Scientific Corp. - Coratus Genetics Inc.
2/05/03 - Genstar Therapeutics Corp. - Vascular Genetics, Inc.
7/03/02 - Schering AG - Collateral Therapeutics, Inc.
4/18/02 - Qiagen NV - Xeragon, Inc.
9/05/01 - Cell Genesys, Inc. - Calydon, Inc.
1/11/01 - Cell Genesys, Inc. - Neurologic Gene Therapeutics
1/08/01 - Cell Genesys, Inc. - Gene Therapy Business (Chiron Corp.)
The selected merger and acquisition transactions were not useful for
comparative purposes because the target companies did not have similar products
in comparable stages of development as Neurologix. Accordingly, BNY Capital
Markets, Inc. did not use the merger and acquisition transaction approach to
value Neurologix.
Selected Comparative Venture Capital Transaction Analysis. Using publicly
available information, BNY Capital Markets, Inc. reviewed the venture capital
transactions completed since January 1, 2001, including the amount raised and
post-money valuation, for the following eight biotechnology companies focused on
gene therapy:
- Athersys, Inc.;
- BioForce Nanosciences, Inc.;
- Copernicus Therapeutics, Inc.;
- Discovery Genomics, Inc.;
- Intronn LLC;
31
- Osiris Therapeutics, Inc.;
- Salus Therapeutics, Inc.; and
- Selective Genetics, Inc.
BNY Capital Markets, Inc. did not use the comparative venture capital
transaction approach because of the lack of publicly available information
regarding the target companies, including: (i) the product pipeline; (ii) the
overall size of the market for each product; and (iii) the estimated market
penetration for each product and the risks inherent with achieving such
penetration rates.
Selected Comparative Companies Analysis. Using publicly available
information, BNY Capital Markets, Inc. reviewed the market values and trading
multiples of the following six selected publicly held biotechnology companies
focused on gene therapy:
- Avigen, Inc.;
- Cell Genesys, Inc.;
- Corautus Genetics Inc.;
- Introgen Therapeutics, Inc.;
- Targeted Genetics Corporation; and
- Transkaryotic Therapies.
BNY Capital Markets, Inc. computed enterprise values, calculated as equity
value on a fully diluted basis, plus debt, less cash and marketable securities,
as a multiple of revenue and earnings before interest, taxes, depreciation and
amortization ("EBITDA"), for each company's last twelve month reporting period.
All multiples were based on closing stock prices on August 8, 2003. BNY Capital
Markets, Inc. also computed the ratio of each company's closing stock price to
its Net Income on a per share basis ("P/E"), for each company's last twelve
month reporting period.
BNY Capital Markets, Inc. did not use the comparative company approach
because of the absence of any publicly-traded gene therapy company with similar
products in comparable stages of development as Neurologix.
BNY Capital Markets, Inc. observed that in the period since Neurologix
raised $2.7 million in February 2002 at a pre-money valuation of $25.0 million
to August 8, 2003, the stock prices for Avigen, Inc. and Cell Genesys, Inc. (the
companies most comparable to Neurologix as they are both gene therapy companies
that are currently developing treatments for Parkinson's disease in addition to
other neurological disorders), had declined collectively by 43.0%. Based on this
decline, BNY Capital Markets, Inc. imputed an implied equity value of $15.8
million for Neurologix, compared to the implied pre-money value in the Merger of
$15.0 million. This analysis, however, does not take into consideration that
during this time period, Neurologix reached an important milestone in achieving
FDA approval to conduct a Phase I human clinical trial for Parkinson's disease,
which suggests that taking a "biotechnology sector discount" of 43.0% is not
appropriate.
Discounted Cash Flow Analysis. BNY Capital Markets, Inc. performed a
discounted cash flow analysis of Neurologix in order to calculate the estimated
present value of the stand-alone, unlevered, after-tax free cash flows that
Neurologix could generate over fiscal years 2003 through 2015. BNY Capital
Markets, Inc. utilized the projections provided by Neurologix's management, as
well as a "downside case", which assumes Neurologix does not reach its estimated
market penetration rates and only achieves 50.0% of its projected Net Income and
EBITDA. BNY Capital Markets, Inc. calculated a range of estimated terminal
values for Neurologix by applying to Neurologix's fiscal year 2015 estimated Net
Income a range of terminal P/E multiples of 25.0x to 35.0x, consistent with
biotechnology comparable stage industry ranges. The present value of the cash
flows and terminal values were calculated using discount rates ranging from
45.0% to 55.0%, also
32
consistent with biotechnology comparable stage industry ranges. This analysis
indicated the following implied equity value ranges for Neurologix:
IMPLIED EQUITY VALUE RANGE ($ IN MILLIONS)
MANAGEMENT PROJECTIONS DOWNSIDE CASE
---------------------- -------------
$32.2 - $106.9 $13.2 - $50.0
BNY Capital Markets, Inc. noted, however, the fact that $7.5 million of
cash is not sufficient for Neurologix to become cash flow positive based on
Neurologix's projections. Neurologix projects a future need to raise an
additional $17.0 million to fund clinical trials prior to FDA approval. BNY
Capital Markets, Inc. pointed out that the additional funding requirement would
be dilutive if the funds raised in the future are in whole or in part additional
equity. BNY Capital Markets, Inc. also stated that it believes such funds are
likely to take the form of equity. While such financing would be expected to be
at a pre-money value that is greater than $22.5 million if Neurologix continues
to achieve its key milestones throughout the FDA process, any equity financing
would be dilutive to existing shareholders.
In order to model the effect of raising additional funds in the future, BNY
Capital Markets, Inc. selected the mid-point of the discounted cash flow
valuation and assumed the pre-money valuation for the next financing round would
be at least equal to $22.5 million (the current post-money valuation). This
valuation would result in approximately 40.0% dilution, effectively reducing
existing Neurologix shareholders' to approximately 60.0%. BNY Capital Markets,
Inc. calculated the implied equity values for Neurologix's existing shareholders
(pro forma for the Merger), assuming an ownership stake of between 60.0% (future
external funding requirements being 100.0% equity financed at $22.5 million
pre-money) and 100.0% (100.0% debt financed) post dilution. This analysis
indicated the following implied equity value ranges for Neurologix:
COMMON EQUITY VALUE RANGE
(BASED ON MID-POINT OF DCF METHODOLOGY)
($ IN MILLIONS)
EXISTING NEUROLOGIX SHAREHOLDERS' ASSUMED
OWNERSHIP STAKE POST DILUTION
-------------------------------------------
% OF EBITDA REALIZED 60.0% 70.0% 80.0% 90.0% 100.0%
-------------------- ------ ------ ------ ------ -------
100.0%......................................... $41.7 $48.7 $55.7 $62.6 $69.6
50.0%.......................................... 19.0 22.1 25.3 28.4 31.6
Other Factors. In rendering its opinion, BNY Capital Markets, Inc. also
reviewed and considered other factors, including:
- A group of investors led by Medtronic (publicly-traded biotechnology
company with approximately $8.0 billion in revenue) invested $2.7 million
in February 2002 at a pre-money valuation of $25.0 million; and
- Neurologix's largest shareholder, Palisade Private Partnership, L.P., is
converting its $2.3 million Neurologix Note to Neurologix Common Stock
prior to the consummation of the Merger at a price per share equal to
$6.00, which implies an equity value for Neurologix of approximately
$35.0 million.
Miscellaneous. BNY Capital Markets, Inc. is a nationally recognized
investment banking firm and is acting as exclusive financial advisor to the
Board of Directors of Change and has received a fee for its services. In
addition, Change has agreed to indemnify BNY Capital Markets, Inc. for certain
liabilities that may arise out of the rendering of its opinion. BNY Capital
Markets, Inc. is a wholly owned subsidiary of The Bank of New York Company, Inc.
("BNYCo."). In the ordinary course of business, BNYCo. and its affiliates may
from time to time trade in the securities of Change for the accounts of the
investment funds under their management and for the accounts of their customers
and, accordingly, may at any time hold a long or short position in such
securities.
33
INTERESTS OF CERTAIN PERSONS IN THE MERGER
GENERAL
In considering the recommendations of the respective boards of directors of
Change and Neurologix, you should be aware that members of the boards and
management of each of Change and Neurologix may have interests in the Merger
that are different from, or in addition to, your interests as a stockholder
which may result in potential conflicts of interest. The boards of each company
recognized these interests and determined that these interests neither supported
nor detracted from the fairness of the Merger to you.
INTERESTS OF CHANGE'S DIRECTORS
Some of Change's directors have interests in the Merger that are different
from, or in addition to, your interests generally and that may create a
potential conflict of interest.
As of September 30, 2003, Michael Gleason may be deemed to beneficially own
33,489,130 shares of Change common stock, consisting of 32,000,000 shares of
Change common stock owned by Culmen Technology Partners, L.P. and options to
purchase an aggregate of 1,489,130 shares of Change common stock. Mr. Gleason is
the President and sole director of CTP, Inc., the general partner of Culmen
Technology Partners, L.P. Mr. Gleason holds options which have not vested to
purchase an additional 21,870 shares of Change common stock. Under the terms of
the 2000 Stock Option Plan of Change, these additional options will remain
outstanding but will fully vest as a result of the closing of the Merger, which
is a change of control under such plan.
INTERESTS OF NEUROLOGIX'S DIRECTORS, OFFICERS AND SIGNIFICANT STOCKHOLDERS
Some of Neurologix's officers and directors and significant stockholders
have interests in the Merger that are different from, or in addition to, your
interests generally and that may create a potential conflict of interest.
The merger agreement provides for the survival in the Merger of all
indemnification rights of the members of Neurologix's board of directors and
officers for acts and omissions occurring before the Merger, as their rights
existed on August 13, 2003, in Neurologix's certificate of incorporation and
bylaws. The combined company will observe all of these indemnification rights to
the fullest extent permitted under Delaware law for a period of not less than
six years after the Merger. During this period, the merger agreement also
requires the combined company to maintain directors' and officers' liability
insurance covering all individuals who were directors and officers of Neurologix
immediately prior to the consummation of the Merger with respect to their acts
and omissions as directors and officers of Neurologix prior to the Merger.
Pursuant to the voting agreement, Martin J. Kaplitt, Clark A. Johnson and
Palisade Private Partnership, L.P. have agreed, immediately prior to the
consummation of the Merger, to exchange their interests in the Existing
Neurologix Note for shares of Neurologix common stock. Messrs. Kaplitt and
Johnson are members of Neurologix's board of directors, and Mark Hoffman,
another member of Neurologix's board of directors, is a managing member of
Palisade Private Holdings, LLC, the sole general partner of Palisade Private
Partnership, L.P. The aggregate number of shares of Neurologix common stock that
Palisade Private Partnership, L.P., and Messrs. Johnson and Kaplitt will receive
shall not exceed 400,000 shares and will be determined by dividing (x) the sum
of (a) the product of the outstanding unpaid principal amount of the Existing
Neurologix Note as of the date of the exchange plus (b) the amount of accrued
and unpaid interest on the Existing Neurologix Note as of the date of the
exchange by (y) $6.00. At September 30, 2003, the outstanding principal amount
of the Existing Neurologix Note was $2 million and the accrued interest was
$328,289, so if the Merger had occurred on that date, Palisade Private
Partnership, L.P., and Messrs. Johnson and Clark would have been entitled to
receive approximately 388,048 shares of Neurologix common stock in the
aggregate.
Neurologix has agreed to pay Palisade Capital Securities, L.L.C., an
affiliate of Palisade Private Partnership, L.P., $200,000 contingent upon the
closing of the Merger in exchange for investment banking services rendered by
Palisade Capital Securities in connection with the Merger.
34
REGULATORY APPROVALS
The Merger does not require any federal or state agency regulatory
approvals.
STOCK EXCHANGE LISTING
The common stock of Change, including the common stock to be issued to
Neurologix stockholders in connection with the Merger, will continue to be
quoted on the OTC electronic bulletin board under a new symbol to be applied for
following the Merger.
FEDERAL SECURITIES LAWS CONSEQUENCES
All of the shares of Change common stock received by Neurologix
stockholders in the Merger will be freely transferable under the federal
securities laws, except for shares received by persons who are deemed to be
"affiliates" of Change or Neurologix for purposes of Rule 145 under the
Securities Act prior to the completion of the Merger. These shares may be resold
only in transactions permitted by the resale provisions of Rule 145 under the
Securities Act or Rule 144 under the Securities Act in the case of persons who
become affiliates of Neurologix or as otherwise permitted under the Securities
Act. Persons who may be deemed to be affiliates of Change or Neurologix
generally include individuals or entities that control, are controlled by, or
are under common control with, those companies and may include some of their
officers and directors, as well as their principal stockholders.
FEDERAL INCOME TAX CONSEQUENCES TO THE HOLDERS OF NEUROLOGIX COMMON STOCK OR
SERIES B CONVERTIBLE PREFERRED STOCK
The Merger is structured as a tax-free reorganization under Section 368(a)
of the Internal Revenue Code of 1986, as amended (the "Code"). As a result, U.S.
holders of Neurologix capital stock will not recognize any taxable gain from the
receipt of Change common stock in connection with the Merger. For more
information regarding the tax treatment of the Merger, please refer to the
section of this proxy statement and prospectus entitled "Material United States
Federal Income Tax Consequences of the Merger."
ACCOUNTING TREATMENT
The acquisition is anticipated to be accounted for as a reverse
acquisition. The assets and liabilities of Neurologix will be recorded at their
historical carrying values and the assets and liabilities of Change will be
recorded at their fair values, which approximate their historical values. The
reported financial condition and results of operations of Neurologix after the
Merger will reflect these values, but will not be retroactively restated to
reflect the historical financial position or results of operations of Change.
DIVIDEND POLICY
Under the merger agreement, Change and Neurologix have each agreed not to
declare or pay any dividend on their equity securities until the Merger is
consummated.
The combined company anticipates that for the foreseeable future, its
earnings, if any, will be retained for use in the operation of its business and
that no cash dividends will be paid on its capital stock. The decision of the
combined company's board as to whether or not to pay cash dividends in the
future will depend upon a number of factors, including the combined company's
future earnings, capital requirements, financial condition and the existence or
absence of any contractual limitations on the payment of dividends.
APPRAISAL RIGHTS
If the Merger is completed, holders of Neurologix common stock and Series B
convertible preferred stock who follow the procedures summarized below will be
entitled to appraisal rights under Section 262 of the General Corporation Law of
the State of Delaware.
35
Under Delaware law, the holders of record of shares of Neurologix common
stock and Series B convertible preferred stock who follow the procedures
specified in Section 262 of the Delaware General Corporation Law are entitled to
have their shares appraised by the Delaware Court of Chancery and may receive
the "fair value" of those shares, without taking into account any element of
value arising from the accomplishment or expectation of the Merger, together
with a fair rate of interest, if any, as determined by the court. The "fair
value" could be greater than, less than or the same as the consideration to be
received in the Merger.
In order to exercise these rights, a Neurologix stockholder must demand and
perfect the rights in accordance with Section 262. Under Section 262, where a
Merger is approved without a meeting of stockholders, as in the case of the
adoption of the merger agreement by Neurologix's stockholders, the corporation,
before the effective date of the Merger, or the surviving corporation, within 10
days of the Merger, must notify each of its stockholders entitled to appraisal
rights that such appraisal rights are available and include in this notice a
copy of Section 262. This proxy statement and prospectus serves as this
statutory notice. The estimated effective date of the Merger is February 10,
2004. If this date changes, Neurologix or the surviving corporation will send a
second notice, notifying stockholders of the effective date; provided, however,
that if the second notice is sent more than 20 days following sending this proxy
statement and prospectus, the second notice will only be sent to stockholders
who have demanded appraisal of such holder's shares in accordance with the
statute.
THE FOLLOWING DISCUSSION IS NOT A COMPLETE STATEMENT OF THE LAW PERTAINING
TO APPRAISAL RIGHTS UNDER THE GENERAL CORPORATION LAW OF THE STATE OF DELAWARE
AND IS QUALIFIED IN ITS ENTIRETY BY THE FULL TEXT OF SECTION 262, WHICH IS
ATTACHED HERETO AS APPENDIX E. ALL REFERENCES IN SECTION 262 AND IN THIS SUMMARY
TO A "STOCKHOLDER" ARE TO THE RECORD HOLDER OF THE SHARES OF NEUROLOGIX COMMON
STOCK OR SERIES B CONVERTIBLE PREFERRED STOCK IMMEDIATELY PRIOR TO THE EFFECTIVE
TIME OF THE MERGER AS TO WHICH APPRAISAL RIGHTS ARE ASSERTED. A PERSON HAVING A
BENEFICIAL INTEREST IN SHARES OF NEUROLOGIX COMMON STOCK OR SERIES B CONVERTIBLE
PREFERRED STOCK HELD OF RECORD IN THE NAME OF ANOTHER PERSON, SUCH AS A BROKER
OR A NOMINEE, MUST ACT PROMPTLY TO CAUSE THE RECORD HOLDER TO FOLLOW THE STEPS
SUMMARIZED BELOW PROPERLY AND IN A TIMELY MANNER TO PERFECT APPRAISAL RIGHTS.
NEUROLOGIX STOCKHOLDERS SHOULD CAREFULLY REVIEW SECTION 262 AS WELL AS THE
INFORMATION DISCUSSED BELOW.
Filing Written Demand. If a Neurologix stockholder elects to exercise the
right to an appraisal under Section 262, that stockholder must do ALL of the
following:
- The stockholder must deliver to Neurologix a written demand for appraisal
of shares of Neurologix common stock or Series B convertible preferred
stock held, which demand must reasonably inform Neurologix of the
identity of the stockholder and that the demanding stockholder is
demanding appraisal, within 20 days after the date of mailing of the
notice (i.e., the mailing date of this prospectus and proxy statement).
This written demand for appraisal must be delivered to Neurologix prior
to February 3, 2004, and must be in addition to and separate from any
vote against the merger agreement. Neither voting against, abstaining
from voting nor failing to vote on the merger agreement will constitute a
valid demand for appraisal within the meaning of Section 262.
- The stockholder must not vote in favor of or consent to adopting the
merger agreement. Failing to vote or to consent or abstaining from voting
will satisfy this requirement, but a vote in favor of the merger
agreement, by proxy or in person, or the return of a signed consent that
does not specify an abstention or a vote against adoption of the merger
agreement, will constitute a vote in favor of the merger agreement, a
waiver of the stockholder's right of appraisal and will nullify any
previously delivered written demand for appraisal.
- The stockholder must continuously hold the shares of record from the date
of the written demand for appraisal until the effective time of the
Merger.
All written demands for appraisal should be addressed to Neurologix, Inc.,
One Bridge Plaza, Fort Lee, New Jersey 07024, Attention: Mark Hoffman, and
received before February 3, 2004. The demand must
36
reasonably inform Neurologix of the identity of the stockholder and that the
stockholder is demanding appraisal of his, her or its shares of Neurologix
common stock or Series B convertible preferred stock.
The written demand for appraisal must be executed by or for the record
holder of shares of Neurologix stock, fully and correctly, as the holder's name
appears on the certificate(s) for the holder's shares. If the shares of
Neurologix stock are owned of record in a fiduciary capacity, such as by a
trustee, guardian or custodian, execution of the demand must be made in that
capacity, and if the shares are owned of record by more than one person, such as
in a joint tenancy or tenancy in common, the demand must be executed by or for
all joint owners. An authorized agent, including one of two or more joint
owners, may execute the demand for appraisal for a holder of record; however,
the agent must identify the record owner(s) and expressly disclose the fact
that, in executing the demand, the agent is acting as agent for the record
owner(s).
A record holder, such as a bank broker, fiduciary, depository or other
nominee, who holds shares of Neurologix common stock or Series B convertible
preferred stock as a nominee for others, may exercise appraisal rights with
respect to the shares held for all or less than all beneficial owners of the
shares as to which the person is the record owner. In that case, the written
demand must set forth the number of shares of Neurologix common stock or Series
B convertible preferred stock covered by the demand. Where the number of shares
is not expressly stated, the demand will be presumed to cover all shares of
Neurologix common stock or Series B convertible preferred stock outstanding in
the name of the record owner.
Any Neurologix stockholder may withdraw its demand for appraisal and accept
the Change securities to be issued in the Merger by delivering to Neurologix a
written withdrawal of the demand for appraisal. However, any such attempt to
withdraw made more than 60 days after the effective date of the Merger will
require written approval of the surviving corporation. No appraisal proceeding
in the Delaware Court of Chancery will be dismissed without the approval of the
Court and such approval may be conditioned upon such terms as the Court deems
just. If the surviving corporation does not approve a request to withdraw a
demand for appraisal when that approval is required, or if the Delaware Court of
Chancery does not approve the dismissal of an appraisal proceeding, the
Neurologix stockholder will be entitled to receive only the appraised value
determined in any such appraisal proceeding, which value could be less than,
equal to or more than the value of the Change securities to be issued in the
Merger.
Notice by Neurologix. Within 10 days after the effective time of the
Merger, Neurologix will provide written notice of the date of the consummation
of the Merger to each Neurologix stockholder who has not voted in favor of the
Merger and who has properly demanded appraisal and satisfied the requirements of
Section 262, referred to as a "dissenting stockholder." Within 120 days after
the effective date of the Merger, any dissenting stockholder who has complied
with the provisions of Section 262 to that point in time will be entitled to
receive from the combined company, upon written request, a statement setting
forth the aggregate number of shares not voted in favor of the merger agreement
and the Merger and with respect to which demands for appraisal have been
received and the aggregate number of holders of such shares. The combined
company must mail that statement to the dissenting stockholder within 10 days of
receipt of the request or within 10 days after expiration of the period for
delivery of demands for appraisals under Section 262, whichever is later.
Filing a Petition for Appraisal. Within 120 days after the completion of
the Merger, Neurologix or any dissenting stockholder may file a petition in the
Delaware Court of Chancery demanding a determination of the fair value of the
shares of Neurologix common stock or Series B convertible preferred stock that
are held by all dissenting stockholders. Neurologix is under no obligation, and
has no present intention, to file such a petition. Accordingly, it is the
obligation of Neurologix stockholders seeking appraisal rights to initiate all
necessary actions to perfect appraisal rights within the time period prescribed
by Section 262. A Neurologix stockholder timely filing a petition for appraisal
with the Delaware Court of Chancery must deliver a copy to the combined company,
which will then be obligated within 20 days to provide the Register in Chancery
with a duly verified list containing the names and addresses of all Neurologix
stockholders who have demanded payment for their shares and with whom agreements
as to the value of their shares have not been reached by the combined company.
After providing notice to those Neurologix stockholders, the Delaware Court of
Chancery may conduct a hearing on the petition to determine which Neurologix
stockholders have become
37
entitled to appraisal rights. The Delaware Court of Chancery may require
Neurologix stockholders who have demanded an appraisal of their shares and who
hold stock represented by certificates to submit their certificates to the
Register in Chancery for notation thereon of the fact that appraisal proceedings
are pending. If any Neurologix stockholder fails to comply with the requirement,
the Delaware Court of Chancery may dismiss the proceedings as to that Neurologix
stockholder.
Determination of Fair Value. If a petition for appraisal is timely filed,
the Delaware Court of Chancery will determine the fair value of the shares of
Neurologix stock held by dissenting stockholders, exclusive of any element of
value arising from the accomplishment or expectation of the Merger, together
with a fair rate of interest, if any, to be paid on the amount determined to be
fair value. In determining fair value, the court will take into account all
relevant factors. Holders of Neurologix stock considering seeking appraisal
should be aware that (i) the fair value of their shares of Neurologix stock as
so determined could be more than, the same as or less than the consideration
they would receive pursuant to the Merger if they did not seek appraisal of
their shares of Neurologix stock and (ii) investment banking opinions as to
fairness from a financial point of view are not necessarily opinions as to fair
value under Section 262. The Delaware Supreme Court stated in Weinberger v. UOP,
Inc., among other things, that "proof of value by any techniques or methods
which are generally acceptable in the financial community and otherwise
admissible in court" should be considered in an appraisal proceeding.
In addition, Delaware courts have decided that the statutory appraisal
remedy may or may not be, depending on the factual circumstances, a Neurologix
stockholder's exclusive remedy in connection with transactions such as the
Merger. If a petition for appraisal is not timely filed, then the right to an
appraisal will cease.
The costs of the appraisal proceeding shall be determined by the Delaware
Court of Chancery and taxed against the parties as the court determines to be
equitable under the circumstances. The Delaware Court of Chancery will also
determine the amount of interest, if any, to be paid upon the amounts to be
received by persons whose shares of Neurologix common stock or Series B
convertible preferred stock have been appraised. Upon application of a
Neurologix stockholder, the court may order all or a portion of the expenses
incurred by any Neurologix stockholder in connection with the appraisal
proceeding, including reasonable attorneys' fees and the fees and expenses of
experts, to be charged pro rata against the value of all shares of Neurologix
common stock entitled to appraisal.
From and after the completion of the Merger, no dissenting stockholder
shall have any rights of a Neurologix stockholder with respect to that holder's
shares for any purpose, except to receive payment of fair value and to receive
payment of dividends or other distributions, on the holder's shares of
Neurologix stock, if any, payable to Neurologix stockholders of record as of a
time prior to the completion of the Merger. If a dissenting stockholder delivers
to the combined company a written withdrawal of the demand for an appraisal
within 60 days after the completion of the Merger or subsequently with the
written approval of the combined company, or, if no petition for appraisal is
filed within 120 days after the completion of the Merger, then the right of that
dissenting stockholder to an appraisal will cease and the dissenting stockholder
will be entitled to receive only the Merger consideration. Once a petition for
appraisal is filed with the Delaware court, the appraisal proceeding may not be
dismissed as to any Neurologix stockholder without the approval of the court.
ANY NEUROLOGIX STOCKHOLDER WISHING TO EXERCISE APPRAISAL RIGHTS IS URGED TO
CONSULT LEGAL COUNSEL BEFORE ATTEMPTING TO EXERCISE APPRAISAL RIGHTS. FAILURE TO
COMPLY STRICTLY WITH ALL OF THE PROCEDURES SET FORTH IN SECTION 262 MAY RESULT
IN THE LOSS OF A NEUROLOGIX STOCKHOLDER'S STATUTORY APPRAISAL RIGHTS.
38
THE MERGER AGREEMENT
The following summarizes the material provisions of the merger agreement.
Copies of the merger agreement and amendment no. 1 to the merger agreement are
attached as Appendix A and Appendix B, respectively, to this proxy statement and
prospectus and are incorporated by reference. You should read the merger
agreement carefully and in its entirety for a more complete understanding of its
terms. The provisions of related agreements are summarized in the next section
entitled "Description of Related Agreements."
GENERAL
The merger agreement provides that, following the receipt of the requisite
approvals of Change's stockholders and the satisfaction or waiver of the other
conditions to the Merger, Subcorp, a wholly-owned subsidiary of Change, will be
merged with and into Neurologix. As a result of the Merger, Neurologix will
continue as a wholly-owned subsidiary of Change. Upon completion of the Merger,
Change will change its corporate name to "Neurologix, Inc."
The Merger will be effective at 12:01 a.m. on the date that Change and
Neurologix file a certificate of merger with the Delaware Secretary of State.
This filing will occur as soon as is practicable after the closing under the
merger agreement. Unless agreed otherwise, the closing will occur on a date
specified by Neurologix, provided that specified conditions set forth in the
merger agreement have been satisfied or waived at or prior to such date.
CONVERSION OF SECURITIES
As of the date of the merger agreement, Neurologix's capital stock
consisted of common stock, par value $.001 per share, its initial series of
convertible preferred stock, par value $.001 per share, and Series B convertible
preferred stock, par value $.001 per share. As described in this proxy statement
and prospectus, under the voting agreement, holders of 100% of Neurologix's
initial series of convertible preferred stock and approximately 79.2% of the
Neurologix Series B convertible preferred stock agreed to convert their shares
into shares of Neurologix common stock immediately prior to the Merger. In
addition, all of the persons having an interest in the Existing Neurologix Note
agreed to convert their interests into shares of Neurologix common stock.
Accordingly, at the effective time of the Merger, the capital stock of
Neurologix is expected to consist solely of common stock and Series B
convertible preferred stock.
At the effective time of the Merger, each issued and outstanding share of
Neurologix common stock and Series B convertible preferred stock, on an
as-converted to Neurologix common stock basis, will be converted into that
number of shares of Change common stock multiplied by the exchange ratio, as
defined below.
EXCHANGE RATIO IF CHANGE'S NET CASH ASSETS (AS DEFINED IN THE MERGER
AGREEMENT) ARE AT LEAST $7.5 MILLION.
If immediately prior to the closing, Change's Net Cash Assets are at least
$7.5 million and Neurologix has not raised cash proceeds through the issuance of
additional equity, then each share of Neurologix common stock and Series B
convertible preferred stock, on an as-converted to Neurologix common stock
basis, issued and outstanding immediately prior to the effective time of the
Merger, excluding shares owned by Neurologix or Change and dissenting shares,
will be converted into that number of shares of Change common stock multiplied
by the exchange ratio.
Total CTP Existing Shares multiplied by 2
Exchange Ratio = -----------------------------------------
Total Neurologix Existing Shares
Where:
"Total CTP Existing Shares" means the number of shares of Change common
stock (i) issued and outstanding prior to the effective time of the Merger,
(ii) issuable upon conversion of all Change convertible securities
including shares of Change Series A convertible preferred stock, par value
$.10 per share, and (iii) issuable upon exercise of all Change options with
an exercise price per share that is less
39
than or equal to $0.03, which options, provide for the purchase of
12,000,000 shares of Change common stock.
"Total Neurologix Existing Shares" means the number of shares of Neurologix
common stock (i) issued and outstanding prior to the effective time of the
Merger, (ii) issuable upon conversion of all Neurologix convertible
securities including shares of Neurologix's initial series of convertible
preferred stock and Neurologix Series B convertible preferred stock, (iii)
issuable upon exchange of the Existing Neurologix Note as provided in the
voting agreement and (iv) issuable upon exercise of all Neurologix options
with an exercise price per share less than or equal to $0.25, which options
provide for the purchase of 232,000 shares of Neurologix common stock, in
each case, excluding all shares owned by Neurologix or Change but including
all dissenting shares.
EXCHANGE RATIO IF CHANGE'S NET CASH ASSETS ARE LESS THAN $7.5 MILLION.
Total CTP Existing Shares multiplied by X
Exchange Ratio = -----------------------------------------
Total Neurologix Existing Shares
Where "X" is the quotient obtained by dividing (x) $15.0 million by (y) the
lesser of (i) the amount of Change's Net Cash Assets as of the closing of
the Merger or (ii) $7.5 million. In the event that Neurologix sells any
additional equity, the net cash proceeds from such sale (after all expenses
incurred relating thereto) shall be added to the numerator.
THE NUMBER OF SHARES TO BE ISSUED BY CHANGE IN CONNECTION WITH THE MERGER WILL
BE UNCERTAIN UNTIL IMMEDIATELY PRIOR TO THE EFFECTIVE TIME OF THE MERGER.
As described in this proxy statement and prospectus, the number of shares
of Change common stock to be issued to holders of Neurologix common stock and
Neurologix Series B convertible preferred stock is directly related to Change's
Net Cash Assets as of the closing of the Merger. Because Change's Net Cash
Assets is to be determined as of the closing of the Merger, the number of shares
to be issued by Change in connection with the Merger is at this time uncertain.
The chart below sets forth the approximate percentages of the outstanding
common stock of the combined company to be held after the Merger by the existing
stockholders of Change and Neurologix based upon varying assumptions of Change's
Net Cash Assets and assuming Neurologix does not raise any funds from the sale
of additional equity prior to the closing. The chart assumes that Total CTP
Existing Shares was equal to 194,004,564 and Total Neurologix Existing Shares
was equal to 5,804,712.
% OF OUTSTANDING % OF OUTSTANDING
COMMON STOCK OF THE COMMON STOCK OF THE
COMBINED COMPANY COMBINED COMPANY
HELD BY EXISTING HELD BY EXISTING
CHANGE NET CASH ASSETS CHANGE STOCKHOLDERS NEUROLOGIX STOCKHOLDERS TOTAL
---------------------- ------------------- ----------------------- ------
$7,500,000 or more.................... 32.82% 67.18% 100.00%
$7,000,000............................ 31.32% 68.68% 100.00%
$6,500,000............................ 29.75% 70.25% 100.00%
$6,000,000............................ 28.10% 71.90% 100.00%
$5,500,000............................ 26.38% 73.62% 100.00%
The merger agreement provides that Neurologix is not obligated to
participate in the Merger if Change's Net Cash Assets are $6,500,000 or less.
In connection with the signing of the merger agreement and based upon
information as of July 31, 2003, Change estimated that its Net Cash Assets at
closing would be approximately $7,139,995. On that date, Total
40
CTP Existing Shares was equal to 194,004,564 and Total Neurologix Existing
Shares was equal to 5,804,712, resulting in the following:
194,004,564 multiplied by 2.1008
Exchange Ratio = --------------------------------
5,804,712
Accordingly, had the Exchange Ratio been determined as of July 31, 2003 or
December 31, 2003, it would have been 70.2127 resulting in approximately 32% and
68% of the common stock of the combined company outstanding after the Merger
being held by existing Change stockholders and existing Neurologix stockholders,
respectively. Change currently expects that Change's Net Cash Assets will be
less than $7.5 million. Change's Net Cash Assets may be more or less than the
$7.1 million of Net Cash Assets it was estimated to hold on July 31, 2003 or
December 31, 2003.
The estimated total number of shares of common stock of the combined
company outstanding after the Merger excludes (per the merger agreement):
- 645 shares of common stock of the combined company issuable upon
conversion of Change's Series A convertible preferred stock outstanding
at September 30, 2003;
- 14,585,747 shares of common stock of the combined company issuable upon
exercise of Change stock options outstanding at September 30, 2003, with
a weighted average exercise price of $0.08 per share;
- 25,856,252 shares of common stock of the combined company issuable upon
exercise of Change stock warrants outstanding at September 30, 2003, with
a weighted average exercise price of $0.49 per share;
- an estimated 18,044,664 shares of common stock of the combined company
issuable upon exercise of Neurologix stock options outstanding at
September 30, 2003, which are to be exchanged in the Merger for Change
stock options having a post-merger weighted average exercise price of
approximately $0.01 per share; and
- an additional 5,414,253 shares of common stock of the combined company
reserved for future issuance under Change's 2000 Stock Option Plan.
The estimated total number of shares of common stock of the combined
company outstanding after the Merger includes:
- 4,500,000 shares of Change that were received by Change as part of the
sale of Canned Interactive on June 30, 2003, and subsequently canceled.
CHANGE WILL ISSUE A PRESS RELEASE 48 HOURS PRIOR TO THE SPECIAL MEETING
ANNOUNCING AN ESTIMATE OF THE NUMBER OF SHARES OF CHANGE COMMON STOCK TO BE
ISSUED IN CONNECTION WITH THE MERGER BASED ON THE VALUE OF CHANGE'S NET CASH
ASSETS AT THAT TIME.
TREATMENT OF STOCK OPTIONS
The merger agreement provides that Change and Neurologix will take all
actions necessary to cause each outstanding option to purchase Neurologix common
stock to be converted into an option to purchase a number of shares of Change
common stock equal to the number of shares of Neurologix common stock covered by
the Neurologix option multiplied by the exchange ratio provided in the merger
agreement. The exercise price per share of the Change common stock issuable upon
exercise of an option to purchase Neurologix common stock will be the exercise
price per share of Neurologix common stock under the option divided by the
applicable exchange ratio.
Each option held under the existing stock option plan of Change will remain
outstanding but will fully vest as a result of the closing of the Merger, which
is a change of control under such plan.
EXCHANGE OF STOCK CERTIFICATES
Exchange agent. Following the Merger, Change will cause the exchange agent
to mail to each record holder of Neurologix common stock or Series B convertible
preferred stock a letter of transmittal with instructions regarding how to
exchange Neurologix common stock or Series B convertible preferred stock
41
certificates for certificate(s) representing shares of Change common stock. Upon
surrender of its Neurologix stock certificate to the exchange agent, each
Neurologix stockholder will be entitled to receive a certificate representing
that number of whole shares of Change common stock, based upon the applicable
exchange ratio provided in the merger agreement, rounded to the nearest whole
number. The Neurologix stock certificates will then be canceled. NEUROLOGIX
STOCKHOLDERS SHOULD NOT SEND STOCK CERTIFICATES TO EITHER NEUROLOGIX OR THE
COMBINED COMPANY UNTIL THEY RECEIVE THE LETTER OF TRANSMITTAL AND ACCOMPANYING
INSTRUCTIONS FROM THE EXCHANGE AGENT.
Fractional shares. Change will not issue any fractional shares of its
common stock in the Merger. Each Neurologix stockholder will be entitled to
receive that number of whole shares of Change common stock, based upon the
applicable exchange ratio provided in the merger agreement, rounded to the
nearest whole number in exchange for the number of shares of Neurologix common
and Series B convertible preferred stock held in aggregate.
Lost certificates. If a Neurologix stockholder's stock certificates have
been lost, stolen or destroyed, the stockholder will only be entitled to obtain
shares of Change common stock by (i) providing appropriate evidence as to such
loss, theft or destruction and as to the stockholder's ownership of such
certificate, and (ii) the receipt by Change and the exchange agent of reasonably
appropriate and customary indemnification in an amount sufficient to protect
against claims related to the Neurologix certificates, all as explained in the
letter of transmittal that will be sent to Neurologix stockholders.
REPRESENTATIONS AND WARRANTIES
Change, Subcorp and Neurologix have made customary representations and
warranties to each other in the merger agreement, relating, among other things,
to:
- their organization and qualification;
- their authority to deliver and execute the merger agreement and its legal
force and effect;
- the absence of conflict between the merger agreement and their charter
documents, existing agreements they have entered into or the laws
applicable to them;
- governmental filings and consents in relation to the merger agreement;
- their capital structure;
- litigation issues;
- the possession of all franchises, licenses, permits and other approvals
required to conduct their respective businesses and compliance with laws;
- the absence of events that could result in material adverse changes;
- tax matters;
- their title to their respective assets;
- intellectual property rights;
- the absence of any undisclosed liabilities;
- environmental matters;
- their use of other business names;
- employee benefit plans;
- material contracts and debt instruments;
- the absence of any funded debt;
- insurance matters;
42
- absence of brokers;
- absence of affiliate transactions of a nature required to be disclosed
under Item 404 of Regulation S-K under the Securities Act of 1933, as
amended; and
- full disclosure.
Change and Subcorp have also made representations and warranties to
Neurologix in the merger agreement relating to:
- documents Change has filed with the Securities and Exchange Commission
and other public disclosures;
- the absence of any default by Change under any existing contract;
- the absence of any current operations;
- Change's Net Cash Assets (as such term is defined in the merger
agreement); and
- payments to Change's former chief executive officer.
Neurologix has also made representations and warranties to Change and
Subcorp in the merger agreement relating to:
- the accuracy of its financial statements;
- the requisite stockholder vote to approve the Merger, the merger
agreement and the transactions contemplated thereby; and
- matters relating to the regulations of the FDA.
None of the representations and warranties made in the merger agreement
will survive the closing of the Merger. The merger agreement does not provide
either of Change, Subcorp, Neurologix or their respective stockholders with any
right to seek indemnification for any breach of the merger agreement by Change,
Subcorp or Neurologix.
MATERIAL COVENANTS
INTERIM OPERATIONS OF CHANGE, SUBCORP AND NEUROLOGIX
Under the merger agreement, each of Change, Subcorp and Neurologix has
agreed that, between the time the merger agreement was executed and the closing
of the transactions contemplated by the merger agreement, each will, and will
cause each of their respective subsidiaries to, subject to limited exceptions:
- use reasonable commercial efforts to keep in full force and effect its
corporate existence and all material rights, franchises, intellectual
property rights and goodwill relating or pertaining to its businesses;
- conduct its operations only in the ordinary course of business consistent
with past practice;
- maintain its books, accounts and records in accordance with past
practice;
- properly pay, timely file and consult with one another with respect to
all tax returns required to be filed by it;
- use reasonable commercial efforts to obtain all authorizations, consents,
waivers, approvals or actions and to make all filings and applications
necessary or desirable to consummate the transactions contemplated by the
merger agreement and cause the respective conditions to the other's
obligation to close the transactions contemplated by the merger agreement
to be satisfied; and
- promptly notify the other parties to the merger agreement in writing if,
prior to the consummation of the transactions contemplated by the merger
agreement, to its knowledge (i) any of the representations and warranties
made by it in the merger agreement cease to be materially accurate and
complete or
43
(ii) it fails to comply with or satisfy any material covenant, condition
or agreement to be complied with or satisfied by it under the merger
agreement.
In addition, each of Change, Subcorp and Neurologix agreed that, between
the time the merger agreement was executed and the closing of the transactions
contemplated by the merger agreement, each will not, and will cause each of
their respective subsidiaries to not, subject to limited exceptions:
- change any method or principle of accounting in a manner that is
inconsistent with past practice;
- take or omit to be taken any action, or permit any of its respective
affiliates to take or to omit to take any action which would reasonably
be expected to result in a material adverse effect;
- take any action that would likely result in any representation or
warranty made by a party becoming false or inaccurate, other than those
representations or warranties made as of a particular date;
- consummate the acquisition of any entity;
- issue, sell or pledge shares of its capital stock or other equity
securities, warrants or options or incur any indebtedness to any party,
other than upon stock option exercises, the conversion of Neurologix's
initial series of convertible preferred stock, Neurologix Series B
convertible preferred stock and the Existing Neurologix Note or the
issuance and sale for cash of not more than $1 million of additional
equity securities by Neurologix;
- other than the adoption of the amendments to Change's certificate of
incorporation described elsewhere in this proxy statement and prospectus,
effect any change to its certificate of incorporation or bylaws;
- make, declare or pay any dividend or distribution on, or, directly or
indirectly, redeem, purchase or otherwise acquire, any shares of its
capital stock or any securities convertible or exchangeable into or
exercisable for any shares of its capital stock;
- increase the compensation or fringe benefits payable or to become payable
to, pay any compensation or benefits not required by any existing plan or
arrangement, or grant any severance or termination pay to, or enter into
any employment or severance agreement with any of its officers, directors
or employees, or take any action to accelerate rights under any
collective bargaining or any employee benefit plan for the benefit or
welfare of any of its directors, officers or current or former employees,
except in each case in accordance with past practice, or to the extent
required by applicable law or any existing agreement and except for
increases in connection with new hires, promotions or other bona fide
changes in job status, or pursuant to existing collective bargaining
agreements;
- incur, assume or prepay any long-term or short-term indebtedness, other
than in the ordinary course of business consistent with past practice
under existing lines of credit;
- assume, guarantee, endorse or otherwise become liable or responsible for
the obligations of any other party;
- make any loans, advances or capital contributions to, or investments in,
any other party except in the ordinary course of business consistent with
past practice or in accordance with the terms of the merger agreement;
- make any loans to its directors, officers or shareholders;
- waive, release, assign, settle or compromise any material rights, claims
or litigation or pay, discharge or satisfy any material liabilities,
except in connection with the disposition and/or termination of the
business and operations of Change and its subsidiaries; or
- propose, authorize, agree or commit to take any of the above-listed
actions.
44
STOCKHOLDERS' MEETING
Change agreed to take all actions necessary in accordance with applicable
laws to obtain the consent and approval of its stockholders to the Merger, the
merger agreement and the transactions contemplated by the merger agreement,
including its board of directors' recommending to its stockholders approval of
each.
CHANGE BOARD OF DIRECTORS
On or prior to the closing of the Merger, Change agreed to deliver to
Neurologix a written resignation from each officer and director of Change (with
the exception of two directors that Change is entitled to designate to the
combined company's board of directors under the merger agreement), effective as
of the effective time of the Merger. Change agreed that at the effective time of
the Merger, its board of directors will consist of no more than two directors
designated by Change, four members of Neurologix's then current board of
directors plus up to three additional members to be designated by Neurologix.
Upon the closing of the Merger, Change agreed that its board of directors will
be divided into three classes, as nearly equal in size as is practicable,
designated as Class I, Class II and Class III, respectively. At the first annual
meeting of the combined company's stockholders following the closing of the
Merger, the term of office of the Class I directors will expire and Class I
directors will be elected for a full term of three years. At the second annual
meeting of the combined company's stockholders following the closing of the
Merger, the term of office of the Class II directors will expire and Class II
directors will be elected for a full term of three years. At the third annual
meeting of the combined company's stockholders following the closing of the
Merger, the term of office of the Class III directors will expire and Class III
directors will be elected for a full term of three years. When the Merger
becomes effective, each of Change's designated directors will be designated as
Class III directors and each of the other directors will be designated by
Neurologix, in its discretion, as either Class I, Class II or Class III
directors as necessary to make each class of directors as nearly equal in size
as possible.
NON-SOLICITATION OF COMPETING TRANSACTIONS
Under the merger agreement, Change agreed that it will not, and will cause
its directors, officers, employees, agents or representatives to not, during the
term of the merger agreement, solicit, initiate, encourage or facilitate, or
furnish or disclose non-public information in furtherance of, any inquiries or
the making of any proposal with respect to any recapitalization, merger,
consolidation or other business combination involving Change or Subcorp, or
acquisition of any capital stock of Change or Subcorp or 5% or more of the
assets of Change or any of its subsidiaries in a single transaction or a series
of related transactions, or any acquisition by Change or Subcorp of any material
assets or capital stock of any other party, or any liquidation of Change or
Subcorp, or any combination of the foregoing (each a "competing transaction").
Additionally, Change agreed that it would not and will cause its directors,
officers, employees, agents or representatives to not, during the term of the
merger agreement, enter into any agreement requiring it to abandon, terminate or
fail to consummate the Merger or any other transaction contemplated by the
merger agreement.
However, Change and its board of directors may ask questions of, consider
and clarify a proposal from, and conduct a due diligence investigation of, any
third party making an unsolicited competing transaction, solely for the purpose
of evaluating such competing transaction, if the Change board of directors or
any committee thereof determines, after consultation with Change's financial
advisor and its legal counsel, that (i) such third party has submitted to Change
a competing transaction that has a reasonable likelihood of resulting in a
superior proposal (as defined in the merger agreement) and (ii) the failure to
participate in such process would constitute a breach of the Change board of
directors' fiduciary duties under applicable law. After notifying Neurologix of
such development and negotiating in good faith with Neurologix during the
subsequent two business days to make adjustments to the terms and conditions of
the merger agreement such that the competing transaction is no longer a superior
proposal, Change may participate in discussions or negotiations with the third
party if the Change board of directors concludes after the negotiations with
Neurologix that the competing transaction continues to be a superior proposal.
45
Neurologix is bound by a similar non-solicitation provision under the
merger agreement. Although it is not provided a fiduciary out similar to that of
Change described immediately above, a specific exception from Neurologix's
agreement to not solicit a competing transaction provides that Neurologix may
raise up to $1.0 million of additional equity between August 13, 2003 and the
closing of the Merger. Neurologix currently does not intend to exercise this
right to raise additional capital.
DIRECTORS AND OFFICERS INSURANCE
Change agreed, for a period of six years after the closing of the Merger,
to maintain in effect a policy of directors' and officers' liability insurance
covering all individuals who were directors and officers of Neurologix
immediately prior to the closing of the Merger. All rights to indemnification
now existing in favor of any such director or officer as provided in the
certificate of incorporation and bylaws of Neurologix in effect on the date of
the merger agreement will survive the Merger and continue in full force and
effect for a period of not less than six years after the closing of the Merger.
CHANGE STOCK OPTION PLAN
Under the merger agreement, Change may establish a new incentive stock
option plan after the closing of the Merger, provided that all options under the
plan, if fully exercised, would represent no more than 5% of the total number of
shares of Change common stock outstanding immediately after its adoption. Such
new plan may not be amended or replaced for a period ending 18 months after the
date on which the Merger becomes effective.
LOAN TO NEUROLOGIX
Under the merger agreement as amended by amendment no. 1, Change agreed to
loan to Neurologix the principal amount of $1,100,000 secured by all of the
assets of Neurologix. Interest on the unpaid principal will accrue at the rate
of 4% per year. An initial amount of $750,000 of the loan was funded on August
13, 2003. On November 14, 2003 Neurologix, Change and Subcorp amended the merger
agreement to increase the principal amount of the loan from $750,000 to
$1,100,000. On December 18, 2003, Change funded the additional $350,000 of the
loan. The outstanding principal amount of the loan and the accrued interest on
that amount will be due and payable on demand at any time after June 30, 2004.
CONDITIONS TO THE MERGER
CONDITIONS TO NEUROLOGIX'S, CHANGE'S AND SUBCORP'S OBLIGATIONS TO CONSUMMATE
THE MERGER
The respective obligations of Neurologix, Change and Subcorp to consummate
the transactions contemplated by the merger agreement are subject to the
satisfaction of the following conditions:
- no governmental entity shall have enacted, issued, promulgated, enforced
or entered any statute, rule, regulation, judgment, decree, injunction or
other order which is in effect, which would prohibit consummation of the
Merger and the transactions contemplated by the merger agreement;
- the absence of any legal proceeding by any governmental entity or other
third party (i) challenging or seeking to restrain or prohibit the
consummation of the Merger or any of the other transactions contemplated
by the merger agreement, (ii) seeking to prohibit or limit the ownership
or operation by Neurologix, Change or Subcorp of, or to compel
Neurologix, Change or Subcorp to dispose of or hold separate, any
material portion of the business or assets of Neurologix, Change or any
subsidiary of Change, as a result of the Merger or any of the other
transactions contemplated by the merger agreement, or (iii) seeking to
impose limitations on the ability of Change to acquire or hold, or
exercise full rights of ownership of, any shares of capital stock of the
combined company, including the right to vote the capital stock on all
matters properly presented to the stockholders of the combined company;
- the Merger, the merger agreement and the transactions contemplated by the
merger agreement and the amendments proposed to Change's certificate of
incorporation in connection with the Merger shall
46
have been approved and adopted by Change's stockholders in the manner
required by any applicable law;
- the registration statement of which this proxy statement and prospectus
is a part shall have become effective under the Securities Act, no stop
order suspending the effectiveness of the registration statement shall be
in effect and no proceedings for such purpose shall be pending before or
threatened by the Securities Exchange Commission or any state securities
administrator; and
- all consents, approvals and action of any governmental entity required to
permit the consummation of the Merger and the other transactions
contemplated by the merger agreement shall have been obtained or made.
CONDITIONS TO CHANGE'S AND SUBCORP'S OBLIGATIONS TO CONSUMMATE THE MERGER
The respective obligations of Change and Subcorp to consummate the
transactions contemplated by the merger agreement are also subject to the
fulfillment of the following conditions at or prior to the closing:
- all of Neurologix's representations and warranties made in the merger
agreement shall be true and correct in all material respects as of the
date of the merger agreement and on and as of the date on which the
Merger is to close;
- Neurologix shall have complied in all material respects with its
obligations under the merger agreement;
- Neurologix shall not have experienced a material adverse effect since
December 31, 2002;
- Neurologix shall have received all material authorizations, consents,
waivers, approvals or other actions required in connection with the
execution, delivery and performance of the merger agreement by
Neurologix, each of which shall be in full force and effect, and
Neurologix shall also have obtained any authorizations, consents,
waivers, approvals or other actions required to prevent a material breach
or default by Neurologix under any material contract to which Neurologix
is a party or for the continuation of any material agreement to which
Neurologix is a party; and
- the aggregate number of shares for which appraisal rights are sought
shall not exceed 5% of the aggregate number of shares of Neurologix
common stock and Series B convertible preferred stock outstanding on the
date of the closing of the Merger.
CONDITIONS TO NEUROLOGIX'S OBLIGATION TO CONSUMMATE THE MERGER
The obligation of Neurologix to consummate the transactions contemplated by
the merger agreement is also subject to the fulfillment of the following
conditions at or prior to the closing:
- all of the representations and warranties made by Change and Subcorp in
the merger agreement shall be true and correct in all material respects
as of the date of the merger agreement and on and as of the date on which
the Merger is to close;
- Change and Subcorp shall have complied in all material respects with
their respective obligations under the merger agreement;
- Change and its subsidiaries, taken as a whole, shall not have experienced
a material adverse effect since December 31, 2002;
- prior to, or on the date of the closing of the Merger, Neurologix shall
have received written resignations from each of the directors of Change
and Subcorp (with the exception of the two directors Change is entitled
to designate to the combined company's board of directors under the
merger agreement), effective as of the date of the closing of the Merger;
- Change and Subcorp shall have received all material authorizations,
consents, waivers, approvals or other actions required in connection with
the execution, delivery and performance of the merger agreement by Change
and Subcorp, each of which shall be in full force and effect, and Change
and
47
Subcorp shall also have obtained any authorizations, consents, waivers,
approvals or other actions required to prevent a material breach or
default by Change and Subcorp under any material contract to which Change
or Subcorp is a party or for the continuation of any material agreement
to which Change or Subcorp is a party;
- Change's Net Cash Assets, as such term is defined in the merger
agreement, as of the date of the closing of the Merger shall be at least
$6.5 million; and
- Change shall have terminated all of its employee benefit plans, except
for the Change 2000 Stock Option Plan.
TERMINATION OF THE MERGER AGREEMENT
The merger agreement may be terminated by mutual written consent of Change
and Neurologix.
In addition, either Change or Neurologix may terminate the merger
agreement:
- if there exists any law or regulation that, as supported by the written
opinion of legal counsel, makes consummation of the Merger illegal or
otherwise prohibited, or if any judgment, injunction, order or decree of
a governmental entity enjoining Change or Neurologix from consummating
the Merger shall have been entered and such judgment, injunction, order
or decree shall have become final and nonappealable;
- if the Merger shall not have been consummated on or before February 15,
2004; provided, however, that this right to terminate the merger
agreement shall not be available to any party whose failure or whose
affiliate's failure to perform any material covenant or obligation under
the merger agreement has been the cause of, or resulted in the failure
of, the Merger to occur on or before such date;
- if at or before the completion of the closing of the Merger, either
Change or Neurologix discovers that any representation or warranty made
in the merger agreement for its benefit is untrue in any material respect
and, but only if, the failure to be true in any material respect (i)
would give rise to the failure of certain conditions to the obligations
of the parties to close the Merger or (ii) would reasonably be expected
to prevent Change or Neurologix, respectively, from obtaining the
material portion of the benefits intended by the parties to be derived by
Change or Neurologix, as applicable, from the merger agreement and the
transactions contemplated by the merger agreement, with limited
exception; or
- if (i) at Change's special meeting the requisite vote of Change's
stockholders to approve the Merger, the merger agreement and the
transactions contemplated by it and the amendments to Change's
certificate of incorporation shall not have been obtained or (ii) the
Change board of directors withdraws its recommendation to its
stockholders to approve the Merger, the merger agreement and the
transactions contemplated by the merger agreement.
Change may terminate the merger agreement:
- if (i) Neurologix shall have defaulted in the performance of any material
obligation under the merger agreement and the default would reasonably be
expected to prevent Change from obtaining the material portion of the
benefits intended by the parties to be derived by Change from the merger
agreement and the transactions contemplated by the merger agreement or
(ii) any party, other than Change or Subcorp, shall have defaulted in the
performance of any material obligation under the voting agreement
executed in connection with the Merger such that Neurologix cannot
represent that it has requisite stockholder approval for the Merger, with
limited exceptions in each case;
- if any authorization, consent, waiver or approval required for the
consummation of the transactions contemplated by the merger agreement
requires the divestiture or cessation of any of the present material
business or operations conducted by Neurologix or imposes any other
condition or requirement, which divestiture, cessation, condition or
requirement would constitute a material adverse effect on Neurologix's
business, operations, assets or financial condition upon consummation of
the transactions contemplated by the merger agreement; or
48
- in the event that any of the conditions to its obligation to close the
Merger have not been satisfied or waived by February 15, 2004 or in the
event that any such condition cannot possibly be satisfied prior to
February 15, 2004.
Neurologix may terminate the merger agreement if:
- Change shall have defaulted in the performance of any material obligation
under the merger agreement and the default would reasonably be expected
to prevent Neurologix from obtaining a material portion of the benefits
intended by the parties to be derived by Neurologix from the merger
agreement and the transactions contemplated by the merger agreement, with
limited exception; or
- in the event that any of the conditions to its obligation to close the
Merger have not been satisfied or waived by February 15, 2004 or in the
event that any such condition cannot possibly be satisfied prior to
February 15, 2004.
EXPENSES AND TERMINATION FEES
PAYMENT OF EXPENSES OF THE MERGER GENERALLY
Upon consummation of the Merger, Change will pay all transaction expenses,
including legal and accounting fees and disbursements, incurred by Change,
Subcorp and Neurologix relating to the Merger, the merger agreement and the
transactions contemplated by the merger agreement. If the Merger is not
consummated, subject to the limitations described below, all costs and expenses
incurred in connection with the merger agreement and the transactions
contemplated by the merger agreement are to be paid by the respective party
incurring such expenses. However, reasonable out-of-pocket expenses that the
parties incurred in connection with this registration statement and proxy
statement and prospectus are to be paid by Change.
Neurologix has agreed to pay Palisade Capital Securities, L.L.C., an
affiliate of Palisade Private Partnership, L.P., $200,000 upon the closing of
the Merger in exchange for investment banking services rendered by Palisade
Capital Securities in connection with the Merger.
PAYMENTS FROM CHANGE TO NEUROLOGIX UPON TERMINATION
Under the merger agreement, if Neurologix or Change terminates the merger
agreement because, at Change's special meeting, the requisite vote of Change's
stockholders to approve the Merger, the merger agreement and the transactions
contemplated by the merger agreement and the amendments to Change's certificate
of incorporation is not obtained, then upon termination, Change will pay to
Neurologix $225,000 in cash. However, if within 120 days after such termination,
Change acquires or offers, or makes a proposal or agrees to acquire in any
manner, whether directly or indirectly, any business or company (including, but
not limited to, the assets, capital stock or ownership interests thereof) then
Neurologix shall be entitled to $1,100,000 in cash.
If Neurologix or Change terminates the merger agreement in connection with
Change's entry into a competing transaction, or if the Change board of directors
withdraws its recommendation to its stockholders to approve the Merger, the
merger agreement and the transactions contemplated by the merger agreement,
then, upon such termination or withdrawal, Change will pay to Neurologix an
amount equal to $1,100,000 in cash. Change may offset the payment against the
unpaid principal of the $1,100,000 loan it provided to Neurologix under the
merger agreement.
In the event that the merger agreement is terminated such that Neurologix
would be entitled to receive from Change both of the payments described in the
preceding two paragraphs, Neurologix will only be entitled to the $1,100,000
payment described above.
49
DESCRIPTION OF RELATED AGREEMENTS
VOTING AGREEMENT
The following summarizes the material provisions of the voting agreement.
You should read, carefully and in its entirety, the copy of the voting agreement
that is attached to this proxy statement and prospectus as Appendix C.
In connection with the merger agreement, Change, Subcorp, Neurologix,
holders of approximately 86.1% of the outstanding shares of Neurologix common
stock, 100% of the outstanding shares of Neurologix's initial series of
convertible preferred stock, 79.2% of the outstanding shares of Neurologix
Series B convertible preferred stock, and all of the interests in the Existing
Neurologix Note entered into a voting agreement. As described below, under the
voting agreement, these holders of Neurologix securities and debt agreed to (i)
vote for the Merger and the transactions related to the Merger, (ii) convert
their Neurologix securities into Neurologix common stock and (iii) waive their
appraisal rights with respect to their Neurologix securities under Delaware law.
VOTING OF SHARES
The Neurologix stockholders who are party to the voting agreement hold a
majority of the outstanding shares of each class of Neurologix capital stock
and, concurrently with the execution of the merger agreement, executed a written
consent approving the adoption of the merger agreement and all of the
transactions contemplated by the merger agreement. These stockholders also
agreed to vote in favor of any other matter necessary for the consummation of
the transactions contemplated by the merger agreement.
CONVERSION OF SECURITIES
The securityholders party to the voting agreement agreed to, immediately
prior to the consummation of the Merger, convert all of their shares of
Neurologix's initial series of convertible preferred stock and Neurologix Series
B convertible preferred stock into Neurologix common stock. These stockholders'
shares of Neurologix's initial series of convertible preferred stock will
convert on a 1:15,000 basis into 2,205,000 shares of Neurologix common stock and
their shares of Neurologix Series B convertible preferred stock will convert on
a 1:1 basis into 388,894 shares of Neurologix common stock. Holders of interests
in the Existing Neurologix Note agreed to exchange their interests in the
Existing Neurologix Note for the number of whole shares of Neurologix common
stock, which will not exceed an aggregate of 400,000 shares, determined by
dividing (x) the sum of (a) the product of the outstanding unpaid principal
amount of the Existing Neurologix Note as of the date of the exchange multiplied
by such holder's percentage participatory interest in the Existing Neurologix
Note plus (b) the amount of accrued and unpaid interest on the holder's portion
as of the date of the exchange by (y) $6.00.
WAIVER OF APPRAISAL RIGHTS
The holders of Neurologix securities and debt party to the voting agreement
waived, with respect to all of such holders' shares of Neurologix capital stock
and to the fullest extent permitted by applicable law, all appraisal or other
rights to which such holder may be entitled under Section 262 of the General
Corporation Law of the State of Delaware in connection with the Merger. The
waiver is binding upon all of such holders' heirs, representatives, executors,
successors and assigns.
In addition, Neurologix agreed not to issue any shares with respect to any
new class or series of capital stock authorized after the date of the merger
agreement unless the prospective holders of such shares become party to the
voting agreement or a enter into a similar written agreement for the benefit of
Change, Subcorp and Neurologix. The holders of Neurologix securities and debt
party to the voting agreement agreed not to transfer or assign any of their
shares prior to the effective time of the merger agreement, except to any other
holder who is a party to the voting agreement and remains bound by the voting
agreement.
50
The voting agreement terminates upon the earlier of the consummation of the
Merger and the termination of the merger agreement.
SENIOR SECURED PROMISSORY NOTE
The following summarizes the material provisions of the senior secured
promissory note due April 30, 2004 issued by Neurologix in favor of Change.
On August 13, 2003, in connection with execution of the merger agreement,
Change loaned Neurologix $750,000 and Neurologix issued a senior secured
promissory note due April 30, 2004, in the aggregate principal amount of
$750,000 in favor of Change and on December 18, 2003, in connection with
amendment no. 1 to the merger agreement, Change loaned Neurologix an additional
$350,000, and Neurologix issued an amended and restated senior secured
promissory note due June 30, 2004 in the aggregate principal amount of
$1,100,000 (as amended and restated, the "New Note"). The New Note accrues
interest at a rate of 4% per year from the date of issuance until repayment of
the principal amount and accrued interest in full. Neurologix may prepay any
portion of the principal amount and accrued interest without penalty or premium.
To secure the due and punctual payment of the principal of and interest on
the New Note, whether at maturity, by acceleration or otherwise, Neurologix
granted a first priority lien and security interest in all of its assets
pursuant to a security agreement between Change and Neurologix, which the
Parties amended in connection with the additional loan by Change to Neurologix
(as amended the "security agreement"). The security agreement is described in
more detail below.
To ensure that the security interest granted by Neurologix to Change is
entitled to priority over all of Neurologix's existing secured indebtedness,
Change, the holders of the Existing Neurologix Note (Palisade Private
Partnership, L.P., Dr. Martin J. Kaplitt and Clark A. Johnson) and Neurologix
entered into a subordination and intercreditor agreement, which the parties
amended in connection with the additional loan to Neurologix (as amended, the
"subordination agreement"). The subordination agreement is described in more
detailed below.
Under the New Note, Change may accelerate the note and declare the
principal of and accrued interest on the New Note due and immediately payable if
any of the following events of default occurs and is continuing:
- Neurologix defaults in the payment of the principal or interest under the
New Note;
- Neurologix defaults in the observance or performance of any covenant,
condition or agreement under the New Note, security agreement or
subordination agreement and such default continues for 15 days;
- Neurologix commences any proceeding or other action seeking an order for
relief, or seeking to adjudicate it bankrupt or insolvent, or seeking
reorganization, composition, extension or other such relief with respect
to it or its debts, or seeking appointment of a receiver, trustee,
custodian or other similar official for all or any substantial part of
its assets (each a "bankruptcy action"); or
- Neurologix becomes the debtor named in any bankruptcy action which
results in the entry of an order for relief or any such adjudication or
appointment remains undismissed or undischarged for a period of 60 days.
SECURITY AGREEMENT
The following summarizes the material provisions of the security agreement.
To secure the due and punctual payment of the principal of and interest on
the New Note, Neurologix and Change entered into a security agreement, dated as
of August 13, 2003, and amended as of December 18, 2003.
51
Under the security agreement, Neurologix granted a first priority lien and
security interest in all of its assets, whether now owned or acquired after the
date of the security agreement, and all proceeds from such assets. The
collateral includes, but is not limited to, the following:
- any machinery, equipment, furniture, fixtures, inventory or
work-in-progress;
- cash and cash equivalents;
- accounts receivable;
- contracts, leases, software, source and operating codes, designs or
marketing and other plans;
- all patents and patent applications to which the Neurologix acquires any
right, title or interest in or to, including without limitation, the
inventions and improvements described and/or claimed in the patents and
patent applications, together with any reissues, divisions,
continuations, renewals, extensions and continuations in part of the
patents and patent applications and any United States and foreign patents
that may issue on the patents and patent applications for the United
States and all other countries ("Patents");
- all agreements, whether written or oral, providing for the grant to or by
Neurologix of any right to manufacture, use or sell any invention covered
by a Patent, including without limitation, the patent license agreement
between Neurologix and The Rockefeller University, except to the extent
that the grant of a security interest or assignment (a) is prohibited
under any licensing agreement currently in effect and (b) would result in
a breach of such licensing agreement that would allow termination of such
licensing agreement ("Patent Licenses");
- all proceeds and products of each Patent and Patent License, including
without limitation, all income, royalties, damages and payments now or
hereafter due and/or payable with respect to any Patent or Patent
License, including damages and payments for past or future infringements
thereof, the right to sue for past, present and future infringements
thereof, and all rights corresponding thereto throughout the world;
- all of Neurologix's trademarks, trade names, corporate names, company
names, business names, fictitious business names, trade styles, trade
dress and other designations, service marks, logos, other source or
business identifiers, prints and labels on which any of the foregoing
have appeared or appear, designs and general intangibles of like nature,
now existing or hereafter adopted or acquired, all registrations and
recordings thereof, and all applications in connection therewith,
including, without limitation, registrations, recordings and applications
in the Patent and Trademark Office or in any similar office or agency of
the United States, any State thereof or any other country or any
political subdivision thereof, and all reissues, extensions or renewals
thereof ("Trademarks");
- all agreements, whether written or oral, now or hereafter in existence,
providing for the grant to or by Neurologix of any right to use any
Trademark, except to the extent that such grant of a security interest or
assignment (a) is prohibited under any licensing agreement currently in
effect and (b) such grant of a security interest or assignment would
result in a breach of such licensing agreement that would allow
termination of such licensing agreement ("Trademark Licenses");
- all of the goodwill of Neurologix's business connected with the use of,
and symbolized by, each Trademark and Trademark License;
- all products and proceeds of each Trademark and Trademark License,
including, without limitation, any claim by Neurologix against third
parties for past, present or future infringement or dilution of any
Trademark, or for injury to the goodwill associated with any Trademark;
- all general intangibles, as defined in the Uniform Commercial Code of
each jurisdiction where any of the collateral is located, and whether or
not so included in such definition, all intangible assets of whatever
kind or nature of Neurologix, whether now owned or acquired after the
date of the security agreement, including, without limitation, all
copyrights, copyright applications, all franchises, licenses,
52
permits, all good will associated with Neurologix's business, customer lists,
proprietary rights and know-how, trade secrets, choses in action and rights to
indemnity; and
- all products and proceeds of any and all of the foregoing.
Under the security agreement, until Neurologix repays all of the principal
of and accrued interest on the New Note, Neurologix cannot, without the consent
of Change, take any of the following actions:
- create, incur, assume or suffer to exist any liability for borrowed
money, except (i) purchase money indebtedness for the purchase of new
equipment (but not for the refinancing of any collateral securing this
loan); (ii) indebtedness to Change contemplated by the New Note; (iii)
other indebtedness for borrowed money (whether or not constituting a
refinancing of existing indebtedness) so long as (x) such indebtedness is
not secured by collateral securing repayment of the New Note and (y) the
incurrence of which will not cause an event of default under the security
agreement, or an event which with notice or the lapse of time or both
would constitute an event of default;
- create, incur, assume or suffer to exist any security interest, mortgage,
pledge, lien, charge or other encumbrance of any nature whatsoever,
except: (i) liens securing purchase money indebtedness for the purchase
of new equipment (but not for the refinancing of any collateral securing
this loan); (ii) liens and security interests of Change; (iii) liens
securing the payment of taxes, either not yet overdue or the validity of
which are being contested in good faith by appropriate proceedings
diligently pursued and available to Neurologix and with respect to which
adequate reserves have been set aside on its books; (iv) nonconsensual
statutory liens (other than liens securing the payment of taxes) arising
in the ordinary course of Neurologix's business to the extent: (x) such
liens secure indebtedness which is not overdue or (y) such liens secure
indebtedness relating to claims or liabilities which are fully insured
and being defended at the sole cost and expense and at the sole risk of
the insurer or being contested in good faith by appropriate proceedings
diligently pursued and available to Neurologix, in each case prior to the
commencement of foreclosure or other similar proceedings and with respect
to which adequate reserves have been set aside on its books; and the
security interests and liens created under the security agreement;
- assume, endorse, be or become liable for or guarantee the obligations of
any other person except by the endorsement of negotiable instruments for
deposit or collection in the ordinary course of business;
- lend or advance money, credit or property to or invest in (by capital
contribution, loan, purchase or otherwise) any firm, corporation, or
other person except (i) investments in United States Government
obligations and certificates of deposit of any bank institution with
combined capital and surplus of at least $200,000,000, (ii) trade credit,
or (iii) security deposits;
- make, declare or pay any dividend or distribution on, or, directly or
indirectly, redeem, purchase or otherwise acquire, any shares of its
capital stock or any securities convertible or exchangeable into or
exercisable for any shares of Neurologix's capital stock, except to the
extent necessary to satisfy its obligation pursuant to Section 262 of the
General Corporation Law of the State of Delaware as set forth in the
merger agreement; or
- enter into any transaction, agreement, arrangement or understanding
between Neurologix, on the one hand, and any officer, director, employee,
family member of any of the foregoing, or any affiliate (including
Palisade Capital Management LLC and its affiliates) of Neurologix or
other persons, on the other hand, except (i) in the ordinary course of
business consistent with past practice or (ii) as contemplated by the
merger agreement.
The security agreement terminates upon the payment in full by Neurologix to
Change of all principal of and accrued interest on the New Note.
53
SUBORDINATION AND INTERCREDITOR AGREEMENT
The following summarizes the material provisions of the subordination
agreement.
Neurologix is presently indebted to Palisade Private Partnership, L.P., Dr.
Martin J. Kaplitt and Clark A. Johnson pursuant to the Existing Neurologix Note
which is secured by the grant of a security interest by Neurologix in some of
its properties and assets.
As described in this proxy statement and prospectus, concurrent with the
execution of the merger agreement, Neurologix issued the New Note. Neurologix's
obligations under the New Note are secured by all of the assets of Neurologix
pursuant to the security agreement described above. To ensure that the security
interest granted by Neurologix to Change under the security agreement is
entitled to priority over any security interest granted to secure Neurologix's
existing indebtedness, Change, Palisade Private Partnership, L.P., Dr. Martin J.
Kaplitt, Clark A. Johnson and Neurologix entered into the subordination
agreement.
Under the subordination agreement, the repayment of the Existing Neurologix
Note is expressly subordinated and made junior to the payment of the principal
amount, all interest and any other amounts due on the New Note. Accordingly, the
New Note must first be paid in full before any payment or distribution of any
character, whether in cash, securities, obligations or other property, is made
in respect of the Existing Neurologix Note.
In addition, so long as the New Note remains unpaid, Change may at all
times and in its sole discretion, exercise any and all powers and rights,
including, without limitation, the right to foreclose, upon any asset or
property of Neurologix in the possession of any secured party without the
necessity of obtaining the consent or approval of such secured party.
Prior to the payment in full of the New Note, holders of the Existing
Neurologix Note may not, without the prior written consent of Change, take any
of the following actions:
- amend, modify or supplement the Existing Neurologix Note or any agreement
relating to the Existing Neurologix Note in any manner;
- sell, transfer, pledge, assign, grant a security interest in, or
otherwise dispose of or encumber its interest as a secured party or
mortgagee with respect to any assets and properties of Neurologix in the
possession of such secured party; or
- accelerate the maturity of all or any portion of the Existing Neurologix
Note, or take any action towards collection of all such indebtedness or
enforcement of any rights, powers or remedies under the existing
indebtedness or any agreement related to the existing indebtedness.
The subordination agreement terminates upon the earlier of (i) the payment
in full by Neurologix to Change of all principal of and accrued interest on the
New Note and (ii) the conversion of the Existing Neurologix Note pursuant to the
terms of the voting agreement.
54
PROPOSED AMENDMENTS TO CHANGE'S
CERTIFICATE OF INCORPORATION IN CONNECTION
WITH THE MERGER
In connection with the Merger, the Change board of directors has adopted a
resolution to amend selected provisions of the Change certificate of
incorporation. As described below, the amendments to the Change certificate of
incorporation will change Change's corporate name to "Neurologix, Inc.,"
increase the number of authorized shares of capital stock, decrease the par
value of Change common stock to $.001, increase the number of directors on the
Change board of directors and implement a classified board of directors with
three-year terms. The amendments would become effective only at the effective
time of the Merger. If for any reason the Merger is not consummated, the
amendments to the Change certificate of incorporation will not be effected.
AMENDMENTS TO THE CERTIFICATE OF INCORPORATION
The following are the proposed amendments to the Change certificate of
incorporation:
- Article 1 of the Change certificate of incorporation shall be deleted in
its entirety and replaced with the following new Article 1:
"NAME. The name of the corporation is Neurologix, Inc. (the
"Corporation")."
- Article 4.1 of the Change certificate of incorporation shall be deleted
in its entirety and replaced with the following new Article 4.1:
"NUMBER OF SHARES. The total number of shares of stock that the
Corporation shall have authority to issue is: seven hundred fifty-five
million (755,000,000), seven hundred fifty million (750,000,000) of
which shall be shares of Common Stock of the par value of one-tenth of
one cent ($.001) each and five million (5,000,000) of which shall be
shares of Preferred Stock of the par value of ten cents ($.10) each."
- Article 6 of the Change certificate of incorporation shall be deleted in
its entirety and replaced with the following new Article 6:
"6. BOARD OF DIRECTORS
6.1 NUMBER OF DIRECTORS. The business and affairs of the Corporation
shall be managed by, or under the direction of, the Board of Directors
(the "Board"). The total number of directors constituting the entire
Board shall be not less than three nor more than twelve, with the then-
authorized number of directors being fixed from time to time by the
Board.
6.2 STAGGERED BOARD. The Board shall be divided into three classes, as
nearly equal in number as possible, designated Class I, Class II and
Class III. Class I directors shall initially serve until the 2004 annual
meeting of stockholders; Class II directors shall initially serve until
the 2005 annual meeting of stockholders; and Class III directors shall
initially serve until the 2006 annual meeting of stockholders.
Commencing with the annual meeting of stockholders in 2004, directors of
each class the term of which shall then expire shall be elected to hold
office for a three-year term and until the election and qualification of
their respective successors in office. In case of any increase or
decrease, from time to time, in the number of directors, the number of
directors in each class shall be apportioned as nearly equal as
possible.
6.3 ELECTION OF DIRECTORS. Members of the Board may be elected either
by written ballot or by voice vote."
IN CONNECTION WITH APPROVING AND ADOPTING THE OTHER PROPOSALS RELATING TO
THE MERGER, THE CHANGE BOARD OF DIRECTORS HAS UNANIMOUSLY APPROVED THE
AMENDMENTS DESCRIBED ABOVE AND UNANIMOUSLY RECOMMENDS THAT THE HOLDERS OF CHANGE
CAPITAL STOCK VOTE FOR THE APPROVAL AND ADOPTION OF THIS PROPOSAL.
55
MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES
OF THE MERGER
GENERAL
The following describes the material U.S. federal income tax consequences
of the Merger that are generally applicable to U.S. holders of Neurologix common
stock or Series B convertible preferred stock. However, this discussion does not
address all aspects of taxation that may be relevant to particular U.S. holders
in light of their personal investment or tax circumstances, or to persons that
are subject to special tax rules. In particular, this discussion deals only with
U.S. holders that hold Neurologix common stock or Series B convertible preferred
stock as capital assets within the meaning of the Code of 1986, as amended. This
description of U.S. federal income tax consequences does not address the tax
treatment of special classes of stockholders such as banks, insurance companies,
tax-exempt entities, financial institutions, broker-dealers, persons holding
Neurologix common stock or Series B convertible preferred stock as part of a
hedging or conversion transaction or as part of a "straddle," U.S. expatriates,
persons subject to the alternative minimum tax, non-U.S. holders and holders who
acquired Neurologix common stock or Series B convertible preferred stock
pursuant to the exercise of options or warrants or otherwise as compensation. In
addition, this discussion does not set forth any state, local or foreign tax
consequences of the Merger. YOU ARE URGED TO CONSULT YOUR OWN TAX ADVISOR AS TO
THE SPECIFIC TAX CONSEQUENCES OF THE MERGER, INCLUDING THE APPLICABLE U.S.
FEDERAL, STATE, LOCAL AND FOREIGN TAX CONSEQUENCES TO YOU OF THE MERGER.
A U.S. holder of Neurologix common stock or Series B convertible preferred
stock is a stockholder who or that is for U.S. federal income tax purposes:
- a citizen or resident alien individual of the United States;
- a corporation, partnership or other entity organized under the laws of
the United States or any political subdivision of it, including the
States and the District of Columbia;
- an estate, the income of which is subject to U.S. federal income taxation
regardless of its source;
- a trust, if a court within the United States is able to exercise primary
supervision over the administration of the trust and one or more U.S.
persons have the authority to control all substantial decisions of the
trust, or the trust has validly made an election to be treated as a U.S.
person under applicable United States Department of Treasury regulations;
or
- any person that is subject to U.S. federal income tax on its worldwide
income.
This discussion is based on the Internal Revenue Code, applicable
Department of Treasury regulations, judicial authority and administrative
rulings and practice, all as in effect as of the date of this proxy statement
and prospectus, as well as representations, covenants and assumptions as to
factual matters made by, among others, Change and Neurologix. Future
legislative, judicial, or administrative changes or interpretations, which may
or may not be retroactive, or the failure of any such factual representations,
covenants, or assumptions to be true, accurate and complete in all material
respects, may adversely affect the accuracy of the statements and conclusions
described in this discussion.
MATERIAL TAX CONSEQUENCES OF THE MERGER
The material U.S. federal income tax consequences of the Merger will be as
follows:
- the Merger will be treated as a reorganization within the meaning of
Section 368(a) of the Code for U.S. federal income tax purposes and
Change, Subcorp and Neurologix will each be a party to that
reorganization within the meaning of Section 368(b) of the Code;
- no gain or loss will be recognized by Change, Subcorp or Neurologix as a
result of the Merger, except for amounts resulting from any required
change in accounting methods or any income or deferred gain recognized
under the relevant consolidated return regulations;
56
- no gain or loss will be recognized by holders of Neurologix common stock
or Series B convertible preferred stock upon their receipt of Change
common stock in exchange for their Neurologix common stock or Series B
convertible preferred stock in the Merger;
- the aggregate tax basis of the shares of Change common stock that
Neurologix stockholders receive in exchange for their Neurologix common
stock or Series B convertible preferred stock in the Merger will be the
same as the aggregate tax basis of their Neurologix common stock or
Series B convertible preferred stock exchanged in the Merger;
- the holding period for shares of Change common stock received in exchange
for shares of Neurologix common stock or Series B convertible preferred
stock in the Merger will include the holding period of the Neurologix
common stock or Series B convertible preferred stock exchanged, provided
such Neurologix common stock or Series B convertible preferred stock was
held as a capital asset at the time the Merger is completed; and
- if holders of Neurologix common stock or Series B convertible preferred
stock exercise dissenters' rights, such stockholders generally will
recognize taxable gain or loss based upon the difference between the
amount of cash received by such stockholder and the tax basis of their
Neurologix common stock or Series B convertible preferred stock
exchanged; this gain or loss generally will constitute long-term capital
gain or loss if the stock was held by such Neurologix stockholder as a
capital asset for more than one year.
REPORTING REQUIREMENTS
Neurologix stockholders will be required to attach a statement to their tax
returns for the taxable year in which the Merger is completed that contains the
information set forth in Section 1.368-3(b) of the Department of Treasury
regulations. The statement must include your tax basis in the Neurologix common
stock or Series B convertible preferred stock surrendered in the Merger and a
description of the Change common stock received in the Merger.
57
MARKET PRICE AND DIVIDEND POLICY
CHANGE
Change's common stock is traded on the over-the-counter market and prices
are quoted on the OTC electronic bulletin board under the symbol "CTPI." The
last reported sale price of Change's common stock on the OTC electronic bulletin
board on August 12, 2003, the day before the Merger was announced, was $0.03.
The following table lists, for the fiscal quarters indicated, the range of
high and low bid prices per share of Change's common stock in U.S. dollars, as
reported on the OTC electronic bulletin board.
HIGH LOW
----- -----
FISCAL 2001:
First Quarter............................................. $2.00 $0.25
Second Quarter............................................ 0.31 0.07
Third Quarter............................................. 0.14 0.02
Fourth Quarter............................................ 0.10 0.03
FISCAL 2002:
First Quarter............................................. 0.07 0.04
Second Quarter............................................ 0.07 0.03
Third Quarter............................................. 0.02 0.01
Fourth Quarter............................................ 0.03 0.02
FISCAL 2003:
First Quarter............................................. 0.02 0.02
Second Quarter............................................ 0.09 0.01
Third Quarter............................................. 0.08 0.03
Fourth Quarter............................................ 0.06 0.03
As of September 30, 2003, 177,503,919 shares of Change's common stock were
issued and outstanding, held by approximately 458 record holders. The last
reported sale price of Change's common stock on the OTC electronic bulletin
board on December 31, 2003 was $0.04.
Since 1999, Change has not paid cash dividends on its common stock and does
not intend to pay cash dividends in the foreseeable future.
The combined company anticipates that for the foreseeable future, its
earnings, if any, will be retained for use in the operation of its business and
that no cash dividends will be paid on its capital stock. Any determination to
pay cash dividends after the Merger is completed will be at the discretion of
the combined company's board of directors and will be dependent upon its results
of operations, financial condition, contractual restrictions and other factors
deemed relevant by the board of directors.
NEUROLOGIX
No established public trading market exists for any class of Neurologix's
capital stock.
As of September 30, 2003, Neurologix's common stock was held by seven
record holders, its initial series of convertible preferred stock was held by
three record holders and its Series B convertible preferred stock was held by 12
record holders.
Neurologix has never declared or paid any cash dividends on its capital
stock. Neurologix currently expects to retain future earnings, if any, for use
in the operation and expansion of its business and does not anticipate paying
any cash dividends. The agreements governing Change's loan to Neurologix
prohibit the payment of dividends by Neurologix without Change's prior approval.
58
UNAUDITED PRO FORMA FINANCIAL STATEMENTS
INTRODUCTION TO UNAUDITED PRO FORMA
CONDENSED COMBINED FINANCIAL STATEMENTS
The merger agreement provides for Change to complete a reverse acquisition
of Neurologix. Under the merger agreement, Subcorp will merge with and into
Neurologix, with Neurologix being the surviving corporation and becoming a
wholly-owned subsidiary of Change. Change will change its corporate name to
Neurologix, Inc. Under the merger agreement, at the effective time of the
Merger, the outstanding shares of Neurologix common stock and preferred stock
will automatically convert into Change common stock. The actual number of shares
of Change common stock to be issued in the Merger is directly related to
Change's Net Cash Assets as of the closing of the Merger. As of July 31, 2003
and December 31, 2003, Change estimated that its Net Cash Assets at closing
would be approximately $7.1 million. Accordingly, had the Exchange Ratio been
determined as of July 31, 2003, or December 31, 2003 it would have been 70.2127
resulting in an aggregate of 391,275,156 shares of Change common stock being
issued to existing Neurologix stockholders and approximately 32% and 68% of the
common stock of the combined company outstanding after the Merger being held by
existing Change stockholders and existing Neurologix stockholders, respectively.
In addition, Neurologix has outstanding options to purchase an aggregate of
257,000 shares of its common stock, which, in accordance with the terms of the
merger agreement, would automatically convert into options to purchase an
aggregate of 18,044,664 shares of Change common stock based on an estimated
Exchange Ratio of 70.2127. Since the stockholders of Neurologix will receive the
majority of the voting shares of the combined company, and the board of
directors and management of the combined company will be controlled by members
of the board of directors and management of Neurologix, the Merger will be
accounted for as a reverse acquisition whereby Neurologix will be the acquirer
and Change will be the acquiree for accounting purposes.
Following the Merger, none of Change's current net operating loss
carryforwards will be available to the combined company due to a lack of
continuity of business enterprise under Section 382 of the Code.
The unaudited pro forma condensed combined statements of operations combine
the historical consolidated statements of operations of Neurologix and Change
giving effect to the Merger as if it had been consummated at the beginning of
the periods presented. The unaudited pro forma condensed combined balance sheet
combines the historical consolidated balance sheet of Neurologix and the
historical balance sheet of Change, giving effect to the Merger as if it had
been consummated on September 30, 2003.
You should read this information in conjunction with the:
- accompanying notes to the unaudited pro forma condensed combined
financial statements;
- historical financial statements of Change as of and for the year ended
December 31, 2002 included elsewhere in this proxy statement and
prospectus;
- historical unaudited financial statements of Change as of and for the
nine months ended September 30, 2003 included elsewhere in this proxy
statement and prospectus;
- historical financial statements of Neurologix for the year ended December
31, 2002 and the historical unaudited financial statements of Neurologix
as of September 30, 2003 and for the nine months ended September 30, 2003
which are included in this proxy statement and prospectus.
The unaudited pro forma condensed combined financial information is
presented for informational purposes only. The pro forma information is not
necessarily indicative of what the financial position or results of operations
of the combined company would have actually been had the Merger occurred on
September 30, 2003 or January 1, 2002. In addition, the unaudited pro forma
condensed combined financial information does not purport to project the future
financial position or results of operations of the combined company.
59
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET
SEPTEMBER 30, 2003
CHANGE
TECHNOLOGY PRO FORMA PRO FORMA
NEUROLOGIX, INC. PARTNERS, INC. ADJUSTMENTS COMBINED
---------------- -------------- ----------- ---------
(IN THOUSANDS OF DOLLARS)
ASSETS:
CURRENT ASSETS:
Cash and cash equivalents...... $ 887 $ 5,963 $ 6,850
Related party receivable....... -- 102 102
Other receivable............... -- 754 (750)(g) 4
Prepaid expenses and other
current assets............... -- 729 729
------- -------- -------- -------
Total current assets........... 887 7,548 (750) 7,685
Investments in and loans to
unconsolidated
subsidiaries................. -- 89 89
Property and equipment, net.... 173 68 241
Intangible assets, net......... 316 -- -- 316
Goodwill....................... -- -- 345 (f) 345
------- -------- -------- -------
Total assets............... $ 1,376 $ 7,705 (405) $ 8,676
======= ======== ======== =======
LIABILITIES AND STOCKHOLDERS'
EQUITY:
CURRENT LIABILITIES:
Note payable................... $ 750 (750)(g) $ --
Accounts payable and accrued
expenses..................... 59 296 650 (f) 1,005
Current portion of capital
lease obligations............ 20 3 -- 23
------- -------- -------- -------
Total current liabilities...... 829 299 (100) 1,028
Note payable to related
party........................ 2,328 -- $ (2,328)(a) --
Capital lease obligations, net
of current portion........... 11 -- -- 11
------- -------- -------- -------
Total liabilities.............. 3,168 299 (2,428) 1,039
------- -------- -------- -------
Mandatorily redeemable
convertible preferred
stock........................ 500 -- (500)(b) --
------- -------- -------- -------
STOCKHOLDERS' EQUITY
(DEFICIENCY):
Preferred stock.............. -- -- -- --
Common stock................. 2 1,775 (1,208)(a)(b)(c)(d)(f) 569
Additional paid-in capital... 3,656 94,334 (84,972)(a)(b)(c)(d)(e)(f) 13,018
Unearned compensation........ (815) -- -- (815)
Accumulated deficit.......... (5,135) (88,703) 88,703 (e) (5,135)
------- -------- -------- -------
Total stockholder's equity
(deficiency)................. (2,292) 7,406 2,523 7,637
------- -------- -------- -------
Total liabilities and
stockholders' equity....... $ 1,376 $ 7,705 $ (405) $ 8,676
======= ======== ======== =======
See notes to unaudited condensed combined financial statements.
60
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
YEAR ENDED DECEMBER 31, 2002
CHANGE
TECHNOLOGY PRO FORMA PRO FORMA
NEUROLOGIX, INC. PARTNERS, INC. ADJUSTMENTS COMBINED
---------------- -------------- ----------- ------------
(IN THOUSANDS OF DOLLARS, EXCEPT PER SHARE INFORMATION)
Operating expenses:
General and administrative
expenses.......................... $ 486 $ 3,719 $ $ 4,205
Research and licensing............... 441 -- -- 441
Scientific consulting................ 286 -- -- 286
Impairment charge.................... -- 69 -- 69
------- ------- -------- ------------
Loss from operations................... (1,213) (3,788) (5,001)
------- ------- -------- ------------
Other income (expense):
Interest and dividend income
(expense), net.................... (97) 743 -- 646
Equity in losses and impairment of
investments in unconsolidated
subsidiaries...................... (549) -- (549)
------- ------- -------- ------------
Totals............................ (97) 194 -- 97
------- ------- -------- ------------
Loss from continuing operations........ (1,310) (3,594) (4,904)
Income from discontinued operations.... -- 93 -- 93
------- ------- -------- ------------
Net loss............................... $(1,310) $(3,501) $ $ (4,811)
------- ------- -------- ------------
Basic and diluted loss per common share
from continuing operations........... $ (0.01)
Discontinued operations................ $ (0.00)
Basic and diluted net loss per common
share................................ $ (0.01)
============
Weighted average common shares
outstanding, basic and diluted....... 564,505,532
============
See notes to unaudited condensed combined financial statements.
61
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
NINE MONTHS ENDED SEPTEMBER 30, 2003
CHANGE
TECHNOLOGY PRO FORMA PRO FORMA
NEUROLOGIX, INC. PARTNERS, INC. ADJUSTMENTS COMBINED
---------------- -------------- ----------- ------------
(IN THOUSANDS OF DOLLARS, EXCEPT PER SHARE INFORMATION)
Operating expenses:
Selling, general, and administrative
expenses........................... $ 540 $ 2,773 $ $ 3,313
Research and licensing................ 730 -- -- 730
Scientific consulting................. 220 -- -- 220
------- ------- -------- ------------
Loss from operations.................... (1,490) (2,773) (4,263)
------- ------- -------- ------------
Other income (expense):
Interest and dividend income
(expense), net..................... (82) 95 -- 13
Equity in losses and impairment of
investments in unconsolidated
subsidiaries....................... -- (110) -- (110)
Realized gain on sale of investment... -- 286 -- 286
------- ------- -------- ------------
Totals........................... (82) 271 -- 189
------- ------- -------- ------------
Loss from continuing operations......... (1,572) (2,502) (4,074)
Loss from discontinued operations
(including loss on disposal), net..... -- (1,899) -- (1,899)
------- ------- -------- ------------
Net loss................................ $(1,572) $(4,401) $ $ (5,973)
------- ------- -------- ------------
Basic and diluted loss per common share
from continuing operations............ $ (0.01)
Discontinued operations................. $ (0.00)
Basic and diluted net loss per common
share................................. $ (0.01)
============
Weighted average common shares
outstanding, basic and diluted........ 575,815,900
============
See notes to unaudited condensed combined financial statements.
62
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
Description of transaction and basis of presentation:
(1) On August 13, 2003, Change, Subcorp and Neurologix entered into
the merger agreement, which provides for Change to complete a reverse
acquisition of Neurologix. Under the merger agreement, Subcorp will merge
with and into Neurologix, with Neurologix being the surviving corporation
and becoming a wholly-owned subsidiary of Change. Under the merger
agreement, at the effective time of the Merger, the outstanding shares of
Neurologix common stock and preferred stock will automatically convert into
Change common stock. The actual number of shares of Change common stock to
be issued in the Merger is directly related to Change's Net Cash Assets as
of the closing of the Merger. As of July 31, 2003 or December 31, 2003
Change estimated that its Net Cash Assets at closing would be approximately
$7.1 million. Accordingly, had the Exchange Ratio been determined as of
July 31, 2003 and December 31, 2003 it would have been 70.2127 resulting in
an aggregate of 391,275,156 shares of Change common stock being issued to
existing Neurologix stockholders and approximately 32% and 68% of the
common stock of the combined company outstanding after the Merger being
held by existing Change stockholders and existing Neurologix stockholders,
respectively. In addition, Neurologix has outstanding options to purchase
an aggregate of 257,000 shares of its common stock, which, in accordance
with the terms of the merger agreement, would automatically convert into
options to purchase an aggregate of 18,044,664 shares of Change's common
stock based on an estimated Exchange Ratio of 70.2127.
Since the stockholders of Neurologix will receive the majority of the
voting shares of the combined company, and the board of directors and
management of the combined company will be controlled by members of the
board of directors and management of Neurologix, the Merger will be
accounted for as a reverse acquisition whereby Neurologix will be the
acquirer and Change will be the acquiree for accounting purposes.
Accordingly, the assets and liabilities of Neurologix will be recorded at
their historical carrying values and the assets and liabilities of Change
will be recorded at their fair values which approximate their historical
values. The reported financial condition and results of operations of
Neurologix after the Merger will not be retroactively restated to reflect
the historical financial position or results of operations of Change.
(2) Pro forma adjustments:
(a) To adjust for the conversion of the Existing Neurologix Note
payable into 27,128,432 shares of common stock at $0.001 par value.
(b) To adjust for the conversion of mandatorily redeemable
preferred stock into 154,819,004 shares of common stock at $0.001 par
value.
(c) To adjust for the conversion of Neurologix Series B convertible
preferred stock into 34,457,163 shares of common stock at $0.001 par
value.
(d) To reflect the issuance of 174,870,557 shares of common stock
to the current holders of Neurologix's common stock at $0.001 par value.
(e) To eliminate the equity of Change.
(f) To reflect purchase accounting adjustments comprised of:
(1) Purchase price, totaling $7,751,000 including:
(a) 177,503,920 shares of common stock to be retained by
Change shareholders, valued at $6,745,000;
(b) 40,441,999 options and warrants to purchase Change common
stock that will be retained by current holders, valued at
$356,000;
63
(c) 645 shares of preferred stock to be retained by Change
shareholders, valued at $0;
(d) Estimated transaction costs of the acquiror, totaling
$650,000.
(2) Goodwill of $345,000 represents the excess of the
purchase price over the estimated fair value of Change
net assets at September 30, 2003, which is directly
attributable to the transaction. This amount has been
calculated on a pro forma basis as the difference
between the purchase price of $7,751,000 and the net
assets of Change at September 30, 2003 of $7,406,000.
Goodwill recognized upon consummation of the Merger will
be based upon the fair value of the Change net assets at
that date.
(g) To eliminate the $750,000 loan to Neurologix by Change.
64
MANAGEMENT OF THE COMBINED COMPANY AFTER THE MERGER
DIRECTORS AND EXECUTIVE OFFICERS
Set forth below is information concerning each individual who will serve on
the combined company's initial board of directors and each individual to be
appointed as an executive officer of the combined company upon completion of the
Merger:
NAME AGE POSITION WITH THE COMBINED COMPANY
---- --- ----------------------------------
Martin Kaplitt, M.D....................... 64 President and Director, Class II
Mark Hoffman.............................. 42 Secretary, Treasurer and Director, Class
II
Clark Johnson............................. 72 Director, Class I
Jan Robinson Willinger.................... 64 Director, Class I
Austin M. Long, III....................... 59 Director, Class III
Craig J. Nickels.......................... 50 Director, Class III
Michael Gleason, the current chairman of the Change board of directors and chief
executive officer of Change, will resign prior to the completion of the Merger.
Should any of the proposals relating to the Merger set forth in this proxy
statement and prospectus fail to be approved by the required vote of the
stockholders of Change at the special meeting, or if the Merger is not
consummated for any other reason, then the Change board of directors will not be
composed of the above individuals, but will instead continue as currently
constituted.
The combined company's certificate of incorporation will provide for a
board of directors consisting of three classes of directors with the directors
in each class serving staggered three-year terms. Each class will consist, as
nearly as may be possible, of one-third of the directors constituting the entire
board. The Class I nominees are Mr. Johnson and Ms. Willinger, the Class II
nominees are Messrs. Hoffman and Kaplitt and the Class III nominees are Messrs.
Long and Nickels. The terms of the Class I, Class II and Class III directors
will expire at the combined company's annual meetings of stockholders following
the end of the 2003, 2004 and 2005 fiscal years, respectively. At each annual
meeting of the stockholders, the successors to the class of directors whose term
expires will be elected for a three year term.
Martin Kaplitt, M.D., President and Director. Dr. Martin Kaplitt has been
the president and a director of Neurologix since August 1999. Dr. Kaplitt is the
Associate Attending in Surgery at North Shore University Hospital and a clinical
associate professor of surgery at Cornell University Medical College. Dr.
Kaplitt is a graduate of Cornell University and the State University of New
York, Downstate Medical Center. Dr. Kaplitt is a director of the Trust Company
of New Jersey. Dr. Kaplitt is a fellow of the American College of Surgeons and
the American College of Cardiology.
Mark Hoffman, Secretary, Treasurer and Director. Mr. Hoffman has been the
secretary and treasurer and a director of Neurologix since November 1999. Since
1995, Mr. Hoffman has been a managing director of Palisade Capital Management,
L.L.C., a private investment firm. Mr. Hoffman is also a director of OptiCare
Health Systems, Inc. and Refac, an intellectual property licensing company. Mr.
Hoffman received his B.S. in Economics from the Wharton School of the University
of Pennsylvania in 1983.
Clark A. Johnson, Director. Mr. Johnson has been a director of Neurologix
since November 1999. He has been the chairman of the board of directors of PSS
World Medical, a distributor of medical equipment and supplies since October
2000 and a director of PSS World Medical since 1999. Mr. Johnson served as the
chairman and chief executive officer of Pier 1 Imports from March 1985 to June
1998. Mr. Johnson is a director of Metromedia International Group, a
communications company, and OptiCare Health Systems, Inc., Refac, Inc., an
intellectual property licensing company and PSS World Medical, Inc.
Jan Robinson Willinger, Director. Ms. Robinson Willinger has been a
director of Neurologix since July 2000. Ms. Robinson Willinger is a retired
health care consultant. In 1976, Ms. Robinson Willinger founded
65
AVMD, an international health care communications company, which was sold on a
division by division basis from 1990 to 1992.
Austin M. Long, III, Director. Mr. Long has been a director of Change
since June 2003. Mr. Long has worked as an investment professional in private
markets since 1987, when he co-founded the University of Texas Management
System's private investment group. Mr. Long left the University of Texas in
March 2000 to co-found Alignment Capital Partners, LLC, a private market
portfolio management advisory operation based in Austin, Texas that was
reorganized in October 2001 as Alignment Capital Group, LLC. Mr. Long holds a
Masters in Professional Accounting from the University of Texas at Austin and is
a Certified Public Accountant.
Craig J. Nickels, Director. Mr. Nickels has been a director of Change
since June 2003. Mr. Nickels has worked as an investment professional in private
markets since 1993, when he joined Mr. Long at The University of Texas
Management System's private investment group. Mr. Nickels left the University of
Texas in March of 2000 to co-found Alignment Capital Partners, LLC, a private
investment management firm based in Austin, Texas that was reorganized in
October 2001 as Alignment Capital Group, LLC, specializing in alternative asset
consulting.
SCIENTIFIC ADVISORY BOARD
Neurologix has assembled a scientific advisory board that currently
consists of 5 members. The scientific advisory board advises Neurologix on the
selection, implementation and prioritization of its research programs.
Neurologix's scientific advisory board consists of the following
individuals:
Dr. Paul Greengard, Scientific Advisory Board Chairman. Dr. Greengard has
been a member and chairman of Neurologix's scientific advisory board since July
2003. Dr. Greengard is the Vincent Astor Professor and Chairman of the
Laboratory of Molecular and Cellular Neuroscience at The Rockefeller University.
Dr. Greengard was awarded the 2000 Nobel Prize in Physiology or Medicine. Dr.
Greengard received a Ph.D. in biophysics from Johns Hopkins University. Prior to
joining The Rockefeller University in 1983, Dr. Greengard was the director of
biochemical research at the Geigy Research Laboratories and subsequently
Professor of Pharmacology and Professor of Psychiatry at the Yale University
School of Medicine. Dr. Greengard is an elected member of the U.S. National
Academy of Sciences and its Institute of Medicine and of the American Academy of
Arts and Sciences. He is also a foreign member of the Royal Swedish Academy of
Sciences and a member of the Norwegian Academy of Science and Letters.
Andrew Brooks, Ph.D., Scientific Advisory Board Member. Dr. Brooks has
been a member of Neurologix's scientific advisory board since January 2002. Dr.
Brooks is currently the Director of the Center for Functional Genomics in the
Aab Institute for Biomedical Science at the University of Rochester from which
he also received his Ph.D.
Matthew J. During, M.D., Scientific Consultant, Scientific Advisory Board
Member. Dr. During has been a member of Neurologix's scientific advisory board
since October 1999. He is currently Professor of Molecular Medicine and
Pathology at University of Auckland in New Zealand where he directs neuroscience
and gene therapy programs. He also served as Director of the CNS Gene Therapy
Center and Professor of Neurosurgery at Jefferson Medical College from 1998
through 2002. From 1989 through 1998, Dr. During was a faculty member at Yale
University where he directed a program on the molecular basis of learning and
memory and headed Yale's first gene therapy protocol. Dr. During is a graduate
of University of Auckland School of Medicine and did further postgraduate
training at M.I.T. from 1985 to 1987, Harvard Medical School from 1986 to 1989
and Yale from 1988 to 1989.
Michael G. Kaplitt, M.D., Ph.D., Scientific Consultant, Scientific Advisory
Board Member. Dr. Kaplitt has been a member of Neurologix's scientific advisory
board since October 1999. Dr. Kaplitt is Assistant Professor of Neurosurgery,
Director of Stereotactic and Functional Neurosurgery and Director of the
Laboratory of Molecular Neurosurgery at Weill Medical College of Cornell
University. He is also Clinical Assistant Attending, Division of Neurosurgery,
Department of Surgery at Memorial-Sloan Kettering Cancer Center, and Adjunct
Faculty, Laboratory of Neurobiology and Behavior at The Rockefeller University.
66
Dr. Kaplitt graduated magna cum laude with a bachelor's degree in molecular
biology from Princeton University. Dr. Kaplitt received his M.D. from Cornell
University School of Medicine in 1995, where he completed his residency in
Neurosurgery. Dr. Kaplitt also received a Ph.D. in molecular neurobiology from
The Rockefeller University. Michael Kaplitt is the son of Martin Kaplitt, who is
Neurologix's President, a member of its board of directors and one of its
principal stockholders.
Andres M. Lozano, M.D., Ph.D., Scientific Advisory Board Member. Dr.
Lozano has been a member of Neurologix's scientific advisory board since April
2001. He is currently Professor of Neurosurgery and holds the Ronald Tasker
Chair in Stereotactic and Functional Neurosurgery at The University of Toronto.
Dr. Lozano received his M.D. from the University of Ottawa and a Ph.D. from
McGill University. He completed a residency in Neurosurgery at the Montreal
Neurological Institute prior to joining the staff at the University of Toronto.
Dr. Lozano is currently the Secretary of both the American Society for
Stereotactic and Functional Neurosurgery and the World Society for Stereotactic
and Functional Neurosurgery.
AUDIT COMMITTEE
Messrs. Long and Nickels will serve on the audit committee of the combined
company.
EXECUTIVE COMPENSATION
SUMMARY COMPENSATION TABLE
The following table sets forth all compensation paid by Change or
Neurologix for the last three fiscal years to the chief executive officer
(president) and the other executive officer of the combined company.
ANNUAL COMPENSATION LONG-TERM COMPENSATION
----------------------------------- --------------------------------------
OTHER RESTRICTED SECURITIES
NAME AND ANNUAL STOCK UNDERLYING ALL OTHER
PRINCIPAL POSITION YEAR SALARY BONUS COMPENSATION AWARDS OPTIONS LTIP PAYOUTS COMPENSATION
------------------ ---- ------- ----- ------------ ---------- ---------- ------------ ------------
Martin Kaplitt,...... 2002 $24,000 $0 $0 -- -- -- $0
president and 2001 24,000 0 0 -- -- -- 0
director 2000 24,000 0 0 -- -- -- 0
Mark Hoffman,........ 2002 $ 0 $0 $0 -- -- -- $0
secretary, 2001 0 0 0 -- -- -- 0
treasurer
and director 2000 0 0 0 -- -- -- 0
OTHER LONG-TERM COMPENSATION AWARDED OR EXERCISED IN THE LAST FISCAL YEAR
No individual grants of stock options or freestanding stock appreciation
rights ("SARs") were made to Messrs. Kaplitt and Hoffman in the last completed
fiscal year nor did they hold any unexercised options at the end of the last
fiscal year. Messrs. Kaplitt and Hoffman did not exercise any stock options (or
tandem SARs) or freestanding SARS during the last completed fiscal year. No
awards were made to Messrs. Kaplitt and Hoffman under any long-term incentive
plan in the last fiscal year.
DIRECTOR COMPENSATION
Following the Merger, the combined company intends to evaluate potential
compensation arrangements for non-employee directors and implement a new
compensation policy. Directors who are employees of the combined company will
not receive any fees for their service on the board of directors or a committee.
EMPLOYMENT AGREEMENTS
CHANGE
Change is not a party to any employment agreement with any individual who
is expected to serve as a director or executive officer of the combined company.
67
NEUROLOGIX
Neurologix is not a party to any employment agreement with any individual
who is expected to serve as a director or executive officer of the combined
company.
CONSULTING AGREEMENTS
Dr. Michael Kaplitt. In October 1999, Neurologix entered into a consulting
agreement with Dr. Michael Kaplitt. Under the agreement, Dr. Kaplitt has agreed
to serve on Neurologix's scientific advisory board and provide to Neurologix, on
an exclusive basis, scientific and other requested consulting services regarding
human gene therapy using adenovirus and adeno-associated virus vectors in the
nervous system, which is referred to in the agreement as the "Field." Neurologix
agreed to pay Dr. Kaplitt $12,500 per quarter as compensation for his services,
which quarterly amount was increased to $18,500 beginning on April 1, 2002.
Because of his role in the pending Phase I clinical trial of Neurologix's gene
therapy products to treat Parkinson's disease, Dr. Kaplitt agreed to waive these
payments effective as of April 2, 2003. The agreement expires on September 30,
2007, unless earlier terminated for cause by either party upon 30 days' written
notice to the other party. Dr. Kaplitt has agreed to indemnify Neurologix and
its directors, officers and controlling shareholders against any claims or suits
arising from Dr. Kaplitt's performance of services to Neurologix under the
agreement or from the use of any information or products which result from his
performance under the agreement.
As part of his consulting agreement with Neurologix, Dr. Kaplitt entered
into a confidentiality, proprietary information and inventions agreement for
Neurologix's benefit. Under this agreement, Dr. Kaplitt has assigned to
Neurologix all of his rights to any intellectual property related to the Field
that arises from research or consulting services performed during the course of
the consulting arrangement. The assignment specifically excludes any
intellectual property developed outside the course of Dr. Kaplitt's engagement
by Neurologix or in which the academic institution with which he is affiliated
claims rights. Dr. Kaplitt has agreed to keep confidential all of Neurologix's
proprietary information and not to disclose or permit the use or disclosure of
any of Neurologix's proprietary information without Neurologix's prior written
consent. Dr. Kaplitt has agreed that during the term of his consulting
relationship with Neurologix and for one year after its termination not to
engage, directly or indirectly, in any activity concerning the Field in the
United States or Canada that Neurologix determines in good faith to be in
competition with it. During the term of his consulting relationship with
Neurologix and for two years thereafter, Dr. Kaplitt will not solicit or
encourage any employee of or consultant to Neurologix to leave Neurologix or
compete with Neurologix. Dr. Kaplitt also will not, during the term of his
consulting relationship, plan or take preliminary steps to set up or engage in
any competing business in the Field. In accordance with the policies of the
educational institutions with which Dr. Kaplitt is associated, Dr. Kaplitt is
entitled to receive a portion of the income that such institutions receive from
patents on which Dr. Kaplitt is listed as an inventor, which includes patents
licensed to Neurologix.
Dr. Matthew During. In October 1999, Neurologix entered into a consulting
agreement with Dr. Matthew During. Under the agreement, Dr. During has agreed to
serve on Neurologix's scientific advisory board and provide to Neurologix, on an
exclusive basis, scientific and other requested consulting services regarding
the Field. Neurologix agreed to pay Dr. During $25,000 per quarter as
compensation for his services, which quarterly amount was increased to $31,000
beginning on April 1, 2002. The agreement expires on September 30, 2007, unless
earlier terminated for cause by either party upon 30 days' written notice to the
other party. Dr. During has agreed to indemnify Neurologix and its directors,
officers and controlling shareholders against any claims or suits arising from
Dr. During's performance of services to Neurologix under the agreement or from
the use of any information or products which result from his performance under
the agreement.
As part of his consulting agreement with Neurologix, Dr. During entered
into a confidentiality, proprietary information and inventions agreement for
Neurologix's benefit. Under this agreement, Dr. During has assigned to
Neurologix all of his rights to any intellectual property related to the Field
that arises from research or consulting services performed during the course of
the consulting arrangement. The assignment specifically excludes any
intellectual property developed outside the course of Dr. During's engagement by
68
Neurologix or in which the academic institution with which he is affiliated
claims rights. Dr. During has agreed to keep confidential all of Neurologix's
proprietary information and not to disclose or permit the use or disclosure of
any of Neurologix's proprietary information without Neurologix's prior written
consent. Dr. During has agreed that during the term of his consulting
relationship with Neurologix and for one year after its termination not to
engage, directly or indirectly, in any activity concerning the Field in the
United States or Canada that Neurologix determines in good faith to be in
competition with it. During the term of his consulting relationship with
Neurologix and for two years thereafter, Dr. During will not solicit or
encourage any employee of or consultant to Neurologix to leave Neurologix or
compete with Neurologix. Dr. During also will not, during the term of his
consulting relationship, plan or take preliminary steps to set up or engage in
any competing business in the Field. In accordance with the policies of the
educational institutions with which Dr. During is associated, Dr. During is
entitled to receive a portion of the income that such institutions receive from
patents for which Dr. During is listed as an inventor, which includes patents
licensed to Neurologix.
BENEFIT PLANS
THE EXISTING CHANGE INCENTIVE PLAN
Outstanding Change stock options are governed by Change's current incentive
plan and option agreements between Change and the optionees, Change's 2000 Stock
Option Plan (the "Plan"). The following description of the Plan merely
summarizes certain provisions and is qualified in its entirety by the full text
of the Plan.
Purpose. The purpose of the Plan is to provide a means through which
Change and its affiliates may attract able persons to enter and remain in the
employ of Change and affiliates and to provide a means whereby employees,
directors and consultants of Change and its affiliates can acquire and maintain
Change common stock ownership, thereby strengthening their commitment to the
welfare of Change and its affiliates and promoting an identity of interest
between shareholders and these directors, employees and consultants.
Administration. The Plan is administered by Change's compensation
committee.
Eligible Participants. Any employee, director or consultant to Change or
an affiliate of Change is eligible to participate in the Plan. However, Change
does not presently allow holders of warrants of Change to participate in the
Plan. The compensation committee has the sole and complete authority to
determine the participants to whom stock options shall be granted (a
"Participant" or the "Participants").
Shares of Change Common Stock Authorized under the Plan. The Plan
authorizes the grant of stock options to Participants with respect to a maximum
of 20,000,000 shares of Change's common stock, which awards may be made in the
form of (a) non- qualified stock options and (b) stock options intended to
qualify as incentive stock options ("ISOs") under Section 422 of the Code. In
any calendar year, a Participant may not receive stock options for more than
3,000,000 shares of Change common stock, subject to adjustments in a manner that
will not cause the stock options granted under the Plan to fail to qualify as
"performance-based compensation" for purposes of Section 162(m) of the Code. To
the extent the aggregate fair market value (determined as of the date of grant)
of stock for which incentive stock options are exercisable for the first time by
any Participant during any calendar year (under all plans of Change) exceeds
$100,000, such excess incentive stock options shall be treated as non-qualified
stock options. If any award granted under the Plan is forfeited, or if an award
has expired, terminated or been canceled for any reason whatsoever (other than
by reason of exercise or vesting), then the shares of Change common stock
covered by such award may be granted to another Participant pursuant to the
terms of the Plan, to the maximum extent permitted under Section 162(m) of the
Code.
Effective Date and Duration of the Plan. The Plan was approved by the
Change board of directors on March 28, 2000 and became effective on the date of
its approval by stockholders of Change. The term during which awards may be
granted under the Plan expire on March 28, 2010.
Stock Option Price. The exercise price per share of Change common stock
for each stock option is set by Change's compensation committee at the time of
grant. The compensation committee is entitled to set an
69
exercise price below the fair market value of a share of Change common stock at
the date of grant solely in the event of it decides to grant non qualified stock
options to a director of Change.
Manner of Exercise and Form of Payment. No shares of Change common stock
may be delivered pursuant to any exercise of an option until payment in full of
the aggregate exercise price therefor is received by Change. Stock options which
have become exercisable may be exercised by delivery of written notice of
exercise to the compensation committee accompanied by payment of the stock
option price. The stock option price shall be payable in cash and if the
compensation committee so permits, partially or completely in shares of Change
common stock valued at the fair market value at the time the stock option is
exercised; provided, however, that such shares are not subject to any pledge or
other security interest and have either been held by the Participant for six
months, previously acquired by the Participant on the open market or meet such
other requirements as the compensation committee may determine necessary in
order to avoid an accounting earnings charge in respect of the stock option) or,
in the discretion of the compensation committee, either (i) in other property
having a fair market value on the date of exercise equal to the stock option
price, or (ii) by such other method as the compensation committee may permit.
Vesting, Stock Option Period and Expiration. Stock options vest and become
exercisable in such manner and on such date or dates determined by the
compensation committee and expire after such period, not to exceed ten years, as
may be determined by the compensation committee all as set forth in an
applicable stock option agreement; provided, that the compensation committee has
the authority to accelerate the exercisability of any outstanding option at such
time and under such circumstances as it, in its sole discretion, deems
appropriate. If a stock option is exercisable in installments, such installments
or portions thereof which become exercisable shall remain exercisable until the
stock option expires. If an incentive stock option is granted to a Participant
who owns stock representing more than ten percent of the voting power of all
classes of stock of Change, the stock option period may not exceed five years
from the date of grant of such option and the stock option price shall be at
least 110 percent of the fair market value (on the date of grant) of the stock
subject to the stock option.
Change of Control or Reorganization. Except to the extent reflected in a
particular stock option agreement:
(a) In the event of a Change in Control (as defined in the Plan),
notwithstanding any vesting schedule, all stock options shall become
immediately exercisable with respect to all shares subject to such stock
option.
(b) The obligations of Change under the Plan are binding upon any
successor corporation or organization resulting from the Merger,
consolidation or other reorganization of Change, or upon any successor
corporation or organization succeeding to substantially all of the assets
and business of Change. Change agreed to make appropriate provisions for
the preservation of Participants' rights under the Plan in any agreement or
plan which it may enter into or adopt to effect any such Merger,
consolidation, reorganization or transfer of assets.
Transferability. Each award and each right under any award, is exercisable
only by the Participant during the Participant's lifetime or if permissible
under applicable law, by the Participant's guardian or legal representative. No
award may be assigned, alienated, pledged, attached, sold or otherwise
transferred or encumbered by a Participant other than by will or by the laws of
descent and distribution and any such purported assignment, alienation, pledge,
attachment, sale, transfer or encumbrance shall be void and unenforceable
against Change or any of its affiliates; provided that the designation of a
beneficiary will not constitute an assignment, alienation, pledge, attachment,
sale, transfer or encumbrance. The Plan provides for limited exceptions to the
non-transferability of the awards (and the rights attached thereto) received
under the Plan, such exceptions to be inserted in the relevant stock option
agreement or amendment thereto.
Amendment. The Change board of directors may amend, alter, suspend,
discontinue, or terminate the Plan or any portion thereof at any time; provided
that no such amendment, alteration, suspension, discontinuation or termination
shall be made without shareholder approval if such approval is necessary to
comply with any tax or regulatory requirement applicable to the Plan (including
as necessary to prevent the
70
stock options granted under the Plan from failing to qualify as
"performance-based compensation" for purposes of Section 162(m) of the Code);
and provided further that any such amendment, alteration, suspension,
discontinuance or termination that would impair the rights of any Participant or
any holder or beneficiary of any stock option theretofore granted shall not to
that extent be effective without the consent of the affected Participant, holder
or beneficiary.
Federal Income Tax Consequences Relating to the Plan. The following
summary of the federal income tax consequences of the grant and exercise of
stock options, both ISOs and non qualified stock options, awarded under the
Plan, and the disposition of Change common stock purchased pursuant to the
exercise of such stock options, is intended to reflect the current provisions of
the Code and the regulations thereunder. The summary is not intended to be a
complete statement of applicable laws, it does not address state and local tax
considerations nor does it address the tax consequences of options granted to
individual tax payers located outside the U.S. and is not intended as tax advice
to any person. Moreover the U.S. Federal income tax consequences to any
particular individual may differ from those described herein by reason of the
particular circumstances of such individual.
No income is realized by an optionee upon grant of a non-qualified stock
option. Upon exercise of a non-qualified stock option, the optionee recognizes
ordinary compensation income in an amount equal to the excess, if any, of the
fair market value of the underlying stock over the option exercise price (the
"Spread") at the time of exercise. The Spread is deductible by Change for
federal income tax purposes subject to the possible limitations on deductibility
under Sections 280G and 162(m) of the Code of compensation paid to executives
designated in those sections. The optionee's tax basis in the underlying shares
acquired by exercise of a non-qualified stock option equals the exercise price
plus the amount taxable as compensation to the optionee. Upon sale of the shares
received by the optionee upon exercise of the non-qualified stock option, any
gain or loss is generally long-term or short-term capital gain or loss,
depending on the holding period. The optionee's holding period for shares
acquired pursuant to the exercise of a non-qualified stock option will begin on
the date of exercise of such option.
Pursuant to currently applicable rules under Section 16(b) of the
Securities Exchange Act of 1933, as amended, the grant of an option (and not its
exercise) to a person who is subject to the reporting and short-swing profit
provisions under Section 16 of the Exchange Act (a "Section 16 Person") begins
the six-month period of potential short-swing liability. The taxable event for
the exercise of an option that has been outstanding at least six months
ordinarily will be the date of exercise. Under current rules promulgated under
Section 16(b), the six month period of potential short-swing liability may be
eliminated if the option grant (i) is approved in advance by the Change board of
directors (or a committee composed solely of two or more non-employee directors)
or (ii) approved in advance, or subsequently ratified, by Change's shareholders
no later than the next annual meeting of shareholders. If the grant satisfies
either of the conditions described in clause (i) or (ii) above, the taxable
event will ordinarily be the date of exercise. However, if an option is
exercised by a Section 16 Person within six months after the date of grant and
neither of the conditions described in clause (i) or (ii) above are satisfied,
taxation will be deferred until the date which is six months after the date of
grant, unless the person has filed a timely election pursuant to section 83(b)
of the Code to be taxed on the date of exercise.
The Code requires that, for ISO treatment, shares acquired through exercise
of an ISO cannot be disposed of before two years from the date of grant of the
option and one year from the date of exercise. ISO holders generally incur no
federal income tax liability at the time of grant or upon exercise of such
options. However, the Spread at exercise will be an "item of tax preference"
which may give rise to "alternative minimum tax" liability for the taxable year
in which the exercise occurs at the time of exercise. If the optionee does not
dispose of the shares before two years following the date of grant and one year
following the date of exercise, the difference between the exercise price and
the amount realized upon disposition of the shares will constitute long-term
capital gain or loss, as the case may be. Assuming both holding periods are
satisfied, no deduction is permitted to be taken by Change for federal income
tax purposes in connection with the grant or exercise of the option. If, within
two years following the date of grant or within one year following the date of
exercise, the holder of shares acquired through the exercise of an ISO disposes
of such shares, the optionee will generally realize ordinary taxable
compensation at the time of such disposition equal to the difference
71
between the exercise price and the lesser of the fair market value of the stock
on the date of initial exercise or the amount realized on the subsequent
disposition, and such amount is generally deductible by Change for federal
income tax purposes, subject to the possible limitations on deductibility under
Sections 280G and 162(m) of the Code for compensation paid to executives
designated in those sections.
The payment of an optionee of the exercise price, in full or in part, with
previously acquired shares will not affect the tax treatment of the exercise
described above. No gain or loss generally will be recognized by the optionee
upon the surrender of the previously acquired shares of Change, and shares
received by the optionee, equal in number to the previously surrendered shares,
have the same tax basis as the shares surrendered to Change and have a holding
period that includes the holding period of the shares surrendered. The value of
shares received by the optionee in excess of the number of shares surrendered to
Change is taxable to the optionee. Such additional shares have a tax basis equal
to the fair market value of such additional shares as of the date ordinary
income is recognized and have a holding period that begins on the date ordinary
income is recognized.
In general, Section 162(m) of the Code denies a publicly held corporation a
deduction for federal income tax purposes for compensation in excess of
$1,000,000 per year per person to its chief executive officer and the four other
officers whose compensation is disclosed in its proxy statement, subject to
certain exceptions. Options will generally qualify under one of these exceptions
if they are granted under a plan that states the maximum number of shares with
respect to which options may be granted to any employee during a specified
period, the exercise price is not less than the fair market value of the common
stock at the time of grant and the plan under which the options are granted is
approved by stockholders and is administered by a compensation committee
comprised of outside directors. The Plan is intended to satisfy these
requirements with respect to grants of options to covered employees.
THE EXISTING NEUROLOGIX INCENTIVE PLAN
Outstanding Neurologix stock options and restricted stock awards are
governed by the Neurologix, Inc. 2001 Stock Plan (the "Stock Plan"), option
agreements between Neurologix and the optionees and restricted stock award
agreements between Neurologix and restricted stock grantees.
Purpose. The purposes of the Stock Plan are to attract and retain the best
available personnel for positions of substantial responsibility within
Neurologix, to provide incentives to existing employees, directors and
consultants of Neurologix and to promote the success of Neurologix's business.
Administration. The Stock Plan may be administered by the Neurologix board
of directors or a committee of the Neurologix board of directors (either, as
applicable, the "Administrator"). Currently, the Stock Plan is administered by
the entire Neurologix board of directors.
Eligible Participants. Any employee, director, consultant or other
independent advisor to Neurologix or an affiliate of Neurologix is eligible to
participate in the Stock Plan. However, the Administrator has the sole and
complete authority to determine the participants to whom stock options shall be
granted (each, a "Participant"; collectively, the "Participants").
Shares of Neurologix Common Stock Authorized under the Stock Plan. The
maximum aggregate number of shares of Neurologix's common stock that can be
optioned and sold or granted under the Stock Plan is 1,400,000 shares. Awards
may be made in the form of (a) non-qualified stock options ("NSOs"); (b) stock
options intended to qualify as incentive stock options ("ISOs") under Section
422 of the Code; or (c) restricted stock awards. If a single optionee becomes
eligible in any given year to exercise ISOs (under all plans of Neurologix and
any parent or subsidiary of Neurologix) for shares having a fair market value
(determined as of the date of grant) in excess of $100,000, those options
representing the excess of fair market value over $100,000 shall be treated as
NSOs. For the purpose of deciding which options apply to shares that "exceed"
the $100,000 limit, ISOs shall be taken into account in the same order as
granted. The shares issued under the Stock Plan may be authorized, but unissued,
or reacquired Neurologix common stock. If a stock option expires, becomes
unexercisable without having been exercised in full or is surrendered in
connection with an option exchange program, the unpurchased shares that were
subject to such option become available
72
for future grant or sale under the Stock Plan (unless the Stock Plan has
terminated); provided, however, that shares that actually have been issued under
the Stock Plan, whether upon exercise of a stock option or stock purchase right,
may not be returned to the Stock Plan and may not become available for future
distribution under the Stock Plan; except that if shares of restricted common
stock of Neurologix are repurchased by Neurologix at their original purchase
price, such shares do become available for future grant or sale under the Stock
Plan.
Effective Date and Duration of the Stock Plan. The Stock Plan was approved
by joint resolution of the Board and stockholders of Neurologix, dated December
12, 2001, and became effective on that date. The term during which awards may be
granted under the Stock Plan expires on December 11, 2011.
Stock Option Price. The exercise price per share of Neurologix common
stock for each stock option is set by the Administrator at the time of grant.
With respect to the issuance of NSOs, the Administrator is entitled to set an
exercise price below the fair market value of a share of Neurologix common stock
at the date of grant. With respect to the issuance of ISOs to an employee who,
at the time the ISO is granted, owns stock representing more than 10% of the
voting power of all classes of stock of Neurologix, Inc., the per-share exercise
price may be no less than 110% of the fair market value per share of common
stock on the date of grant.
Manner of Exercise and Form of Payment. No shares of Neurologix common
stock may be delivered pursuant to any exercise of an option until payment in
full of the aggregate exercise price therefor is received by Neurologix,
together with appropriate proof that the person exercising the option (if other
than the optionee) has the right to effect such exercise. Stock options that
have become exercisable may be exercised by delivery of written notice of
exercise to the Administrator accompanied by payment of the stock option price.
The Administrator is responsible for determining the acceptable form of
consideration for exercising an option, including the method of payment. In the
case of an ISO, the Administrator determines the acceptable form of
consideration at the time of grant. Such consideration may consist entirely of
cash, check, promissory note, such other shares of Neurologix stock owned by the
optionee as meet certain restrictions, consideration received by Neurologix
under a cashless exercise program implemented by Neurologix in connection with
the Stock Plan, a reduction in the amount of any Neurologix liability to the
optionee, including any liability attributable to the optionee's participation
in any Neurologix-sponsored deferred compensation program or arrangement, any
combination of the foregoing methods of payment or such other consideration or
methods of payment as are permitted by applicable law. Optionees are required to
satisfy all applicable income and employment tax withholding requirements at the
time of exercise.
Vesting, Stock Option Period and Expiration. Stock options vest and become
exercisable in such manner and on such date or dates as determined by the
Administrator. They expire after such period, not to exceed ten years, as may be
determined by the Administrator, all as set forth in an applicable stock option
agreement. In the event that the applicable option agreement does not provide
for a vesting schedule, an option vests and becomes exercisable as to one-third
of the shares subject to the option on each of the first three anniversaries of
its date of grant. Unless the Administrator provides otherwise, the vesting of
an optionee's options is tolled during any unpaid leave of absence of that
optionee.
Restricted Stock Awards: Rights and Lapse of Forfeiture Provisions. Except
with respect to the ability to transfer or encumber restricted shares, the
recipient of a restricted stock award receives all of the rights of a
stockholder of Neurologix, with respect to the shares that are the subject of
the award, including the right to vote the shares and the right to receive any
cash dividends. Certificates for shares of unrestricted stock are delivered to
grantees only if and after the period of forfeiture with respect to such shares
expires. The risk of forfeiture with respect to restricted stock awards lapses
in such manner and on such date or dates as determined by the Administrator, all
as set forth in an applicable restricted stock award agreement. In the event
that the restricted stock award agreement does not specify when the risk of
forfeiture shall expire with respect to the subject restricted shares, the Stock
Plan provides that the risk of forfeiture lapses as to one-third of the shares
subject to the restricted stock award agreement on the each of the first three
anniversaries of the grant of the restricted stock award.
73
Changes in Capitalization; Dissolution or Liquidation; Change in
Control. Except to the extent reflected in a particular stock option agreement
or restricted stock award agreement:
(a) Subject to any required action by the stockholders of Neurologix, the
number of shares of Neurologix common stock covered by each outstanding option
and restricted stock award (and the number of shares of Neurologix common stock
authorized for issuance under the Stock Plan but as to which no options or
restricted stock awards have been granted or that have been returned to the
Stock Plan upon cancellation or expiration of an option or forfeiture of a
restricted stock award), as well as the price per share of Neurologix common
stock covered by each such outstanding option or restricted stock award, is to
be proportionately adjusted for any increase or decrease in the number of issued
shares of Neurologix common stock resulting from a stock split, reverse stock
split, stock dividend, combination, or reclassification of the Neurologix common
stock, or any other increase or decrease in the number of issued shares of
Neurologix common stock effected without receipt of consideration by Neurologix.
(b) In the event of the proposed dissolution or liquidation of Neurologix,
the Administrator is to notify each optionee as soon as practicable prior to the
effective date of such proposed transaction. The Administrator, in its
discretion, may provide for an optionee to have the right to exercise his or her
option until 10 days prior to such transaction as to all of the optioned
Neurologix common stock covered thereby, including shares as to which the option
otherwise would not be exercisable. In addition, the Administrator may provide
that any Neurologix repurchase option applicable to restricted shares shall
lapse as to all such shares, provided that the proposed dissolution or
liquidation takes place at the time and in the manner contemplated. To the
extent not been previously exercised, options terminate immediately prior to the
consummation of such proposed action.
(c) In the event of a Merger or consolidation of Neurologix with or into
another corporation or any other entity or the exchange of substantially all of
the outstanding stock of Neurologix for shares of another entity or other
property in which, after either transaction, the prior stockholders of
Neurologix own less than 50% of the voting shares of the continuing or surviving
entity, or in the event of the sale of all or substantially all of the assets of
Neurologix, (either event, a "Change in Control"), the Stock Plan provides that
each outstanding option shall be assumed or an equivalent option or right
substituted by the successor corporation or a parent or subsidiary of the
successor corporation. In the event that the Administrator determines that the
successor corporation or a parent or a subsidiary of the successor corporation
has refused to assume or substitute an equivalent option or right for each
outstanding option, the optionees shall vest fully in and have the right to
exercise each outstanding option as to all of the optioned Neurologix common
stock covered thereby, including shares that otherwise would not be vested or
exercisable. All outstanding options are considered assumed if, following the
consummation of the Change in Control, the option confers the right to purchase
or receive, for each Share of stock subject to the option immediately prior to
the consummation of the Change in Control, the consideration (whether stock,
cash, or other securities property) received in the Change in Control by holders
of Neurologix common stock for each share held on the effective date of the
transaction (and if holders were offered a choice of consideration, the type
chosen by the holders of a majority of the outstanding shares); provided,
however, that if such consideration received in the Change in Control is not
solely common stock of the successor corporation or its parent, the
Administrator may, with the consent of the successor corporation, provide for
the consideration to be received upon the exercise of the option to be, for each
share of optioned stock subject to the option, solely common stock of the
successor corporation or its parent or subsidiary equal in fair market value to
the per-share consideration received by holders of common stock in the Change in
Control.
Transferability. Unless determined otherwise by the Administrator, an
option or restricted stock award may not be sold, pledged, assigned,
hypothecated, transferred, or disposed of in any manner other than by will or by
the laws of descent or distribution and may be exercised, during the lifetime of
the optionee, only by the optionee. In a case in which the Administrator makes
an option or restricted stock award transferable, the Administrator may include
in that option or restricted stock such additional terms and conditions as the
Administrator may deem appropriate.
74
Amendment and Termination. The Neurologix board of directors may at any
time amend, alter, suspend, or terminate the Stock Plan. No amendment,
alteration, suspension, or termination of the Stock Plan may impair the rights
of any optionee, unless mutually agreed otherwise between the optionee and the
Administrator, which agreement must be in writing and signed by the optionee and
Neurologix. Termination of the Stock Plan does not affect the Administrator's
ability to exercise the powers granted to it with respect to options granted
under the Stock Plan prior to the date of termination.
Federal Income Tax Consequences Relating to Stock Plan Options. The
following summary of the federal income tax consequences of the grant and
exercise of stock options, both ISOs and NSOs, awarded under the Stock Plan and
the disposition of Neurologix common stock purchased pursuant to the exercise of
such stock options is intended to reflect the current provisions of the Code and
the regulations thereunder. The summary is not intended to be a complete
statement of applicable laws, it does not address state and local tax
considerations and it does not address the tax consequences of options granted
to individual taxpayers located outside the U.S. It is not intended to be tax
advice to any person. Moreover the U.S. federal income tax consequences to any
particular individual may differ from those described herein by reason of the
particular circumstances of such individual.
(a) No income is recognized by an optionee upon the grant of an NSO. Upon
exercise of an NSO, the optionee recognizes ordinary compensation income at the
time of exercise in an amount equal to the excess, if any, of the fair market
value of the underlying stock over the option exercise price (the "Spread"). The
Spread generally is deductible by Neurologix for federal income tax purposes.
The optionee's tax basis in the underlying shares acquired by exercise of an NSO
equals the exercise price plus the amount taxable as compensation to the
optionee. Upon sale of the shares received by the optionee due to the exercise
of the NSO, any gain or loss generally is long-term or short-term capital gain
or loss, depending upon the holding period. If the Optionee holds NSO shares for
at least one year, any gain realized on disposition of the Shares will be
treated as long-term capital gain for federal income tax purposes. The
optionee's holding period for shares acquired pursuant to the exercise of an NSO
begins on the date of exercise of such option.
(b) The Code requires that, for ISO treatment, shares acquired through
exercise of an ISO cannot be disposed of before two years from the date of grant
of the option and one year from the date of exercise. ISO holders generally
incur no federal income tax liability at the time of grant or upon exercise of
their ISOs. However, the Spread at exercise will be an "item of tax preference,"
which may give rise to alternative minimum tax liability for the taxable year in
which the exercise occurs. If the optionee does not dispose of the shares before
two years following the date of grant and one year following the date of
exercise, the difference between the exercise price and the amount realized upon
disposition of the shares will constitute long-term capital gain or loss, as the
case may be. Assuming both holding periods are satisfied, no deduction is
permitted to be taken by Neurologix for federal income tax purposes in
connection with the grant or exercise of the option. If, within two years
following the date of grant or within one year following the date of exercise,
the holder of shares acquired through the exercise of an ISO disposes of such
shares, the optionee generally will recognize ordinary compensation income at
the time of such disposition. Such income will be equal to the lesser of (x) the
excess of the fair market value of the stock on the date of initial exercise
over the exercise price and (y) the excess of the amount realized on the
subsequent disposition over the exercise price. The amount of such recognized
income generally is deductible by Neurologix for federal income tax purposes.
(c) The payment by an optionee of the exercise price, in full or in part,
with previously acquired shares will not affect the tax treatment of the
exercise described above. No gain or loss generally will be recognized by the
optionee upon the surrender of the previously acquired shares of Neurologix and
shares received by the optionee, equal in number to the previously surrendered
shares, will have the same tax basis as the shares surrendered to Neurologix and
will have a holding period that includes the holding period of the shares
surrendered. The value of shares received by the optionee in excess of the
number of shares surrendered to Neurologix is taxable to the optionee. Such
additional shares have a tax basis equal to the fair market value of such
additional shares as of the date ordinary income is recognized and have a
holding period that begins on the date ordinary income is recognized.
75
Federal Income Tax Consequences Relating to Restricted Stock
Awards. Restricted stock awards under the Stock Plan are transfers of property,
subject to a "substantial risk of forfeiture," in exchange for services.
Consequently, the federal tax consequences of the receipt of a restricted stock
award are governed by section 83 of the Code. Absent an "83(b) election" by the
grantee of the restricted stock award, taxable income will be measured and
recognized by the grantee at the time or times on which Neurologix's repurchase
option lapses. Such gain will be equal to the excess, if any, of the fair market
value of the stock as to which the repurchase option has lapsed (with fair
market value measured at the time of such lapse) over the amount, if any, paid
by the grantee for such stock at the time of grant. An 83(b) election may be
filed by the grantee with the Internal Revenue Service within 30 days of the
grantee's receipt of the restricted shares. The consequence of the election is
that the grantee will be taxed, pursuant to section 83(b) of the Code, at the
time of grant on the excess, if any, of the fair market value of the restricted
shares (with fair market value measured at the time of grant) over the amount
paid, if any, by the grantee for the restricted shares. A grantee who makes such
an election will not recognize income at the time or times that Neurologix's
repurchase option with respect to such shares lapses, notwithstanding that the
fair market value of such shares may increase between the date of grant and the
date or dates on which Neurologix's repurchase option lapses. Neurologix
generally may take a tax deduction with respect to a restricted stock award at
the time and to the extent that the grantee of such restricted stock award
recognizes income.
76
CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS
CHANGE
Members of the board and management of Change have interests in the Merger
and the transactions related to it. Such interests are summarized in the section
of this proxy statement and prospectus entitled "The Merger -- Interests of
Certain Persons in the Merger."
NEUROLOGIX
Members of the board and management of Neurologix have interests in the
Merger. Such interests are summarized in the section of this proxy statement and
prospectus entitled "The Merger -- Interests of Certain Persons in the Merger."
There are a number of transactions that have been entered into by
Neurologix with its officers, directors and significant stockholders in
connection with the Merger and the transactions related to it. Those
transactions are summarized in the section of this proxy statement and
prospectus entitled "The Merger -- Interests of Certain Persons in the Merger."
77
SELECTED HISTORICAL FINANCIAL DATA OF CHANGE
The table below presents Change's selected historical financial data for
the fiscal years ended December 31, 1998, 1999, 2000, 2001 and 2002 and for the
nine months ended September 30, 2002 and 2003. The selected historical financial
data for the fiscal years ended December 31, 1998 and 1999 have been derived
from audited financial statements not included in this proxy statement and
prospectus. The selected historical financial data for the fiscal years ended
December 31, 2000, 2001 and 2002 have been derived from audited financial
statements included elsewhere in this proxy statement and prospectus. The audit
opinion to these financial statements contains an explanatory paragraph that
states that Change adopted a plan of liquidation and dissolution which raises
substantial doubt about its ability to continue as a going concern. The
consolidated financial statements do not include any adjustments that might
result from the outcome of that uncertainty. The audit opinion also contains an
explanatory paragraph that refers to changes in Change's method of accounting
for goodwill and other intangibles. The selected historical financial data for
the nine months ended September 30, 2002 and 2003 have been derived from
unaudited condensed financial statements included elsewhere in this proxy
statement and prospectus. The unaudited condensed financial statements, in the
opinion of management, include all adjustments, consisting only of normal
recurring adjustments, necessary for a fair statement of the results for the
unaudited interim periods. The results for any interim period are not
necessarily indicative of the results that may be expected for a full year.
On June 30, 2003, Change sold all of the issued and outstanding shares of
its Canned Interactive subsidiary. Accordingly, the operations of Canned for all
periods presented have been reclassed into a one-line presentation and are
included in "Income (loss ) from discontinued operations."
You should read this information in conjunction with the audited
consolidated financial statements, including the notes to those statements, and
"Management's Discussion and Analysis of Financial Condition and Results of
Operations of Change" included elsewhere in this report.
NINE MONTHS ENDED
FISCAL YEAR ENDED DECEMBER 31, SEPTEMBER 30,
----------------------------------------------- -----------------
2002 2001 2000 1999 1998 2003 2002
------- -------- -------- ------ ------ ------- -------
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)
STATEMENT OF OPERATIONS DATA:
Revenues............................ $ -- $ 4,596 $ 1,370 $ -- $ -- $ -- $ --
Cost of Revenues.................... -- 6,088 1,119 -- -- -- --
------- -------- -------- ------ ------ ------- -------
Gross (loss) profit................. -- (1,492) 251 -- -- -- --
Operating expenses:
General and administrative.......... 3,342 12,894 3,305 12 11 2,275 2,667
Equity based compensation........... 377 3,086 2,921 -- 358 394
Severance........................... -- 1,326 -- -- -- 140 --
Loss on disposal of subsidiaries.... -- 377 -- -- -- -- --
Impairment losses................... 69 7,263 -- -- -- -- --
------- -------- -------- ------ ------ ------- -------
Loss from operations................ (3,788) (26,438) (5,975) (12) (11) (2,773) (3,061)
Other income (expense).............. 194 (4,687) (263) 20 (42) 271 24
------- -------- -------- ------ ------ ------- -------
(Loss) income from continuing
operations before extraordinary
item.............................. (3,594) (31,125) (6,238) 8 (53) (2,502) (3,037)
Income (loss) from discontinued
operations........................ 93 (1,075) -- -- -- (1,899) (26)
------- -------- -------- ------ ------ ------- -------
(Loss) income before extraordinary
item.............................. (3,501) (32,200) (6,238) 8 (53) (4,401) (3,063)
Extraordinary item.................. -- -- -- -- 666 -- --
------- -------- -------- ------ ------ ------- -------
Net (loss) income................... (3,501) (32,200) (6,238) 8 613 (4,401) (3,063)
Dividends........................... -- -- -- (14) (24) -- --
Deemed dividend attributable to
issuance of convertible preferred
stock............................. -- -- 40,000 -- -- -- --
------- -------- -------- ------ ------ ------- -------
Net (loss) income applicable to
common stockholders............... (3,501) (32,200) (46,238) (6) 589 (4,401) (3,063)
78
NINE MONTHS ENDED
FISCAL YEAR ENDED DECEMBER 31, SEPTEMBER 30,
----------------------------------------------- -----------------
2002 2001 2000 1999 1998 2003 2002
------- -------- -------- ------ ------ ------- -------
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)
Basic and diluted income (loss) per
common share from continuing
operations........................ (0.02) (0.23) (1.31) (0.00) (0.02) (0.01) (0.01)
Discontinued operations............. (0.00) (0.00) (0.00) (0.00) (0.00) (0.01) (0.00)
Extraordinary item.................. (0.00) (0.00) (0.00) (0.00) 0.15 (0.00) (0.00)
------- -------- -------- ------ ------ ------- -------
Basic and diluted net income (loss)
per common share.................. $ (0.02) $ (0.23) $ (1.31) $(0.00) $ 0.13 $ (0.02) $ (0.01)
BALANCE SHEET DATA:
Cash, cash equivalents and
marketable securities............. $ 2,944 $ 8,702 $ 30,333 $ 245 $ 173 $ 5,963 $ 1,533
Working capital..................... 8,413 10,660 30,012 245 236 7,249 8,551
Total assets........................ 12,733 16,152 38,576 246 238 7,705 13,209
Total long-term obligations......... 8 74 15 -- -- -- 38
Stockholders' equity................ 11,619 14,660 37,182 245 236 7,406 12,060
QUARTERLY RESULTS OF OPERATIONS (UNAUDITED)
The following tables set forth unaudited quarterly statement of operations
data of Change for each of Change's ten most recent quarters. In management's
opinion, this unaudited information has been prepared on the same basis as the
audited annual financial statements and includes all adjustments (consisting
only of normal recurring adjustments) necessary for fair presentation of the
unaudited information for the quarters presented. You should read this
information in conjunction with the consolidated financial statements, including
the notes to those statements, included elsewhere in this proxy statement and
prospectus. The results of operations for a quarter are not necessarily
indicative of results that Change may achieve for any subsequent periods and, as
a result of Change's adoption of a plan of liquidation and dissolution,
historical information may not be indicative of future results.
THREE MONTHS ENDED
---------------------------------------------------------------------------
SEPT. 30, JUNE 30, MARCH 31, DEC. 31, SEPT. 30, JUNE 30,
2003 2003 2003 2002 2002 2002
--------- ----------- ----------- --------- --------- -----------
Revenues..................... $ -- $ -- $ -- $ -- $ -- $ --
Cost of revenues............. -- -- -- -- -- --
--------- ----------- ----------- --------- --------- -----------
Gross profit................. -- -- -- -- -- --
General and administrative... 730,000 516,000 1,029,000 744,000 745,000 1,104,000
Equity based compensation
expense.................... 88,000 180,000 90,000 (17,000) 131,000 132,000
Impairment losses............ -- -- -- -- -- 69,000
Severance charges............ -- 140,000 -- -- -- --
Loss on disposal of
subsidiaries............... -- -- -- -- -- --
--------- ----------- ----------- --------- --------- -----------
Loss from operations......... (818,000) (836,000) (1,119,000) (727,000) (876,000) (1,305,000)
Other income (loss), net..... 23,000 (31,000) 279,000 170,000 199,000 (3,000)
--------- ----------- ----------- --------- --------- -----------
Loss from continuing
operations................. (795,000) (867,000) (840,000) (557,000) (677,000) (1,308,000)
Discontinued operations...... -- (1,967,000) 68,000 119,000 (114,000) (44,000)
--------- ----------- ----------- --------- --------- -----------
Net loss..................... (795,000) (2,834,000) (772,000) (438,000) (791,000) (1,352,000)
79
THREE MONTHS ENDED
------------------------------------------------------
MARCH 31, DEC. 31, SEPT. 30, JUNE 30,
2002 2001 2001 2001
----------- ----------- ------------ -----------
Revenues................................ $ -- $ -- $ 1,298,000 $ 1,424,000
Cost of revenues........................ -- -- 1,837,000 2,199,000
----------- ----------- ------------ -----------
Gross profit............................ -- -- (539,000) (775,000)
General and administrative.............. 749,000 2,502,000 2,599,000 5,009,000
Equity based compensation expense....... 131,000 133,000 159,000 165,000
Impairment losses....................... -- -- 7,263,000 --
Severance charges....................... -- -- 1,326,000 --
Loss on disposal of subsidiaries........ -- 377,000 -- --
----------- ----------- ------------ -----------
Loss from operations.................... (880,000) (3,012,000) (11,886,000) (5,949,000)
Other income (loss), net................ (172,000) (518,000) (1,698,000) (2,021,000)
----------- ----------- ------------ -----------
Loss from continuing operations......... (1,052,000) (3,530,000) (13,584,000) (7,970,000)
Discontinued operations................. 132,000 (424,000) (616,000) (35,000)
----------- ----------- ------------ -----------
Net loss................................ (920,000) (3,954,000) (14,200,000) (8,005,000)
80
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF CHANGE
The following discussion should be read in conjunction with Change's
audited consolidated financial statements and accompanying notes for the fiscal
year ended December 31, 2002. Certain statements contained within this
discussion constitute forward-looking statements. Please refer to the section
entitled "Special Note Regarding Forward -- Looking Statements."
ACCOUNTING POLICIES
The preparation of Change's financial statements in conformity with
generally accepted accounting principles in the United States requires Change to
make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Change's estimates, judgments and assumptions are
continually evaluated based on available information and experience. Because of
the use of estimates inherent in the financial reporting process, actual results
could differ from those estimates.
Prior to the divestiture of Papke-Textor, Inc. d/b/a Canned Interactive
("Canned Interactive"), Change derived its revenues from services performed
under one of two pricing arrangements: time-and-materials or fixed-price. The
services performed under either of these arrangements were substantially
identical.
Revenues were recognized for fixed-price arrangements in the period
services were rendered using the percentage-of-completion method, based on the
percentage of costs incurred to date to total estimated projects costs, provided
Change had the ability to produce reasonably dependable estimates, collection of
the resulting receivable was probable and no significant obligations remained.
The cumulative impact of any revision in estimates of the cost to complete and
losses on projects in process were reflected in the period in which they became
known. Canned Interactive's projects were typically short term in nature,
generally spanning less than 90 days.
Revenues were recognized for time-and-materials based arrangements in the
period when the underlying services were rendered, provided collection of the
resulting receivable was probable and no significant obligations remained.
Provisions for estimated project specific losses on both types of contracts
were made during the period in which such losses became probable and could be
estimated. To date, such losses have not been significant.
Any estimation process, including that used in preparing contract
accounting models, involves inherent risk. Change reduced the inherent risk
relating to revenue and cost estimates in percentage-of-completion models
through corporate policy, approval and monitoring processes. Risks relating to
service delivery, productivity and other factors were considered in the
estimation process. For all client contracts, provisions for estimated losses on
individual contracts were made in the period in which the loss first became
apparent.
Change maintained allowances for doubtful accounts for estimated losses
resulting from the inability of customers to make payments. If the financial
condition of Change's customers deteriorated, resulting in the customers'
inability to make payments, additional allowances were required. Additionally,
Change assesses the need for provisions for estimated uncollectible amounts with
respect to its loans receivable resulting from the inability of an issuer to
make payments when they become due. Change bases this estimate on the financial
condition of the issuer, trends in its results of operations or other changes in
circumstances. If the financial condition of an issuer deteriorates, resulting
in such issuer's inability to fulfill its obligation under the promissory note
evidencing such a loan, additional allowances will be required.
Change has reduced its deferred tax assets to an amount that Change
believes is more likely than not to be realized, which was $0 at December 31,
2002 and June 30, 2003. In so doing, Change has estimated future taxable losses
in determining the valuation allowance. In the event that actual results differ
from these estimates or these estimates are adjusted in future periods, Change
may need to modify its valuation allowance which could materially affect its
financial position and results of operations.
81
OVERVIEW AND RECENT DEVELOPMENTS
Prior to commencement of the operational divestiture described below for
the year ended December 31, 2001, Change was a provider of a broad range of
professional consulting services, including e-services and technology strategy,
online branding, web architecture and design systems integration, system
architecture and outsourcing.
On December 4, 2001 Change entered into an agreement and plan of merger
with Franklin Capital Corporation, a Delaware corporation. On July 1, 2002
Change received a notice of termination from Franklin Capital terminating the
proposed merger.
Change made two investments in 2001 and one in the first quarter of 2002 in
Excelsior Radio Networks, Inc. (f/k/a eCom Capital, Inc.), a subsidiary of
Franklin Capital, which produces, syndicates and distributes radio programs and
related services. Change purchased a promissory note and warrant for $2,250,000
from Excelsior in August 2001 and in December 2001 purchased 250,000 common
shares of Excelsior from Franklin Capital for $250,000. In April 2002, Change
purchased an additional promissory note from Excelsior for $4,708,000 in
conjunction with the purchase by Excelsior of Dial Communication Group Inc. and
Dial Communications Group LLC. The $2,250,000 promissory note was paid in full,
together with related accrued interest, on October 1, 2002. The $4,708,000 note
was repaid in full, together with related accrued interest, on January 21, 2003.
On January 15, 2003, Change sold the Excelsior shares and the Excelsior
warrant to Sunshine III, LLC for total consideration of approximately $648,000
in cash.
On September 30, 2002, the Change board of directors announced the adoption
of a plan of liquidation and dissolution in order to maximize stockholder value
and noted that if no suitable business opportunities became available to it,
subject to stockholder approval, it would commence liquidation in 2003. However,
the plan permits the Change board of directors to amend, modify or abandon the
plan, notwithstanding stockholder approval, if the board determines doing so
would be in the best interests of Change and its stockholders.
On June 17, 2003, William Avery, Change's then president, chief executive
officer and chief financial officer, resigned. Mr. Avery had an employment
agreement dated September 17, 2001 governing the terms and conditions of his
employment. On June 17, 2003, the date of Mr. Avery's resignation, Change and
Mr. Avery entered into a separation agreement and general release. Change will
pay the severance he is entitled to under the separation agreement and general
release, totaling $140,000, and has recorded a charge in the Statement of
Operations for the six months ended June 30, 2003 for the value of expected
payments and benefits payable to the former executive.
Change announced on June 18, 2003 that it signed a letter of intent in
connection with its proposed Merger with Neurologix. On August 13, 2003, Change
entered into the merger agreement. The consummation of the Merger remains
subject to the approval of Change's stockholders, which Change will be seeking
at its next meeting of stockholders currently planned to take place in the first
quarter of 2004. In the event the Merger is consummated, Change expects to
abandon the plan of liquidation and dissolution. If the Merger is not
consummated, Change expects to pursue the plan of liquidation and dissolution
previously adopted.
In connection with the Merger, Change, Subcorp, Neurologix, and certain
securityholders of Neurologix entered into the voting agreement. Pursuant to the
voting agreement, all holders of Neurologix's initial series of convertible
preferred stock, certain holders of Neurologix Series B convertible preferred
stock and the holders of a promissory note issued by Neurologix agreed to
convert such preferred stock and promissory note into Neurologix common stock
prior to the Merger. In addition, the securityholders agreed to vote all of
their Neurologix capital stock in favor of the merger agreement and the
transactions contemplated thereby. Such securityholders, who hold a majority of
Neurologix's outstanding shares of common stock, initial series of convertible
preferred stock and Series B convertible preferred stock have approved the
Merger.
Concurrent with the execution of the merger agreement, Change lent to
Neurologix the principal amount of $750,000. The loan is due April 30, 2004,
accrues interest at a rate of 4% per annum, is secured by all of the assets of
Neurologix and is senior to all existing indebtedness of Neurologix. In
connection with an amendment to the Merger Agreement, on November 14, 2003,
Change agreed to loan Neurologix an
82
additional $350,000 and to extend the due date to June 30, 2004. On December 18,
2003, Change funded the additional loan.
On June 30, 2003, Change sold to Textor Family Limited Partnership all of
the issued and outstanding shares of capital stock of Canned Interactive. As a
result of the divestiture, Change has no continuing revenue generating
operations.
OVERVIEW OF OPERATIONS
Canned Interactive was Change's sole revenue generating subsidiary from
December 2001 through June 30, 2003. Canned Interactive is based in Los Angeles,
California and designs and produces interactive media such as digital video
discs (DVDs) and web sites, primarily for entertainment, consumer goods, sports
and technology companies.
Most theatrical films, including new and library releases, are now released
in DVD format. Canned Interactive designed interactive content for those titles,
enriching the viewer experience and creating value for Canned Interactive's
clients. Canned Interactive also used its design and technology skills to create
and enhance web sites with interactive and streaming content.
Agreements entered into in connection with time-and-materials projects were
generally terminable by the client upon 30-days' prior written notice and
clients were required to pay Change for all time, materials and expenses
incurred by Change through the effective date of termination. Agreements entered
into in connection with fixed-price projects were generally terminable by the
client upon payment for work performed and the next progress payment due.
Canned Interactive's costs consisted primarily of compensation and related
costs of personnel dedicated to customer assignments. Project personnel costs
also included fees paid to subcontractors for work performed in connection with
projects and non-reimbursed travel expenses.
Change's selling, general and administrative costs consist primarily of
compensation and related costs of the management and administrative functions,
including finance and accounting, marketing, human resources and internal
information technology, the costs of Change's facilities and other general
corporate expenses.
Change's equity based compensation expense is comprised of amortization of
the deferred compensation associated with the grant of stock options to the
Change board of directors and a former President and Chief Executive Officer
whose employment was terminated by the board in July 2001. Such cost is measured
as the difference between the exercise price of options granted and the fair
market value of the underlying stock on the date of measurement and is being
recognized as expense over the vesting period of the options. Also included in
equity based compensation is a charge, totaling $90,000, associated with the
modification of the former Chief Executive's options upon his resignation in
June 2003. Change incurred approximately $358,000 and $394,000 in equity based
compensation expense during the nine months ended September 30, 2003 and 2002,
respectively.
ACQUISITIONS AND DIVESTITURES
Change evaluated acquisitions based on numerous quantitative and
qualitative factors. Quantitative factors include historical and projected
revenues and profitability, geographic coverage and backlog of projects under
contract. Qualitative factors include strategic and cultural fit, management
skills, customer relationships and technical proficiency.
INSYS
On November 8, 2001 Change sold a 51% voting interest in InSys, a
wholly-owned subsidiary, to a member of its management team in exchange for
$50,000 and concurrently forgave approximately $400,000 of advances to InSys. In
addition, Change loaned InSys $100,000 evidenced by a promissory note. This note
bears interest at a rate equal to the London Interbank Offer Rate plus 2%.
Pursuant to the separation agreement and general release, dated as of June 17,
2003, by and between Change and William B. Avery, Change transferred the
remaining 49% voting interest in InSys as well as the promissory note issued by
InSys to William B. Avery effective October 1, 2003.
83
RAND INTERACTIVE CORPORATION
On November 2, 2001 Change sold all of the issued and outstanding shares of
RAND, a wholly-owned subsidiary, to a member of its management team in exchange
for 375,039 shares of Change common stock and a warrant to purchase such amount
of shares of RAND common stock that equals, at the time of exercise, 30% of the
issued and outstanding shares of RAND common stock on a fully diluted basis. The
warrant has an aggregate exercise price of $1.00, is exercisable upon the
occurrence of certain events and expires on November 3, 2013.
IGUANA
In connection with the acquisition of Iguana in March 2001, 2,300,000
shares of the Change's common stock were placed in escrow. The related
contingency period expired in July 2002, and the fair value of such shares was
included in the aggregate purchase price. As of December 31, 2001 all employees
of Iguana had been terminated and the subsidiary's operating activities had
ceased. The remaining net book value of Iguana intangibles was $0. Accordingly,
Change recorded additional impairment charges in July 2002 totaling $69,000
representing the fair value of such shares.
CANNED INTERACTIVE
On June 12, 2001, Change acquired Canned Interactive, a Los Angeles based
media and entertainment interactive agency, for approximately $1,100,000 in
cash, including acquisition costs, and 6,436,552 shares of Change common stock,
valued at approximately $1,000,000. The business combination was accounted for
using the purchase method of accounting.
Also in connection with the acquisition of Canned Interactive, $200,000 in
cash and 715,172 shares of the Change's common stock were placed in escrow. The
related contingency period expired in December 2002, at which time the cash and
the then fair value of the shares, totaling $214,000, was included in the
aggregate purchase price.
On June 30, 2003, Change sold all of the issued and outstanding shares of
the capital stock of Canned Interactive to Textor Family Limited Partnership in
exchange for 4,500,000 shares of Change's common stock owned by Textor Family
Limited Partnership, with a fair market value of $170,000. In connection with
such sale, all inter-company loans in excess of $300,000 were converted by
Change into equity of Canned Interactive without the issuance to Change of any
additional capital stock or the granting of any right to receive any additional
equity in Canned Interactive. Additionally, Change received $300,000 from Canned
Interactive as payment in full of the outstanding inter-company loans.
BROADSTREAM AND NETPRO
In May 2001, Broadstream completed a recapitalization whereby the holders
of its Series A Convertible Redeemable Preferred Stock exchanged their Series A
shares for shares of Series A-1 Convertible Redeemable Preferred Stock. The
recapitalization modified the conversion ratio, policies regarding dividends and
voting rights for Series A-1 holders. No additional consideration was paid by
Change or any other preferred shareholder in connection with this transaction.
As a result of the recapitalization the voting interest of common shareholders
was reduced from 31% to 13%.
Also in May 2001, in connection with the recapitalization, Change
transferred 1,191,569 shares of Broadstream's Series A-1 convertible redeemable
preferred stock to Adelson Investors, LLC, another shareholder of Broadstream.
This transfer is accounted for as a contribution by Change of such shares to
Broadstream in exchange for no consideration. Subsequent to the
recapitalization, and non-reciprocal share transfer, Change owned 6,434,596
shares of Broadstream Series A-1 convertible redeemable preferred stock,
representing an approximately 43% equity interest (calculated on an
as-if-converted basis) and 49% voting interest.
On August 15, 2001 Change purchased a secured convertible promissory note
from Broadstream in exchange for $600,000 in connection with an aggregate
$1,600,000 bridge loan financing consummated by Broadstream. The aggregate
bridge loan financing was secured by all of Broadstream's assets. The note also
84
contained certain conversion provisions in the event Broadstream closed a new
round of financing or entered into a change of control transaction.
On November 30, 2001 Change assigned its note to a newly formed entity,
NetPro Holdings Inc. in exchange for 13,674,753 shares of NetPro Series A-1
convertible redeemable participating preferred stock. On November 30, 2001 as a
result of the application of the equity method, the net book value of the note
approximated $0. No gain or loss was recorded as a result of this exchange.
Concurrent with this transaction, NetPro foreclosed on the note and elected to
take possession of all of Broadstream's assets in full satisfaction of the
notes. Broadstream remains in existence but is not conducting any business.
On December 24, 2001, Change purchased 1,585,479 shares of NetPro Series
B-1 convertible redeemable participating preferred stock in exchange for
$200,000 in connection with a larger ongoing financing effort by NetPro. On
January 10, 2002, Change invested an additional $100,000 in NetPro Series B-1
stock and on March 7, 2002 Change invested a final $100,000 in NetPro Series B-1
stock. On March 14, 2002, the board of directors of NetPro voted to suspend all
of the company's business operations and immediately terminate substantially all
of its employees due to NetPro's loss of significant clients and associated
revenues.
RESULTS OF OPERATIONS
THREE MONTHS AND NINE MONTHS ENDED SEPTEMBER 30, 2002 COMPARED TO THREE MONTHS
AND NINE MONTHS ENDED SEPTEMBER 30, 2003
Revenues. In connection with the divestiture of Canned Interactive by
Change, revenues are now included in discontinued operations.
Cost of Revenues. Cost of revenues consists principally of costs directly
incurred in the delivery of services to clients, primarily consisting of
compensation of billable employees. Billable employees are full time employees
and sub-contractors whose time spent working on client projects is charged to
that client at agreed-upon rates. Billable employees were Change's primary
source of revenue. In connection with the divestiture of Canned Interactive by
Change, such costs are now included in discontinued operations.
General and Administrative Expenses. General and administrative expenses
consist primarily of compensation and related benefits, professional services
fees, facilities costs and advertising and promotional costs. General and
administrative expenses decreased from $745,000 in the three months ended
September 30, 2002 to $730,000 in the three months ended September 30, 2003 and
from $2,667,000 in the nine months ended September 30, 2002 to $2,275,000 in the
nine months ended September 30, 2003. This decrease was primarily a result of
the decreased rent expense associated with facilities abandoned in the second
quarter of 2002 and a decrease in professional services fees as a result of the
termination in 2002 of the proposed merger with Franklin Capital.
Equity in Losses and Impairment of Investments in Unconsolidated
Affiliates. Equity in losses and Impairment of investments in unconsolidated
affiliates was $22,000 in the three months ended September 30, 2002 and $3,000
in the three months ended September 30, 2003, and $604,000 in the nine months
ended September 30, 2002 and $110,000 in the nine months ended September 30,
2003. Equity in losses of unconsolidated affiliates is a result of Change's
minority ownership in Broadstream, NetPro and InSys that have been accounted for
under the equity method of accounting. Under the equity method of accounting,
Change's proportionate share, calculated on an as-if-converted basis, of the
investee's operating losses and amortization of the Change's net excess
investment over its equity in the investee's net assets is included in equity in
losses of unconsolidated affiliates. Impairment of investments in unconsolidated
affiliates is a result of the cessation of NetPro's and LiveSky's operations in
2002. Change evaluated the recoverability of its investments in light of the
carrying values relative to future cash flows. As a result of this analysis, in
2002 Change recorded impairment charges that reduced the remaining NetPro and
Livesky investment balances to $0.
Interest and Dividend Income. Interest and dividend income was $221,000 in
the three months ended September 30, 2002 and $26,000 in the three months ended
September 30, 2003, and $628,000 in the nine months ended September 30, 2002 and
$95,000 in the nine months ended September 30, 2003. The decrease in interest
and dividend income for the nine months ended September 30, 2003 was
attributable to a decrease
85
in Change's notes receivable as a result of repayment. Interest income in future
periods may fluctuate as a result of the average cash Change maintains and
changes in the market rates of Change's cash equivalents. Change expects that
the average cash balance may continue to decrease as Change continues to incur
operating losses.
Income Taxes. Change has available estimated net operating loss carry
forwards for income tax purposes of approximately $23,839,475 through the
nine-month period ended September 30, 2003, which expire on various dates from
2003 through 2023. A full valuation allowance has been established due to
uncertainty whether the Company will generate sufficient taxable earnings to
utilize the available net operating loss carryforwards. A portion of Change's
net operating loss carryforwards may also be limited due to significant changes
in ownership under Section 382 of the Code.
RESULTS OF OPERATIONS
YEAR ENDED DECEMBER 31, 2002 COMPARED TO YEAR ENDED DECEMBER 31, 2001
Revenues. Revenues decreased from $4,596,000 for the year ended December
31, 2001 to $0 for the year ended December 31, 2002. This decrease is a result
of Change's divestitures of operating businesses. In connection with the
divestiture of Canned Interactive by Change, related revenues have been
reclassed to discontinued operations.
Cost of Revenues. Cost of revenues consists principally of costs directly
incurred in the delivery of services to clients, primarily consisting of
compensation of billable employees. Billable employees are full time employees
and sub-contractors whose time was spent working directly on client projects.
Billable employees were Change's primary source of revenue. Such costs decreased
from $6,088,000 for the year ended December 31, 2001, to $0 for the year ended
December 31, 2002. The decrease in cost is a result of the divestitures of InSys
and RAND, and the downsizing of Iguana's operations. In connection with the
divestiture of Canned Interactive by Change, related costs have been reclassed
to discontinued operations.
Selling, General and Administrative Expenses. Selling, general and
administrative expenses consist primarily of compensation and related benefits,
professional services fees, facilities costs, and advertising and promotional
costs. Selling, general and administrative expenses decreased from $12,894,000
for the year ended December 31, 2001 to $3,342,000 for the year ended December
31, 2002. This decrease was primarily a result of the decreased number of
employees, resulting in decreased compensation, decreased professional services
fees, and decreases in other costs associated with the limited scope of
operations over the prior year.
Impairment Losses. As a result of the aforementioned terminations and
divestitures in 2001, coupled with historical and projected operating and cash
flow losses, Change evaluated the recoverability of its acquired intangible
assets and goodwill by comparison of the carrying values relative to related
future cash flows. As a result of this analysis, Change recorded impairment
charges totaling $7,263,000 and $69,000 in the years ended December 31, 2001 and
2002, respectively, which are included in the "Impairment Losses" in the
Statement of Operations.
Severance Costs. Severance costs were incurred as a result of the
aforementioned terminations in 2001 and totaled $1,326,000 and $0 for the years
ended December 31, 2001 and 2002, respectively.
Equity in Losses and Impairment of Investments in Unconsolidated
Affiliates. Equity in losses of unconsolidated affiliates results from Change's
minority ownership in Broadstream, NetPro and InSys which are accounted for
under the equity method of accounting. Under the equity method of accounting,
Change's proportionate share, calculated on an as-if-converted basis, of the
investee's operating losses, and amortization of Change's net excess investment
over its equity in the investee's net assets, is included in equity in losses of
unconsolidated affiliates. Impairment of investments in unconsolidated
affiliates is a result of the cessation of NetPro's and LiveSky's operations in
2002. Change evaluated the recoverability of its investments in light of the
carrying values relative to future cash flows. As a result of this analysis,
Change recorded impairment charges that reduced the remaining investment
balances to $0. Equity in losses and impairment of investments in unconsolidated
affiliates was $5,546,000 for the year ended December 31, 2001 and $549,000 for
the year ended December 31, 2002.
86
Interest and Dividend Income. Interest and dividend income was $859,000
for the year ended December 31, 2001 and $743,000 for the year ended December
31, 2002. The decrease in interest and dividend income is attributable to a
decrease in Change's invested cash balance as it has funded its ongoing
operations and investments, partially offset by interest income earned on notes
receivable. Interest income in future periods may fluctuate as a result of the
average cash Change maintains and changes in the market rates of interest, and
management expects that the average cash balance may continue to decrease as
Change continues to incur operating losses.
Income Taxes. Change has available estimated net operating loss carry
forwards for income tax purposes of approximately $22,000,000 through the year
ended December 31, 2002, which expire on various dates from 2002 through 2022. A
valuation allowance has been established due to uncertainty as to whether Change
will generate sufficient taxable earnings to utilize the available net operating
loss carryforwards. A portion of Change's net operating loss carryforwards may
also be limited due to significant changes in ownership under Section 382 of the
Code.
YEAR ENDED DECEMBER 31, 2001 COMPARED TO YEAR ENDED DECEMBER 31, 2000
Revenues. Revenues increased from $1,370,000 for the year ended December
31, 2000 to $4,596,000 for the year ended December 31, 2001. This increase is
the result of the contribution to revenues of acquired companies' revenues
streams. As a result of Change's divestitures and continued unfavorable market
conditions for its professional services, revenues from historical service
offerings decreased on a sequential basis during 2001.
Cost of Revenues. Cost of revenues increased from $1,119,000 for the year
ended December 31, 2000 to $6,088,000 for the year ended December 31, 2001. Cost
of revenues consists primarily of compensation of billable employees, travel,
subcontractor costs and other costs directly incurred in the delivery of
services to clients. Billable employees are full time employees and
subcontractors whose time are spent servicing client projects. Also included in
Cost of Revenues is the amortization of certain purchased intangible assets,
representing the value of customer relationship and workforces acquired.
In connection with certain acquisitions, Change recorded intangible assets
representing the value ascribed to the customer lists and assembled workforces
of the acquired companies. The aggregate amortization of these intangible assets
totaled $50,000 and $654,000, for the years ended December 31, 2000 and 2001
respectively, and is included in Cost of Revenues.
As a result of Change's divestitures, terminations and unfavorable market
conditions, cost of revenues decreased on a sequential basis during 2001.
Selling, General and Administrative Expenses. Selling, general and
administrative expenses consist primarily of compensation and related benefits,
professional services fees, facilities costs and advertising and promotional
costs. Selling, general and administrative expenses increased from $3,305,000
for the year ended December 31, 2000 to $12,894,000 for the year ended December
31, 2001. These increases were primarily the result of increased compensation,
increased professional services fees, increased facility costs and increases in
other costs associated with the growth of Change's business and operations over
the prior year.
Impairment Losses. As a result of the aforementioned terminations, coupled
with historical, current and projected operating and cash flow losses, Change
evaluated the recoverability of its acquired intangible assets and goodwill by
comparison of the carrying value relative to future cash flows. As a result,
Change recorded impairment charges totaling $7,263,000 which are included in the
Impairment Losses section of the accompanying Statement of Operations.
Severance Costs. Severance costs were $0 and $1,326,000 in the years ended
December 31, 2000 and 2001, respectively.
Equity in Losses of Unconsolidated Affiliates. Equity in losses of
unconsolidated affiliates was $1,732,000 and $5,546,000 for the years ended
December 31, 2000 and 2001, respectively. Equity in losses of unconsolidated
affiliates resulting from Change's minority ownership in Broadstream, Inc.,
NetPro Holdings, Inc. and InSys LLC have been accounted for under the equity
method of accounting. Under the equity method of accounting, Change's
proportionate share, calculated on an as-if-converted basis, of the investee's
87
operating losses and amortization of Change's net excess investment over its
equity in the investee's net assets is included in equity in losses of
unconsolidated affiliates.
Interest and Dividend Income. Interest and dividend income was $1,469,000
and $859,000 for the years ended December 31, 2000 and 2001, respectively. The
decrease in interest income over the prior year was attributable to a decrease
in Change's invested cash balance, as it has funded its ongoing operations.
Income Taxes. Change had available estimated net operating loss
carryforwards for income tax purposes of approximately $20,000,000 as of
December 31, 2001, which expire on various dates from 2001 through 2021. A
valuation allowance had been established due to uncertainty as to whether Change
will generate sufficient taxable earnings to utilize the available net operating
loss carryforwards.
LIQUIDITY AND CAPITAL RESOURCES
Historical Source of Funding. On March 28, 2000, an investor group led by
Pangea Internet Advisors, LLC purchased 4,000,000 shares of Series B convertible
preferred stock for net proceeds to Change of approximately $39,450,000 in cash.
Also on March 28, 2000, certain other investors purchased warrants to purchase
41,250,000 shares of Change common stock for $100,000.
Working Capital and Results of Operations. Change had $5,963,000 in cash
and cash equivalents available as of September 30, 2003, invested predominantly
in instruments that are highly liquid, investment grade securities that have
maturities of less than 45 days.
Beginning in the third quarter of 2001, in response to continued
unfavorable market conditions for its services, Change embarked on a review of
its operations with the goal of formulating a course of action to minimize near
term losses, capital expenditures and reduce cash outflows. As of September 30,
2003, Change has no revenue generating operations, a limited number of employees
and has significantly reduced fixed expenses. During the nine months ended
September 30, 2003, Change used $1,523,000 to fund operations.
In August 2003, Change loaned Neurologix an aggregate principal amount of
$750,000. The note bears interest at 4% per year, is secured by substantially
all of Neurologix's assets and matures on April 30, 2004. In connection with an
amendment to the merger agreement, Change has agreed to loan Neurologix an
additional $350,000, which was funded on December 18, 2003 and is due June 30,
2004.
Change's future contractual obligations at September 30, 2003 were as
follows:
AMOUNTS DUE IN FISCAL YEAR
ENDING DECEMBER 31,
-----------------------------------------
2007 AND
2003 2004 2005 2006 THEREAFTER
---- ----- ----- ----- ----------
(IN THOUSANDS)
Operating leases................................. $ 28 $ -- $ -- $ -- $ --
Capital Leases................................... 2 1 -- -- --
---- ----- ----- ----- -----
$ 30 $ 1 $ -- $ -- $ --
Change intends to fund these obligations from its cash on hand at September
30, 2003.
In January, 2003, Change sold its shares of Excelsior common stock and the
Excelsior warrant to Sunshine III, LLC for total consideration of approximately
$648,000 in cash. Also in January, 2003 the $4,708,000 note from Excelsior was
repaid in full, together with related accrued interest totaling $142,000.
Given Change's current level of operations, Change's capital resources are
sufficient to meet anticipated cash needs for working capital and capital
expenditures relating to existing operations for at least the next 12 months.
However, if the Merger is consummated, the plan of liquidation and dissolution
adopted by the Change board of directors is abandoned and Change's operations
require significant cash outlays to fund operations, Change may be required to
seek additional sources of financing or to sell certain assets.
If the plan of liquidation and dissolution adopted by the Change board of
directors is pursued, Change will begin the process of negotiating settlements
with respect to its remaining obligations and liabilities. In the event Change
is unable to negotiate successfully the termination of these obligations, Change
may have less or no cash proceeds to distribute to its stockholders. These
matters raise substantial doubt about Change's ability to continue as a going
concern.
88
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Change's primary objective in investing in securities and other instruments
is to preserve principal while at the same time maximizing yields without
significantly increasing risk. To achieve this objective, Change maintains a
portfolio of cash and cash equivalents and money market funds. As of December
31, 2002, Change held cash and cash equivalents with an average maturity of 45
days or less.
89
BUSINESS OF CHANGE
Arinco Computer Systems Inc., the predecessor to Change, was incorporated
on March 31, 1978. Arinco Computer Systems was organized principally to serve
its subsidiary operations, which included the sale of telecommunications
equipment and services and the retail sales of computers. From 1985 to March
2000, Arinco Computer Systems had no business operations. In March 2000, an
investor group acquired control of Arinco Computer Systems for the purpose of
using Arinco Computer Systems to sell business consulting services. In September
2000, Arinco Computer Systems Inc. merged with and into Change, a wholly owned
subsidiary. All of the stockholders of Arinco Computer Systems became
stockholders of Change and Change redomesticated from New Mexico to Delaware.
Change's sole consolidated subsidiaries are Iguana Studios, Inc., which has
limited continuing operating activities, and CTP/N Merger Corp., which has no
operating activities.
Based on Change's assessment of the opportunities in the radio business, in
2001 the Change board of directors decided to merge with Franklin Capital and
jointly develop and acquire network radio programming and sales and syndication
businesses. On December 4, 2001, Change entered into an agreement and plan of
merger with Franklin Capital. On July 1, 2002, Change received a notice of
termination from Franklin Capital terminating the proposed merger.
On September 30, 2002, the Change board of directors adopted a plan of
liquidation and dissolution in order to maximize stockholder value and noted
that if no suitable business opportunities became available to it, subject to
stockholder approval, it would commence liquidation in 2003. However, the plan
permits the Change board of directors to amend, modify or abandon the plan,
notwithstanding stockholder approval, if the board determines doing so would be
in the best interests of Change and its stockholders.
On June 17, 2003, William Avery, Change's then president, chief executive
officer and chief financial officer resigned. Mr. Avery had an employment
agreement dated September 17, 2001 governing the terms and conditions of his
employment. On June 17, 2003, Change and Mr. Avery entered into a separation
agreement and general release. Change will pay Mr. Avery the severance he is
entitled to under the separation agreement and general release, totaling
$140,000, and has recorded a charge in its statement of operations for the three
months ended June 30, 2003 for the value of expected payments and benefits
payable to the former executive.
On June 18, 2003, Change signed a Letter of Intent with Neurologix in
connection with the proposed Merger. On August 13, 2003, Change entered into the
merger agreement. The consummation of the Merger remains subject to the approval
of the Change's stockholders, which Change will be seeking at its next meeting
of stockholders currently planned to take place in the first quarter of 2004. In
the event the Merger is consummated, Change expects to abandon the plan of
liquidation and dissolution. If the Merger is not consummated, Change expects to
pursue the plan of liquidation and dissolution previously adopted.
In connection with the Merger, Change, Subcorp, Neurologix, and certain
securityholders of Neurologix entered into the voting agreement. Pursuant to the
voting agreement, all holders of Neurologix's initial series of convertible
preferred stock, certain holders of Neurologix Series B convertible preferred
stock and the holders of a promissory note issued by Neurologix agreed to
convert such preferred stock and promissory note into Neurologix common stock
prior to the Merger. In addition, the securityholders agreed to vote all of
their Neurologix capital stock in favor of the merger agreement and the
transactions contemplated thereby. Such securityholders, who hold a majority of
Neurologix's outstanding shares of common stock, initial series of preferred
stock and Series B convertible preferred stock have approved the Merger.
Concurrent with the execution of the merger agreement, Change lent to
Neurologix the principal amount of $750,000. The loan is due April 30, 2004,
accrues interest at a rate of 4% per annum, is secured by all of the assets of
Neurologix and is senior to all existing indebtedness of Neurologix. In
connection with an amendment to the merger agreement, on November 14, 2003,
Change agreed to loan Neurologix an additional $350,000, and to extend the due
date to June 30, 2004. On December 18, 2003, Change funded the additional loan.
On June 30, 2003, Change sold to Textor Family Limited Partnership all of
the issued and outstanding shares of capital stock of Canned Interactive.
90
PROPERTIES
As of September 30, 2003, Change leased one floor of office space at 16
West 19th Street, New York, New York. Change currently sublets this space and
the lease will expire in November, 2003.
EMPLOYEES
As of September 30, 2003, Change did not have any employees.
LEGAL PROCEEDINGS
Change is subject to legal claims from time to time and is involved in
litigation that has arisen in the ordinary course of its business. It is the
opinion of Change's management that either it has adequate legal defenses to
these claims or that any liability that might be incurred due to these claims
will not, in the aggregate, exceed the limits of Change's insurance policies or
otherwise result in any material adverse effect on Change's operations or
financial position.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
CHANGE IN ACCOUNTANTS
None.
DISAGREEMENTS WITH ACCOUNTANTS
None.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Change's primary objective in investing in securities and other instruments
is to preserve principal while at the same time maximizing yields without
significantly increasing risk. To achieve this objective, Change maintains a
portfolio of cash and cash equivalents and money market funds. As of December
31, 2002, Change held cash and cash equivalents with an average maturity of 45
days or less.
91
SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF NEUROLOGIX
The following selected financial data as of December 31, 2002 and 2001, and
for the fiscal years ended December 31, 2002, 2001, and 2000, has been derived
from the audited financial statements of Neurologix, which were audited by J.H.
Cohn LLP, Neurologix's current independent auditors. The audit opinion to these
financial statements includes an explanatory paragraph relating to Neurologix's
ability to continue as a going concern. The following selected financial data as
of December 31, 2000 and 1999, as of September 30, 2003 and 2002, for the period
from February 12, 1999 (date of inception) through December 31, 1999 and for the
nine months ended September 30, 2003 and 2002 is unaudited and has been derived
from unaudited financial statements which, in the opinion of management, include
all adjustments, consisting only of normal recurring adjustments, necessary for
a fair statement of the results of operations. You should read this information
in conjunction with the audited consolidated financial statements, and
"Management's Discussion and Analysis of Financial Condition and Results of
Operations of Neurologix" included elsewhere in this proxy statement and
prospectus.
NINE MONTHS ENDED
YEARS ENDED DECEMBER 31, SEPTEMBER 30,
--------------------------------------------------- -----------------------
2002 2001 2000 1999(1) 2003 2002
----------- --------- ----------- ----------- ----------- ---------
(UNAUDITED) (UNAUDITED)
STATEMENT OF OPERATIONS DATA:
Revenues(2)
Operating expenses:
Research and licensing......... $ 440,830 $ 326,000 $ 653,690 $ 180,000 $ 730,388 $ 329,285
Scientific consulting.......... 286,256 202,750 222,000 41,500 220,084 196,545
Administrative expenses........ 485,981 246,121 157,353 107,831 540,027 248,665
----------- --------- ----------- --------- ----------- ---------
Loss from operations............. (1,213,067) (774,871) 1,033,043 (329,331) (1,490,499) (774,495)
----------- --------- ----------- --------- ----------- ---------
Other income (expenses):
Dividend income................ 6,736 -- 2,902 984 662 --
Interest income................ 14,798 -- -- -- 13,055 --
Interest expense............... (118,098) (95,755) (24,438) -- (95,422) (88,097)
----------- --------- ----------- --------- ----------- ---------
Totals....................... (96,564) (95,755) (21,536) 984 (81,705) (88,097)
----------- --------- ----------- --------- ----------- ---------
Net loss......................... $(1,309,631) $(870,626) $(1,054,579) $(328,347) $(1,572,204) $(862,592)
=========== ========= =========== ========= =========== =========
Net income (loss) per
share -- basic and diluted..... $ (.55) $ (.38) $ (.48) $ (.15) $ (.63) $ (.38)
DECEMBER 31, SEPTEMBER 30,
---------------------------------------------------- ------------------------
2002 2001 2000 1999 2003 2002
---------- ----------- ----------- ----------- ----------- ----------
(UNAUDITED) (UNAUDITED) (UNAUDITED)
BALANCE SHEET DATA:
Total assets.................... $1,933,921 $ 288,496 $ 283,628 $ 241,565 $ 1,376,144 $2,266,914
Total long term obligations..... 2,238,251 1,925,153 1,100,038 -- 3,168,624 2,208,250
Mandatorily redeemable
convertible preferred stock... 500,000 500,000 500,000 500,000 500,000 500,000
Total stockholders'
deficiency.................... (889,330) (2,216,642) (1,378,516) (323,937) (2,292,470) (466,336)
---------------
(1) Results for the fiscal year ended December 31, 1999 are from February 12,
1999, the date of inception of Neurologix.
(2) Neurologix has never earned revenues nor declared or paid any cash dividends
on its capital stock.
92
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF NEUROLOGIX
OVERVIEW
Neurologix is a development stage company, involved in the development of
proprietary gene therapies for the treatment of disorders of the brain and
central nervous system.
Since Neurologix's inception in 1999, Neurologix has used its resources to
conduct research and development activities, primarily for gene therapy
treatments for Parkinson's disease and epilepsy and, to a lesser extent, for
other diseases. At September 30, 2003, Neurologix had an accumulated deficit of
approximately $5.1 million. Neurologix expects to incur additional losses in the
future, and these losses may exceed its current cumulative losses. At September
30, 2003, Neurologix had cash and cash equivalents of $0.9 million.
During the year ended December 31, 2002, Neurologix used $1.1 million of
cash for operating activities. This cash usage rate will likely increase in
future periods as Neurologix continues Phase I clinical trials of its NLX gene
therapy technology for the treatment of Parkinson's disease and expands its
research and development of additional gene therapy technologies. To continue
its research and development efforts and commercialize its gene therapy
technologies, Neurologix may need to raise additional funds through public or
private equity offerings, debt financings or corporate collaboration and
licensing arrangements. Neurologix does not know whether such additional
financing will be available when needed, or on terms favorable to it or its
stockholders.
CRITICAL ACCOUNTING POLICIES
USE OF ESTIMATES
Neurologix's preparation of financial statements in conformity with
accounting principles generally accepted in the United States requires its
management to make estimates and assumptions that affect its reported amounts of
assets and liabilities, its disclosure of contingent assets and liabilities at
the date of the financial statements and its reported amounts of revenues and
expenses during the reporting period. Neurologix's actual results could differ
from those estimates.
CARRYING VALUE OF FIXED AND INTANGIBLE ASSETS
Neurologix's fixed assets and certain of its patents have been recorded at
cost and are being amortized on a straight-line basis over the estimated useful
lives of those assets. If Neurologix becomes aware of facts that indicate one or
more of those assets may be impaired, Neurologix assesses whether the carrying
value of such assets can be recovered through undiscounted future operating cash
flows. If Neurologix determines that an asset is impaired, Neurologix measures
the amount of such impairment by comparing the carrying value of the asset to
the present value of the expected future cash flows associated with the use of
the asset. Adverse changes to Neurologix's estimates of the future cash flows to
be received from a particular long-lived asset could indicate that the asset is
impaired, and would require Neurologix to write down the asset's carrying value
at that time.
FAIR VALUE OF EQUITY INSTRUMENTS
Neurologix follows Statement of Financial Accounting Standards No. 123,
"Accounting for Stock-Based Compensation" ("SFAS 123"), which allows companies
to either expense the estimated fair value of stock options or to continue to
follow the intrinsic value method set forth in Accounting Principles Board
Opinion No. 25, "Accounting for Stock Issued to Employees" ("APB 25"), but
discloses the pro forma effect on net income (loss) as if the fair value of
options had been expensed. Neurologix has elected to apply APB 25 in accounting
for its employee stock option incentive plan. Neurologix has used the minimum
value method as permitted by SFAS 123 to estimate the fair value of options
granted to employees for such pro forma disclosures.
93
In accordance with SFAS 123, all other issuances of common stock, stock
options or other equity instruments issued to employees and non-employees as
consideration for goods or services received by Neurologix are accounted for
based on the fair value of the consideration received or the fair value of the
equity instrument, whichever is more readily measurable. Such fair value is
measured at an appropriate date pursuant to the guidance in the consensus
reached for EITF Issue No. 96-18 (generally, the earlier of the date the other
party becomes committed to provide goods or services or the date the performance
by the other party is complete) and capitalized or expensed as if Neurologix had
paid cash for the goods or services.
For purposes of determining the pro forma and historical values of options
granted to employees and non-employees during the years ended December 31, 2002
and 2001 using the minimum value method Neurologix used the following
assumptions:
- risk free interest rate of 4%,
- estimated life of five years,
- volatility of 0%, and
- dividend yield of 0%.
VALUATION OF DEFERRED TAX ASSETS
Neurologix regularly evaluates its ability to recover the reported amount
of its deferred income taxes considering several factors, including its estimate
of the likelihood that it will generate sufficient taxable income in future
years in which temporary differences reverse. Due to the uncertainties related
to, among other things, the extent and timing of future taxable income and the
potential changes in the ownership of Neurologix, which could subject its net
operating loss carryforwards to substantial annual limitations, Neurologix
offset its net deferred tax assets by an equivalent valuation allowance as of
December 31, 2002 and June 30, 2003.
RESULTS OF OPERATIONS
COMPARISON OF NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2003 AND 2002
Revenues
Neurologix did not generate revenues for the nine-month periods ended
September 30, 2003 and 2002.
Costs and Expenses
Research, Licensing and Scientific Consulting. Research, licensing and
scientific consulting expenses were $950,472 for the nine-month period ended
September 30, 2003, and $525,830 for the nine-month period ended September 30,
2002. The 81% increase in research, licensing and scientific consulting expenses
during the nine-month period ended September 30, 2003, was attributable
primarily to costs associated with Phase 1 clinical trials for Parkinson's
disease which commenced in August 2003 and compensation and related expenses
paid to the three scientists Neurologix hired in October 2002 for its laboratory
in Newark, Delaware. The remaining research, licensing and scientific consulting
expenses consisted of licensing fees and royalties Neurologix paid under
licensing agreements with academic and medical institutions as well as
consulting fees Neurologix paid to members of its scientific advisory board.
General and Administrative. General and administrative expenses were
$540,027 for the nine-month period ended September 30, 2003, and $248,665 for
the nine-month period ended September 30, 2002. The 117% increase in general and
administrative expenses during the nine-month period ended September 30, 2003,
was due primarily to the rent expenses associated with Neurologix's
establishment of a laboratory in Newark, Delaware, and associated office costs,
increased travel and depreciation expense as well as professional service fees.
94
Interest Income and Interest Expense. Interest income was $13,055 for the
nine-month period ended September 30, 2003. Neurologix had no interest income
for the nine-month period ended September 30, 2002. The increase in interest
income during the nine-month period ended September 30, 2003, was primarily due
to the interest earned on the proceeds of the sale of Neurologix's Series B
convertible preferred stock during February and March 2002. Interest expense was
$95,422 for the nine-month period ended September 30, 2003, and $88,097 for the
nine-month period ended September 30, 2002. The 8% increase in interest expense
during the nine-month period ended September 30, 2003, was attributable to the
higher average outstanding balance of the Existing Neurologix Note on which
interest accrued during the nine-month period ended September 30, 2003, compared
to the nine-month period ended September 30, 2002.
COMPARISON OF YEARS ENDED DECEMBER 31, 2002 AND 2001
Revenues
Neurologix did not generate revenues during 2002 or 2001.
Costs and Expenses
Research, Licensing and Scientific Consulting. Research, licensing and
scientific consulting expenses were $727,086 in 2002 and $528,750 in 2001. The
38% increase in cash expenses in 2002 compared to 2001 was primarily
attributable to an increase in scientific consulting fees paid to members of the
scientific advisory board, as well as compensation and related expenses that
Neurologix incurred in hiring the three scientists in October 2002 for its
laboratory in Newark, Delaware.
General and Administrative. General and administrative expenses were
$485,981 in 2002 and $246,121 in 2001. This 97% increase in general and
administrative expenses in 2002 was due to the rent expenses incurred as a
result of Neurologix establishing a laboratory in Delaware in October 2002, and
associated office costs, increased depreciation expenses as well as
approximately $84,000 of additional legal and other professional fees.
Interest Income and Interest Expense. Interest income was $14,798 in 2002.
Neurologix had no interest income in 2001. This difference was due to the
interest earned on the proceeds of the sale of Neurologix's Series B convertible
preferred stock in February and March 2002. Interest expense was $118,098 in
2002 and $95,754 in 2001. The 23% increase in interest expense during 2002 was
attributable to the higher average outstanding balance of the Existing
Neurologix Note on which interest accrued during 2002 compared to 2001.
COMPARISON OF YEARS ENDED DECEMBER 31, 2001 AND 2000
Revenues
Neurologix did not generate revenues during 2001 or 2000.
Costs and Expenses
Research, Licensing and Scientific Consulting. Research, licensing and
scientific consulting expenses were $528,750 in 2001 and $875,690 in 2000. The
40% decrease in 2001 compared to 2000 was primarily attributable to a one-time
payment of approximately $329,000 to a university to sponsor research related to
Neurologix's business.
General and Administrative. General and administrative expenses were
$246,121 in 2001 and $157,353 in 2000. This 86% increase in general and
administrative expenses in 2001 was due to an increase in professional fees
incurred by Neurologix in 2001.
Interest Income and Interest Expense. Interest expense was $95,755 in 2001
and $24,438 in 2000. The 292% increase in interest expense during 2001 was
attributable to the higher average outstanding balance of the existing note on
which interest accrued during 2001 compared to 2000.
95
LIQUIDITY AND CAPITAL RESOURCES
Neurologix has incurred annual operating losses since its inception in
February 1999. At September 30, 2003, Neurologix had an accumulated deficit of
$5.1 million. Neurologix is in the development stage and has not generated any
revenue as of September 30, 2003. As a result, Neurologix incurred net losses of
approximately $5.1 million and negative cash flows from operating activities of
$4.4 million during the period from February 12, 1999, date of inception,
through September 30, 2003. In addition, Neurologix expects to continue to incur
net losses and cash flow deficiencies through at least September 30, 2004. These
matters raise substantial doubt about Neurologix's ability to continue as a
going concern.
To enable Neurologix to sustain its operations through at least September
30, 2004, and, ultimately complete its marketing and development program and
achieve profitability, Neurologix expects to seek additional financing through
the sale of debt and equity securities.
In addition, on August 13, 2003 Neurologix entered into a merger agreement
with Change. As of September 30, 2003, Change's assets consisted primarily of
approximately $6.0 million in cash and cash equivalents. Neurologix believes
that the Merger with Change will enable Neurologix to conduct the Phase I
clinical trial of gene therapy that it has developed for the treatment of
Parkinson's disease and to continue the development of therapies for the
treatment of other degenerative neurological disorders.
From Neurologix's inception through September 30, 2003, Neurologix has
financed its operations primarily using the proceeds from the sale of its
capital stock and by borrowing $2 million from several of its shareholders.
In October 1999, Neurologix raised $500,000 through the issuance of 147
shares of its initial series of convertible preferred stock. Each share of the
initial series of convertible preferred stock is entitled to cumulative
dividends at an annual rate equal to 10% of the liquidation preference per
share, which currently is $3,401 per share. Each share of the initial series of
convertible preferred stock is convertible into 15,000 shares of Neurologix's
common stock. In the event that the shares of the initial series of convertible
preferred stock are not converted into common stock on or prior to October 15,
2004, the holders of the shares of the initial series of convertible preferred
stock shall be entitled to have Neurologix repurchase the holders' shares of the
initial series of convertible preferred stock and to receive $3,401 per share
(as adjusted for any share dividends, combinations or subdivisions with respect
to such shares of the initial series of convertible preferred stock) plus all
accrued and unpaid dividends on the repurchased shares of the initial series of
convertible preferred stock. The holders of the initial series of convertible
preferred stock have agreed to convert the initial series of convertible
preferred stock into common stock concurrently with the closing of the Merger.
In February and March 2002, Neurologix raised approximately $2.6 million
through the issuance of 490,754 shares of Series B convertible preferred stock.
Each share of the Series B convertible preferred stock is convertible into one
share of common stock subject to certain anti-dilution provisions. Upon a
liquidation, dissolution or winding up of Neurologix, the holders of the Series
B convertible preferred stock are entitled to receive $5.40 per share prior to
any distribution by Neurologix of its assets to its other common and preferred
stockholders. The holders of 79.2% of the outstanding shares of Series B
convertible preferred stock have agreed to convert their shares of Series B
convertible preferred stock into common stock immediately prior to the closing
of the Merger. Those shares of Neurologix common stock and the remaining
outstanding shares of Series B convertible preferred stock will be converted
into Change common stock pursuant to the terms of the merger agreement.
The Existing Neurologix Note evidences the loan to Neurologix of $2.0
million by several of its stockholders. The Existing Neurologix Note matures in
October 2007 and is collateralized by certain intellectual property of
Neurologix. The Existing Neurologix Note bears interest at 6% per year. Accrued
interest on the Existing Neurologix Note at September 30, 2003, was $328,248.
The persons having an interest in the Existing Neurologix Note have agreed to
convert the Existing Neurologix Note into Neurologix common stock immediately
prior to the closing of the Merger. Upon conversion, such persons would be
entitled to receive a number of shares of Neurologix common stock determined by
dividing (x) the sum of
96
(a) the outstanding unpaid principal amount of the Existing Neurologix Note as
of the date of the exchange plus (b) the amount of accrued and unpaid interest
on the Existing Neurologix Note as of the date of the exchange by (y) $6.00.
On August 13, 2003, Neurologix entered into the merger agreement with
Change. Concurrent with the execution of the merger agreement, Change loaned the
Company $750,000 and the Company issued a promissory note to Change in the
aggregate principal amount of $750,000 due April 30, 2004 and bearing interest
at the rate of 4% per year.
On November 14, 2003, the merger agreement was amended to increase the
amount of the loan from $750,000 to $1,100,000 and to extend the term of the
loan to June 30, 2004. Change funded the additional $350,000 amount of the loan
on December 18, 2003. The note, as amended, will continue to accrue interest at
4% per year, be collateralized by all of the assets of the Company and be senior
to all indebtedness of the Company.
At September 30, 2003, Neurologix had cash and cash equivalents of
approximately $887,000, compared with $2.0 million at September 30, 2002. This
decrease was primarily a result of the use of cash to fund Neurologix's
operations. For at least the next two years, Neurologix expects to focus its
operations on conducting Phase I and Phase II clinical trials of its NLX gene
therapy technology, researching gene therapy treatments for Parkinson's disease
and epilepsy and preparing regulatory documentation including FDA submissions.
Neurologix also expects to continue its research and development of
additional gene therapy technologies. The majority of Neurologix's expenditures
over this two-year period will most likely relate to the clinical trials of
Neurologix's gene therapy treatment for Parkinson's disease and epilepsy. These
activities may increase the rate at which Neurologix uses cash in the future as
compared to the rates at which Neurologix used cash for operating activities
during 2002 and the nine months ended September 30, 2003. Neurologix believes
its existing working capital can fund its operations for the next several
months. Neurologix's existing resources will not be sufficient to support the
commercial introduction of any of its product candidates. Neurologix will need
to raise additional funds through public or private equity offerings, debt
financings or additional corporate collaboration and licensing arrangements.
Neurologix does not know whether additional financing will be available when
needed, or on terms favorable to it or its stockholders.
NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2003 AND 2002
Net cash used in operating activities was $1.3 million for the nine-month
period ended September 30, 2003, compared with $814,924 for the nine-month
period ended September 30, 2002. The increase in cash usage was attributable to
the higher level of operating expenses that Neurologix incurred during the nine-
month period ended September 30, 2003.
Net cash used in investing activities was $217,012 for the nine-month
period ended September 30, 2003, compared with $116,902 for the nine-month
period ended September 30, 2002. The increase was primarily due to the increase
in patent-related expenses during the first nine months of 2003.
Net cash used by financing activities was $741,246 for the nine-month
period ended September 30, 2003, compared with net cash provided by financing
activities of $2.8 million for the nine-month period ended September 30, 2002.
The decrease in cash provided by financing activities was due to the issuance of
$2.65 million of Series B convertible preferred stock in February and March 2002
compared to the issuance of a $750,000 promissory note to Change in August 2003.
YEARS ENDED DECEMBER 31, 2002 AND 2001
Net cash used in operating activities was $1.1 million in 2002, compared
with $728,552 in 2001. The increase in cash usage was attributable to the higher
level of operating expenses that Neurologix incurred in 2002.
97
Net cash used in investing activities was $171,342 in 2002, compared with
$93,958 in 2001. The increase was primarily due to the purchase of equipment for
$125,800 in 2002.
Net cash provided by financing activities was $2.8 million in 2002,
compared with $729,360 in 2001. The increase was due to the sale of $2.65
million of Series B convertible preferred stock in February and March 2002.
YEARS ENDED DECEMBER 31, 2001 AND 2000
Net cash used in operating activities was $728,552 in 2001 compared with
$1,023,374 in 2000. The decrease in cash usage in 2001 was attributable to the
lower level of operating expenses that Neurologix incurred in 2001.
Net cash used in investing activities was $93,958 in 2001, compared with
$62,527 in 2000. The increase was primarily due to an increase in capitalized
legal expenses regarding its patent prosecution efforts.
Net cash provided by financing activities was $729,360 in 2001, compared
with $1,075,600 in 2000. The decrease was due to the lower borrowings under the
existing note in 2001 compared to 2000.
In September 2003, Neurologix relocated its laboratory from Delaware to New
York. The lease for the New York facility has a term of one year and provides
for aggregate annual lease payments of $43,200.
CONTRACTUAL OBLIGATIONS
As of September 30, 2003, Neurologix's material future contractual
obligations were as follows:
PAYMENTS DUE BY PERIOD
----------------------------------------------------------
LESS THAN MORE THAN
CONTRACTUAL OBLIGATION TOTAL 1 YEAR 1-3 YEARS 3-5 YEARS 5 YEARS
---------------------- ---------- --------- --------- --------- ---------
Capital Lease.......................... $ 31,376 $ 20,545 $ 10,831 $ $
Rental Lease........................... $ 43,200 $ 43,200 $ -- $ $
Payments under License, Research and
Consulting Agreements................ $1,337,167 $546,750 $530,417 $260,000 $
RECENT ACCOUNTING PRONOUNCEMENTS
The Financial Accounting Standards Board, the Emerging Issues Task Force
and the Accounting Standards Executive Committee of the American Institute of
Certified Public Accountants have issued certain accounting pronouncements that
will become effective in subsequent periods; however, management of Neurologix
does not believe that any of those pronouncements would have significantly
affected Neurologix's financial accounting measurements or disclosures had they
been in effect during the periods reported, and it does not believe that any of
those pronouncements will have a significant impact on Neurologix's financial
statements at the time they become effective.
98
BUSINESS OF NEUROLOGIX
GENERAL
Neurologix, Inc., is a development stage company, involved in developing
treatments for disorders of the brain and central nervous system using gene
therapy and other innovative therapies. These treatments are designed as
alternatives to conventional surgical and pharmacological treatments.
The Company's scientific founders, Dr. Matthew J. During and Dr. Michael G.
Kaplitt, have collaborated for more than ten years in working with central
nervous system disorders. Their research spans from animal studies (for gene
therapy in Parkinson's disease) to completed Phase I human clinical trials (for
Canavan's disease, a fatal degenerative disorder).
Neurologix's initial development efforts are focused on gene therapy
products for treating Parkinson's disease and epilepsy. Neurologix's core gene
therapy technology, which it refers to as NLX, is currently being tested in a
Phase I human clinical trial, sponsored by Neurologix, to treat Parkinson's
disease. A Phase I clinical trial tests the safety, as opposed to efficacy, of a
proposed treatment. The clinical trial is being conducted by Dr. During and Dr.
Kaplitt. As part of this clinical trial, twelve patients with Parkinson's
disease will undergo surgical gene therapy at The New York Presbyterian
Hospital/Weill Medical College of Cornell University. The first of these
surgeries was performed in August 2003 and marks the first time that gene
therapy products have been used in a human to attempt to treat Parkinson's
disease. A second patient underwent surgery as part of the clinical trial in
September 2003. Neurologix expects the remaining ten surgeries to be conducted
over the next year. With guidance during the approval process from the National
Institutes of Health, or NIH, and the Food and Drug Administration, or FDA, Dr.
During and Dr. Kaplitt designed a clinical trial to minimize complications to
patients participating in the study. Upon successful completion of the Phase I
clinical trial, Neurologix expects to proceed with a Phase II human clinical
trial to demonstrate the efficacy of NLX in treating Parkinson's disease.
Neurologix was established in 1999. Between 1999 and 2002, Neurologix
conducted its gene therapy research through sponsorship agreements with Thomas
Jefferson University, The Rockefeller University and the University of Auckland.
In October 2002, Neurologix opened a laboratory facility and hired a staff, with
the objective of manufacturing its current gene therapy products for use in
pre-clinical trials and to continue research and development of additional gene
therapy products. In September 2003, Neurologix relocated this laboratory from
Delaware to New York.
BUSINESS STRATEGY
Neurologix's objective is to develop and commercialize long-term,
cost-effective treatments for disorders of the brain and central nervous system.
Key elements of Neurologix's strategy are:
- Focus resources on development of NLX technology. Neurologix intends to
focus its research and development efforts on what it believes are
achievable technologies having practical applications. Consequently,
Neurologix expects to initially allocate substantially all of its
resources and efforts to the development of its first-generation NLX
products for the treatment of Parkinson's disease and epilepsy.
- Focus on central nervous system disorders that are likely to be receptive
to gene therapy treatment. To attempt to reduce the technical and
commercial risks inherent in the development of new gene therapies,
Neurologix intends to pursue treatments for neurological diseases for
which:
-- the gene function is defined;
-- animal studies, including studies involving non-human primates, have
indicated that gene therapy technology may be effective in treating
the disease;
-- partial correction of the disease is expected to be established;
-- clinical testing can be conducted in a relatively small number of
patients within a reasonably short time period.
99
- Design treatment strategies that are likely to receive relatively quick
regulatory approvals and which minimize the risk to the patient. In this
regard, Neurologix has benefited from guidance provided by the NIH and
FDA in formulating Phase I of its current Parkinson's disease clinical
trial. It is Neurologix's hope that successful completion of the Phase I
trial will lead to more rapid approval of clinical trials for other
products intended to demonstrate that gene therapy in the brain can be
both safe and effective. Neurologix NLX gene therapy technology involves
using adeno-associated virus, or AAV, vector to deliver genes to cells.
AAV is not known to cause disease in humans.
- Establish strategic relationships to facilitate research and
manufacturing. Neurologix intends to seek to establish collaborative
research and manufacturing relationships with universities and companies
involved in the development of gene therapy and other technologies.
Neurologix expects that such relationships, if established, will reduce
the resources that Neurologix needs to provide to manufacture gene
therapy products and conduct clinical trials involving these products,
which may accelerate their commercialization.
TECHNOLOGY OVERVIEW
DNA is organized into segments called genes with each gene representing the
information necessary to make one particular protein. Occasionally, the DNA for
one or more genes can be defective, resulting in the absence or improper
production of a functioning protein in the cell. This improper expression can
alter a cell's normal function and can frequently result in a disease. One goal
of gene therapy is to treat these diseases by delivering DNA containing the
corrected gene into cells. Also, gene therapy can increase or decrease the
synthesis of gene products, or introduce new genes in a cell and thus provide
new functions to that cell. There are several different ways of delivering genes
to cells. Each of the methods of delivery uses carriers, called "vectors," to
transport the genes into cells. Similar to the relationship between a delivery
truck and its cargo, the vector (the "truck") provides a mode of transport and
the therapeutic agent (the "cargo") provides the disease remedy. These carriers
can be either man-made components or modified viruses. The use of viruses takes
advantage of their natural ability to introduce DNA into cells. Gene therapy
takes advantage of this property by replacing viral DNA with a specific gene.
Once the vector inserts the gene into the cell, the gene acts as a blueprint
directing the cell to make the therapeutic protein.
For its first-generation of products, Neurologix intends to exclusively
utilize the AAV vector. In 1994, Dr. Kaplitt and Dr. During demonstrated that
AAV could be a safe and effective vehicle for gene therapy in the brain. Since
that time, AAV has been used safely in a variety of clinical gene therapy
trials, and to Neurologix's knowledge, the virus has never been associated with
any human disease.
Producing an AAV vector involves three steps. First, the AAV virus is
modified by removing all of its viral genes and replacing them with a gene that
produces the therapeutic protein. Second, a human cell line is constructed,
which contains, among other things, the original AAV viral genes. Finally, the
AAV viral gene is stripped of the helper virus (the virus needed to facilitate
production of the additional stock of AAV) in order to eliminate contamination
of the final product.
Neurologix believes that the benefits of AAV vector gene therapy technology
include:
- Safety. AAV vectors are based on a virus that, to Neurologix's
knowledge, has never been associated with a human disease.
- Efficiency of Delivery. AAV vectors are effective at delivering genes to
cells. Once in the cell, genes delivered by AAV vectors in animal models
have produced large amounts of protein on a continuous basis, often for
months or longer from a single administration.
- Ability to Deliver Many Different Genes. The vast majority of genes fit
into AAV vectors and have been successfully delivered to a wide range of
cell types.
- A Simpler and Safer Option than Surgery. Neurologix intends to
administer the AAV vector-based products in a procedure that is simpler
and safer than other common surgical procedures such as lesion removal.
100
- Stability. Unlike other viruses, AAV is stable under a wide range of
conditions. This allows AAV vectors to be handled like normal
pharmaceutical products, lending themselves to traditional shipping and
storing procedures.
PRODUCT DEVELOPMENT
Neurologix's initial focus is to develop therapeutic products to meet the
needs of two classes of patients: those suffering from Parkinson's disease and
those suffering from epilepsy.
PARKINSON'S DISEASE
Parkinson's disease is a neurodegenerative disorder; it arises from the
gradual death of nerve cells. Parkinson's disease is a progressive and
debilitating disease that affects the control of movement and is characterized
by four principal symptoms:
- rigidity of the limbs,
- tremor of the limbs,
- bradykinesia of the limbs and body evidenced by difficulty and slowness
of movement, and
- postural instability.
Physicians and patients have long recognized that this disease, or
treatment complications, can cause a wide spectrum of other symptoms, including
dementia, abnormal speech, sleep disturbances, swallowing problems, sexual
dysfunction, and depression.
Rigidity, tremor, and bradykinesia result, primarily, from a loss of
dopamine in two regions of the brain: the substantia nigra and striatum.
Dopamine is a chemical, or neurotransmitter, which enhances or facilitates the
flow of impulses from nerve cells (neurons) in the substantia nigra to nerve
cells in the striatum. Standard therapy for Parkinson's disease often involves
use of levodopa, a drug which stimulates production of dopamine. However, over
extended periods of time levodopa often declines in its effectiveness. In
advanced stages of Parkinson's disease, as the disease becomes more and more
debilitating, it becomes necessary and advisable to accept a riskier and
potentially more invasive medical procedure to treat the disease. It is at this
juncture that surgical procedures (deep brain stimulators, lesion removal, etc.)
are commonly advised.
Neurologix believes that the glutamic acid decarboxylase, or GAD, gene can
be used to selectively target gene expression and alter the neural circuitry
affected in Parkinson's disease. Neurologix's technology inserts a GAD gene into
the AAV based viral vector. The GAD gene is responsible for making gamma
aminobutyric acid, which is released by nerve cells to inhibit or dampen
activity. Neurologix's gene therapy is designed to reset the overactive brain
cells to inhibit electrical activity and return brain network activity to more
normal levels without destroying brain tissue and without implanting hardware.
EPILEPSY
Epilepsy, which involves recurring seizures, is caused by periodic episodes
of repetitive, abnormal electrochemical disturbance in the central nervous
system, beginning in the brain. Generalized seizures happen when massive bursts
of electrical energy sweep through the whole brain at once, causing loss of
consciousness, falls, convulsions or intense muscle spasms. Partial seizures
happen when the disturbance occurs in only one part of the brain, affecting the
physical or mental activity that area of the brain controls. Seizures may also
begin as partial or focal seizures and then generalize.
Neurologix believes that its technology can be applied to the treatment of
epilepsy with advantages over the currently available treatments for epilepsy.
Neurologix's proposed treatment includes the following:
- Using gene-transfer technology to deliver genes which restore the
chemical balance but only in the areas in which the disease process is
occurring; and
- Using vaccine technology to selectively target the epileptic regions of
the brain, dampening excessive activity and preventing seizures and brain
damage.
101
PATENTS AND OTHER PROPRIETARY RIGHTS
Neurologix believes that its success will depend on its ability to protect
its proprietary technology. Neurologix is actively pursuing a policy of seeking
patent protection for its proprietary products and technologies which Neurologix
believes are patentable and where Neurologix believes its interests are best
served by seeking patent protection. Neurologix has 2 issued U.S. patents, 6
pending U.S. patent applications and 6 pending foreign patent applications.
Neurologix has acquired licenses to or assignments of 3 additional U.S. patents
covering gene therapy technologies.
Neurologix has entered into agreements with The Rockefeller University,
Auckland UniServices, Ltd., Thomas Jefferson University and University Health
Network to fund gene therapy research projects at these institutions. These
agreements grant Neurologix a right of first refusal to obtain, upon
commercially reasonable terms, exclusive license rights to any intellectual
property developed in the course of the sponsored research projects.
Neurologix relies on trade secrets, technical know-how and continuing
technological innovation to develop and maintain its competitive position.
Neurologix requires all of its employees and consultants to execute
confidentiality and assignment of invention agreements. These agreements
typically provide that (i) all materials and confidential information developed
or made known to the individual during the course of the individual's
relationship with Neurologix is to be kept confidential and not disclosed to
third parties except in specific circumstances and (ii) all inventions arising
out of the relationship with Neurologix shall be Neurologix's exclusive
property. These agreements may not provide meaningful protection for
Neurologix's trade secrets in the event of unauthorized use or disclosure of
Neurologix's confidential information.
COMPETITION
Although Neurologix is not aware of any other company currently conducting
clinical trials of gene therapy products in humans to treat Parkinson's disease
or epilepsy, Neurologix faces intense competition from pharmaceutical companies,
biotechnology companies, universities, governmental entities and other
healthcare providers developing alternative treatments for these diseases.
Alternative treatments include surgery, deep brain stimulator implants and
pharmaceutical. Neurologix may face competition from companies and institutions
involved in developing gene therapy and cell therapy treatments for other
diseases, whose technologies may be adapted for the treatment of central nervous
system disorders. Some companies, such as Avigen, Inc., Cell Genesys, Inc., and
Targeted Genetics Corporation, have significant experience in developing and
using AAV vectors to deliver gene therapy products.
Many of Neurologix's competitors have significantly greater research and
development capabilities than Neurologix, as well as substantial marketing,
manufacturing, financial and managerial resources. Acquisitions of, or
investments in, Neurologix's competitors by larger companies, as well as
competitors' entry into collaborative relationships with large pharmaceutical
companies and academic institutions, could increase Neurologix's competitors'
financial, marketing, manufacturing and other resources. Developments by others
may render Neurologix's products or technologies noncompetitive or obsolete.
GOVERNMENT REGULATION
The production and marketing of Neurologix's proposed products and research
and development activities are subject to regulation for safety, efficacy and
quality by numerous governmental authorities in the United States and
potentially other foreign countries. In the United States, the FDA regulates,
among other things, the testing, manufacturing, safety, efficacy, labeling,
storage, record keeping, advertising and promotional practices and import and
export of drugs and biological products.
In addition, in the event that Neurologix seeks to commercialize a product
embodying technology covered by a patent that was exclusively licensed to
Neurologix by an educational or other non-profit institution in the United
States, Neurologix may be required to manufacture such product substantially in
the United States, if the technology resulted from federally funded research.
102
FACILITIES
Neurologix leases approximately 2,000 square feet of laboratory space in
New York, New York. This lease, which provides for an aggregate annual rental
payment of $43,620 expires August 31, 2004. Neurologix's corporate offices are
located at the following address: One Bridge Plaza, Fort Lee, New Jersey, 07024.
Neurologix currently uses these premises on a month-to-month basis under a
verbal agreement with Palisade that does not require the payment of any rent by
Neurologix.
EMPLOYEES
At September 1, 2003, Neurologix had 3 full-time employees, including 2
research scientists with doctoral degrees. Neurologix's researchers have
expertise in virology, protein chemistry and molecular biology. Neurologix uses
consultants and temporary employees to complement its staffing. Neurologix's
employees are not subject to any collective bargaining agreements, and it
regards its relations with its employees to be good.
LEGAL PROCEEDINGS
Neurologix is not a party to any material legal proceedings.
103
COMPARISON OF THE RIGHTS OF THE HOLDERS
OF NEUROLOGIX COMMON STOCK OR SERIES B CONVERTIBLE
PREFERRED STOCK AND THE HOLDERS OF CHANGE COMMON STOCK
Some significant differences exist between the rights of Neurologix
stockholders and those of Change stockholders. The differences between the
rights of Neurologix stockholders and Change stockholders result from
differences in the respective certificates of incorporation and bylaws of Change
and Neurologix. Additionally, Change's certificate of incorporation will be
amended in connection with the Merger. For more information regarding these
amendments, please refer to the section of this proxy statement and prospectus
entitled "Proposed Amendments to Change's Certificate of Incorporation in
Connection with the Merger."
The following summarizes the material differences between the rights of the
holders of Change common stock and the rights of the holders of Neurologix
common stock and Series B convertible preferred stock. The summary does not
purport to be a complete comparison of the respective rights of Change
stockholders and Neurologix stockholders or a complete description of the
specific provisions referred to in this section. The identification of specific
differences is not meant to indicate that other equally or more significant
differences do not exist. However, the following summary includes a description
of those differences that Change believes are material. The summary is qualified
in its entirety by reference to the governing statutes and corporate instruments
of Change and Neurologix, including the Delaware General Corporation Law. The
certificate of incorporation and bylaws of Change have been filed with the SEC
as Exhibits 3.1 and 3.2, respectively, to Change's Quarterly Report on Form 10-Q
for the fiscal quarter ended September 30, 2000, filed on November 20, 2000.
The summary concludes with a brief description of the rights of holders of
Change Series A convertible preferred stock. No shares of Change Series A
convertible preferred stock will be issued in connection with Merger.
AUTHORIZED CAPITAL STOCK
CHANGE
The authorized capital stock of Change as of the date of this proxy
statement and prospectus consists of 505,000,000 shares divided into 500,000,000
shares of Change common stock and 5,000,000 shares of Change preferred stock.
The par value of Change's common stock is $0.01 per share and the par value of
Change's preferred stock is $0.10 per share. The authorized capital stock of the
Change will be increased to 755,000,000 in connection with the Merger. The par
value of all of Change's common stock will be decreased to $0.001 per share in
connection with the Merger. As of the date of this proxy statement and
prospectus, 177,503,919 shares of Change common stock and 645 shares of Change
Series A preferred stock were issued and outstanding.
NEUROLOGIX
Neurologix's authorized capital stock consists of 21,000,000 shares, with a
par value of $.001 per share, divided into 20,000,000 shares of Neurologix
common stock and 1,000,000 shares of Neurologix preferred stock, of which 147
shares have been designated as its initial series of convertible preferred stock
and 562,500 shares have been designated as Series B convertible preferred stock.
As of the date of this proxy statement and prospectus, 2,490,583 shares of
Neurologix common stock, 147 shares of Neurologix's initial series of
convertible preferred stock and 490,754 shares of Neurologix Series B
convertible preferred stock were issued and outstanding. Each share of
Neurologix's initial series of convertible preferred stock is convertible into
15,000 shares of Neurologix common stock and each share of Neurologix Series B
convertible preferred stock is convertible into one share of Neurologix common
stock. The holders of (i) all of the shares of Neurologix's initial series of
convertible preferred stock and (ii) 388,894 shares of Neurologix Series B
convertible preferred stock have agreed in the voting agreement to convert all
of those shares into shares of Neurologix common stock immediately prior to the
consummation of the Merger.
104
DIVIDEND RIGHTS
CHANGE COMMON STOCK
Change's certificate of incorporation provides that, subject to the rights
of any holders of shares of Change preferred stock, the holders of shares of
Change common stock are entitled to receive all lawful dividends declared by the
Change board of directors.
NEUROLOGIX
Neurologix Common Stock. Neurologix's certificate of incorporation
provides that, subject to the rights of any holders of shares of Neurologix
preferred stock, the holders of shares of Neurologix common stock are entitled
to receive all lawful dividends declared by the Neurologix board of directors on
the Neurologix common stock.
Neurologix Series B Convertible Preferred Stock. Neurologix's certificate
of incorporation provides that no dividend may be paid on the Neurologix common
stock, other than a dividend in Neurologix common stock, unless an equivalent
dividend is paid on the Neurologix Series B convertible preferred stock.
PREEMPTIVE RIGHTS
CHANGE COMMON STOCK
Holders of shares of Change common stock do not have any preemptive rights
under Change's certificate of incorporation or bylaws to acquire shares of
Change common stock.
NEUROLOGIX
Neurologix Common Stock. Holders of Neurologix common stock do not have
any preemptive rights under Neurologix's certificate of incorporation or bylaws
to acquire shares of Neurologix common stock.
Neurologix Series B Convertible Preferred Stock. Holders of Neurologix
Series B convertible preferred stock do not have any preemptive rights under
Neurologix's certificate of incorporation or bylaws to acquire shares of
Neurologix common stock.
LIQUIDATION RIGHTS
CHANGE COMMON STOCK
Change's certificate of incorporation provides that upon the liquidation,
dissolution or winding-up of Change, after payment has been made to the holders
of Change preferred stock of the full amount to which they are entitled, the
holders of shares of Change common stock are entitled to share, ratably
according to the number of shares of Change common stock held by them, in all
remaining assets of Change available for distribution to its stockholders.
NEUROLOGIX
Neurologix Common Stock. Neurologix's certificate of incorporation
provides that upon the liquidation, dissolution, or winding-up of Neurologix,
after payment has been made to the holders of Neurologix Series B convertible
preferred stock and Neurologix's initial series of convertible preferred stock
of the specified amounts to which they are entitled, the holders of shares of
Neurologix common stock and Neurologix's initial series of convertible preferred
stock are entitled to share, ratably according to the number of shares of
Neurologix common stock held by them or issuable to them upon conversion of
Neurologix's initial series of convertible preferred stock, in all of the
remaining assets of Neurologix available for distribution to its stockholders.
Neurologix Series B Convertible Preferred Stock. Neurologix's certificate
of incorporation provides that upon the liquidation, dissolution, or winding-up
of Neurologix, the holders of the Neurologix Series B convertible preferred
stock will be entitled to receive, before any distribution of Neurologix's
assets is made to
105
the holders of the Neurologix common stock and Neurologix's initial series of
convertible preferred stock, $5.40 for each share of Series B convertible
preferred stock. After this liquidation preference is paid to the holders of the
Series B convertible preferred stock, the remaining assets of Neurologix
available for distribution to Neurologix's stockholders will be distributed
among the holders of the Neurologix common stock and Neurologix's initial series
of convertible preferred stock as provided in Neurologix's certificate of
incorporation.
VOTING RIGHTS OF STOCKHOLDERS
CHANGE
Change's bylaws provide that except as otherwise provided by any statute,
Change's certificate of incorporation or Change's bylaws, the holders of
one-third of all outstanding shares of stock entitled to vote at any meeting of
Change's stockholders, present in person or represented by proxy, constitutes a
quorum for the transaction of business. If a quorum exists, all matters are
decided by a majority of the votes cast at the meeting by the holders of shares
present in person or represented by proxy and entitled to vote thereon, except
as otherwise provided by statute, Change's certificate of incorporation or
Change's bylaws. Change's bylaws further provide that, except as otherwise
provided by any statute or Change's certificate of incorporation, directors of
Change are elected by a plurality of the votes cast at a meeting of stockholders
by the holders of shares entitled to vote in the election.
NEUROLOGIX
Neurologix's bylaws provide that except as otherwise provided by any
statute or Neurologix's certificate of incorporation, the presence, in person or
represented by proxy, at a meeting of Neurologix's stockholders of the holders
of a majority of the outstanding shares of Neurologix stock entitled to vote at
the meeting constitutes a quorum for the transaction of business. If a quorum
exists, all matters are decided by a majority of the votes cast at the meeting
by the holders of shares present, in person or represented by proxy, and
entitled to vote thereon, except as otherwise provided by statute, Neurologix's
certificate of incorporation or Neurologix's bylaws. Neurologix's bylaws further
provide that directors of Neurologix are elected by a plurality of the votes
cast at a meeting of stockholders by the holders of shares of Neurologix capital
stock present, in person or represented by proxy, and entitled to vote in the
election.
STOCKHOLDER ACTION BY WRITTEN CONSENT
CHANGE
Change's bylaws provide that unless otherwise provided in Change's
certificate of incorporation, any action required by the Delaware General
Corporation Law to be taken at any annual or special meeting of stockholders may
be taken without a meeting, without prior notice and without a vote, if a
consent or consents in writing, setting forth the action so taken, is signed by
the holders of outstanding stock having not less than the minimum number of
votes that would be necessary to authorize or take such action at a meeting at
which all shares entitled to vote thereon were present and voted.
NEUROLOGIX
Neurologix's bylaws provide that any action required or permitted by the
Delaware General Corporation Law to be taken at any annual or special meeting of
stockholders may be taken without a meeting, without prior notice and without a
vote, if a consent or consents in writing, setting forth the action so taken, is
signed by the holders of outstanding stock having not less than the minimum
number of votes that would be necessary to authorize or take such action at a
meeting at which all stockholders entitled to vote thereon were present and
voted.
106
SPECIAL MEETINGS OF STOCKHOLDERS
CHANGE
Change's bylaws provide that a special meeting of stockholders, other than
a special meeting for the election of directors, unless otherwise prescribed by
statute, may be called at any time by the Change board of directors, president
or secretary. At any special meeting of Change's stockholders, only business
that is related to the purpose or purposes of such meeting as indicated in the
notice of the special meeting or in any waiver of notice may be transacted.
NEUROLOGIX
Neurologix's bylaws provide that a special meeting of stockholders, unless
otherwise prescribed by statute or Neurologix's certificate of incorporation,
may be called at any time by the chairperson of Neurologix's board of directors,
the president or any other officer instructed by Neurologix's board of directors
to call a meeting of the stockholders and shall be called upon the written
request of a majority of Neurologix's directors or the holders of record of
least one-third of the outstanding capital stock of Neurologix entitled to vote
at the meeting. At any special meeting of stockholders, only business that is
related to the purpose or purposes of such meeting as indicated in the notice of
the special meeting or in any waiver of notice may be transacted.
AMENDMENT OF THE CERTIFICATE OF INCORPORATION AND BYLAWS
CHANGE
Under Delaware law, the amendment of a corporation's certificate of
incorporation generally requires the approval of the corporation's board of
directors and the affirmative vote of the holders of a majority of the
corporation's outstanding voting stock, unless the certificate of incorporation
of the corporation otherwise provides. Change's certificate of incorporation
does not otherwise provide for an alternative means of amendment.
Under Delaware law, an amendment to a corporation's bylaws requires the
approval of the stockholders, unless the certificate of incorporation also
confers the power to amend the bylaws upon the board of directors. Change's
certificate of incorporation provides that the Change board of directors may
adopt, amend or repeal Change's bylaws; provided, however, that any bylaws
adopted or amended by the board may be amended or repealed, and any bylaws may
be adopted, by Change's stockholders by the vote of a majority of the holders of
shares of Change's stock entitled to vote in the election of the directors of
Change.
NEUROLOGIX
Under Delaware law, the amendment of a corporation's certificate of
incorporation generally requires the approval of the corporation's board of
directors and the affirmative vote of the holders of a majority of the
corporation's outstanding voting stock, unless the corporation's certificate of
incorporation otherwise provides. Neurologix's certificate of incorporation does
not require for purposes of its amendment the approval by a greater number or
proportion of Neurologix's directors or stockholders than is otherwise required
by Delaware law.
Under Delaware law, an amendment to a corporation's bylaws requires the
approval of the stockholders, unless the certificate of incorporation also
confers the power to amend the bylaws upon the corporation's board of directors.
Neurologix's bylaws provide that, except as otherwise provided by statute,
Neurologix's certificate of incorporation or the bylaws, the board of directors
of Neurologix may adopt, amend or repeal Neurologix's bylaws; provided, however,
that Neurologix's stockholders shall retain the power to adopt, amend or repeal
the bylaws.
107
NUMBER AND CLASSIFICATION OF THE BOARD OF DIRECTORS
CHANGE
Change's bylaws provide that the Change board of directors will consist of
one or more members. The number of directors may be changed from time to time by
action of Change's stockholders or by the Change board of directors. Each
director holds office until a successor is elected and qualified or until such
director's death, resignation or removal.
The combined company's certificate of incorporation will provide that the
Change board of directors will consist of not less than three nor more than
twelve directors, with the then-authorized number of directors being fixed from
time to time by the board of directors. Additionally, the Change board of
directors will be divided into three classes, as nearly equal in number as
possible, designated Class I, Class II and Class III. Class I directors will
initially serve until the 2004 annual meeting of Change's stockholders; Class II
directors will initially serve until the 2005 annual meeting of Change's
stockholders; and Class III directors will initially serve until the 2006 annual
meeting of Change's stockholders. Commencing with the annual meeting of Change's
stockholders in 2004, directors of each class, the term of which will then
expire, will be elected to hold office for a three-year term and until the
election and qualification of their respective successors in office. In the case
of any increase or decrease, from time to time, in the number of directors of
the combined company, the number of directors in each class will be apportioned
so as to keep the number of directors in each class as equal as possible.
NEUROLOGIX
Neurologix's bylaws provide that Neurologix's board of directors will
consist of not less than two nor more than seven directors, unless there is only
one stockholder, in which case, there may be only one director. The exact number
of directors within such range may be fixed from time to time by action of
Neurologix's stockholders or by Neurologix's board of directors. Each director
holds office until a successor is elected and qualified or until such director's
death, resignation or removal.
QUORUM FOR DIRECTOR MEETINGS
CHANGE
Change's bylaws provide that the presence in person of a majority of the
entire Change board of directors constitutes a quorum for the transaction of
business at any meeting of the board, but a majority of a smaller number may
adjourn any such meeting to a later date.
NEUROLOGIX
Neurologix's bylaws provide that the presence in person of a majority of
the whole board of directors of Neurologix constitutes a quorum for the
transaction of business at any meeting of the board, except that when one or
more vacancies prevent such a majority, a majority of the directors then in
office constitutes a quorum, provided such majority constitutes at least
one-third of the whole board of directors. A majority of the directors present,
whether or not they constitute a quorum, may adjourn a meeting to another place
and time.
LIMITATION OF LIABILITY OF DIRECTORS AND OFFICERS
CHANGE
Change's certificate of incorporation provides that no director will be
personally liable to Change or its stockholders for monetary damages for breach
of fiduciary duty as a director, except for liability in connection with:
- breaches of the director's duty of loyalty to Change or its stockholders;
- acts or omissions not in good faith or involving intentional misconduct
or a knowing violation of law;
108
- the payment of unlawful dividends or unlawful stock repurchases or
redemptions; or
- transactions in which the director derived an improper personal benefit.
NEUROLOGIX
Neurologix's certificate of incorporation provides that no director will be
personally liable to Neurologix or its stockholders for monetary damages for
breach of fiduciary duty as a director, except for liability for:
- breaches of the director's duty of loyalty to Neurologix or its
stockholders;
- acts or omissions not in good faith or involving intentional misconduct
or a knowing violation of law;
- the payment of unlawful dividends or unlawful stock repurchases or
redemptions; or
- transactions from which the director derived an improper personal
benefit.
INDEMNIFICATION OF DIRECTORS AND OFFICERS
CHANGE
Change's certificate of incorporation and bylaws require Change, to the
extent permitted by applicable law, to indemnify any person against whom a claim
is made by reason of the fact that the person, or a person of whom such person
is the legal representative, is or was a director or officer of Change or is or
was serving, at the request of Change, in similar capacity for any other entity
against judgments, fines, penalties, excise taxes, amounts paid in settlement,
costs, charges and expenses associated with that claim. Persons not directors or
officers of Change may be similarly indemnified at the option of Change to the
extent the board of Change so specifies. Any director or officer of Change
serving in any capacity in a majority-owned direct or indirect subsidiary of
Change or any Change benefit plan is deemed to be serving at the request of
Change. Change has the power to purchase and maintain insurance on behalf of any
director, officer, employee or agent of Change, or who is or was serving at the
request of Change in a similar capacity for any other entity.
NEUROLOGIX
Neurologix's certificate of incorporation requires Neurologix, to the
fullest extent permitted by Section 145 of the Delaware General Corporation Law,
to indemnify Neurologix's officers and directors against all expenses,
liabilities or other matters referred to in or covered by Section 145. Persons
who are not directors or officers of Neurologix may be similarly indemnified at
the option of Neurologix to the extent that Neurologix's board of directors so
specifies. Neurologix has the power to purchase and maintain insurance on behalf
of any person who is or was a director, officer, employee or agent of
Neurologix, or who is or was serving at the request of Neurologix in a similar
capacity for any other entity, against any liability asserted against the person
and incurred by the person in any such capacity, or arising out of the person's
status as such.
Section 145 of the Delaware General Corporation Law authorizes a
corporation to indemnify its directors, officers, employees and agents against
expenses (including attorneys' fees), judgments, fines and amounts paid in
settlement reasonably incurred, provided that they act in good faith and in a
manner reasonably believed to be in or not opposed to the best interests of the
corporation, and, with respect to any criminal proceeding, had no reasonable
cause to believe their conduct was unlawful, although in the case of proceedings
brought by or on behalf of the corporation, such indemnification is limited to
expenses and is not permitted if the individual is adjudged liable to the
corporation, unless the Delaware Court of Chancery or the court in which such
proceeding was brought determines otherwise in accordance with the Delaware
General Corporation Law.
VOTING WITH RESPECT TO CERTAIN BUSINESS COMBINATIONS
CHANGE
Section 203 of the Delaware General Corporation Law provides that a
corporation may not engage in any business combination, generally defined as a
merger, consolidation, sale of greater than 10% of assets, issuance of stock or
granting of other financial benefits, with any interested stockholder, generally
defined as any person
109
owning greater than 15% of the voting stock of a corporation, for a period of
three years following the time that such stockholder became an interested
stockholder, unless:
- prior to that time, the board of directors of the corporation approved
either the business combination or the transaction which resulted in the
stockholder becoming an interested stockholder;
- upon consummation of the transaction which resulted in the stockholder
becoming an interested stockholder, the interested stockholder owned at
least 85% of the voting stock of the corporation outstanding at the time
the transaction commenced, excluding for purposes of determining the
number of shares outstanding those shares owned by persons who are
directors, and also officers and employee stock plans in which employee
participants do not have the right to determine confidentially whether
shares held subject to the plan will be tendered in a tender or exchange
offer; or
- at or subsequent to such time the business combination is approved by the
board of directors and authorized at an annual or special meeting of
stockholders, and not by written consent, by the affirmative vote of at
least two-thirds of the outstanding stock which is not owned by the
interested stockholder.
Change is subject to Section 203 and the combined company will be subject
to Section 203.
NEUROLOGIX
Neurologix is not subject to Section 203 of the Delaware General
Corporation Law but the combined company will be subject to Section 203.
REQUIRED VOTE FOR AUTHORIZATION OF FUNDAMENTAL CORPORATE TRANSACTIONS
CHANGE
Under the Delaware General Corporation Law, fundamental corporate
transactions, such as mergers, sales of all or substantially all of the
corporation's assets and dissolutions, require the approval of the holders of a
majority of the shares outstanding and entitled to vote. The Delaware General
Corporation Law permits a corporation to increase the minimum percentage vote
required. The certificate of incorporation and bylaws of Change do not contain
provisions increasing such percentage.
NEUROLOGIX
Under the Delaware General Corporation Law, fundamental corporate
transactions, such as mergers, sales of all or substantially all of the
corporation's assets and dissolutions, require the approval of the holders of a
majority of the shares outstanding and entitled to vote. The Delaware General
Corporation Law permits a corporation to increase the minimum percentage vote
required. The certificate of incorporation and bylaws of Neurologix do not
contain provisions increasing such percentage.
TRANSFER RESTRICTIONS
CHANGE
Transfers of shares of the capital stock of Change may be made only on the
books of Change by the holder thereof or by the holder's duly authorized
attorney and on surrender of the certificate or certificates representing such
shares of capital stock properly endorsed for transfer and upon payment of all
necessary transfer taxes. Change's bylaws provide that a person in whose name
shares of capital stock stands in the books of Change is deemed the owner
thereof to receive dividends, to vote as such owner and for all other purposes
with respect to Change. Change's bylaws further provide that no transfer of
shares of capital stock is valid as against Change, its stockholders and
creditors for any purpose, except to render the transferee liable for the debts
of Change to the extent provided by applicable law, until such transfer is
entered into the books of Change, showing from and to whom transferred.
110
NEUROLOGIX
Transfers of shares of the capital stock of Neurologix may be made only on
the books of Neurologix by the holder thereof or by the holder's duly authorized
attorney and on surrender of the certificate or certificates representing such
shares of capital stock properly endorsed for transfer and upon payment of all
necessary transfer taxes.
CHANGE SERIES A PREFERRED STOCK
Shares of Change Series A preferred stock are convertible to Change common
stock on a share-for-share basis and have voting rights on an as if converted to
common stock basis. Change Series A preferred stock accumulates $0.06 per share
cumulative dividends annually, payable each May 31st at the discretion of the
Change board of directors. Holders of Change Series A preferred stock are not
entitled to payment of any accrued but unpaid dividends existing at the time of
a voluntary conversion of such stock to common stock. As of September 30, 2003,
there were 645 shares of Change Series A convertible preferred stock issued and
outstanding, with an aggregate liquidation preference of $1.00 per share.
111
INFORMATION REGARDING BENEFICIAL OWNERSHIP OF
MANAGEMENT AND PRINCIPAL STOCKHOLDERS OF CHANGE
INFORMATION AS TO DIRECTORS AND OFFICERS OF CHANGE AND 5% OR LARGER STOCKHOLDERS
The following table sets forth certain information as of September 30, 2003
regarding (i) each person known by Change, based upon filings by such persons
with the Commission or information provided by such persons to Change, to be the
beneficial owner of more than 5% of the outstanding shares of Change common
stock or Series A preferred stock, (ii) each current director of Change, (iii)
the current chief executive officer of Change and (iv) all current executive
officers and directors as a group. Except as otherwise indicated, each person
has sole voting and dispositive power with respect to such shares. The address
for all beneficial owners, unless stated otherwise below, is c/o Change
Technology Partners, Inc., 537 Steamboat Road, Greenwich, Connecticut 06830.
Each share of the Change Series A preferred stock is convertible into one
share of Change common stock.
Beneficial ownership includes shares for which a person, directly or
indirectly, has or shares voting or investment power, or both, and also includes
options and warrants which are exercisable within sixty days of September 30,
2003.
SERIES A
COMMON STOCK PREFERRED STOCK
----------------------------- -------------------------
NAME OF BENEFICIAL OWNER SHARES PERCENT OF CLASS SHARES PERCENT OF CLASS
------------------------ ---------- ---------------- ------ ----------------
Michael Gleason..................... 33,489,130(1) 18.71% -- --
Culmen Technology Partners, L.P. ... 32,000,000 18.03% -- --
6226 Colleyville Blvd
Suite A
Colleyville, Texas 76034
Christopher H.B. Mills.............. 12,939,700(2) 7.29% -- --
c/o J.O. Hambro Capital
Management Limited
Ryder Court, 14 Ryder St.
London SW1Y 6QB, England
Gordon Bryant....................... -- -- 645 100%
9408 Avenido Del Oso NE
Albuquerque, NM 87111
Austin M. Long...................... -- -- -- --
Craig J. Nickels.................... -- -- -- --
All officers and directors as a
group (1 person)(3)............... 33,489,130(4) 18.71% -- --
---------------
(1) Represents 32,000,000 shares of Change common stock owned by Culmen
Technology Partners, L.P. ("Culmen"). Mr. Gleason is the President and sole
director of CTP, Inc., the general partner of Culmen. As a result, he may be
deemed to have beneficial ownership over these shares. However, Mr. Gleason
disclaims beneficial ownership of 30,200,000 shares of Change common stock.
Also includes options to purchase an aggregate of 1,489,130 shares of Change
common stock.
(2) According to a Schedule 13G filed with the Securities and Exchange
Commission on July 19, 2001, Mr. Mills (i) shares voting and dispositive
power over such shares with J.O. Hambro Capital Management (Holdings)
Limited and J.O. Hambro Capital Management Limited, (ii) shares voting and
dispositive power over 1,280,000 such shares with American Opportunity Trust
plc, (iii) shares voting and dispositive power over 4,400,000 such shares
with Growth Financial Services and North Atlantic Smaller Companies
Investment Trust plc, (iv) shares voting and dispositive power over 640,000
such shares with Oryx International Growth Fund Limited and Consulta
(Channel Islands) Limited and
112
(v) shares voting and dispositive power over 1,498,000 such shares with The
Trident North Atlantic Fund.
(3) Duplications eliminated.
(4) Represents 32,000,000 shares of Change common stock and options to purchase
1,489,130 shares of Change common stock. Includes 32,000,000 shares of
Change common stock owned by Culmen, which Mr. Gleason may be deemed to
beneficially own.
113
INFORMATION REGARDING BENEFICIAL OWNERSHIP
OF MANAGEMENT AND PRINCIPAL STOCKHOLDERS
OF NEUROLOGIX
The following table provides information about the beneficial ownership of
Neurologix's capital stock at September 30, 2003 by:
- each person known by Neurologix to beneficially own more than 5% of the
outstanding shares of Neurologix's common stock, convertible preferred
stock or Series B convertible preferred stock,
- each of Neurologix's directors and executive officers, and
- all of Neurologix's directors and officers as a group.
Beneficial ownership is determined under the rules of the Securities and
Exchange Commission. In computing the number of shares beneficially owned by a
person and the percentage ownership of that person, shares of Neurologix capital
stock issuable upon the exercise of options held by that person that are
exercisable within sixty days of September 30, 2003, are assumed to be issued
and outstanding. These shares, however, are not assumed to be outstanding for
purposes of computing the percentage ownership of any other stockholder. Except
as indicated in the footnotes to this table, each stockholder named in the table
has sole voting and investment power over the shares shown as beneficially owned
by them.
The percentage of Neurologix capital stock beneficially owned is based on
2,490,583 shares of Neurologix common stock, 147 shares of Neurologix's initial
series of convertible preferred stock and 490,754 shares of Neurologix Series B
convertible preferred stock outstanding on September 30, 2003. Each share of
Neurologix's initial series of convertible preferred stock is convertible into
15,000 shares of Neurologix common stock, and each share of Neurologix Series B
convertible preferred stock is convertible into one share of Neurologix common
stock.
114
The address for all beneficial owners, unless stated otherwise below, is
c/o Neurologix, Inc., One Bridge Plaza, Fort Lee, New Jersey 07024.
SERIES B
CONVERTIBLE CONVERTIBLE
COMMON STOCK PREFERRED STOCK PREFERRED STOCK
--------------------- ------------------ ------------------
PERCENT PERCENT PERCENT
NAME OF BENEFICIAL OWNER SHARES OF CLASS SHARES OF CLASS SHARES OF CLASS
------------------------ --------- -------- ------- -------- ------- --------
Auckland Technology Enabling
Corporation Limited........... 1,312,500 52.70% -- -- -- --
P.O. Box 10-359
8th Floor, Lumley House
93 The Terrace
Wellington, New Zealand
Zenith Partners................. 832,500 33.43% -- -- -- --
Palisade Private Partnership,
L.P........................... 2,457,097(1) 49.66% 138.768 94.40% 9,260 1.89%
Medtronic International, Ltd.... 324,074(2) 11.51% -- -- 324,074 66.04%
710 Medtronic Parkway
Minneapolis, MN 55421
The Rockefeller University...... 133,583 5.36% -- -- -- --
1230 York Avenue
New York, NY 10021
Martin J. Kaplitt............... 873,989(3) 34.52% 2.352 1.60% -- --
Mark S. Hoffman................. 2,457,097(1) 49.66% 138.768 94.40% 9,260 1.89%
Clark A. Johnson................ 159,282(4) 6.01% 5.880 4.00% 55,560 11.32%
Janice K. Robinson Willinger.... 50,000(5) 1.97% -- -- -- --
Steven R. LaPorte............... 324,074(2) 11.51% -- -- 324,074 66.04%
All directors and officers as a
group (5 persons)............. 3,864,442(6) 69.98% 147.000 100.00% 388,894 79.24%
---------------
(1) Of the 2,457,097 shares:
- 2,081,520 shares may be acquired by Palisade Private Partnership, L.P.,
upon the conversion of 138.768 shares of Neurologix's initial series of
convertible preferred stock within 60 days after September 30, 2003;
- 9,260 shares may be acquired by Palisade Private Partnership, L.P., upon
the conversion of 9,260 shares of Neurologix Series B convertible
preferred stock within 60 days after September 30, 2003; and
- 366,317 shares may be acquired by Palisade Private Partnership, L.P.,
upon the exchange of its interest in the Existing Neurologix Note
pursuant to the voting agreement within 60 days after September 30, 2003.
The sole general partner of Palisade Private Partnership, L.P., is Palisade
Private Holdings, LLC. Mark Hoffman, one of Neurologix's directors, is a
managing member of Palisade Private Holdings, LLC. Mr. Hoffman shares
voting and investment power over the shares held by Palisade Private
Partnership, L.P. with the other members of Palisade Private Holdings, LLC.
Mr. Hoffman and the other managing members of Palisade Private Holdings,
LLC, disclaim beneficial ownership of the shares held by Palisade Private
Partnership, L.P., except to the extent of their pecuniary interest in the
shares.
(2) The 324,074 shares may be acquired by Medtronic International, Ltd., upon
the conversion of 324,074 shares of Neurologix Series B convertible
preferred stock within 60 days after September 30, 2003.
Mr. LaPorte, one of Neurologix's directors, is the vice president and
general manager of Medtronic Neurological Ventures and as such exercises
sole voting and investment power over the shares held by Medtronic
International, Ltd. Mr. LaPorte disclaims beneficial ownership of the
shares held by Medtronic International, Ltd., except to the extent of his
pecuniary interest in the shares.
115
(3) Of the 873,989 shares:
- 832,500 shares are held by Zenith Partners;
- 35,280 shares may be acquired by the Martin J. Kaplitt Keogh-Profit
Sharing Plan upon the conversion of 2.352 shares of Neurologix's initial
series of convertible preferred stock within 60 days after September 30,
2003; and
- 6,209 shares may be acquired by Mr. Kaplitt upon the exchange of his
interest in the Existing Neurologix Note pursuant to the voting agreement
within 60 days after September 30, 2003.
Mr. Kaplitt, one of Neurologix's directors and its president, is the sole
general partner of Zenith Partners and manages the Martin J. Kaplitt
Keogh-Profit Sharing Plan.
(4) Of the 159,282 shares:
- 88,200 shares may be acquired by Mr. Johnson upon the conversion of 5.880
shares of Neurologix's initial series of convertible preferred stock
within 60 days after September 30, 2003;
- 55,560 shares may be acquired by Mr. Johnson upon the conversion of
55,560 shares of Neurologix Series B convertible preferred stock within
60 days after September 30, 2003; and
- 15,522 shares may be acquired by Mr. Johnson upon the exchange of his
interest in the Existing Neurologix Note pursuant to the voting agreement
within 60 days after September 30, 2003.
(5) Of the 50,000 shares:
- 25,000 shares may be acquired by Ms. Willinger upon the exercise of stock
options with 60 days after September 30, 2003; and
- 25,000 shares may be acquired by the Janice K. Robinson Revocable Trust
upon the exercise of stock options within 60 days after September 30,
2003.
(6) Includes 3,031,942 shares issuable upon the conversion of shares of
Neurologix's initial series of convertible preferred stock and Neurologix
Series B convertible preferred stock, the exercise of options to purchase
Neurologix common stock, and the exchange of interests in the Existing
Neurologix Note as referenced in notes 1, 2, 3, 4 and 5 above.
116
INFORMATION REGARDING BENEFICIAL OWNERSHIP OF MANAGEMENT
AND PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY
The following table shows beneficial ownership of Change common stock and
Series A preferred stock after giving effect to the completion of the Merger and
the transactions related to the Merger as of September 30, 2003, by beneficial
owners of more than 5% of either Change's or Neurologix's common and preferred
stock, the current directors of Change and Neurologix, the nominees to the board
of directors of the combined company, all directors and named executive officers
of Change as a group and all directors and "named executive officers" of
Neurologix as a group. All of the share ownership amounts for the Change parties
and the Neurologix parties are based on the share ownership amounts for those
parties listed in the tables under the captions "Information Regarding
Beneficial Ownership of Management and Principal Stockholders of Change" and
"Information Regarding Beneficial Ownership of Management and Principal
Stockholders of Neurologix."
SHARES BENEFICIALLY OWNED(1)
-----------------------------------------------
COMMON SERIES A PREFERRED
------------------------- -------------------
NAME NUMBER PERCENTAGE NUMBER PERCENTAGE
---- ----------- ---------- ------ ----------
Holders of 5% or more of Change's common stock or
Series A preferred stock or Neurologix's common
stock, initial series of convertible preferred
stock or Series B convertible preferred stock:
Michael Gleason(2)............................. 33,500,000(3) 5.87% -- --
Culmen Technology Partners, L.P.(4)............ 32,000,000 5.63% -- --
Christopher H.B. Mills(5)...................... 12,939,700(6) 2.27% -- --
Gordon Bryant(7)............................... -- -- 645 100%
Auckland Technology Enabling Corporation
Limited(8).................................. 92,154,169 16.20% -- --
Zenith Partners(9)............................. 58,452,073 10.28% -- --
Palisade Private Partnership, L.P.(9).......... 172,519,415(10) 30.33% -- --
Medtronic International, Ltd.(11).............. 22,754,111(12) 4.00% -- --
The Rockefeller University(13)................. 9,379,223 1.65%
Martin J. Kaplitt(9)........................... 61,365,127(14) 10.79% -- --
Clark A. Johnson(9)............................ 11,183,619(15) 1.97% -- --
Mark S. Hoffman(9)............................. 172,519,415(10) 30.33% -- --
Steven R. LaPorte(9)........................... 22,754,111(12) 4.00% -- --
Current Directors of Change
Michael Gleason(2)............................. 33,500,000(3) 5.87% -- --
Austin M. Long(2).............................. -- -- -- --
Craig J. Nickels(2)............................ -- -- -- --
All Directors and named executive officers of
Change as a group (1 person)(16)............ 33,500,000(17) 5.87% -- --
Current Directors of Neurologix
Martin J. Kaplitt(9)........................... 61,365,127(14) 10.79% -- --
Mark S. Hoffman(9)............................. 172,519,415(10) 30.33% -- --
Clark A. Johnson(9)............................ 11,183,619(15) 1.97% -- --
Janice K. Robinson Willinger(9)................ 3,510,635(18) * -- --
Steven R. LaPorte(9)........................... 22,754,111(12) 4.00% -- --
All Directors and named executive officers of
Neurologix as a group (5 persons)(16)....... 271,332,907(19) 47.41% -- --
117
SHARES BENEFICIALLY OWNED(1)
-----------------------------------------------
COMMON SERIES A PREFERRED
------------------------- -------------------
NAME NUMBER PERCENTAGE NUMBER PERCENTAGE
---- ----------- ---------- ------ ----------
Nominees for Directors of the Combined Company
Martin J. Kaplitt(9)........................... 61,365,127(14) 10.79% -- --
Mark S. Hoffman(9)............................. 172,519,415(10) 30.33% -- --
Clark A. Johnson(9)............................ 11,183,619(15) 1.97% -- --
Janice K. Robinson Willinger(9)................ 3,510,635(18) * -- --
Austin M. Long(2).............................. -- -- -- --
Craig J. Nickels(2)............................ -- -- -- --
All Directors and named executive officers of
the combined company as a group(16)......... 248,578,796 43.44% -- --
---------------
* Less than one percent (1.00%).
(1) As of September 30, 2003, there were 177,503,919 shares of Change common
stock issued and outstanding. We estimated that as of September 30, 2003,
after giving effect to the completion of the Merger and the transactions
related to the Merger, former holders of Neurologix common stock,
Neurologix's initial series of convertible preferred stock, Neurologix
Series B convertible preferred stock and the Existing Neurologix Note would
hold 391,275,156 shares of Change common stock based on an estimated
exchange ratio of 70.2127. For additional information regarding the
estimated exchange ratio, refer to the section of this proxy statement and
prospectus entitled "The Merger -- Conversion of Securities."
(2) The address of this beneficial owner is c/o Change Technology Partners,
Inc., 537 Steamboat Road, Greenwich, Connecticut 06830.
(3) Represents 32,000,000 shares of Change common stock owned by Culmen
Technology Partners, L.P. ("Culmen"). Mr. Gleason is the President and sole
director of CTP, Inc., the general partner of Culmen. As a result, he may
be deemed to have beneficial ownership over these shares. However, Mr.
Gleason disclaims beneficial ownership of 30,200,000 shares of Change
common stock. Also includes options to purchase an aggregate of 1,500,000
shares of Change common stock.
(4) Culmen's address is Culmen Technology Partners, L.P., 6226 Colleyville
Boulevard, Suite A, Colleyville, Texas 76034.
(5) Mr. Mills' address is c/o J.O. Hambro Capital, Management Limited, Ryder
Court, 14 Ryder St., London SW1Y 6QB, England.
(6) According to a Schedule 13G filed with the Securities and Exchange
Commission on July 19, 2001, Mr. Mills (i) shares voting and dispositive
power over such shares with J.O. Hambro Capital Management (Holdings)
Limited and J.O. Hambro Capital Management Limited, (ii) shares voting and
dispositive power over 1,280,000 such shares with American Opportunity
Trust plc, (iii) shares voting and dispositive power over 4,400,000 such
shares with Growth Financial Services and North Atlantic Smaller Companies
Investment Trust plc, (iv) shares voting and dispositive power over 640,000
such shares with Oryx International Growth Fund Limited and Consulta
(Channel Islands) Limited and (v) shares voting and dispositive power over
1,498,000 such shares with The Trident North Atlantic Fund.
(7) Mr. Bryant's address is 9408 Avenido Del Oso NE, Albuquerque, New Mexico
87111.
(8) The address of this beneficial owner is Auckland Technology Enabling
Corporation Limited, P.O. Box 10-359, 8th Floor, Lumley House, 93 The
Terrace, Wellington, New Zealand.
(9) The address for this beneficial owner is c/o Neurologix, Inc., One Bridge
Plaza, Fort Lee, New Jersey 07024.
118
(10) Of the 172,519,415 shares:
- 146,149,139 shares may be acquired by Palisade Private Partnership, L.P.,
upon the conversion of 138.768 shares of Neurologix's initial series of
convertible preferred stock within 60 days after September 30, 2003;
- 650,170 shares may be acquired by Palisade Private Partnership, L.P.,
upon the conversion of 9,260 shares of Neurologix Series B convertible
preferred stock within 60 days after September 30, 2003; and
- 25,720,106 shares may be acquired by Palisade Private Partnership, L.P.,
upon the exchange of its interest in the Existing Neurologix Note
pursuant to the voting agreement within 60 days after September 30, 2003.
The sole general partner of Palisade Private Partnership, L.P., is
Palisade Private Holdings, LLC. Mark Hoffman, one of Neurologix's
directors, is a managing member of Palisade Private Holdings, LLC. Mr.
Hoffman shares voting and investment power over the shares held by
Palisade Private Partnership, L.P. with the other members of Palisade
Private Holdings, LLC. Mr. Hoffman and the other managing members of
Palisade Private Holdings, LLC, disclaim beneficial ownership of the
shares held by Palisade Private Partnership, L.P., except to the extent of
their pecuniary interest in the shares.
(11) The address for this beneficial owner is Medtronic International, Ltd., 710
Medtronic Parkway, Minneapolis, MN 55421.
(12) The 22,754,111 shares may be acquired by Medtronic International, Ltd.,
upon the conversion of 324,074 shares of Neurologix Series B convertible
preferred stock within 60 days after September 30, 2003.
Mr. LaPorte, one of Neurologix's directors, is the vice president and
general manager of Medtronic Neurological Ventures and as such exercises
sole voting and investment power over the shares held by Medtronic
International, Ltd. Mr. LaPorte disclaims beneficial ownership of the
shares held by Medtronic International, Ltd., except to the extent of his
pecuniary interest in the shares.
(13) The address for this beneficial owner is The Rockefeller University, 1230
York Avenue, New York, New York 10021.
(14) Of the 61,365,127 shares:
- 58,452,073 shares are held by Zenith Partners;
- 2,477,104 shares may be acquired by the Martin J. Kaplitt Keogh-Profit
Sharing Plan upon the conversion of 2.352 shares of Neurologix's initial
series of convertible preferred stock within 60 days after September 30,
2003; and
- 435,951 shares may be acquired by Mr. Kaplitt upon the exchange of his
interest in the Existing Neurologix Note pursuant to the voting agreement
within 60 days after September 30, 2003.
Mr. Kaplitt, one of Neurologix's directors and its president, is the sole
general partner of Zenith Partners and manages the Martin J. Kaplitt
Keogh-Profit Sharing Plan.
(15) Of the 11,183,619 shares:
- 6,192,760 shares may be acquired by Mr. Johnson upon the conversion of
5.880 shares of Neurologix's initial series of convertible preferred
stock within 60 days after September 30, 2003;
- 3,901,018 shares may be acquired by Mr. Johnson upon the conversion of
55,560 shares of Neurologix Series B convertible preferred stock within
60 days after September 30, 2003; and
- 1,089,842 shares may be acquired by Mr. Johnson upon the exchange of his
interest in the Existing Neurologix Note pursuant to the voting agreement
within 60 days after September 30, 2003.
(16) Duplications eliminated.
(17) Represents 32,000,000 shares of Change common stock and options to purchase
1,500,000 shares of Change common stock. Includes 32,000,000 shares of
Change common stock owned by Culmen, which Mr. Gleason may be deemed to
beneficially own.
119
(18) Of the 3,510,635 shares:
- 1,755,318 shares may be acquired by Ms. Willinger upon the exercise of
stock options with 60 days after September 30, 2003; and
- 1,755,318 shares may be acquired by the Janice K. Robinson Revocable
Trust upon the exercise of stock options within 60 days after September
30, 2003.
(19) Includes 212,880,834 shares issuable upon the conversion of shares of
Neurologix's initial series of convertible preferred stock and Neurologix
Series B convertible preferred stock, the exercise of options to purchase
Neurologix common stock, and the exchange of interests in the Existing
Neurologix Note as referenced in notes 10, 12, 14, 15 and 18 above.
(20) Includes 248,578,796 shares issuable upon the conversion of shares of
Neurologix's initial series of convertible preferred stock and Series B
convertible preferred stock, the exercise of options to purchase Neurologix
common stock, and the exchange of interests in the Existing Neurologix Note
as referenced in notes 10, 14, 15 and 18.
120
LEGAL MATTERS
The legality of the shares of Change common stock offered to the holders of
Neurologix common stock and Series B convertible preferred stock will be passed
upon by Paul, Weiss, Rifkind, Wharton & Garrison, LLP, New York, New York.
EXPERTS
The consolidated financial statements of Change Technology Partners, Inc.
and subsidiaries as of December 31, 2001 and December 31, 2002, and for each of
the three years in the period ended December 31, 2002 have been included in this
registration statement in reliance upon the report of KPMG LLP, independent
accountants, included in this proxy statement and prospectus, and upon the
authority of said firm as experts in accounting and auditing. The report
contains an explanatory paragraph that states that Change adopted a plan of
liquidation and dissolution which raises substantial doubt about its ability to
continue as a going concern. The consolidated financial statements do not
include any adjustments that might result from the outcome of that uncertainty.
The report also contains an explanatory paragraph that refers to a Change's
method of accounting for goodwill and other intangibles.
The financial statements of Neurologix, Inc. as of December 31, 2001 and
December 31, 2002 and for each of the years in the three-year period ended
December 31, 2002 and for the period from February 12, 1999 (date of inception)
through December 31, 2002 have been included in this registration statement in
reliance upon the report of J.H. Cohn LLP, independent accountants, which
includes an explanatory paragraph relating to Neurologix's ability to continue
as a going concern, included in this proxy statement and prospectus, and upon
the authority of said firm as experts in accounting and auditing.
STOCKHOLDER PROPOSALS
If any stockholder of the combined company intends to present a proposal
for consideration at the next annual meeting of stockholders and wishes to have
such proposal in the proxy statement and form of proxy distributed by the board
of directors with respect to that meeting, the proposal must be received at the
combined company's principal executive offices, One Bridge Plaza, Fort Lee, New
Jersey 07024, Attention: Mark Hoffman, Secretary, between 60 and 90 days before
the annual meeting of stockholders in 2004. In addition, any stockholder
intending to present a proposal for consideration at the next annual meeting of
stockholders must also comply with certain provisions of the combined company's
certificate of incorporation and bylaws.
WHERE YOU CAN FIND MORE INFORMATION
Change files annual, quarterly and current reports, proxy statements and
other information with the Securities and Exchange Commission. You may read and
copy any reports, statements or other information filed by Change at the
Securities and Exchange Commissions public reference rooms located at 450 Fifth
Street, N.W., Washington, DC 20549. You can call the SEC at 1-800-SEC-0330 for
further information on the public reference rooms. The SEC filings are also
available to the public from commercial document retrieval services and at the
Internet world wide website maintained by the SEC at "http://www.sec.gov."
Change has filed a registration statement on Form S-4 to register with the
Securities and Exchange Commission the issuance of the shares of its common
stock in connection with the Merger to Neurologix stockholders. This proxy
statement and prospectus is a part of the registration statement and constitutes
a prospectus of Change for the issuance of that common stock. As permitted by
SEC rules, this proxy statement and prospectus does not contain all of the
information you can find in the registration statement or the exhibits to the
registration statement.
121
Change stockholders should rely only on the information contained in this
proxy statement and prospectus in making their decision about how to vote on the
approval and adoption of the merger agreement. Neither Change nor Neurologix has
authorized anyone to provide you with information that is different from what is
contained in this proxy statement and prospectus. You should not assume that the
information in this proxy statement and prospectus is accurate as of any date
other than the date set forth on the cover and should view neither the mailing
of this proxy statement and prospectus to stockholders nor the issuance of
Change common stock in the Merger as implying otherwise.
122
FINANCIAL STATEMENTS
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
Consolidated Balance Sheets as of September 30, 2003 and
December 31, 2002 (Unaudited)............................. F-2
Consolidated Statements of Operations for the Three Months
Ended September 30, 2003 and 2002 (Unaudited)............. F-3
Consolidated Statements of Operations for the Nine Months
Ended September 30, 2003 and 2002 (Unaudited)............. F-4
Consolidated Statements of Stockholders' Equity for the Nine
Months Ended September 30, 2003 (Unaudited)............... F-5
Consolidated Statements of Cash Flows for the Nine Months
Ended September 30, 2003 and 2002 (Unaudited)............. F-6
Notes To Unaudited Condensed Consolidated Interim Financial
Statements................................................ F-7
Report of KPMG LLP, Independent Accountants................. F-18
Consolidated Balance Sheets as of December 31, 2002 and
2001...................................................... F-19
Consolidated Statements of Operations for the Years Ended
December 31, 2002, 2001 and 2000.......................... F-20
Consolidated Statements of Stockholders' Equity and
Redeemable Preferred Stock for the Years Ended December
31, 2002, 2001 and 2000................................... F-21
Consolidated Statements of Cash Flows for the Years Ended
December 31, 2002, 2001 and 2000.......................... F-22
Notes To Consolidated Financial Statements.................. F-23
NEUROLOGIX, INC.
Condensed Balance Sheet September 30, 2003 (Unaudited)...... F-45
Condensed Statements of Operations Nine Months Ended
September 30, 2003 and 2002 (Unaudited) and Period From
February 12, 1999 (Date of Inception) through September
30, 2003 (Unaudited)...................................... F-46
Condensed Statements of Changes In Stockholders' Equity
Deficiency Nine Months Ended September 30, 2003 and 2002
(Unaudited) and Period From February 12, 1999 (Date of
Inception) through September 30, 2003 (Unaudited)......... F-47
Condensed Statements of Cash Flows Nine Months Ended
September 30, 2003 and 2002 (Unaudited) and Period From
February 12, 1999 (Date of Inception) through September
30, 2003 (Unaudited)...................................... F-48
Notes to Unaudited Condensed Financial Statements........... F-49
Report of Independent Public Accountants.................... F-52
Balance Sheet December 31, 2002 and 2001.................... F-53
Statements of Operations Years Ended December 31, 2002, 2001
and 2000 and Period From February 12, 1999 (Date of
Inception) through December 31, 2002...................... F-54
Statements of Changes In Stockholders' Deficiency Years
Ended December 31, 2002, 2001 and 2000 and Period From
February 12, 1999 (Date of Inception) through December 31,
2002...................................................... F-55
Statements of Cash Flows Years Ended December 31, 2002 and
2001 and Period From February 12, 1999 (Date of Inception)
through December 31, 2002................................. F-56
Notes To Financial Statements............................... F-57
F-1
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
UNAUDITED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
SEPTEMBER 30, DECEMBER 31,
2003 2002
------------- ------------
(IN THOUSANDS, EXCEPT SHARE
AND PER SHARE AMOUNTS)
ASSETS
Cash and cash equivalents................................... $ 5,963 $ 2,944
Related party receivable.................................... 102 194
Other Receivable............................................ -- 318
Notes receivable............................................ 754 4,926
Prepaid expenses and other current assets................... 729 672
Current assets related to discontinued operations........... -- 465
-------- --------
Total current assets...................................... 7,548 9,519
Notes receivable, excluding current portion................. -- 424
Investments in and loans to unconsolidated subsidiaries..... 89 449
Property and equipment, net................................. 68 281
Goodwill related to discontinued operations................. -- 1,782
Long term assets related to discontinued operations......... -- 155
Other assets................................................ -- 123
-------- --------
Total assets.............................................. 7,705 12,733
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable............................................ 153 123
Accrued expenses............................................ 143 580
Capital lease obligation.................................... 3 70
Liabilities related to discontinued operations, net......... -- 333
-------- --------
Total current liabilities................................. 299 1,106
Capital lease obligation, less current portion.............. -- 8
-------- --------
Total liabilities......................................... 299 1,114
Stockholders' equity:
Preferred stock:
Series A -- $.06 per share cumulative, convertible
share-for-share into common stock; $.10 par value;
500,000 shares authorized, 645 shares issued and
outstanding at September 30, 2003 and December 31,
2002, with an aggregate liquidation preference of $1... -- --
Common stock:
$.01 par value; 500,000,000 shares authorized, 177,503,920
and 182,003,920 shares issued and outstanding at
September 30, 2003 and December 31, 2002,
respectively........................................... 1,775 1,820
Additional paid-in capital.................................. 94,334 94,369
Deferred compensation....................................... -- (268)
Accumulated deficit......................................... (88,703) (84,302)
-------- --------
Total stockholders' equity................................ 7,406 11,619
-------- --------
Total liabilities and stockholders' equity................ $ 7,705 $ 12,733
======== ========
See accompanying notes to unaudited condensed consolidated interim financial
statements.
F-2
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
THREE MONTHS ENDED
SEPTEMBER 30,
-----------------------------------
2003 2002
---------------- ----------------
(IN THOUSANDS, EXCEPT SHARE AND PER
SHARE AMOUNTS)
Operating expenses:
General and administrative expenses, exclusive of equity
based compensation of $88 and $131, respectively....... $ 730 $ 745
Equity based compensation................................. 88 131
------------ ------------
Loss from operations................................... (818) (876)
Other income (expense):
Interest and dividend income.............................. 26 221
Equity in losses and impairment of investments in
unconsolidated affiliates.............................. (3) (22)
------------ ------------
Total other income........................................ 23 199
------------ ------------
Net loss from continuing operations.................... (795) (677)
Loss from discontinued operations (including loss on
disposal), net......................................... -- (114)
------------ ------------
Net loss............................................... (795) (791)
============ ============
Weighted average common shares outstanding, basic and
diluted................................................... 177,503,920 181,322,881
============ ============
Basic and diluted net loss per common share from continuing
operations................................................ (0.00) (0.00)
Basic and diluted net loss per common share from
discontinued operations................................... (0.00) (0.00)
------------ ------------
Basic and diluted net loss per common share................. (0.00) (0.00)
============ ============
See accompanying notes to unaudited condensed consolidated interim financial
statements.
F-3
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
NINE MONTHS ENDED SEPTEMBER 30,
-------------------------------
2003 2002
-------------- --------------
(IN THOUSANDS, EXCEPT SHARE AND
PER SHARE AMOUNTS)
Operating expenses:
General, and administrative expenses, exclusive of equity
based compensation of $358 and $394, respectively...... $ 2,275 $ 2,667
Equity based compensation................................. 358 394
Severance, exclusive of equity based compensation of
$90.................................................... 140 --
------------ ------------
Loss from operations................................... (2,773) (3,061)
Other income (expense):
Interest and dividend income.............................. 95 628
Equity in losses and impairment of investments in
unconsolidated affiliates.............................. (110) (604)
Realized gain on sale of Excelsior stock and warrants..... 286 --
------------ ------------
Total other income........................................ 271 24
------------ ------------
Net loss from continuing operations.................... (2,502) (3,037)
Loss from discontinued operations (including loss on
disposal), net......................................... (1,899) (26)
------------ ------------
Net loss............................................. $ (4,401) $ (3,063)
============ ============
Weighted average common shares outstanding, basic and
diluted................................................... 180,487,436 179,798,066
============ ============
Basic and diluted net loss per common share from continuing
operations................................................ $(0.01) $(0.02)
Basic and diluted net loss per common share from
discontinued operations................................... (0.01) (0.00)
------------ ------------
Basic and diluted net loss per common share................. $(0.02) $(0.02)
============ ============
See accompanying notes to unaudited condensed consolidated interim financial
statements.
F-4
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
NINE MONTHS ENDED SEPTEMBER 30, 2003
SERIES A
PREFERRED STOCK COMMON STOCK ADDITIONAL TOTAL
--------------- -------------------- PAID IN DEFERRED ACCUMULATED STOCKHOLDERS'
SHARES AMOUNT SHARES AMOUNT CAPITAL COMPENSATION DEFICIT EQUITY
------ ------ ----------- ------ ---------- ------------ ----------- -------------
(IN THOUSANDS, EXCEPT SHARE AMOUNTS)
Balance at December 31,
2002...................... 645 $-- 182,003,920 $1,820 $94,369 $(268) $(84,302) $11,619
Common stock received as
consideration for
Canned.................... -- -- (4,500,000) (45) (125) -- -- (170)
Modification of former Chief
Executive Officer's
options................... -- -- -- -- 90 -- -- 90
Amortization of deferred
compensation.............. -- -- -- -- -- 268 -- 268
Net loss.................. -- -- -- -- -- -- (4,401) (4,401)
--- --- ----------- ------ ------- ----- -------- -------
Balance at September 30,
2003 (unaudited).......... 645 $-- 177,503,920 $1,775 $94,334 $ -- $(88,703) $ 7,406
--- === ----------- ====== ======= ===== ======== =======
See accompanying notes to unaudited condensed consolidated interim financial
statements.
F-5
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED
SEPTEMBER 30,
-----------------
2003 2002
------- -------
(IN THOUSANDS)
Cash flows from operating activities:
Net loss.................................................. $(4,401) $(3,063)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation........................................... 213 211
Equity based compensation.............................. 358 394
Equity in losses of unconsolidated subsidiary.......... 110 177
Accretion of loan discount............................. -- (72)
Impairment loss........................................ -- 427
Accrued interest on notes receivable................... (12) (438)
Receipt of accrued interest on notes receivable........ 166 96
Gain on sale of Excelsior stock and warrant............ (286) --
Valuation allowance on notes receivable................ 473 --
Discontinued operations, net........................... 1,899 26
Changes in operating assets and liabilities, net of
acquisitions:
Related party receivable............................... 92 19
Receivable from Canned................................. 318 (149)
Prepaid expenses and other assets...................... (46) (29)
Accounts payable and accrued liabilities............... (407) (486)
------- -------
Net cash used in operating activities................ (1,523) (2,887)
Cash flows from investing activities:
Cash paid for notes receivable............................ (750) (4,708)
Principle payments -- received............................ 4,719 399
Sale of Excelsior investment and warrant.................. 648 --
Cash paid for cost method investments and acquisitions,
net of cash acquired................................... -- (278)
------- -------
Net cash provided by (used in) investing
activities.......................................... 4,617 (4,587)
Cash flows from financing activities:
Principal payments under capital leases................... (75) (74)
------- -------
Net cash used in financing activities................ (75) (74)
Net increase (decrease) in cash and cash
equivalents......................................... $ 3,019 $(7,548)
Cash and cash equivalents at beginning of period............ $ 2,944 $ 8,702
------- -------
Cash and cash equivalents at end of period.................. $ 5,963 $ 1,154
======= =======
See accompanying notes to unaudited condensed consolidated interim financial
statements.
F-6
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS
SEPTEMBER 30, 2003
(IN THOUSANDS, EXCEPT SHARE DATA)
(1) DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Arinco Computer Systems Inc., the predecessor of the Company and its
subsidiaries, (the "Company"), was incorporated on March 31, 1978; however, the
Company formally commenced implementation of its plan to provide professional
consulting services on June 15, 2000. The Company provided a broad range of
professional consulting services, including e-services and technology strategy,
online branding, web architecture and design, systems integration, systems
architecture and outsourcing. The Company has served clients throughout the
United States and, as of September 30, 2003, has offices in Connecticut. During
the year ended December 31, 2001, the Board of Directors voted to divest the
Company of a majority of its then existing operations.
At September 30, 2003, the Company's sole consolidated subsidiary is:
- Iguana Studios, Inc. (which has limited continuing operating activities)
Based on the Company's assessment of the opportunities in the radio
business, in 2001 the Board of Directors decided to merge with Franklin Capital
Corporation and jointly develop and acquire network radio programming and sales
and syndication businesses. On December 4, 2001 the Company entered into an
agreement and plan of merger with Franklin Capital. On July 1, 2002, the Company
received a notice of termination from Franklin Capital terminating the proposed
merger.
On September 30, 2002, the Board of Directors announced the adoption of a
plan of liquidation and dissolution in order to maximize stockholder value and
noted that if no suitable business opportunities became available to it, subject
to stockholder approval, it would commence liquidation in 2003. However, the
plan permits the Board of Directors to amend, modify or abandon the plan,
notwithstanding stockholder approval, if the Board determines doing so would be
in the best interests of the Company and its stockholders.
On June 17, 2003, the individual filling the roles of President, Chief
Executive Officer and Chief Financial Officer of the Company resigned. The
former executive had an employment agreement dated September 17, 2001 governing
the terms and conditions of his employment. On June 17, 2003, the Company and
such former executive entered into a separation agreement and general release
(the "Separation Agreement"). The Company recorded a charge in the Statement of
Operations for the three months ended June 30, 2003 for the value of expected
severance payments and benefits payable to the former executive totaling $140.
In addition, the Company recorded a $90 stock compensation charge related to a
modification of the former executive's options. This amount was paid in full in
July, 2003.
The Company announced on June 18, 2003 that it signed a Letter of Intent
(the "Letter of Intent") with Neurologix, Inc. ("Neurologix") to merge a
newly-formed, wholly-owned subsidiary of the Company ("CTP/N Merger Corp.") with
and into Neurologix, with Neurologix surviving as a wholly-owned subsidiary of
the Company (the "Merger"). On August 13, 2003, the Company entered into an
Agreement and Plan of Merger (the "Merger Agreement"), with Neurologix and CTP/N
Merger Corp. The consummation of the Merger remains subject to the approval of
the Company's stockholders, which the Company will be seeking at its next
meeting of stockholders currently planned to take place in the fourth quarter of
2003. In the event the Merger is consummated, the Company expects to abandon the
plan of liquidation and dissolution. If the Merger is not consummated, the
Company expects to pursue the plan of liquidation and dissolution previously
adopted.
In connection with the Merger, the Company, CTP/N Merger Corp., Neurologix,
and certain securityholders of Neurologix entered into a Voting Agreement dated
as of August 13, 2003 (the "Voting
F-7
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS -- (CONTINUED)
Agreement"). Pursuant to the Voting Agreement, all holders of Neurologix's
initial series of convertible preferred stock, certain holders of Neurologix
Series B convertible preferred stock and the holders of a promissory note issued
by Neurologix agreed to convert such preferred stock and promissory note into
Neurologix's common stock prior to the Merger. In addition, the securityholders
agreed to vote all of their Neurologix capital stock in favor of the Merger
Agreement and the transactions contemplated thereby. Such securityholders hold a
majority of Neurologix's outstanding shares of common stock, initial series of
convertible preferred stock and Series B convertible preferred stock have
approved the Merger.
Concurrent with the execution of the Merger Agreement, the Company loaned
Neurologix $750 (the "Neurologix Loan"). The Neurologix Loan is due April 30,
2004, accrues interest at a rate of 4% per annum and is secured by all of the
assets of Neurologix. The note is senior to all existing indebtedness of
Neurologix. The Neurologix Loan, together with accrued interest thereon, is
presented in notes receivable in the accompanying Balance Sheet. In connection
with an amendment to the Merger Agreement, on November 14, 2003, the Company
agreed to loan Neurologix an additional $350 and to extend the due date of the
loan to June 30, 2004. On December 18, 2003, Change funded the additional loan.
On June 30, 2003, the Company sold to Textor Family Limited Partnership all
of the issued and outstanding shares of capital stock of Papke-Textor, Inc.
d/b/a Canned Interactive ("Canned"). Accordingly, the results of operations for
Canned, including the loss on sale and goodwill impairment in 2003, are reported
as discontinued operations.
INTERIM RESULTS
The accompanying unaudited consolidated balance sheet as of September 30,
2003, the unaudited consolidated statements of operations and cash flows for the
periods ended September 30, 2003 and 2002, and the unaudited consolidated
statement of stockholders' equity as of September 30, 2003 have been prepared by
the Company. In the opinion of management, the accompanying condensed
consolidated financial statements have been prepared on the same basis as the
annual audited financial statements and contain all adjustments, which include
only normal recurring adjustments, considered necessary for a fair presentation
of the Company's financial position, results of operations and cash flows at the
dates and for the periods presented in conformity with accounting principles
generally accepted in the United States applicable to interim periods. Certain
prior period amounts have been reclassified to conform to the current period's
presentation.
USE OF ESTIMATES
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities, the
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expense during the reporting
period. Actual results could differ from those estimates.
While the Company believes that the disclosures presented are adequate to
make the information not misleading, these condensed consolidated financial
statements should be read in conjunction with the audited financial statements
and related notes for the fiscal year ended December 31, 2002, which are
contained in the Company's Annual Report on Form 10-K. As a result of the
divestiture of Canned, the Company's last remaining revenue generating
operation, the results for the nine month period ended September 30, 2003 will
not be indicative of the results to be expected for the full fiscal year or for
any future periods.
F-8
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS -- (CONTINUED)
PRINCIPLES OF CONSOLIDATION
The accompanying unaudited condensed consolidated financial statements
include the accounts of Change Technology Partners, Inc. and its majority-owned
and controlled subsidiaries from the date of acquisition. All significant
intercompany transactions and balances have been eliminated in consolidation.
Investments in less than majority-owned entities over which the Company has
significant influence are accounted for using the equity method.
REVENUE RECOGNITION
Revenues are recognized for fixed price arrangements in the period services
are rendered using the percentage-of-completion method, provided the Company has
the ability to produce reasonably dependable estimates, collection of the
resulting receivable is probable and no significant obligations remain. The
cumulative impact of any revision in estimates of the cost to complete and
losses on projects in process are reflected in the period in which they become
known. Through September 30, 2002 the Company's revenues were recognized under
the completed contract method of accounting as the Company did not have
reasonably dependable estimates with respect to projects at its former
subsidiary, Canned. Beginning in the fourth quarter of 2002, Canned's revenues
were recognized using the percentage of completion method. Canned's projects
were typically short term in nature, generally spanning less than 90 days.
Revenues are recognized for time-and-materials based arrangements in the
period when the underlying services are rendered, provided collection of the
resulting receivable is probable and no significant obligations remain.
The Company enters into project specific contracts with its clients who are
generally billed in the same period in which services are rendered. If services
are rendered in advance of billings, the Company records and presents the
related amounts as unbilled revenue. If amounts are received in advance of
services being performed, the amounts are recorded and presented as deferred
revenues.
In connection with the divestiture of Canned by the Company, revenues are
now presented in discontinued operations.
COST OF REVENUES
Cost of revenues consists primarily of compensation of billable employees,
travel, subcontractor costs, and other costs directly incurred in the delivery
of services to clients. Billable employees are full time employees and
subcontractors whose time is spent servicing client projects.
In connection with the divestiture of Canned by the Company, such costs are
now presented in discontinued operations.
EQUITY-BASED COMPENSATION
The Company accounts for its employee stock option plans in accordance with
the provisions of the Accounting Principles Board ("APB") Opinion No. 25,
"Accounting for Stock Issued to Employees," and related interpretations
including Financial Accounting Standards Board Interpretation No. 44. As such,
compensation expense related to employee stock options is recorded only if, on
the date of grant, the fair value of the underlying stock exceeds the exercise
price. All such deferred compensation is amortized over the related vesting
period on a straight-line basis. The Company adopted the disclosure-only
requirements of SFAS No. 123 "Accounting for Stock-Based Compensation," which
allows entities to continue to apply the provisions of APB Opinion No. 25 for
transactions with employees and provide pro forma net income
F-9
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS -- (CONTINUED)
(loss) and pro forma earnings (loss) per share disclosures for employee stock
grants made as if the fair value based method of accounting in SFAS No. 123 had
been applied to these transactions.
Had compensation cost for these awards been determined based on the fair
value at the grant dates consistent with the method prescribed by SFAS No. 123,
the Company's net loss would have been adjusted to the pro forma amounts
indicated below:
THREE MONTHS
ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
------------- -----------------
2003 2002 2003 2002
----- ----- ------- -------
Net loss, as reported............................. $(795) $(791) $(4,401) $(3,063)
Add back: compensation expense related to stock
options, as reported............................ 88 131 358 394
Deduct: compensation expense related to stock
options under fair value based method........... (98) (135) (394) (406)
----- ----- ------- -------
Pro forma net loss................................ $(805) $(795) $(4,437) $(3,075)
===== ===== ======= =======
Basic and diluted net loss per share as
reported........................................ (0.00) (0.00) (0.02) (0.02)
Pro forma basic income loss per share............. (0.00) (0.00) (0.02) (0.02)
BASIC AND DILUTED NET LOSS PER COMMON SHARE
Basic net loss per common share excludes the effect of potentially dilutive
securities and is computed by dividing net income or loss available to common
stockholders by the weighted average number of common shares outstanding for the
period. Diluted net loss per share adjusts for the effect of convertible
securities, warrants and other potentially dilutive financial instruments only
in the periods in which such effect would have been dilutive.
The following securities were not included in the computation of diluted
net loss per share because to do so would have had an antidilutive effect for
the periods presented:
SEPTEMBER 30, SEPTEMBER 30,
2003 2002
------------------ ------------------
Stock Options....................................... 14,585,747 15,790,373
Warrants............................................ 25,856,252 25,856,252
Series A Convertible Preferred Stock................ 645 645
As a result, the basic and diluted net loss per share is equal for all
periods presented.
GOODWILL
Effective January 1, 2002, the Company adopted SFAS 142, "Goodwill and
Intangible Assets." At January 1, 2002 the intangible assets consisted of
goodwill and the subsumed workforce acquired in connection with the acquisition
of the Company's former subsidiary, Canned. Management reviewed goodwill for
impairment in the fourth quarter of each year or earlier if indicators of
potential impairment exist. In connection with the sale of the Canned reporting
unit in June 2003, goodwill totaling $1,782 was charged to loss on disposal of
discontinued operations.
F-10
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS -- (CONTINUED)
RECENT ACCOUNTING PRONOUNCEMENTS
In July 2002, the FASB issued SFAS No. 146, "Accounting for Costs
Associated with Exit or Disposal Activities". SFAS No. 146, which is effective
prospectively for exit or disposal activities initiated after December 31, 2002,
applies to costs associated with an exit activity, including restructurings, or
with a disposal of long-lived assets. Those activities can include eliminating
or reducing product lines, terminating employees and contracts and relocating
plant facilities or personnel. SFAS No. 146 requires that exit or disposal costs
are recorded as an operating expense when the liability is incurred and can be
measured at fair value. Commitment to an exit plan or a plan of disposal by
itself will not meet the requirement for recognizing a liability and the related
expense under SFAS No. 146. SFAS No. 146 grandfathers the accounting for
liabilities that were previously recorded under EITF Issue 94-3. Accordingly,
the adoption of SFAS No. 146 had no effect on the exit costs recorded by the
Company prior to December 31, 2002.
Statement of Financial Accounting Standards No. 148, "Accounting for
Stock-Based Compensation" ("SFAS 148"), is an amendment to Statement of
Financial Accounting Standards No. 123, "Accounting for Stock-Based
Compensation", and provides alternative methods of transition for an entity that
voluntarily changes from the intrinsic value based method of accounting for
stock-based employee compensation prescribed in APB No. 25 to the fair value
method prescribed in SFAS 123. As permitted under SFAS 148, the Company has
continued to apply the accounting provisions of APB No. 25, and to provide the
annual pro forma disclosures of the effect of adopting the fair value method as
required by SFAS 123. SFAS 148 also requires pro forma disclosure to be provided
on a quarterly basis. The Financial Accounting Standards Board recently
indicated that they will require stock-based employee compensation to be
recorded as a charge to earnings beginning in 2004. The Company will continue to
monitor their progress on the issuance of this standard, as well as evaluate the
Company's position with respect to current guidance.
(2) INVESTMENTS IN AND LOANS TO UNCONSOLIDATED SUBSIDIARIES
The following summarizes the Company's ownership interests in
unconsolidated subsidiaries accounted for under the equity method or cost method
of accounting (in thousands):
CARRYING VALUE
-------------------------------------
SEPTEMBER 30, DECEMBER 31, COST
2003 2002 BASIS
------------- ------------ ------
Equity method investments:
Broadstream.com Inc. ("Broadstream")............. $ -- $ -- $7,100
NetPro Holdings, Inc. ("NetPro")................. -- -- 400
InSys LLC ("InSys").............................. 11 121 323
Cost method investments:
Livesky, Inc. ("Livesky")........................ -- -- 125
Excelsior Radio Networks, Inc. ("Excelsior")..... -- 250 250
Alacra, Inc. ("Alacra").......................... 78 78 78
----- ---- ------
Total investments.................................. $ 89 $449 $8,276
===== ==== ======
INVESTMENTS IN BROADSTREAM AND NETPRO
In June 2000, the Company purchased 7,626,165 shares of Series A
Convertible Redeemable Preferred Stock ("Series A") of Broadstream, Inc. (d/b/a
Network Prophecy) ("Broadstream"), representing an
F-11
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS -- (CONTINUED)
approximately 30% equity interest (calculated on an as-if-converted basis) and
approximately 47% voting interest, in exchange for $6,500.
Broadstream is a streaming media management services company that provides
software to measure, manage and monitor delivery of streaming media content and
data. The investment in Broadstream is being accounted for under the equity
method. Based upon the capital structure of, and the equity participation in,
the equity investee, the Company has assumed conversion of Series A shares in
computing its share of losses of this investee.
In May 2001, Broadstream completed a recapitalization whereby all of the
holders of Series A shares exchanged their Series A shares for shares of Series
A-1 Convertible Redeemable Preferred Stock ("Series A-1"). The recapitalization
modified the conversion ratio, policies regarding dividends and voting rights
for Series A-1 holders. No additional consideration was paid by the Company or
any other Series A-1 shareholder in connection with this transaction. As a
result of the recapitalization the voting interest of common shareholders was
reduced from 31% to 13%.
Also in May 2001, in connection with the recapitalization, the Company
transferred 1,191,569 Series A-1 shares to Adelson Investors, LLC ("Adelson"),
another shareholder of Broadstream, as payment for certain financing-related
services performed by Adelson on behalf of Broadstream. This transfer has been
accounted for as a contribution by the Company of such shares to Broadstream in
exchange for no consideration. Subsequent to the recapitalization and
non-reciprocal share transfer, the Company owned 6,434,596 shares of Series A-1
Convertible Redeemable Preferred Stock of Broadstream, representing an
approximately 43% equity interest (calculated on an as-if-converted basis) and a
49% voting interest.
On August 15, 2001 the Company purchased a secured convertible promissory
note from Broadstream in exchange for $600 in connection with an aggregate
$1,600 bridge loan financing consummated by Broadstream. The aggregate bridge
loan financing was secured by all of Broadstream's assets. The note also
contained certain conversion provisions in the event Broadstream were to close a
new round of financing or enter into certain transactions.
On November 30, 2001 the Company assigned its Broadstream promissory note
to a newly formed entity, NetPro Holdings Inc. ("NetPro") in exchange for
13,674,753 shares of NetPro Series A-1 Convertible Redeemable Participating
Preferred Stock. On November 30, 2001 as a result of the application of the
equity method, the net book value of the note approximated zero and no gain or
loss was recorded as a result of this exchange. Concurrent with this
transaction, NetPro foreclosed on the note and elected to take possession of all
of Broadstream's assets in full satisfaction of the notes.
On December 15, 2001, the Company purchased 1,585,479 shares of NetPro
Series B-1 Convertible Redeemable Participating Preferred Stock in exchange for
$200 in connection with a larger ongoing financing arrangement.
As of December 31, 2001 the Company's interest in NetPro represented
approximately 38% of NetPro outstanding equity, and was being accounted for
under the equity method of accounting. The Company's proportionate share of
NetPro's net losses totaled $167 from the date of investment through December
31, 2001.
On January 10, 2002, the Company invested an additional $100 in NetPro
Series B-1 stock, and on March 7, 2002 the Company invested a final $100 in
NetPro Series B-1 stock. On March 14, 2002, the board of directors of NetPro
voted to suspend all of NetPro's business operations and immediately terminate
substantially all of its employees due to NetPro's loss of significant clients
and associated revenues. The Company has no obligation to provide additional
funding to NetPro. As a result of this action, the Company
F-12
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS -- (CONTINUED)
evaluated the recoverability of this investment by comparison of its carrying
value relative to estimated future cash flows. As a result of this analysis, the
Company recorded an impairment charge to reduce the remaining investment balance
to $0. The Company's proportionate share of net loss, and impairment charge, for
the nine months ended September 30, 2003, totaling $0, is included in equity in
losses and impairment of investments in unconsolidated affiliates in the
accompanying statement of operations.
INVESTMENT IN AND NOTE RECEIVABLE FROM EXCELSIOR RADIO NETWORKS
The Company made two investments in 2001 and one in the first quarter of
2002 in Excelsior Radio Networks, Inc. (f/k/a eCom Capital, Inc.), a subsidiary
of Franklin Capital, which produces, syndicates and distributes radio programs
and related services. The Company purchased a promissory note and warrant for
$2,250 from Excelsior in August 2001 and in December 2001 purchased 250,000
common shares of Excelsior from Franklin Capital for $250. In April 2002 the
Company purchased an additional promissory note from Excelsior for $4,708 in
conjunction with the purchase by Excelsior of Dial Communication Group Inc. and
Dial Communications Group LLC. The $2,250 promissory note was paid in full,
together with related accrued interest, on October 1, 2002. The $4,708 note was
repaid in full, together with related accrued interest, on January 21, 2003.
On January 15, 2003, the Company sold the Excelsior shares and the
Excelsior warrant to Sunshine III, LLC for total consideration of approximately
$648 in cash.
INVESTMENT IN LIVESKY
On December 21, 2000, the Company purchased 625,001 shares of Series A
Convertible preferred stock, representing an approximate 2% equity interest of
LiveSky Solutions, Inc. ("LiveSky") in exchange for $125. LiveSky is a developer
of wireless technology, including mobile business strategy and assessment as
well as mobile application design and development. This investment is being
accounted for under the cost method of accounting.
In June 2002, the Company received notice that the board of directors of
LiveSky had voted to liquidate LiveSky in the context of a Chapter 7 bankruptcy
case. The Company has no obligation to provide additional funding to LiveSky. As
a result of this action, the Company evaluated the recoverability of this
investment by comparison of its carrying value relative to future cash flows. As
a result of this analysis, the Company recorded an impairment charge totaling
$125 in the second quarter of 2002 to reduce the remaining balance to $0.
INVESTMENT IN ALACRA
On January 31, 2002, the Company purchased 38,840 shares of common stock,
representing less than 1% equity interest, of Alacra, Inc. ("Alacra") in
exchange for $78. The Company has no obligation to provide additional funding to
Alacra. Alacra provides a diverse portfolio of online and offline services that
allow users to quickly find, analyze, package and present mission-critical
business information. This investment is being accounted for under the cost
method of accounting.
(3) ACQUISITIONS AND DIVESTITURES
DIVESTITURE OF INSYS TECHNOLOGIES, LLC
On November 8, 2001 the Company sold a 51% voting interest in InSys
Technology, Inc. ("InSys"), a wholly-owned subsidiary, to a certain member of
the management team in exchange for $50 and concurrently
F-13
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS -- (CONTINUED)
forgave approximately $400 of advances to InSys. The Company has no obligation
to provide additional funding to InSys.
Concurrently, the Company loaned InSys $100 evidenced by a promissory note.
The note bears interest at a rate equal to the London Interbank offer rate plus
2%, until the principal amount of the note is paid in full. InSys is obligated
to pay, on an annual basis, at a minimum, 50% of the excess of its annual
earnings before taxes.
The Company's retained equity interest and note receivable, net of the
Company's pro rata share of InSys' net losses absorbed during the period from
November 8, 2001 to December 31, 2001, totaled $312. The Company's pro rata
share of InSys' net loss for the nine months ended September 30, 2003 and 2002
totaled $110 and $177, respectively, which is included in equity in losses and
impairment of investments in unconsolidated affiliates in the accompanying
statement of operations.
On June 17, 2003, in connection with the resignation of the Company's Chief
Executive Officer, the Company entered into an agreement to transfer its
interest in InSys to the former executive, contingent upon the approval of the
other member of InSys. In the fourth quarter of 2003 the Company transferred its
interest in InSys to the former executive and will record an additional
severance expense equal to the remaining book value of this investment totaling
$11.
DIVESTITURE OF RAND INTERACTIVE CORPORATION
On November 2, 2001 the Company sold all issued and outstanding shares of
RAND Interactive Corporation ("RAND"), a wholly-owned subsidiary, to certain
members of management in exchange for 375,039 shares of the Company's common
stock, and a warrant to purchase such amount of shares of common stock that
shall equal, at the time of exercise, 30% of the issued and outstanding shares
of RAND common stock on a fully diluted basis. Such warrants have a stated
exercise price of $1.00 in the aggregate, expire on November 3, 2013, and are
contingently exercisable upon the occurrence of certain prospective events, as
defined.
ACQUISITION OF IGUANA STUDIOS, INC.
In connection with the acquisition of Iguana Studios, Inc. ("Iguana"), in
March 2001, 2,300,000 shares of the Company's common stock were placed in
escrow. The related contingency period expired in July 2002, and the fair value
of such shares was included in the aggregate purchase price at that time. As of
December 31, 2001 all employees of Iguana had been terminated, and the
subsidiary's operating activities had ceased. The remaining net book value of
Iguana intangibles was $0. Accordingly, the Company recorded additional
impairment charges in July 2002 totaling $69 representing the fair value of such
shares.
ACQUISITION AND DIVESTITURE OF PAPKE-TEXTOR, INC.
In June 2001, the Company acquired Papke-Textor, Inc. d/b/a Canned
Interactive ("Canned"), a Los Angeles-based media and entertainment interactive
agency, for approximately $1,100 in cash, including acquisition costs, and
6,436,552 shares of the Company's common stock valued at approximately $1,000.
The business combination was accounted for using the purchase method of
accounting and, accordingly, the total consideration was allocated to the
tangible and intangible assets acquired and liabilities assumed on the basis of
their respective fair values on the date of acquisition. The results of
operations of Canned, and the estimated fair value of the assets acquired and
liabilities assumed are included in the Company's consolidated financial
statements from the date of acquisition. Of the total purchase price,
approximately $104 was allocated to the net tangible liabilities assumed, $2,177
was allocated to identified intangible assets, primarily
F-14
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS -- (CONTINUED)
assembled workforce, and to goodwill. The fair value of the identified
intangible assets was determined using the replacement cost approach for the
assembled workforce. On January 1, 2002, in connection with the Company's
adoption of SFAS 142, the value ascribed to the acquired workforce was subsumed
into goodwill, and amortization of these assets ceased. Also in connection with
the acquisition of Canned, $200 in cash and 715,172 shares of the Company's
common stock were placed in escrow. The related contingency period expired in
December 2002, at which time the cash and the then fair value of the shares,
totaling $214, was included in the aggregate purchase price.
On June 30, 2003, the Company sold all of the issued and outstanding shares
of Canned to a limited partnership of which Canned's managing director is the
general partner. Consideration paid to the Company consisted of 4,500,000 shares
of the Company's common stock with a fair market value of $170. As a result of
this divestiture, the Company recognized a loss of $274. Additionally, the
Company recognized an impairment charge of $1,782, which is included in
discontinued operations, to reduce the carrying amount of the Company's goodwill
ascribed to its single reporting unit to zero.
The results of operations for Canned, including the loss on sale and
goodwill impairment in 2003, are reported as discontinued operations for all
periods presented. The accompanying consolidated Statements of Operations for
the three and nine month periods ending September 30, 2002 were restated to
reflect such classification. Revenues included in discontinued operations were
$0 and $511 for the three months ended September 30, 2003 and 2002,
respectively, and $1,547 and $1,844 for the nine months ended September 30, 2003
and 2002, respectively. Net income (loss) of Canned included in discontinued
operations was $0 and $(114) for the three months ended September 30, 2003 and
2002, respectively, and $159 and $(26) for the nine months ended September 30,
2003 and 2002, respectively. Additionally, Canned's assets and liabilities were
classified as discontinued operations in the accompanying consolidated Balance
Sheet as of December 31, 2002.
At June 30, 2003, there was a remaining receivable balance of $300, which
was subsequently repaid by Canned.
(4) NOTES RECEIVABLE
In April 2001, the Company loaned two consultants an aggregate of $500. The
full recourse promissory notes, with initial principal amounts of $350 and $150,
respectively, accrue interest at the rate of 7.25% per annum. Payments are due
in various installments of principal plus accrued interest commencing on April
25, 2002 and continuing annually thereafter through April 25, 2006. During the
second quarter of 2003, the Company received installment payments totaling $36.
This amount was less than the $86 due in that period. No further payments have
been received. As a result of the underpayment and management's assessment of
the likelihood of future collection, the Company established a valuation
allowance for the remaining principal amount of the notes totaling $473.
See, also, discussion of the Neurologix Loan in note 1.
(5) COMMITMENTS AND CONTINGENCIES
In July 2001, the Board of Directors terminated the employment of the
Company's then President and Chief Executive Officer. The former executive had
an employment agreement dated August 21, 2000 that provided for severance
benefits. As of June 30, 2003, the Company had paid the former executive the
full severance he was entitled to under his employment agreement; the related
obligation totaled $0 at September 30, 2003.
F-15
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS -- (CONTINUED)
OPERATING LEASES
The Company leases its facilities under operating lease agreements. The
following are the future minimum lease payments under non-cancelable leases as
of September 30, 2003:
PERIOD ENDED DECEMBER 31, OPERATING CAPITAL
------------------------- --------- -------
2003........................................................ $28 $2
2004........................................................ -- 1
Thereafter.................................................. -- --
--- --
Total Lease Obligation...................................... $28 3
Amount Representing Interest................................ --
--- --
3
Current Portion............................................. 3
--- --
Long Term Portion........................................... $0
=== ==
Total minimum lease payments, above, have not been reduced for future
minimum sublease rentals totaling approximately $13.
As a result of the Company's divestiture of certain operations, employee
terminations and terminated business combination, the Company evaluated its
alternatives with respect to its contractual obligations concerning leased
facilities. As of June 30, 2002, the Company determined that certain facilities
had no substantive future use or benefit to the Company. The Company accrued the
remaining costs relating to these leases, net of sublease income, in the second
quarter of 2002. At September 30, 2003, $15 of this amount remained and is
included in accrued expenses in the accompanying Balance Sheet.
LEGAL PROCEEDINGS
The Company is involved in various legal actions arising in the ordinary
course of business. In the opinion of management, the ultimate disposition of
these matters will not have a material adverse effect on the Company's
consolidated financial position, results of operation or liquidity.
(6) STOCKHOLDER'S EQUITY
In April, 2002 the Company cancelled 15,468,748 outstanding warrants with a
weighted average exercise price of $0.85 in exchange for no consideration.
In August, 2002 the Company's shareholders approved the grant to the former
Chief Executive Officer of an option to purchase 6,000,000 shares of the
Company's common stock. Under the Separation Agreement entered into in
connection with such former Chief Executive Officer's resignation on June 17,
2003, such options, together with 3,000,000 previously granted, were immediately
vested and may be exercised at any time on or before March 31, 2005. As a result
of this modification to the terms of the options, the Company recorded a charge
of $90. This amount is included in stock based compensation in the accompanying
statement of operations for the nine month period ended September 30, 2003.
(7) RELATED PARTY TRANSACTIONS
During the three months ended March 31, 2002, the Company incurred
management and investment advisory service fees in connection with identifying,
evaluating, negotiating, and managing investment opportunities for the Company.
These services were provided by a firm with which the former President and
F-16
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS -- (CONTINUED)
Chief Executive Officer of the Company was previously affiliated. Such former
President and Chief Executive Officer of the Company resigned on June 17, 2003.
Fees incurred by the Company to this firm totaled $75 in the three months ended
March 31, 2002. Subsequent to that date, the Company has not utilized this firm
to perform any services for the Company. Additionally, this firm occupies a
portion of the Company's office space in Connecticut, for which it pays rent at
an amount which approximates fair market value. Such payments to the Company
totaled $220 and $134 during the nine months ended September 30, 2003 and 2002,
respectively. Furthermore, the firm was indebted to the Company in the amount of
$102 and $194 at September 30, 2003 and December 31, 2002, respectively, for its
pro rata share of certain leasehold improvements and rental payments due, which
are reflected in the Related Party Receivable in the accompanying Balance Sheet.
F-17
REPORT OF KPMG LLP, INDEPENDENT ACCOUNTANTS
The Board of Directors and Stockholders of
Change Technology Partners, Inc.
We have audited the accompanying consolidated balance sheets of Change
Technology Partners, Inc. and subsidiaries (the "Company") as of December 31,
2002 and 2001 and the related consolidated statements of operations,
stockholders' equity and redeemable preferred stock, and cash flows for each of
the years in the three-year period ended December 31, 2002. These consolidated
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these consolidated financial
statements based on our audits.
We conducted our audits in accordance with auditing standards generally
accepted in the United States of America. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Change Technology Partners,
Inc. and subsidiaries as of December 31, 2002 and 2001 and the results of its
operations and cash flows for each of the years in the three-year period ended
December 31, 2002 in conformity with accounting principles generally accepted in
the United States of America.
As discussed in Note 2 to the consolidated financial statements, in 2002
the Company changed its method of accounting for goodwill and other intangible
assets.
The accompanying consolidated financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in Note
1 to the consolidated financial statements, the Company adopted a plan of
liquidation and dissolution that raises substantial doubt about its ability to
continue as a going concern. The Company's plans with regard to these matters
are also described in Note 1. The consolidated financial statements do not
include any adjustments that might arise from the outcome of this uncertainty.
KPMG LLP
New York, New York
March 27, 2003, except for the reclassification and presentation of the
discounted operations of Papke Textor, Inc., as discussed in Note 3, as to which
the date is November 14, 2003.
F-18
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
YEAR ENDED
DECEMBER 31,
---------------------
2002 2001
--------- ---------
(IN THOUSANDS, EXCEPT
SHARE AND PER SHARE
AMOUNTS)
ASSETS
Cash and cash equivalents................................... $ 2,944 $ 8,702
Related party receivable.................................... 194 204
Other Receivable............................................ 318 229
Notes receivable............................................ 4,926 2,393
Prepaid expenses and other current assets, including
restricted cash of $200 at December 31, 2001.............. 672 479
Current assets related to discounted operations............. 465 71
-------- --------
Total current assets...................................... $ 9,519 $ 12,078
Notes receivable, excluding current portion................. 424 333
Investments in and loans to unconsolidated subsidiaries..... 449 720
Property and equipment, net................................. 281 562
Goodwill related to discontinued operations................. 1,782 1,568
Long term assets related to discontinued operations......... 155 238
Other assets................................................ 123 653
-------- --------
Total assets.............................................. $ 12,733 $ 16,152
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable............................................ $ 123 $ 272
Accrued expenses............................................ 580 976
Capital lease obligation.................................... 70 55
Liabilities related to discontinued operations, net......... 333 115
-------- --------
Total current liabilities................................. 1,106 1,418
Capital lease obligation, less current portion.............. 8 74
-------- --------
Total liabilities......................................... 1,114 1,492
Stockholders' equity:
Preferred stock:
Series A -- $.06 per share cumulative, convertible
share-for-share into common stock; $.10 par value;
500,000 shares authorized, 645 issued and outstanding
at December 31, 2002 and 2001, with an aggregate
liquidation preference of $1 per share................. -- --
Series B -- convertible into common on a 1:40 basis; $.10
par value; 4,000,000 shares authorized; 0 shares issued
and outstanding at December 31, 2002 and 2001.......... -- --
Common stock:
$.01 par value; 500,000,000 shares authorized,
182,003,920 and 179,022,881 issued and outstanding at
December 31, 2002 and 2001, respectively.............. 1,820 1,790
Additional paid-in capital.................................. 94,369 94,637
Deferred compensation....................................... (268) (966)
Accumulated deficit......................................... (84,302) (80,801)
-------- --------
Total stockholders' equity............................. 11,619 14,660
-------- --------
Total liabilities and stockholders' equity............. $ 12,733 $ 16,152
======== ========
See accompanying notes to consolidated financial statements.
F-19
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
YEAR ENDED DECEMBER 31,
--------------------------------------------------
2002 2001 2000
--------------- --------------- --------------
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
Revenues............................................ $ -- $ 4,596 $ 1,370
Cost of revenues including the amortization of
purchased intangibles of $654 and $50 in 2001 and
2000, respectively................................ -- 6,088 1,119
------------ ------------ -----------
Gross Profit (loss)................................. -- (1,492) 251
Operating expenses:
General and administrative expenses, exclusive of
equity based compensation of $377, $3,086 and
$2,921 in 2002, 2001 and 2000, respectively....... 3,342 12,894 3,305
Equity based compensation........................... 377 3,086 2,921
Severance........................................... -- 1,326 --
Loss on disposal of subsidiaries.................... -- 377 --
Impairment.......................................... 69 7,263 --
------------ ------------ -----------
Loss from operations................................ (3,788) (26,438) (5,975)
Other income (expense):
Interest and dividend income, net................... 743 859 1,469
Equity in losses and impairment of investments in
unconsolidated subsidiaries....................... (549) (5,546) (1,732)
------------ ------------ -----------
Loss from continuing operations..................... (3,594) (31,125) (6,238)
Income (loss) from discontinued operations.......... 93 (1,075) --
------------ ------------ -----------
Net loss.......................................... (3,501) (32,200) (6,238)
------------ ------------ -----------
Deemed dividend attributable to issuance of Series B
convertible preferred stock....................... -- -- 40,000
------------ ------------ -----------
Net loss attributable to common stockholders........ $ (3,501) $ (32,200) $ (46,238)
Basic and diluted loss per common share from
continuing operations............................. $ (0.02) $ (0.23) $ (1.31)
Discontinued operations............................. (0.00) (0.00) (0.00)
------------ ------------ -----------
Basic and diluted net loss per common share......... $ (0.02) $ (0.23) $ (1.31)
Weighted average common shares outstanding, basic
and diluted....................................... 180,251,646 138,478,550 35,424,000
See accompanying notes to consolidated financial statements.
F-20
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY AND REDEEMABLE PREFERRED STOCK
YEARS ENDED DECEMBER 31, 2002, 2001 AND 2000
SERIES B
REDEEMABLE SERIES A SERIES B
PREFERRED STOCK PREFERRED STOCK PREFERRED STOCK COMMON STOCK
--------------------- --------------- ------------------- --------------------
SHARES AMOUNT SHARES AMOUNT SHARES AMOUNT SHARES AMOUNT
---------- -------- ------ ------ ---------- ------ ----------- ------
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
Balance as of December 31, 1999.... -- -- 3,221 -- -- -- 4,958,234 49
Sale of warrants to purchase common
stock............................. -- -- -- -- -- -- -- --
Issuance of Series B redeemable
preferred stock, net of offering
costs............................. 4,000,000 40,000 -- -- -- -- -- --
Beneficial conversion feature
related to Series B redeemable
convertible preferred stock....... -- (40,000) -- -- -- -- -- --
Amortization of beneficial
conversion feature................ -- 40,000 -- -- -- -- -- --
Conversion of Series B preferred
stock into common stock........... (1,000,000) (10,000) -- -- -- -- 40,000,000 400
Nullification of redemption feature
of Series B preferred stock....... (3,000,000) (30,000) -- -- 3,000,000 300 -- --
Deferred compensation.............. -- -- -- -- -- -- -- --
Amortization of deferred
compensation...................... -- -- -- -- -- -- -- --
Removal of restrictions on
subsidiary stock to employee and
independent contractors........... -- -- -- -- -- -- -- --
Issuance of subsidiary stock for
acquisition....................... -- -- -- -- -- -- -- --
Net loss for the year ended
December 31, 2000................. -- -- -- -- -- -- -- --
---------- -------- ------ ----- ---------- ----- ----------- ------
Balance as of December 31, 2000.... -- $ -- 3,221 $ -- 3,000,000 $ 300 44,958,234 $ 449
Amortization of deferred
compensation...................... -- -- -- -- -- -- -- --
Forfeiture of unvested options..... -- -- -- -- -- -- --
Options Granted to Executive (Note
8)................................ -- -- -- -- -- -- -- --
Reacquisition of stock in
connection with sale of RAND...... -- -- -- -- -- -- (375,039) (4)
Acquisition of Iguana Studios,
Inc............................... -- -- -- -- -- -- 2,700,000 27
Settlement of stock award to CEO
and acquisition of outstanding
minority interest of eHotHouse,
Inc............................... -- -- -- -- -- -- 5,300,013 54
Acquisition of Canned Interactive,
Inc............................... -- -- -- -- -- -- 6,436,552 64
Conversion of series A preferred
shares to common.................. -- -- -- -- -- -- -- --
Conversion of preferred shares to
common............................ -- -- (2,576) -- (3,000,000) (300) 120,002,576 1,200
Net loss for the year ended
December 31, 2001................. -- -- -- -- -- -- -- --
---------- -------- ------ ----- ---------- ----- ----------- ------
Balance at December 31, 2001....... -- $ -- 645 $ -- -- $ -- 179,022,336 $1,790
Amortization of deferred
compensation...................... -- -- -- -- -- -- -- --
Forfeiture of unvested options..... -- -- -- -- -- -- -- --
Release of shares from escrow in
connection with the acquisition of
Iguana Studios, Inc............... -- -- -- -- -- -- 2,300,000 23
Reacquisition of stock from
shareholder....................... -- -- -- -- -- -- (33,588) --
Release of shares from escrow in
connection with the acquisition of
Canned Interactive, Inc........... 715,172 7
Net loss for the year ended
December 31, 2002................. -- -- -- -- -- -- -- --
---------- -------- ------ ----- ---------- ----- ----------- ------
Balance at December 31, 2002....... -- $ -- 645 $ -- -- $ -- 182,003,920 $1,820
========== ======== ====== ===== ========== ===== =========== ======
ADDITIONAL TOTAL
PAID-IN DEFERRED ACCUMULATED STOCKHOLDERS'
CAPITAL COMPENSATION DEFICIT EQUITY
---------- ------------ ----------- -------------
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
Balance as of December 31, 1999.... 2,559 -- (2,363) 245
Sale of warrants to purchase common
stock............................. 100 -- -- 100
Issuance of Series B redeemable
preferred stock, net of offering
costs............................. (550) -- -- (550)
Beneficial conversion feature
related to Series B redeemable
convertible preferred stock....... 40,000 -- -- 40,000
Amortization of beneficial
conversion feature................ -- -- (40,000) (40,000)
Conversion of Series B preferred
stock into common stock........... 9,600 -- -- 10,000
Nullification of redemption feature
of Series B preferred stock....... 29,700 -- -- 30,000
Deferred compensation.............. 2,480 (2,480) -- --
Amortization of deferred
compensation...................... -- 693 -- 693
Removal of restrictions on
subsidiary stock to employee and
independent contractors........... 2,228 -- -- 2,228
Issuance of subsidiary stock for
acquisition....................... 704 -- -- 704
Net loss for the year ended
December 31, 2000................. -- -- (6,238) (6,238)
------- ------- -------- --------
Balance as of December 31, 2000.... $86,821 $(1,787) $(48,601) $ 37,182
Amortization of deferred
compensation...................... -- 621 -- 621
Forfeiture of unvested options..... (320) 320 -- --
Options Granted to Executive (Note
8)................................ 120 (120) -- --
Reacquisition of stock in
connection with sale of RAND...... (22) -- -- (26)
Acquisition of Iguana Studios,
Inc............................... 2,958 -- -- 2,985
Settlement of stock award to CEO
and acquisition of outstanding
minority interest of eHotHouse,
Inc............................... 5,091 -- -- 5,145
Acquisition of Canned Interactive,
Inc............................... 889 -- -- 953
Conversion of series A preferred
shares to common.................. -- -- -- --
Conversion of preferred shares to
common............................ (900) -- -- --
Net loss for the year ended
December 31, 2001................. -- -- (32,200) (32,200)
------- ------- -------- --------
Balance at December 31, 2001....... $94,637 $ (966) $(80,801) $ 14,660
Amortization of deferred
compensation...................... -- 377 -- 377
Forfeiture of unvested options..... (321) 321 -- --
Release of shares from escrow in
connection with the acquisition of
Iguana Studios, Inc............... 46 -- -- 69
Reacquisition of stock from
shareholder....................... -- -- -- --
Release of shares from escrow in
connection with the acquisition of
Canned Interactive, Inc........... 7 14
Net loss for the year ended
December 31, 2002................. -- -- (3,501) (3,501)
------- ------- -------- --------
Balance at December 31, 2002....... $94,369 $ (268) $(84,302) $ 11,619
======= ======= ======== ========
F-21
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEAR ENDED DECEMBER 31,
-------------------------------------
2002 2001 2000
---------- ----------- ----------
(IN THOUSANDS, EXCEPT SHARE AND PER
SHARE AMOUNTS)
Cash flows from operating activities:
Net income (loss)......................................... $(3,501) $(32,200) $(6,238)
Adjustments to reconcile net income (loss) to net cash in
operating activities:
Depreciation and amortization.......................... 284 2,519 56
Impairment losses...................................... 69 7,263 --
Decrease in trading activities......................... -- -- 112
Equity based compensation.............................. 377 3,086 2,921
Equity in losses and impairment of investments in
unconsolidated affiliates............................ 549 5,546 1,732
Accretion of loan discount............................. (72) (36) --
Accrued interest on loans receivable................... (625) (52) --
Provision for doubtful accounts........................ -- 111 --
Loss on disposal of property and equipment............. -- 537 --
Loss on disposal of subsidiaries, net of cash
disposed............................................. -- 141 --
Discontinued operations, net........................... (93) 1,075 --
Changes in operating assets and liabilities net of
acquisitions:
Accounts receivable.................................... -- 471 142
Prepaid expenses and other assets...................... 58 (513) (456)
Deferred revenues...................................... -- 211 8
Accounts payable and accrued liabilities............... (545) (336) 904
------- -------- -------
Net cash used in operating activities.................. (3,499) (12,177) (819)
Cash flows from investing activities:
Investments in affiliates.............................. (278) (450) (6,625)
Capital contribution to discontinued operations........ -- (560) --
Purchase of property and equipment..................... (3) (655) (336)
Cash proceeds from sale of property and equipment...... -- 35 --
Cash paid for acquisitions............................. -- (4,076) (1,542)
Advances on notes receivable........................... (4,708) (3,450) --
Receipts on notes receivable........................... 2,781 -- --
------- -------- -------
Net cash used in investing activities................ (2,208) (9,156) (8,503)
Cash flows from financing activities:
Principal payments under capital leases................ (51) (34) --
Payment of notes payable............................... -- (264) (28)
Issuance of Series B preferred stock and warrants, net
of offering costs.................................... -- -- 39,550
------- -------- -------
Net cash (used in) provided by financing activities......... (51) (298) 39,522
------- -------- -------
Net (decrease) increase in cash and cash equivalents........ (5,758) (21,631) 30,200
Cash and cash equivalents at beginning of period............ 8,702 30,333 133
------- -------- -------
Cash and cash equivalents at end of period.................. $ 2,944 $ 8,702 $30,333
======= ======== =======
F-22
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2002
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
(1) DESCRIPTION OF BUSINESS
Arinco Computer Systems Inc., the predecessor of the Company together with
its subsidiaries, (the "Company"), was incorporated on March 31, 1978; however,
the Company formally commenced implementation of its plan to provide
professional consulting services on June 15, 2000. The Company provided a broad
range of professional consulting services, including e-services and technology
strategy, online branding, web architecture and design, systems integration,
systems architecture and outsourcing. The Company has served clients throughout
the United States and, as of December 31, 2002, has offices in Connecticut and
California. During the year ended December 31, 2001, the Board of Directors
voted to divest the Company of a majority of its then existing operations.
At December 31, 2002, the Company's remaining consolidated subsidiaries
are:
- Iguana Studios, Inc. (which has limited continuing operating activities)
- Papke-Textor, Inc. d/b/a Canned Interactive ("Canned")
Based on the Company's assessment of the opportunities in the radio
business, the Board of Directors decided to merge with Franklin Capital
Corporation and jointly develop and acquire network radio programming and sales
and syndication businesses. On December 4, 2001, the Company entered into an
agreement and plan of merger with Franklin Capital. On July 1, 2002, the Company
received a notice of termination from Franklin Capital terminating the proposed
merger.
On September 30, 2002, the Board of Directors adopted a plan of liquidation
and dissolution. The plan remains subject to stockholder approval, which the
Company intends to seek at its next annual meeting. The plan anticipates the
continuation of the Company's business activities pending an orderly wind down
of its operations, but permits the Board of Directors to amend, modify or
abandon the plan, notwithstanding stockholder approval, if the Board determines
that doing so would be in the best interests of the Company and its
stockholders. The Company continues to review other alternatives to liquidation.
However, if no appropriate alternative can be found, the Company anticipates
that it will commence liquidation in 2003. The consolidated financial statements
do not include any adjustments to reflect the possible future effects on the
recoverability of assets or the amounts of liabilities that may result from the
outcome of this uncertainty.
(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(A) USE OF ESTIMATES
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities, the disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from those
estimates. Significant estimates embedded in the consolidated financial
statements for the periods presented concern the allowances for doubtful
accounts, the estimates used in the percentage of completion method, the fair
value of purchased intangible assets, and the estimated useful lives of
purchased intangible assets.
(B) PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of the Company
and its majority-owned and controlled subsidiaries from the date of acquisition
through the date of disposition, if applicable. All significant intercompany
transactions and balances have been eliminated in consolidation. Investments in
less than
F-23
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
majority-owned entities over which the Company has significant influence are
accounted for using the equity method.
Since the Company was the only contributor of capital to a majority-owned
subsidiary, eHotHouse, Inc. ("eHotHouse"), and the minority interest holders had
no obligation to provide additional capital, 100% of those losses were included
in the Company's results for the period prior to the Company's acquisition of
the outstanding minority interest in February, 2001. In May, 2001, eHotHouse
merged with and into the Company.
(C) REVENUE RECOGNITION
Revenues are recognized for fixed-price arrangements in the period services
are rendered using the percentage-of-completion method, based on the percentage
of costs incurred to date to total estimated projects costs, provided the
Company has the ability to produce reasonably dependable estimates, collection
of the resulting receivable is probable and no significant obligations remain.
The cumulative impact of any revision in estimates of the cost to complete and
losses on projects in process are reflected in the period in which they become
known.
Revenues are recognized for time-and-materials based arrangements in the
period when the underlying services are rendered, provided collection of the
resulting receivable is probable and no significant obligations remain.
The Company generally enters into short-term, project specific contracts
with its clients who are generally billed in the same period in which services
are rendered. If services are rendered in advance of billings, the Company
records and presents the related amounts as unbilled revenue. If amounts are
received in advance of services being performed, the amounts are recorded and
presented as deferred revenues.
In November 2001, the Emerging Issues Task Force ("EITF") concluded that
reimbursements for out-of-pocket-expenses incurred should be included in revenue
in the income statement and subsequently issued EITF 01-14, "Income Statement
Characterization of Reimbursements Received for 'Out-of-Pocket' Expenses
Incurred" in January 2002. The Company adopted EITF 01-14 effective January 1,
2002 and has reclassified financial statements for prior periods to comply with
the guidance in this EITF. Reimbursable expenses were de minimis for all periods
presented.
(D) COST OF REVENUES
Cost of revenues consists primarily of compensation of billable employees,
travel, subcontractor costs, and other costs directly incurred in the delivery
of services to clients. Billable employees are full time employees and
subcontractors who spent time servicing client projects. Also included in cost
of revenues in the statement of operations for the twelve months ended December
31, 2001 and 2000 is the amortization of certain purchased intangible assets,
representing the value of customer relationships and workforces acquired. In
connection with the adoption of SFAS 142 on January 1, 2002, acquired workforce
was subsumed into goodwill and, accordingly, amortization of the remaining
acquired workforce ceased.
(E) CONCENTRATION OF CREDIT RISK
Financial instruments that subject the Company to credit risks consist
primarily of cash and cash equivalents, notes receivable, and trade accounts
receivable. Cash and cash equivalents consist of deposits, money market funds,
and investments in short term "AAA" rated debt instruments. The Company performs
ongoing credit evaluations, generally does not require collateral, and
establishes an allowance for doubtful accounts based upon factors surrounding
the credit risk of customers, historical trends, and other information.
F-24
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
To date, such losses have been within management's expectations. Notes
receivable are generally collateralized and bear a market rate of interest
commensurate with the associated risks.
Revenues from significant customers are as follows:
TWELVE MONTHS ENDED
DECEMBER 31,
---------------------
2002 2001 2000
----- ----- -----
Customer A.................................................. 0% 0% 37%
Customer B.................................................. 0% 0% 29%
Customer C.................................................. 0% 0% 26%
Customer D.................................................. 0% 0% 0%
Customer E.................................................. 12% 15% 0%
Customer F.................................................. 37% 47% 0%
Customer G.................................................. 0% 0% 0%
Customer H.................................................. 5% 0% 0%
Customer I.................................................. 9% 0% 0%
Accounts receivable from significant customers are as follows:
DECEMBER 31,
------------------
2002 2001 2000
---- ---- ----
Customer A.................................................. 0% 0% 13%
Customer B.................................................. 0% 0% 19%
Customer C.................................................. 0% 0% 15%
Customer D.................................................. 0% 0% 10%
Customer E.................................................. 29% 1% 0%
Customer F.................................................. 12% 0% 0%
Customer G.................................................. 27% 0% 0%
Customer H.................................................. 13% 0% 0%
Customer I.................................................. 11% 0% 0%
(F) CASH AND CASH EQUIVALENTS
Cash equivalents consist of highly liquid investments with original
maturities of less than three months.
(G) PROPERTY AND EQUIPMENT
Property and equipment are stated at cost, net of accumulated depreciation
and amortization. Leasehold improvements are amortized utilizing the
straight-line method over the lesser of the estimated useful life of the asset
or the respective lease term. The Company provides for depreciation of other
machinery and equipment over their estimated useful lives, using the
straight-line method, as follows:
ASSET CLASSIFICATION ESTIMATED USEFUL LIFE
-------------------- ---------------------
Computers and equipment..................................... 3 - 5 years
Furniture and fixtures...................................... 5 years
Leasehold improvements...................................... 5 - 10 years (lease term)
F-25
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(H) PURCHASED INTANGIBLE ASSETS
At December 31, 2001, purchased intangible assets, comprised primarily of
the customer lists and the workforce acquired in connection with the acquisition
of Canned, were being amortized over a period of 3 years, the estimated period
of benefit considering the underlying contractual relationships, the project
oriented continuing revenue stream, and analysis of the Company's retention
efforts.
Effective June 2001, the Company adopted Financial Accounting Standards
Board Statement of Accounting Standards (SFAS) 141, "Business Combinations".
Effective January 1, 2002, the Company adopted SFAS 142, "Goodwill and
Intangible Assets" and SFAS 144, "Accounting for the Impairment or Disposal of
Long-Lived Assets." SFAS 141 requires that acquisitions entered into after June
30, 2001 be accounted for using the purchase method and establishes criteria to
be used in determining whether acquired intangible assets are to be separated
from goodwill. At January 1, 2002 the intangible assets consisted of goodwill
and the subsumed workforce acquired in connection with the acquisition of
Canned.
SFAS 142 sets forth the accounting for goodwill and intangible assets
already recorded. Commencing January 1, 2002, goodwill is no longer being
amortized into results of operations. Management conducted valuations of its
reporting units in order to test goodwill for impairment by comparing the
asset's fair value to the carrying value. This analysis did not indicate
impairment as of January 1, 2002.
The following table reflects the reconciliation of reported net loss and
loss per share to amounts adjusted for the exclusion of goodwill amortization:
TWELVE MONTHS ENDED
DECEMBER 31,
----------------------------
2002 2001 2000
------- -------- -------
NET LOSS
Reported loss.......................................... $(3,501) $(32,200) $(6,238)
Add back: Goodwill amortization........................ ----
-- 677
$(6,238)
Adjusted net loss...................................... $(3,501) $(31,523)
======= ======== =======
PER SHARE OF COMMON STOCK
Basic and Diluted:
$ (.02) $ (0.23) $ (1.31)
Reported loss........................................
Add back: Goodwill amortization...................... ---- ----
--
$ (0.23) $ (1.31)
Adjusted net loss.................................... $ (.02)
======= ======== =======
(I) EQUITY-BASED COMPENSATION
The Company accounts for its employee stock option plans in accordance with
the provisions of the Accounting Principles Board ("APB") Opinion No. 25,
"Accounting for Stock Issued to Employees," and related interpretations
including Financial Accounting Standards Board Interpretation No. 44. As such,
compensation expense related to employee stock options is recorded only if, on
the date of grant, the fair value of the underlying stock exceeds the exercise
price. All such deferred compensation is amortized over the related vesting
period on a straight-line basis. The Company adopted the disclosure-only
requirements of SFAS No. 123 "Accounting for Stock-Based Compensation", which
allows entities to continue to apply the provisions of APB Opinion No. 25 for
transactions with employees and provide pro forma net income (loss) and pro
forma earnings (loss) per share disclosures for employee stock grants made as if
the fair value based method of accounting in SFAS No. 123 had been applied to
these transactions.
F-26
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Had compensation cost for these awards been determined based on the fair
value at the grant dates consistent with the method prescribed by SFAS No. 123,
the Company's net loss would have been adjusted to the pro forma amounts
indicated below:
YEAR ENDED DECEMBER 31,
-----------------------------
2002 2001 2000
------- -------- --------
Net loss, as reported................................. $(3,501) $(32,200) $(46,238)
Add back: compensation expense related to stock
options, as reported................................ 377 621 693
Deduct: compensation expense related to stock options
under fair value based method....................... (514) (1,334) (1,191)
------- -------- --------
Pro forma net loss.................................... $(3,638) $(32,913) $(46,736)
======= ======== ========
Basic and diluted net loss per share as reported...... $ (.02) $ (0.23) $ (1.31)
======= ======== ========
Pro forma basic income loss per share................. $ (.02) $ (0.23) $ (1.32)
======= ======== ========
Each year the Company has estimated the fair value of stock option grants
made in that year by using the Black-Scholes option-pricing model. Following are
the weighted-average assumptions used:
2001 2000
---- ----
Expected option term (years)................................ 10 10
Risk-free interest rate(%).................................. 6.00% 5.78%
Expected volatility(%)...................................... 81% 59%
Dividend yield(%)........................................... 0% 0%
There were no options granted during the year ended December 31, 2002.
(J) BASIC AND DILUTED NET LOSS PER COMMON SHARE
Basic net loss per common share excludes the effect of potentially dilutive
securities and is computed by dividing net income or loss available to common
stockholders by the weighted average number of common shares outstanding for the
period. Diluted net income or loss per share is adjusted for the effect of
convertible securities, warrants and other potentially dilutive financial
instruments only in the periods in which such effect would have been dilutive.
The following securities were not included in the computation of diluted
net loss per share because to do so would have had an antidilutive effect for
the periods presented:
AT DECEMBER 31,
------------------------------------
2002 2001 2000
---------- ---------- ----------
Stock Options.................................... 14,585,747 16,133,768 4,600,000
Warrants......................................... 25,856,252 41,250,000 41,250,000
Series A Convertible Preferred Stock............. 645 645 3,221
Series B Convertible Preferred Stock............. -- -- 3,000,000
As a result, the basic and diluted net loss per share is equal for all
periods presented.
F-27
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(K) INCOME TAXES
The Company uses the asset and liability method of accounting for income
taxes. Under this method, deferred tax assets and liabilities are recognized for
the future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their tax
bases and to operating loss and tax credit carry forwards. Deferred tax assets
and liabilities are measured using enacted tax rates expected to apply to
taxable income in the years in which those temporary differences are expected to
be recovered or settled. The effect on deferred tax assets or liabilities of a
change in tax rates is recognized in the period that the rate change occurs. A
valuation allowance is provided for the amount of deferred tax assets for which,
based on available evidence, realization is not assured.
(L) COMPREHENSIVE INCOME
The Company accounts for comprehensive income (loss) under SFAS No. 130
"Reporting Comprehensive Income." This statement established standards for
reporting and displaying comprehensive income and its components in a financial
statement that is displayed with the same prominence as other financial
statements. For all periods presented, comprehensive income (loss) equals net
income (loss) as reported.
(M) SEGMENT REPORTING
Although the Company has divested itself of certain of its operations, and
is evaluating other business opportunities, it has historically offered, largely
through its acquired businesses, a wide variety of professional consulting
services such as e-services, technology services and systems integration.
Management does not manage its operations by these product offerings, but
instead views the Company as one operating segment when making business
decisions, with one operating decision maker, the Chief Executive Officer. The
Company manages its operations as a cross-disciplinary integrated solutions
provider, which attempts to bring forth a coordinated service offering to its
clients.
(N) NEW ACCOUNTING PRONOUNCEMENTS
Statement of Financial Accounting Standards No. 144, "Accounting for the
Impairment or Disposal of Long-Lived Assets" ("SFAS 144"), establishes a single
accounting model for the impairment or disposal of long-lived assets, including
discontinued operations. Effective January 1, 2002, the Company adopted SFAS
144. Adoption of SFAS 144 has not resulted in an impairment charge.
Statement of Financial Accounting Standards No. 146, "Accounting for Costs
Associated with Exit or Disposal Activities" ("SFAS 146"), requires that costs
associated with exit or disposal activities be measured initially at fair value,
and recognized only when the liability is incurred. SFAS 146 is effective for
exit or disposal activities that are initiated after December 31, 2002. The
Company plans to adopt SFAS 146 effective January 1, 2003. The impact of SFAS
146 on the Company's financial statements will depend on a variety of factors,
including interpretive guidance from the FASB. However, the Company does not
expect that the adoption will have a material impact on its consolidated results
of operations or financial position.
Statement of Financial Accounting Standards No. 148, "Accounting for
Stock-Based Compensation" ("SFAS 148"), is an amendment to Statement of
Financial Accounting Standards No. 123, "Accounting for Stock-Based
Compensation", and provides alternative methods of transition for an entity that
voluntarily changes from the intrinsic value based method of accounting for
stock-based employee compensation prescribed in APB No. 25 to the fair value
method prescribed in SFAS 123. As permitted under SFAS 148, the Company has
continued to apply the accounting provisions of APB No 25, and to provide the
annual pro forma disclosures of the effect of adopting the fair value method as
required by SFAS 123. SFAS 148 also
F-28
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
requires pro forma disclosure to be provided on a quarterly basis. The Company
plans to adopt the quarterly disclosure requirement during the first quarter of
2003.
(3) DISCONTINUED OPERATIONS
On June 30, 2003, the Company sold all of the issued and outstanding shares
of its Canned Interactive subsidiary to a limited partnership of which Canned's
managing director is the general partner. Accordingly, the assets and
liabilities of Canned have been segregated and presented separately in the
accompanying balance sheet for the years ended December 31, 2002 and 2001.
Additionally, the operations and cash flows of Canned for the years ending
December 31, 2002, 2001 and 2000 have been reclassed into a one-line
presentation and are included in Loss from Discontinued Operations and Net Cash
Used by Discontinued Operations. Revenues included in discontinued operations
were $2,678, $971, and $0 for the years ended December 31, 2002, 2001 and 2000,
respectively. Net income (loss) of Canned included in discontinued operations
was $93, $(466), and $0 for the years ended December 31, 2002, 2001 and 2000,
respectively.
(4) SEVERANCE AND IMPAIRMENT CHARGES
In 2001, in response to continued unfavorable market conditions for its
services, the Company embarked on a review of all operations with the goal of
formulating a course of action to minimize near-term losses and capital
expenditures and reduce cash outflows. As an initial course of action, primarily
during July and August 2001, the Company terminated the employment of
approximately 90% of its then existing workforce. As a result, the Company
incurred severance charges of $1,326, which are included in severance charges in
the accompanying Statement of Operations for the year ended December 31, 2001.
Of this amount, $1,145 of the severance obligations have been paid as of
December 31, 2002.
(5) INVESTMENTS IN AND LOANS TO UNCONSOLIDATED SUBSIDIARIES
The following summarizes the Company's ownership interests in, and loans
to, unconsolidated subsidiaries accounted for under the equity method, and
investments accounted for under the cost method of accounting:
CARRYING VALUE
DECEMBER 31,
---------------
2002 2001 COST BASIS
------ ------ ----------
Equity method investments:
Broadstream.com Inc. ("Broadstream")........................ $ -- $ -- $7,100
NetPro Holdings, Inc. ("NetPro")............................ -- 33 400
InSys LLC ("InSys")......................................... 121 312 323
Cost method investments:
Livesky, Inc. ("Livesky")................................... -- 125 125
Alacra, Inc. ("Alacra")..................................... 78 -- 78
Excelsior Radio Networks, Inc. ("Excelsior")................ 250 250 250
---- ---- ------
Total investments:.......................................... $449 $720 $8,276
==== ==== ======
INVESTMENTS IN BROADSTREAM AND NETPRO
In June 2000, the Company purchased 7,626,165 shares of Series A
Convertible Redeemable Preferred Stock ("Series A") of Broadstream, Inc. (d/b/a
Network Prophecy) ("Broadstream"), representing an
F-29
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
approximately 30% equity interest (calculated on an as-if-converted basis) and
approximately 47% voting interest, in exchange for $6,500.
Broadstream is a streaming media management services company that provides
software to measure, manage and monitor delivery of streaming media content and
data. The investment in Broadstream is being accounted for under the equity
method. Based upon the capital structure of, and the equity participation in,
the equity investee, the Company has assumed conversion of Series A shares in
computing its share of losses of this investee. The Company's proportionate
share of Broadstream's net loss was $3,177 and $1,097 in 2001 and 2000,
respectively, and the amortization of the excess of cost over the Company's
proportionate interest in the underlying equity was $1,175 and $635 for 2001 and
2000, respectively. These amounts are included in equity in losses of affiliate
in the accompanying Statement of Operations.
In May 2001, Broadstream completed a recapitalization whereby all of the
holders of Series A shares exchanged their Series A shares for shares of Series
A-1 Convertible Redeemable Preferred Stock ("Series A-1"). The recapitalization
modified the conversion ratio, policies regarding dividends and voting rights
for Series A-1 holders. No additional consideration was paid by the Company or
any other Series A-1 shareholder in connection with this transaction. As a
result of the recapitalization the voting interest of common shareholders was
reduced from 31% to 13%.
Also in May 2001, in connection with the recapitalization, the Company
transferred 1,191,569 Series A-1 shares to Adelson Investors, LLC ("Adelson"),
another shareholder of Broadstream, as payment for certain financing-related
services performed by Adelson on behalf of Broadstream. This transfer has been
accounted for as a contribution by the Company of such shares to Broadstream in
exchange for no consideration. As a result of this non-reciprocal transfer of
shares the Company recorded a charge of $1,016 equal to the Company's cost basis
in such shares, which approximated fair value, and has been included in equity
in losses of affiliate in the accompanying Statement of Operations for the year
ended December 31, 2001. Subsequent to the recapitalization and non-reciprocal
share transfer, the Company owned 6,434,596 shares of Series A-1 Convertible
Redeemable Preferred Stock of Broadstream, representing an approximately 43%
equity interest (calculated on an as-if-converted basis) and a 49% voting
interest.
On August 15, 2001 the Company purchased a secured convertible promissory
note from Broadstream in exchange for $600 in connection with an aggregate
$1,600 bridge loan financing consummated by Broadstream. The aggregate bridge
loan financing was secured by all of Broadstream's assets. The note also
contained certain conversion provisions in the event Broadstream were to close a
new round of financing or enter into certain transactions.
On November 30, 2001 the Company assigned its Broadstream promissory note
to a newly formed entity, NetPro Holdings Inc. ("NetPro") in exchange for
13,674,753 shares of NetPro Series A-1 Convertible Redeemable Participating
Preferred Stock. On November 30, 2001 as a result of the application of the
equity method, the net book value of the note approximated zero and no gain or
loss was recorded as a result of this exchange. Concurrent with this
transaction, NetPro foreclosed on the note and elected to take possession of all
of Broadstream's assets in full satisfaction of the notes.
On December 15, 2001, the Company purchased 1,585,479 shares of NetPro
Series B-1 Convertible Redeemable Participating Preferred Stock in exchange for
$200 in connection with a larger ongoing financing arrangement.
As of December 31, 2001, the Company's interest in NetPro represented
approximately 38% of NetPro outstanding equity, and was being accounted for
under the equity method of accounting. The Company's proportionate share of
NetPro's net losses totaling $167 from the date of investment through December
31, 2001, is included in equity in losses of unconsolidated subsidiaries in the
accompanying Statement of Operations.
F-30
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
On January 10, 2002, the Company invested an additional $100 in NetPro
Series B-1 stock, and on March 7, 2002 the Company invested a final $100 in
NetPro Series B-1 stock. On March 14, 2002, the board of directors of NetPro
voted to suspend all of NetPro's business operations and immediately terminate
substantially all of its employees due to NetPro's loss of significant clients
and associated revenues. The Company has no obligation to provide additional
funding to NetPro. In connection with this action, the Company evaluated the
recoverability of this investment by comparison of its carrying value relative
to estimated future cash flows. As a result of this analysis, the Company
recorded an impairment charge to reduce the remaining investment balance to $0.
The Company's proportionate share of net loss, and impairment charge, for the
twelve months ended December 31, 2002, totaling $233, is included in equity in
losses and impairment of investments in unconsolidated affiliates in the
accompanying Statement of Operations.
INVESTMENT IN AND NOTE RECEIVABLE FROM EXCELSIOR RADIO NETWORKS
On December 4, 2001 the Company initiated a business combination whereby
the Company planned to acquire all issued and outstanding common stock of
Franklin Capital Corporation ("Franklin") in a stock-for-stock exchange. On July
1, 2002 the Company received a notice of termination from Franklin terminating
the proposed merger.
On August 28, 2001 the Company purchased a promissory note and warrant from
Excelsior Radio Networks, Inc. (d/b/a eCom Capital, Inc.) ("Excelsior") for
$2,250. Excelsior, a subsidiary of Franklin, concurrently purchased certain
assets from affiliates of Winstar Communications, Inc., which produce, syndicate
and distribute radio programs and services. Excelsior had substantially no
operations prior to this transaction.
The warrant to purchase 482,955 shares of Excelsior common stock at an
exercise price of $1.125 per share had an allocated fair value of approximately
$112 and represented 11% of Excelsior's fully diluted capital stock as of the
date of issuance. The warrant is included in other assets in the accompanying
Balance Sheet.
The allocated fair value at issuance of the note receivable, totaling
$2,138, is included in Notes Receivable in the accompanying Balance Sheet at
December 31, 2001. Also included in notes receivable is the periodic accretion
of the note discount, totaling $76, and $36 for the years ended December 31,
2002 and 2001, respectively, which is included in interest income in the
accompanying Statement of Operations. On October 1, 2002 the Company received
full payment of interest and principal on this note receivable.
On December 4, 2001 the Company purchased from Franklin 250,000 shares of
common stock or an approximate 10% equity interest of Excelsior for $250. This
investment is being accounted for under the cost method of accounting.
On April 3, 2002, the Company loaned to Excelsior an aggregate principal
amount of approximately $4,708 for the purpose of funding a portion of the
initial cash purchase price of Excelsior's acquisition of certain assets of Dial
Communications Group, LLC and Dial Communications Group, Inc. The note earns
interest at a rate of 12% per annum, matures on April 3, 2003 and is secured by
substantially all of the assets of Excelsior.
On January 15, 2003, the Company sold the 250,000 shares of Excelsior
common stock, and the Excelsior warrant to Sunshine III, LLC, a shareholder of
Excelsior, for total consideration of approximately $648 in cash.
On January 21, 2003 the Company received full prepayment of interest and
principal on the $4,708 note.
F-31
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
INVESTMENT IN LIVESKY, INC.
On December 21, 2000, the Company purchased 625,001 shares of Series A
Convertible preferred stock, representing an approximate 2% equity interest of
LiveSky Solutions, Inc. ("LiveSky") in exchange for $125. LiveSky is a developer
of wireless technology, including mobile business strategy and assessment as
well as mobile application design and development. This investment is being
accounted for under the cost method of accounting.
In June 2002, the Company received notice that the board of directors of
LiveSky had voted to liquidate LiveSky in the context of a Chapter 7 bankruptcy
case. The Company has no obligation to provide additional funding to LiveSky. In
connection with this action, the Company evaluated the recoverability of this
investment by comparison of its carrying value relative to future cash flows. As
a result of this analysis, the Company recorded an impairment charge in the
second quarter to reduce the remaining balance to $0. The impairment charge,
totaling $125 for the year ended December 31, 2002, is included in equity in
losses and impairment of investments in unconsolidated affiliates in the
accompanying Statement of Operations.
INVESTMENT IN ALACRA
On January 31, 2002, the Company purchased 38,840 shares of common stock,
representing less than 1% equity interest, of Alacra, Inc. ("Alacra") in
exchange for $78. The Company has no obligation to provide additional funding to
Alacra. Alacra provides a diverse portfolio of online and offline services that
allow users to quickly find, analyze, package and present mission-critical
business information. This investment is being accounted for under the cost
method of accounting.
(6) ACQUISITIONS AND DIVESTITURES
ACQUISITION OF EHOTHOUSE, INC.
In February 2001, the Company acquired the remaining outstanding minority
interest of its subsidiary, eHotHouse, for 2,155,519 shares of the Company's
common stock valued at $2,700 and approximately $218 in cash. The acquisition
was accounted for using the purchase method of accounting and accordingly, the
purchase price was allocated to the pro rata portion of tangible and intangible
assets acquired on the basis of their respective fair values on the date of
acquisition. Of the total purchase price, approximately $2,900 was allocated to
identified intangible assets, including the assembled workforce. The fair value
of acquired intangible assets was capitalized and was being amortized over the
estimated useful life of three years. Related amortization for the year ended
December 31, 2001 totaled $648.
Also in February 2001, the Company acquired the former Chief Executive
Officer's (of the Company and eHotHouse) shares of eHotHouse common stock in
exchange for approximately $182 in cash and 3,144,494 shares of Company common
stock. This transaction was accounted for as the settlement of a prior stock
award and, accordingly, the Company recognized $2,682 in related compensation
expense, representing the excess of the fair value of the cash and Company
shares issued as settlement over the fair value of the eHotHouse shares on the
original date of grant. Of this amount, $2,500, representing the stock portion
of the settlement, was included in equity-based compensation in the statement of
operations for the year ended December 31, 2001.
Subsequent to the acquisition of the remaining outstanding minority
interest, eHotHouse was merged with and into the Company.
In July 2001, the Board of Directors terminated the employment of the
Company's then President and Chief Executive Officer. The former executive had
an employment agreement dated August 21, 2000 that provided for severance
benefits. The Company has paid, and will continue to pay, the former executive
the
F-32
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
severance he is entitled to under his employment agreement. The related
obligation totaled $181 at December 31, 2002 and is included in accrued expenses
in the accompanying balance sheet.
Additionally, the Company recorded an impairment loss reflecting the impact
of the executive's termination upon the carrying value of certain acquired
intangible assets, and reversed certain unamortized deferred compensation
related to unvested options that were forfeited in connection with the
termination. The impairment loss reduced the remaining carrying value of the
related intangibles to $0 as of December 31, 2001.
ACQUISITION AND DIVESTITURE OF INSYS TECHNOLOGIES, INC.
On October 18, 2000, eHotHouse acquired substantially all of the operating
assets and assumed certain liabilities of InSys Technology, Inc. ("InSys"), a
provider of systems integration services. The acquisition was accounted for
using the purchase method of accounting and accordingly, the purchase price was
allocated to the tangible and identified intangible assets acquired on the basis
of their respective fair values on the date of acquisition. The results of
operations of InSys and the estimated fair value of the assets acquired and
liabilities assumed are included in the Company's consolidated financial
statements from the date of acquisition. The fair value of the intangible assets
was determined based upon a combination of methods, including the income
approach for the customer list, and the replacement cost approach for the value
of the assembled workforce.
The total purchase price of $867 consisted of cash, including acquisition
related expenses consisting primarily of payments for legal and financial
advisory services. Of the total purchase price, approximately $700 was allocated
to net tangible assets and the remainder was allocated to identify intangible
assets, including the customer list and assembled workforce. The fair value of
acquired intangible assets was capitalized and is being amortized over their
estimated useful lives of three years. Related amortization for the years ended
December 31, 2001 and 2000 totaled $39 and $11, respectively.
The InSys acquisition is summarized as follows:
Fair value of tangible assets acquired...................... $1,006
Fair value of identified intangible assets acquired......... 155
Liabilities assumed......................................... (294)
------
Cash paid, including acquisition costs of $200.............. $ 867
======
Less cash acquired.......................................... --
Total transaction consideration............................. $ 867
======
During the year ended December 31, 2001, as a result of the aforementioned
terminations, coupled with the historical, current and projected operating and
cash flow losses, the Company evaluated the recoverability of its acquired
intangible assets by comparison of the carrying value relative to future cash
flows. As a result, the Company recorded impairment charges totaling $105, which
reduced the remaining carrying value of the related intangibles to $0 as of
December 31, 2001.
On November 8, 2001 the Company sold a 51% voting interest in InSys to a
certain member of the management team in exchange for $50 and concurrently
forgave approximately $400 of advances to InSys. After considering the net book
value of InSys, the level of retained ownership interest, and the value of the
consideration exchanged, the Company incurred a loss on the disposition of the
majority voting control totaling $183 which is included in loss on disposal of
subsidiaries in the accompanying Statement of Operations.
F-33
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Concurrently, the Company loaned InSys $100 evidenced by a promissory note.
The note bears interest at a rate equal to the London Interbank Offer Rate plus
2%, until the principal amount of the note is paid in full. InSys is obligated
to pay, at a minimum, on an annual basis 50% of the excess of its annual
earnings before taxes. Such amount totaled $0 for the year ended December 31,
2002.
The Company's retained equity interest and note receivable, net of the
Company's pro rata share of InSys' equity losses absorbed during the period from
November 8, 2001 to December 31, 2002, totals $121 and is included in
investments in and loans to unconsolidated subsidiaries on the accompanying
Balance Sheet. The Company's pro rata share of InSys' net loss for the year
ended December 31, 2002 and for the period from November 8, 2001 to December 31,
2001 totaled $191 and $11, respectively. This amount is included in equity in
losses and impairment of investments in unconsolidated affiliates in the
accompanying Statement of Operations.
Condensed financial information for InSys is summarized as follows
(unaudited).
INSYS
-----------------
DECEMBER 31, 2002
-----------------
Current assets.............................................. $ 311
Non-current assets.......................................... 153
Current liabilities......................................... (121)
Non-current liabilities..................................... (100)
-------
Total stockholders' capital (deficit)....................... $ 243
Other stockholders' share of capital........................ 124
-------
Company's share of capital.................................. $ 119
-------
Carrying value of investment................................ $ 121
-------
Operating revenues.......................................... $ 2,174
Cost of revenues............................................ (1,733)
Operating expenses.......................................... (827)
Other income(expense), net.................................. (3)
-------
Net loss.................................................. (389)
Other stockholders' share of net loss....................... (198)
-------
Equity in losses of affiliate............................... (191)
ACQUISITION AND DIVESTITURE OF RAND INTERACTIVE CORPORATION
On November 30, 2000, eHotHouse acquired all of the issued and outstanding
common stock of RAND Interactive Corporation ("RAND"), a leading provider of
media and technical services. The acquisition was accounted for using the
purchase method of accounting and, accordingly, the total consideration was
allocated to the tangible and intangible net assets acquired and liabilities
assumed on the basis of their respective fair values on the date of acquisition.
The results of operations of RAND and the estimated fair value of the assets
acquired and liabilities assumed are included in the Company's consolidated
financial statements from the date of acquisition.
The total purchase price of approximately $1,400 consisted of $700 of
eHotHouse common stock (1,020,000 shares), $700 in cash including other
acquisition related expenses, consisting primarily of payments for legal and
financial advisory services. Of the total purchase price, $47 was allocated to
net tangible liabilities assumed, and the remainder was allocated to identify
intangible assets, including customer lists and the
F-34
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
assembled workforce. The fair value of the identified intangible assets was
determined using the income approach for the customer list, and the replacement
cost approach for the value of the assembled workforce. The purchased intangible
assets are being amortized over their estimated useful lives of three years.
Related amortization for the years ended December 31, 2001 and 2000 totaled $357
and $39, respectively.
The RAND acquisition is summarized as follows:
Fair value of tangible assets acquired...................... $ 169
Fair value of identified intangible assets acquired......... 1,426
Liabilities assumed......................................... (216)
------
$1,379
======
Cash paid, including acquisition costs of $325.............. $ 675
Less cash acquired.......................................... --
Net cash paid............................................. 675
eHotHouse common stock issued............................... 704
------
Total transaction consideration........................... $1,379
======
As a result of the aforementioned terminations during 2001, coupled with
the historical and projected operating and cash flow losses, the Company
evaluated the recoverability of its acquired intangible assets by comparison of
the carrying value relative to future cash flows. As a result, the Company
recorded impairment charges totaling $1,030, which are included in impairment
charges in the accompanying Statement of Operations for the year ended December
31, 2001.
On November 2, 2001 the Company sold all issued and outstanding shares of
RAND to certain members of management in exchange for 375,039 shares of the
Company's common stock, and a warrant to purchase such amount of shares of
common stock that shall equal, at the time of exercise, 30% of the issued and
outstanding shares of RAND common stock on a fully diluted basis. Such warrant
has a stated exercise price of $1.00 in the aggregate, expires on November 3,
2013, and is contingently exercisable upon the occurrence of certain prospective
events, as defined. After considering the net book value of RAND, the
consideration received and the fair value of the warrants received, the Company
incurred a loss on the disposition of RAND totaling $194 which is included in
loss on disposal of subsidiaries on the consolidated Statement of Operations for
the year ended December 31, 2001.
ACQUISITION OF IGUANA STUDIOS, INC.
In March 2001, the Company acquired Iguana Studios, Inc. ("Iguana"), a New
York City-based interactive agency, for approximately $5,771, including $2,786
in cash, 2,700,000 shares of the Company's common stock valued at approximately
$1,990, and replacement options to purchase 1,681,888 shares of Company common
stock, which vested upon the change in control, valued at approximately $995.
The business combination was accounted for using the purchase method of
accounting and, accordingly, the total consideration was allocated to the
tangible and intangible assets acquired and liabilities assumed on the basis of
their respective fair values on the date of acquisition. The results of
operations of Iguana, and the estimated fair value of the assets acquired and
liabilities assumed are included in the Company's consolidated financial
statements from the date of acquisition. Of the total purchase price,
approximately $1,815 was allocated to the net tangible assets acquired, $1,300
was allocated to identify intangible assets, including customer base and
assembled workforce, and the remainder was allocated to goodwill. The fair value
of the identified intangible assets was determined using the income approach for
the customer base, and the
F-35
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
replacement cost approach for the assembled workforce. The purchased intangible
assets and goodwill were being amortized over their estimated useful lives of
three years. Related amortization for the year ended December 31, 2001 totaled
$935.
The Iguana acquisition is summarized as follows:
Fair value of tangible assets acquired...................... $1,815
Fair value of identified intangible assets acquired......... 4,813
Liabilities assumed......................................... (857)
------
$5,771
======
Cash paid, including acquisition costs of $238.............. $2,817
Less cash acquired.......................................... 31
Net cash paid............................................. 2,786
Common stock of the Company issued.......................... 1,990
Replacement Options....................................... 995
------
$5,771
======
As a result of the aforementioned terminations, coupled with the historical
cash flow losses, the Company evaluated the recoverability of its acquired
intangible assets and goodwill by comparison of the carrying value relative to
future cash flows. As a result, the Company recorded impairment charges totaling
$3,878, which reduced the remaining carrying value of the related intangibles to
$0 as of December 31, 2001.
Also in connection with the acquisition of Iguana, 2,300,000 shares of the
Company's common stock were placed in escrow (the "Escrow Shares"). The related
contingency period expired in July 2002, at which time the fair value of such
shares was included in the aggregate purchase price. As of December 31, 2001 all
employees of Iguana had been terminated, and the subsidiary's operating
activities had ceased. The remaining net book value of Iguana intangibles was
$0. Accordingly, the Company has recorded additional impairment charges totaling
$69 representing the fair value of such shares. This amount is included in
Impairment Losses in the accompanying Statement of Operations for the year ended
December 31, 2002.
ACQUISITION OF PAPKE-TEXTOR, INC.
In June 2001, the Company acquired Papke-Textor, Inc. d/b/a Canned
Interactive ("Canned"), a Los Angeles-based media and entertainment interactive
agency, for approximately $1,137 in cash, including acquisition costs, and
6,436,552 shares of the Company's common stock valued at approximately $953.
The business combination was accounted for using the purchase method of
accounting and, accordingly, the total consideration was allocated to the
tangible and intangible assets acquired and liabilities assumed on the basis of
their respective fair values on the date of acquisition. The results of
operations of Canned, and the estimated fair value of the assets acquired and
liabilities assumed are included in the Company's consolidated financial
statements from the date of acquisition. Of the total purchase price,
approximately $104 was allocated to the net tangible liabilities assumed, $2,177
was allocated to identified intangible assets, primarily assembled workforce,
and to goodwill. The fair value of the identified intangible assets was
determined using the replacement cost approach for the assembled workforce. The
purchased intangible assets and goodwill were being amortized over their
estimated useful lives of three years. On January 1, 2002, in connection with
the Company's adoption of SFAS 142, the value ascribed to the acquired workforce
was subsumed into goodwill, and amortization of these assets ceased. The
remaining unamortized amount, totaling $1,568 at December 31, 2002 is included
in goodwill in the accompanying balance sheet.
F-36
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The Canned acquisition is summarized as follows:
Fair value of tangible assets acquired...................... $ 329
Fair value of identified intangible assets acquired......... 2,177
Liabilities assumed......................................... (433)
------
$2,073
======
Cash paid, including acquisition costs of $250.............. $1,137
Less cash acquired.......................................... 17
------
Net cash paid............................................. 1,120
Common stock of the Company issued........................ 953
------
$2,073
======
Also in connection with the acquisition of Canned, $200 in cash and 715,172
shares of the Company's common stock were placed in escrow (the "Escrow
Shares"). The related contingency period expired in December 2002, at which time
the cash and the then fair value of the shares, totaling $214, was included in
the aggregate purchase price.
(7) NOTE RECEIVABLE
In April 2001, the Company loaned two consultants an aggregate of $500. The
full recourse promissory notes, with initial principal amounts of $350 and $150,
respectively, accrue interest at the rate of 7.25% per annum. Payments are due
in various installments of principal plus accrued interest commencing on April
25, 2002 and continuing annually thereafter through April 25, 2006. In April
2002, the Company received the first such installment, totaling $61.
(8) COMMITMENTS AND CONTINGENCIES
OPERATING LEASES
The Company leases its facilities and equipment under operating and capital
lease agreements. The following are the future minimum lease payments under
non-cancelable operating leases as of December 31, 2002:
YEAR ENDED DECEMBER 31, OPERATING CAPITAL
----------------------- --------- -------
2003........................................................ $ 850 $ 114
2004........................................................ 184 31
2005........................................................ 46 4
2006........................................................ -- --
2007........................................................ -- --
------ -----
$1,080 $ 149
------ -----
Total lease obligation
Amount representing interest................................ (0)
-----
149
Current Portion............................................. (114)
-----
Long Term Portion........................................... $ 35
=====
F-37
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Total minimum lease payments have not been reduced for future minimum
sublease rentals totaling approximately $342.
As a result of the company's divestiture of certain operations, employee
terminations and terminated business combination, the Company has evaluated its
alternatives with respects to its contractual obligations concerning leased
facilities. As of June 30, 2002, the Company determined that certain facilities
have no substantive future use of benefit to the Company. The Company accrued
the remaining costs, net of sublease income, relating to these leases in the
second quarter. At December 31, 2002, $738 of this amount remained.
Rent expense was approximately $1,183 and $963 for the years ended December
31, 2002 and 2001, respectively.
LEGAL PROCEEDINGS
The Company is involved in various legal actions arising in the ordinary
course of business. In the opinion of management, the ultimate disposition of
these matters will not have a material adverse effect on the Company's
consolidated financial position, results of operation or liquidity.
(9) STOCKHOLDERS' EQUITY
On March 28, 2000, Arinco Computer Systems Inc. (the predecessor to the
Company, see September 12, 2000 transaction below) was acquired by an investor
group led by Pangea Internet Advisors, LLC. Prior to this transaction, neither
Arinco Computer Systems Inc., a public shell, or Pangea Internet Advisors, LLC
were active or had substantive business operations. Investors purchased
4,000,000 shares of Series B Convertible Preferred Stock ("Series B Stock") for
net proceeds to the Company of $39,450. Each share of Series B stock is
convertible into 40 common shares, and the Series B Stock, collectively,
represents approximately 97% of the voting interest of the Company. If by
December 31, 2000 the Company's authorized common stock had not been increased
to provide for the conversion of all Series B Stock, holders of 50% of the
Series B stock could require the Company to redeem all such Series B Stock at
$10 per share on demand. Accordingly, Series B Stock was classified as temporary
equity until shareholder approval was obtained to sufficiently increase the
number of authorized common shares. However, as the Series B shareholders
effectively controlled the Company, shareholder approval was perfunctory and,
accordingly, the full deemed dividend was recognized immediately.
Also on March 28, 2000, certain other investors purchased warrants
("warrants") to purchase 41,250,000 shares of common stock for $100. Of these
warrants, 20% have an exercise price of $.25 per share, 30% have an exercise
price of $.50 per share, 30% have an exercise price of $.75 per share and 20%
have an exercise price of $1.00 per share. The warrants are exercisable at the
election of the holder for a period of five years.
In April, 2002 the Company cancelled 15,468,748 of these outstanding
warrants to purchase common stock, with a weighted average exercise price of
$0.85, in exchange for no consideration.
The difference between the price of the Series B Stock on an as converted
basis of $0.25 and $4.88 (the fair value of common stock on the date of issuance
of the Series B Stock), or $4.63, multiplied by the number of shares of Series B
Stock on an as if converted basis, represents the intrinsic value of the
beneficial conversion feature, which totaled approximately $741,000. However, as
the intrinsic value of the beneficial conversion feature is greater than the
$40,000 in gross proceeds received from the Series B Stock issuance, the amount
of the discount attributed to the beneficial conversion feature is limited to
the $40,000 of gross proceeds received. The beneficial conversion feature was
recorded in the quarter ended March 31, 2000 as a non-cash preferred stock
dividend because the Series B Stock is effectively convertible at the option of
the preferred stockholders. The $40,000 non-cash dividend increased the
Company's net loss attributable to common stockholders by the same amount.
F-38
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
On March 28, 2000, 1,000,000 shares of Series B Stock were converted into
40,000,000 shares of common stock.
On September 12, 2000, Arinco Computer Systems Inc. merged with and into
the Company (d/b/a Pangea Internet, Inc.), a wholly owned subsidiary. All
shareholders of Arinco Computer Systems Inc. became stockholders of the Company.
Pursuant to the terms of the merger agreement, each outstanding share of Arinco
Computer Systems Inc. common stock, Series A preferred stock and Series B
preferred stock and warrants was converted into one share of common stock,
Series A preferred stock, and Series B preferred stock and warrants,
respectively, of the Company. As a result of the merger, the total number of
shares of stock which the Company has authority to issue was increased to
505,000,000 shares, of which 500,000,000 are common stock, par value $0.01 per
share and 5,000,000 are preferred stock, par value $0.10 per share. This
transaction was accounted for as a transaction between companies under common
control and therefore there was no adjustment to the historical basis of the
assets and liabilities of Arinco Computer Systems Inc. Additionally, as a result
of this transaction and the resulting increase in the number of authorized
shares of common stock, the redemption feature on the Series B preferred shares
was nullified and, accordingly, the Series B Preferred Stock was reclassified to
stockholders equity.
In 2002, the Company purchased an aggregate of 33,588 shares of the
Company's common stock from certain stockholders in exchange for an amount which
approximated fair value.
The Company's Series A and Series B Preferred stock are convertible to
common stock on a 1 for 1 and 40 for 1 basis respectively, and have voting
rights on an as if converted basis. Series A Preferred stock accumulates $0.06
per share cumulative dividends annually, payable each May 31st at the discretion
of the Board of Directors. Series A Preferred stockholders are not entitled to
payment of any accrued but unpaid dividends existing at the time of a voluntary
conversion of such stock to common stock.
(10) EQUITY BASED COMPENSATION
Under the terms of the Company's incentive stock option plans, employees,
directors, and consultants may be granted options to purchase the Company's
common stock at no less than 100% of the market price on the date the option is
granted (110% of fair market value for incentive stock options granted to
holders of more than 10% of the voting stock of the Company). Options generally
vest over three or four years and have a maximum term of 10 years.
F-39
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Information related to all CTPI stock options granted by the Company is as
follows:
WEIGHTED
NUMBER OF AVERAGE
SHARES EXERCISE PRICE
---------- --------------
December 31, 1999........................................... -- --
Granted................................................... 4,600,000 $1.21
---------- =====
December 31, 2000........................................... 4,600,000 $1.21
---------- =====
Granted................................................... 14,200,000 0.04
Exercised................................................. -- --
Options issued in connection with acquisition of Iguana... 1,658,638 1.05
Forfeited/Cancelled....................................... (4,324,870) 1.45
---------- -----
December 31, 2001........................................... 16,133,768 $0.10
---------- =====
Granted................................................... -- --
Exercised................................................. -- --
Forfeited/Cancelled....................................... (1,548,021) .19
---------- -----
December 31, 2002........................................... 14,585,747 $ .08
---------- =====
The following table summarizes information about CTPI stock options
outstanding at December 31, 2002:
OPTIONS OUTSTANDING
------------------------------------------------------- OPTIONS EXERCISABLE
WEIGHTED AVERAGE -------------------------------------
EXERCISE OUTSTANDING AT CONTRACTUAL LIFE WEIGHTED AVERAGE WEIGHTED AVERAGE
PRICES DECEMBER 31, 2002 REMAINING EXERCISE PRICE NUMBER EXERCISABLE EXERCISE PRICE
-------- ----------------- ---------------- ---------------- ------------------ ----------------
0.03... 12,000,000 8.71 0.03 5,250,000 0.03
0.06... 700,000 8.83 0.06 700,000 0.06
0.29... 540,747 1.43 0.29 540,747 0.29
0.32... 15,000 8.00 0.32 15,000 0.32
0.41... 15,000 7.83 0.41 15,000 0.41
0.50... 1,300,000 7.75 0.50 1,148,732 0.50
0.67... 15,000 1.85 0.67 15,000 0.67
---------- ----- --------- -----
TOTAL.. 14,585,747 $ .08 7,684,479 $ .12
---------- ===== --------- =====
During 2000, the Company granted stock options to purchase 4,600,000 shares
of common stock to the former Chief Executive Officer and members of the Board
of Directors at a weighted average exercise price of $1.21, all of which were
granted at less than the fair value of the common stock on the measurement date.
The Company recorded deferred compensation of approximately $2,480 in connection
with the grant of these options. This amount is presented as deferred
compensation within the accompanying balance sheet and is being amortized over
the related vesting period, of either three or four years. In 2001, in
connection with the termination of the former Chief Executive Officer, and in
2002, in connection with the voluntary departure of a member of the board of
directors, the Company reversed certain of this unamortized deferred
compensation related to unvested options forfeited as a result of the
departures. The Company amortized $377, $615 and $693 of deferred compensation
during the years ended December 31, 2002, 2001 and 2000, respectively. The
F-40
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Company will amortize the remaining deferred compensation of $268 over the
remaining vesting period of 21 months.
In September 2001, the Compensation Committee of the Board of Directors,
granted to the newly appointed Chief Executive Officer options to purchase
9,000,000 shares of the Company's common stock at an exercise price of $0.03 per
share, the then fair value of the underlying common stock. Of this grant,
options to purchase 6,000,000 shares of the Company's common stock were subject
to shareholder approval, which was obtained in August 2002 when the fair value
of the underlying stock was $0.02 per share.
During the year ended December 31, 2001, the Compensation Committee of the
Board of Directors granted to certain members of the Board of Directors options
to purchase an aggregate of 3,000,000 and 200,000 shares of the Company's common
stock at an exercise price of $0.03 and $0.50 per share, respectively, the then
fair value of the underlying common stock.
On November 7, 2001, the Compensation Committee of the Board of Directors
granted to a new member of the Board of Directors options to purchase an
aggregate of 2,000,000 shares of the Company's common stock at an exercise price
of $0.06 per share, the then fair value of the underlying common stock. However,
in connection with such new member of the Board of Directors' resignation on
December 31, 2002, he surrendered options to purchase 1,300,000 shares of the
Company's common stock. He retained options to purchase the remaining 700,000
shares of the Company's common stock.
(11) RELATED PARTY TRANSACTIONS
During the year ended December 31, 2002, the Company incurred legal fees in
connection with certain transactions and other matters in the normal course of
business. A portion of these services was provided by a firm of which a member
of the Board of Directors of the Company is a partner. Fees incurred by this
firm totaled approximately $387 and $881 for the years ended December 31, 2002
and 2001, respectively.
Additionally, during the year ended December 31, 2002, the Company incurred
management and investment advisory service fees in connection with identifying,
evaluating, negotiating, and managing investment opportunities for the Company.
These services were provided by a firm of which the current President and Chief
Executive Officer of the Company was previously affiliated. Fees incurred by the
Company to this firm totaled $135 and $510 in the years ended December 31, 2002
and 2001, respectively. Additionally, this firm occupies a portion of the
Company's office space in Connecticut, for which it pays rent at an amount,
which approximates fair market value. Such payments to the Company totaled $230
and $283 during the years ended December 31, 2002 and 2001, respectively.
Furthermore, the firm was indebted to the Company in the amount of $194 at
December 31, 2002, for its pro rata share of certain leasehold improvements and
rental payments due, which are reflected in the Related Party Receivable in the
accompanying Balance Sheet. As of December 31, 2002, the Company is no longer
utilizing this firm to perform any services for the Company.
F-41
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(12) PROPERTY & EQUIPMENT
Property and equipment consist of the following:
DECEMBER 31,
---------------
2002 2001
------ ------
Computer and office equipment............................... $ 735 $ 660
Furniture and fixtures...................................... 362 364
Leasehold improvements...................................... 245 245
------ ------
Total property and equipment................................ 1,342 1,269
Less accumulated depreciation and amortization.............. 906 483
------ ------
Property and equipment, net................................. $ 436 $ 786
====== ======
At December 31, 2002 and 2001, the Company had approximately $332 and $220,
respectively, of equipment under capital leases included in computer and office
equipment and related accumulated amortization of approximately $288 and $120,
respectively. Amortization of these assets recorded under capital leases is
included in depreciation expense.
Depreciation and amortization aggregated $423, $609 and $10 for the years
ended December 31, 2002, 2001 and 2000, respectively.
(13) ACCRUED EXPENSES
Accrued expenses consist of the following:
DECEMBER 31,
-------------
2002 2001
----- -----
Accrued severance........................................... $181 $431
Accrued professional fees................................... 150 535
Accrued NY office leases.................................... 244 --
Accrued employee payroll & benefits......................... 204 --
Accrued other............................................... 6 17
---- ----
Total....................................................... $785 $983
==== ====
F-42
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(14) INCOME TAXES
The tax effects of temporary differences that give rise to a significant
portion of the net deferred income tax assets (liabilities) are as follows:
DECEMBER 31,
-------------------
2002 2001
-------- --------
Net deferred income tax assets (liabilities):
Equity losses............................................... $ 3,064 $ 2,844
Equity based compensation................................... 692 541
Net operating loss.......................................... 8,783 8,024
Property and equipment...................................... (6) 40
Intangibles................................................. (627) (715)
Other....................................................... 28 --
-------- --------
Total net deferred income tax assets........................ 11,934 10,734
Valuation allowance......................................... (11,934) (10,734)
-------- --------
Total net deferred income tax assets........................ $ -- $ --
======== ========
The benefit for income taxes differed from the amounts computed by applying
the federal income tax rate of 35% to pretax losses as a result of the
following:
RATE RECONCILIATION
----------------------------------------------------
2002 2001 2000
--------------- ---------------- ---------------
$ % $ % $ %
------- ----- -------- ----- ------- -----
Expected tax benefit............. (1,190) 35.00% (11,165) 35.00% (2,121) 34.00%
State and local tax benefit...... (119) 3.39% (1,037) 3.25% (364) 6.00%
Non-deductible expenses.......... 20 0.57% 3,023 9.48% -- --
Valuation allowance.............. 1,200 34.28% 8,689 27.24% 1,881 29.90%
Other............................ 89 2.53% 490 1.54% 604 10.10%
------- ----- -------- ----- ------- -----
Tax Expense...................... $ -- 0.00% $ -- 0.00% $ -- 0.00%
======= ----- ======== ----- ======= -----
The Company has available estimated net operating loss carry forwards for
income tax purposes of approximately $22,000 which expire on various dates from
2002 through 2022. A valuation allowance has been established due to uncertainty
as to whether the Company will generate sufficient taxable earnings to utilize
the available net operating loss carry forwards. A portion of the Company's net
operating loss carry forwards may also be limited due to significant changes in
ownership under Section 382 of the Tax Reform Act of 1986.
(15) SUPPLEMENTARY CASH FLOW INFORMATION
During the years ended December 31, 2002, 2001 and 2000, the Company paid
interest of $15, $30 and $1, respectively.
F-43
CHANGE TECHNOLOGY PARTNERS, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(16) VALUATION AND QUALIFYING ACCOUNTS
ADDITIONS ADDITIONS DELETIONS
BALANCE AT CHARGED TO INCLUDED IN INCLUDED BALANCE
BEGINNING COSTS AND ACQUIRED IN AT END
DESCRIPTION OF PERIOD EXPENSED NET ASSETS DISPOSALS OF PERIOD
----------- ---------- ---------- ----------- --------- ---------
2002:
Allowances for doubtful accounts.......... $-- $ -- $ -- $ -- $--
2001:
Allowances for doubtful accounts.......... $62 $ -- $197 $(259) $--
2000:
Allowances for doubtful accounts.......... $-- $ -- $ 62 $ -- $62
F-44
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
CONDENSED BALANCE SHEET
SEPTEMBER 30, 2003 (UNAUDITED) AND DECEMBER 31, 2002
SEPTEMBER 30, DECEMBER 31,
2003 2002
------------- ------------
ASSETS
Current assets -- cash and cash equivalents................. $ 886,593 $ 1,635,761
Equipment, less accumulated depreciation of $104,523 and
$51,953................................................... 173,060 113,516
Intangible assets, less accumulated amortization of $35,795
and $21,682............................................... 316,491 184,644
------------- ------------
Total....................................................... $ 1,376,144 $ 1,933,921
============= ============
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
Current liabilities:
Note payable.............................................. $ 750,000
Accrued expenses.......................................... 59,000 $ 85,000
Current portion of capital lease obligations.............. 20,535
------------- ------------
Total current liabilities.............................. 829,535 85,000
Note payable to related parties............................. 2,328,248 2,238,251
Capital lease obligations, net of current portion........... 10,831
------------- ------------
Total liabilities.................................... 3,168,614 2,323,251
------------- ------------
Commitments and contingencies:
Mandatorily redeemable convertible preferred stock, $.001
par value; 147 shares designated, issued and
outstanding............................................ 500,000 500,000
------------- ------------
Stockholders' deficiency:
Series B convertible preferred stock, $.001 par value;
562,500 shares designated, 490,754 shares issued and
outstanding............................................ 491 491
Common stock, $.001 par value; 20,000,000 shares
authorized; 2,490,583 and 2,390,583 shares issued and
outstanding............................................ 2,491 2,391
Additional paid-in capital................................ 3,655,904 3,224,004
Unearned compensation..................................... (815,969) (553,033)
Deficit accumulated during the development stage.......... (5,135,387) (3,563,183)
------------- ------------
Total stockholders' deficiency......................... (2,292,470) (889,330)
------------- ------------
Total................................................ $ 1,376,144 $ 1,933,921
============= ============
See Notes to Unaudited Condensed Financial Statements.
F-45
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
CONDENSED STATEMENTS OF OPERATIONS
NINE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002 (UNAUDITED)
AND PERIOD FROM FEBRUARY 12, 1999 (DATE OF INCEPTION)
THROUGH SEPTEMBER 30, 2003 (UNAUDITED)
NINE MONTHS ENDED
SEPTEMBER 30,
------------------------
2003 2002 CUMULATIVE
----------- ---------- -----------
Operating expenses:
Research and licensing.................................. $ 730,388 $ 329,285 $ 2,330,908
Scientific consulting................................... 220,084 196,545 972,600
Administrative expenses................................. 540,027 248,665 1,537,303
----------- ---------- -----------
Loss from operations...................................... (1,490,499) (774,495) (4,840,811)
----------- ---------- -----------
Other income (expenses):
Dividend income......................................... 662 -- 11,284
Interest income primarily to related parties............ 13,055 -- 27,853
Interest expense........................................ (95,422) (88,097) (333,713)
----------- ---------- -----------
Totals............................................... (81,705) (88,097) (294,576)
----------- ---------- -----------
Net loss.................................................. $(1,572,204) $ (862,592) $(5,135,387)
=========== ========== ===========
Basic and diluted net loss per share...................... $ (.63) $ (.38)
=========== ==========
Weighted average common shares outstanding, basic and
diluted................................................. 2,490,583 2,269,000
=========== ==========
See Notes to Unaudited Condensed Financial Statements.
F-46
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIENCY
NINE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002 (UNAUDITED) AND
PERIOD FROM FEBRUARY 12, 1999 (DATE OF INCEPTION) THROUGH
SEPTEMBER 30, 2003
(UNAUDITED)
SERIES B DEFICIT
CONVERTIBLE ACCUMULATED
PREFERRED STOCK COMMON STOCK ADDITIONAL DURING THE
---------------- ------------------ PAID-IN UNEARNED DEVELOPMENT
SHARES AMOUNT SHARES AMOUNT CAPITAL COMPENSATION STAGE TOTAL
------- ------ --------- ------ ---------- ------------ ----------- -----------
Sale of common stock to founders
at $.002 per share.............. 2,175,000 $2,175 $ 2,235 $ 4,410
Net loss.......................... $ (328,347) (328,347)
------- ---- --------- ------ ---------- --------- ----------- -----------
Balance, December 31, 1999........ 2,175,000 2,175 2,235 (328,347) (323,937)
Net loss.......................... (1,054,579) (1,054,579)
------- ---- --------- ------ ---------- --------- ----------- -----------
Balance, December 31, 2000........ 2,175,000 2,175 2,235 (1,382,926) (1,378,516)
Stock options granted for
services........................ 9,000 9,000
Common stock issued for intangible
assets at $.25 per share........ 94,000 94 23,406 23,500
Net loss.......................... (870,626) (870,626)
------- ---- --------- ------ ---------- --------- ----------- -----------
Balance, December 31, 2001........ 2,269,000 2,269 34,641 (2,253,552) (2,216,642)
Retirement of founder shares...... (12,000) (12) 12
Common stock issued pursuant to
license agreement at $4.32 per
share........................... 133,583 134 576,944 $(577,078)
Private placement of Series B
preferred stock, net of expenses
of $37,102 at $5.40 per share... 490,754 $491 2,612,407 2,612,898
Amortization of unearned
compensation.................... 24,045 24,045
Net loss.......................... (1,309,631) (1,309,631)
------- ---- --------- ------ ---------- --------- ----------- -----------
Balance, December 31, 2002........ 490,754 491 2,390,583 2,391 3,224,004 (553,033) (3,563,183) (889,330)
Sale of common stock.............. 100,000 100 431,900 (431,000) 1,000
Amortization of unearned
compensation.................... 168,064 168,064
Net loss.......................... (1,572,204) (1,572,204)
------- ---- --------- ------ ---------- --------- ----------- -----------
Balance, September 30, 2003....... 490,754 $491 2,490,583 $2,491 $3,655,904 $(815,969) $(5,135,387) $(2,292,470)
======= ==== ========= ====== ========== ========= =========== ===========
See Notes to Unaudited Condensed Financial Statements.
F-47
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
CONDENSED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002 (UNAUDITED) AND
PERIOD FROM FEBRUARY 12, 1999 (DATE OF INCEPTION) THROUGH SEPTEMBER 30, 2003
NINE MONTHS ENDED
SEPTEMBER 30,
------------------------
2003 2002 CUMULATIVE
----------- ---------- -----------
Operating activities:
Net loss............................................. $(1,572,204) $ (862,592) $(5,135,387)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation...................................... 52,570 5,712 104,523
Amortization...................................... 14,171 8,844 35,853
Stock options granted for services................ 9,000
Amortization of unearned compensation............. 168,064 192,109
Noncash interest.................................. 89,997 88,097 332,288
Changes in operating assets and
liabilities -- accrued expenses................. (26,000) (54,985) 55,000
----------- ---------- -----------
Net cash used in operating activities........... (1,273,402) (814,924) (4,406,614)
----------- ---------- -----------
Investing activities:
Purchases of equipment............................... (70,994) (83,638) (236,463)
Purchases of intangible assets....................... (146,018) (33,264) (328,844)
----------- ---------- -----------
Net cash used in investing activities........... (217,012) (116,902) (565,307)
----------- ---------- -----------
Financing activities:
Proceeds from note payable........................... 750,000 750,000
Borrowings from related party........................ 195,000 1,999,960
Payments of capital lease obligation................. (9,754) (9,754)
Proceeds from issuance of common stock............... 1,000 5,410
Proceeds from issuance of preferred stock............ 2,612,898 3,112,898
----------- ---------- -----------
Net cash provided by (used in) financing
activities................................... 741,246 2,807,898 5,858,514
----------- ---------- -----------
Net increase (decrease) in cash and cash equivalents... (749,168) 1,876,072 886,593
Cash and cash equivalents, beginning of period......... 1,635,761 118,328 --
----------- ---------- -----------
Cash and cash equivalents, end of period............... $ 886,593 $1,994,440 $ 886,593
=========== ========== ===========
Supplemental disclosure of noncash investing and
financing activities -- common stock issued for
intangible assets.................................... $ 23,500
===========
See Notes to Unaudited Condensed Financial Statements.
F-48
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
NOTE 1 -- BASIS OF PRESENTATION:
In the opinion of management, the accompanying unaudited condensed
financial statements reflect all adjustments, consisting of normal recurring
accruals, necessary to present fairly the financial position of the Company as
of September 30, 2003, its results of operations and cash flows for the nine
months ended September 30, 2003 and 2002 and for the period from February 12,
1999 (date of inception) through September 30, 2003, and their changes in
stockholders' equity (deficiency) for the nine months ended September 30, 2003
and for the period from February 12, 1999 (date of inception) through September
30, 2003. Pursuant to the rules and regulations of the Securities and Exchange
Commission (the "SEC"), certain information and disclosures normally included in
financial statements prepared in accordance with accounting principles generally
accepted in the United States of America have been condensed or omitted from
these financial statements unless significant changes have taken place since the
end of the most recent fiscal year. Accordingly, these condensed financial
statements should be read in conjunction with the financial statements, notes to
financial statements and the other information in the audited financial
statements of the Company as of December 31, 2002 and for the years ended
December 31, 2002, 2001 and 2000 and for the period from February 12, 1999 (date
of inception) through December 31, 2002 (the "Audited Financial Statements")
also included in the Prospectus of this Registration Statement.
The accompanying unaudited condensed financial statements have been
prepared assuming that the Company will continue as a going concern. The Company
is in the development stage and has not generated any revenue as of September
30, 2003. As a result, the Company incurred cumulative net losses of
approximately $5,135,000 and cumulative negative cash flows from operating
activities of $4,407,000 during the period from February 12, 1999 (date of
inception) through September 30, 2003. In addition, management believes that the
Company will continue to incur net losses and cash flow deficiencies through at
least September 30, 2004. These matters raise substantial doubt about the
Company's ability to continue as a going concern.
The Company's existing resources will not be sufficient to support the
commercial introduction of any of its product candidates. The Company will need
to raise additional funds through public or private equity offerings, debt
financings or additional corporate collaboration and licensing arrangements. The
Company does not know whether additional financing will be available when
needed, or on terms favorable to it or its stockholders.
To enable the Company to sustain its operations through at least September
30, 2004, and, ultimately complete its marketing and development program and
achieve profitability, management plans to seek additional financing for the
Company through the sale of debt and equity securities.
As discussed in Notes 2 and 8 to the Audited Financial Statements, on
August 13, 2003 the Company entered into the merger agreement with Change. As of
September 30, 2003, Change's assets consisted primarily of approximately
$6,000,000 in cash and cash equivalents. Management believes the merger with
Change will enable the Company to conduct the Phase I clinical trial of gene
therapy that it has developed for the treatment of Parkinson's disease and to
continue the development of innovative therapies for the treatment of other
degenerative neurological disorders.
The accompanying unaudited condensed financial statements do not include
any adjustments related to the recoverability and classification of assets or
amounts and classification of liabilities that might be necessary should the
Company be unable to continue its operations as a going concern.
NOTE 2 -- CAPITAL LEASE OBLIGATIONS:
During the nine months ended September 30, 2003, the Company acquired
equipment with a capitalized cost of $41,130 pursuant to a capital lease
obligation. The acquisition of such equipment was a noncash
F-49
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS -- (CONTINUED)
transaction and, accordingly, is not reflected in the accompanying unaudited
condensed statement of cash flows for the nine months ended September 30, 2003
and for the period from February 12, 1999 (date of inception) to September 30,
2003.
Future minimum lease payments under capital leases in each of the years
subsequent to September 30, 2003 are as follows:
YEAR ENDING SEPTEMBER 30, AMOUNT
------------------------- -------
2004........................................................ $22,245
2005........................................................ 11,066
-------
Total minimum lease payments................................ 33,311
Less amount representing interest........................... 1,945
-------
Present value of net minimum lease payments................. 31,366
Less current portion........................................ 20,535
-------
Long-term portion........................................... $10,831
=======
NOTE 3 -- CONSULTING AGREEMENT:
In May 2003, the Company entered into a stock purchase agreement to sell
100,000 shares of common stock at a purchase price of $.10 per share to an
individual. At the time of such agreement, the fair value per share of common
stock based on a prior transaction was deemed to be $4.32 per share. The reduced
purchase price was provided to the individual as an enticement for the
individual to serve as the Chairman of the Company's Advisory Board.
Accordingly, the fair value of the shares of approximately $431,000, based on
the difference between the purchase price of $.10 per share and the fair value
per share of $4.32, will be recognized as an advisory board fee over the vesting
period of the shares of three years.
In addition, on July 1, 2003, the Company entered into a consulting
agreement with the individual to serve as the Chairman of its Advisory Board for
a three year term. Pursuant to the terms of the agreement, the individual is to
receive compensation of $25,000 annually, payable in quarterly installments.
NOTE 4 -- MERGER AGREEMENT
On August 13, 2003, the Company entered into the merger agreement with
Change. Under the merger agreement, Subcorp will merge with and into Neurologix,
with Neurologix being the surviving corporation and becoming a wholly-owned
subsidiary of Change. Under the merger agreement, at the effective time of the
Merger, the outstanding shares of Neurologix common stock and preferred stock
will automatically convert into Change common stock. The actual number of shares
of Change common stock to be issued in the Merger is directly related to
Change's Net Cash Assets as of the closing of the Merger. As of July 31, 2003,
Change estimated that its Net Cash Assets at closing would be approximately
$7,139,995. Accordingly, had the Exchange Ratio been determined as of July 31,
2003, it would have been 70.2127 resulting in an aggregate of 391,275,156 shares
of Change common stock being issued to existing Neurologix stockholders and
approximately 32% and 68% of the common stock of the combined company
outstanding after the Merger being held by existing Change stockholders and
existing Neurologix stockholders, respectively. In addition, Neurologix has
outstanding options to purchase an aggregate of 257,000 shares of its common
stock, which, in accordance with the terms of the merger agreement, would
automatically convert into options to purchase an aggregate of 18,044,664 shares
of Change common stock based on an estimated Exchange Ratio of 70.2127. Since
the stockholders of Neurologix will receive the majority of the voting shares of
the combined company, and the board of directors and management of the combined
company will be controlled by members of the board of
F-50
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS -- (CONTINUED)
directors and management of Neurologix, the Merger will be accounted for as a
reverse acquisition whereby Neurologix will be the acquirer and Change will be
the acquiree for accounting purposes.
The voting agreement, dated as of August 13, 2003, by and among Change,
Neurologix, Subcorp and certain stockholders of Neurologix, further provides for
all of the outstanding shares of the initial series of convertible preferred
stock of the Company and approximately 79.2% of the outstanding shares of Series
B convertible preferred stock of the Company to be converted into shares of
common stock of the Company prior to the Merger and for the note payable with
the related party to be converted into shares of common stock of the Company at
the conversion price of $6 per share.
Concurrent with the execution of the merger agreement, Change loaned the
Company $750,000 and the Company issued a promissory note in the aggregate
principal amount of $750,000 due April 30, 2004 in favor of Change. On November
14, 2003, the merger agreement was amended to increase the amount of the loan to
$1,100,000 and to extend the term of the loan to June 30, 2004. Change funded
the additional $350,000 amount of the loan on December 18, 2003. The note
accrues interest at 4% per annum, is secured by all of the assets of the Company
and is senior to all existing indebtedness of the Company.
* * *
F-51
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To the Board of Directors
Neurologix, Inc.
We have audited the accompanying balance sheets of NEUROLOGIX, INC. (A
Development Stage Company) (the "Company") as of December 31, 2002 and 2001, and
the related statements of operations, changes in stockholders' deficiency and
cash flows for the years ended December 31, 2002, 2001 and 2000 and the period
from February 12, 1999 (date of inception) through December 31, 2002. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with auditing standards generally
accepted in the United States of America. These standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Neurologix, Inc. as of
December 31, 2002 and 2001, and its results of operations and cash flows for the
years ended December 31, 2002, 2001 and 2000 and the period from February 12,
1999 (date of inception) to December 31, 2002, in conformity with accounting
principles generally accepted in the United States of America.
The financial statements referred to above have been prepared assuming that
the Company will continue as a going concern. As further discussed in Note 2 to
the financial statements, the Company's operations have generated recurring
losses and it had a stockholders' deficiency as of December 31, 2002. Such
matters raise substantial doubt about the Company's ability to continue as a
going concern. Management's plans concerning these matters are also described in
Note 2. The accompanying financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
/s/ J.H. COHN LLP
Roseland, New Jersey
October 14, 2003, except for
Notes 2 and 8 which
are as of December 18, 2003
F-52
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
BALANCE SHEETS
DECEMBER 31, 2002 AND 2001
2002 2001
----------- -----------
ASSETS
Current assets -- cash and cash equivalents................. $ 1,635,761 $ 118,328
Equipment, less accumulated depreciation of $51,953 and
$20,628................................................... 113,516 19,041
Intangible assets, less accumulated amortization of $21,682
and $9,657................................................ 184,644 151,127
----------- -----------
Totals................................................. $ 1,933,921 $ 288,496
=========== ===========
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
Current liabilities -- accrued expenses..................... $ 85,000 $ 79,985
Note payable to related party............................... 2,238,251 1,925,153
----------- -----------
Total liabilities...................................... 2,323,251 2,005,138
----------- -----------
Commitments and contingencies
Mandatorily redeemable convertible preferred stock, $.001
par value; 147 shares designated, issued and
outstanding............................................... 500,000 500,000
----------- -----------
Stockholders' deficiency:
Series B convertible preferred stock, $.001 par value;
562,500 shares designated, 490,754 shares issued and
outstanding............................................ 491
Common stock, $.001 par value; 20,000,000 shares
authorized; 2,390,583 and 2,269,000 shares issued and
outstanding............................................ 2,391 2,269
Additional paid-in capital................................ 3,224,004 34,641
Unearned compensation..................................... (553,033)
Deficit accumulated during the development stage.......... (3,563,183) (2,253,552)
----------- -----------
Total stockholders' deficiency......................... (889,330) (2,216,642)
----------- -----------
Total.................................................. $ 1,933,921 $ 288,496
=========== ===========
See Notes to Financial Statements.
F-53
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 2002, 2001 AND 2000 AND PERIOD FROM
FEBRUARY 12, 1999 (DATE OF INCEPTION) THROUGH DECEMBER 31, 2002
YEARS ENDED DECEMBER 31,
-------------------------------------
2002 2001 2000 CUMULATIVE
----------- --------- ----------- -----------
Operating expenses:
Research and licensing.................. $ 440,830 $ 326,000 $ 653,690 $ 1,600,520
Scientific consulting................... 286,256 202,750 222,000 752,506
Administrative expenses................. 485,981 246,121 157,353 997,286
----------- --------- ----------- -----------
Loss from operations...................... (1,213,067) (774,871) (1,033,043) (3,350,312)
----------- --------- ----------- -----------
Other income (expenses):
Dividend income......................... 6,736 2,902 10,622
Interest income......................... 14,798 14,798
Interest expense related parties........ (118,098) (95,755) (24,438) (238,291)
----------- --------- ----------- -----------
Totals............................... (96,564) (95,755) (21,536) (212,871)
----------- --------- ----------- -----------
Net loss.................................. $(1,309,631) $(870,626) $(1,054,579) $(3,563,183)
=========== ========= =========== ===========
Basic and diluted net loss per common
share................................... $ (.55) $ (.38) $ (.48)
=========== ========= ===========
Weighted average common shares
outstanding, basic and diluted.......... 2,390,583 2,269,000 2,175,000
=========== ========= ===========
See Notes to Financial Statements.
F-54
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIENCY
YEARS ENDED DECEMBER 31, 2002 AND 2001 AND PERIOD FROM
FEBRUARY 12, 1999 (DATE OF INCEPTION) THROUGH DECEMBER 31, 2002
SERIES B DEFICIT
CONVERTIBLE ACCUMULATED
PREFERRED STOCK COMMON STOCK ADDITIONAL DURING THE
---------------- ------------------ PAID-IN UNEARNED DEVELOPMENT
SHARES AMOUNT SHARES AMOUNT CAPITAL COMPENSATION STAGE TOTAL
------- ------ --------- ------ ---------- ------------ ----------- -----------
Sale of common stock to
founders at $.002 per
share....................... 2,175,000 $2,175 $ 2,235 $ 4,410
Net loss...................... $ (328,347) (328,347)
--------- ------ ---------- ----------- -----------
Balance, December 31, 1999.... 2,175,000 2,175 2,235 (328,347) (323,937)
Net loss...................... (1,054,579) (1,054,579)
--------- ------ ---------- ----------- -----------
Balance, December 31, 2000.... 2,175,000 2,175 2,235 (1,382,926) (1,378,516)
Stock options granted for
services.................... 9,000 9,000
Common stock issued for
intangible assets at $.25
per share................... 94,000 94 23,406 23,500
Net loss...................... (870,626) (870,626)
--------- ------ ---------- ----------- -----------
Balance, December 31, 2001.... 2,269,000 2,269 34,641 (2,253,552) (2,216,642)
Retirement of founder
shares...................... (12,000) (12) 12
Common stock issued pursuant
to license agreement at
$4.32 per share............. 133,583 134 576,944 $(577,078)
Private placement of Series B
preferred stock, net of
expenses of $37,100 at $5.40
per share................... 490,754 $491 2,612,407 2,612,898
Amortization of unearned
compensation................ 24,045 24,045
Net loss...................... (1,309,631) (1,309,631)
------- ---- --------- ------ ---------- --------- ----------- -----------
Balance, December 31, 2002.... 490,754 $491 2,390,583 $2,391 $3,224,004 $(553,033) $(3,563,183) $ (889,330)
------- ==== --------- ====== ========== ========= =========== ===========
See Notes to Financial Statements.
F-55
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2002, 2001 AND 2000 AND PERIOD FROM
FEBRUARY 12, 1999 (DATE OF INCEPTION) THROUGH DECEMBER 31, 2002
YEARS ENDED DECEMBER 31,
-------------------------------------
2002 2001 2000 CUMULATIVE
----------- --------- ----------- -----------
Operating activities:
Net loss................................ $(1,309,631) $(870,626) $(1,054,579) $(3,563,183)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation......................... 31,325 12,694 7,934 51,953
Amortization......................... 12,025 6,746 2,229 21,682
Stock options granted for services... -- 9,000 -- 9,000
Amortization of unearned
compensation....................... 24,045 -- -- 24,045
Noncash interest..................... 118,098 95,755 24,438 238,291
Changes in operating assets and
liabilities -- accrued expenses.... 5,015 17,879 (3,396) 85,000
----------- --------- ----------- -----------
Net cash used in operating
activities...................... (1,119,123) (728,552) (1,023,374) (3,133,212)
----------- --------- ----------- -----------
Investing activities:
Purchases of equipment.................. (125,800) -- (39,669) (165,469)
Purchases of intangible assets.......... (45,542) (93,958) (22,858) (182,826)
----------- --------- ----------- -----------
Net cash used in financing
activities...................... (171,342) (93,958) (62,527) (348,295)
----------- --------- ----------- -----------
Financing activities:
Borrowings from related party........... 195,000 729,360 1,075,600 1,999,960
Proceeds from issuance of common
stock................................ 4,410
Proceeds from issuance of preferred
stock................................ 2,612,898 -- -- 3,112,898
----------- --------- ----------- -----------
Net cash used in investing
activities...................... 2,807,898 729,360 1,075,600 5,117,268
----------- --------- ----------- -----------
Net increase (decrease) in cash and cash
equivalents............................. 1,517,433 (93,150) (10,301) 1,635,761
Cash and cash equivalents, beginning of
period.................................. 118,328 211,478 221,779 --
----------- --------- ----------- -----------
Cash and cash equivalents, end of
period.................................. $ 1,635,761 $ 118,328 $ 211,478 $ 1,635,761
=========== ========= =========== ===========
Supplemental disclosure of noncash
investing and financing
activities -- common stock issued for
intangible assets....................... -- $ 23,500 $ -- $ 23,500
=========== ========= =========== ===========
See Notes to Financial Statements.
F-56
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
NOTE 1 -- NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NATURE OF OPERATIONS:
Neurologix, Inc. (A Development Stage Company) (the "Company") was
incorporated in the State of Delaware in February 1999. The Company owns or
licenses and is developing technologies to deliver gene therapy as a treatment
for central nervous system disorders.
DEVELOPMENT STAGE:
The Company is in the development stage as defined in Statement of
Financial Accounting Standards ("SFAS") No. 7, "Accounting and Reporting for
Development Stage Enterprises." Through December 31, 2002, the Company has not
generated revenues and has devoted its efforts to various start-up activities
including technology development and raising capital. The Company anticipates
requiring additional capital to complete its development stage activities.
USE OF ESTIMATES:
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect certain reported
amounts and disclosures. Accordingly, actual results could differ from those
estimates.
CASH AND CASH EQUIVALENTS:
The Company considers money market accounts and all highly-liquid debt
instruments with maturities of three months or less when acquired to be cash
equivalents.
EQUIPMENT:
Equipment is stated at cost less accumulated depreciation. The Company
records depreciation using the declining balance method over the estimated
useful life of five years.
INTANGIBLE ASSETS:
Intangible assets consist of patents and patent rights obtained under
licensing agreements and are amortized on a straight-line basis over the
estimated useful lives which range from five to 15 years. The Company estimates
amortization expenses related to these intangible assets to be approximately
$15,000 per year for the next five years.
IMPAIRMENT OF LONG-LIVED ASSETS:
The Company periodically assesses the recoverability of the carrying
amounts of long-lived assets, including intangible assets. A loss is recognized
when expected undiscounted future cash flows are less than the carrying amount
of the asset. The impairment loss is the amount by which the carrying amount of
the asset exceeds its fair value.
INCOME TAXES:
The Company complies with SFAS No. 109, "Accounting for Income Taxes,"
which requires an asset and liability approach to financial accounting and
reporting for income taxes. Deferred income tax assets and liabilities are
computed for temporary differences between the financial statement and tax bases
of assets and liabilities that will result in future taxable or deductible
amounts, based on enacted tax laws and rates
F-57
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
applicable to the periods in which the differences are expected to affect
taxable income. Valuation allowances are established, when necessary, to reduce
deferred tax assets to the amount expected to be realized.
STOCK-BASED COMPENSATION:
The Company follows SFAS No. 123, "Accounting for Stock-Based Compensation"
which allows companies to either expense the estimated fair value of stock
options or to continue to follow the intrinsic value method set forth in APB
Opinion 25, "Accounting for Stock Issued to Employees" ("APB 25"), and disclose
the pro forma effect on net income (loss) as if the fair value of the options
had been expensed. The Company has elected to apply APB 25 in accounting for its
employee stock option incentive plans and make the required pro forma
disclosures. The Company has used the minimum value method as permitted by SFAS
123 to estimate the fair value of options granted to employees for such pro
forma disclosures.
In accordance with SFAS 123, all other issuances of common stock, stock
options or other equity instruments issued to employees and non-employees as
consideration for goods or services received by the Company are accounted for
based on the fair value of the consideration received or the fair value of the
equity instrument, whichever is more readily measurable. Such fair value is
measured at an appropriate date pursuant to the guidance in the consensus
reached for EITF Issue No. 96-18 (generally, the earlier of the date the other
party becomes committed to provide goods or services or the date the performance
by the other party is complete) and capitalized or expensed.
NOTE 2 -- BASIS OF PRESENTATION:
The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. The Company is in the development
stage and has not generated any revenues as of December 31, 2002. As a result,
the Company incurred net losses of $1,310,000, $870,000, $1,055,000 and
$3,563,000 and negative cash flows from operating activities of $1,119,000,
$729,000, $1,023,000 and $3,133,000 for the years ended December 31, 2002, 2001
and 2000 and for the period from February 12, 1999 (date of inception) to
December 31, 2002, respectively. As a result, the Company had an accumulated
deficit of approximately $3,563,000 as of December 31, 2002. In addition,
management believes that the Company will continue to incur net losses and cash
flow deficiencies from operating activities through at least December 31, 2003.
These matters raise substantial doubt about the Company's ability to continue as
a going concern.
To enable the Company to sustain its operations through at least December
31, 2003 and, ultimately complete its marketing and development program and
achieve profitability, management plans to seek additional financing for the
Company through the sale of debt and equity securities.
On August 13, 2003, the Company entered into a merger agreement (the
"merger agreement") with Change Technology Partners, Inc. ("Change"), a
publicly-traded company, that is expected to be accounted for as a "reverse
acquisition." As of June 30, 2003, Change's assets consisted primarily of
approximately $7,300,000 (unaudited) in cash and cash equivalents. Management
believes that the merger with Change will enable the Company to conduct the
Phase I clinical trial of gene therapy that it has developed for the treatment
of Parkinson's disease and to continue the development of innovative therapies
for the treatment of other degenerative neurological disorders (see Note 8).
Concurrent with the execution of the merger agreement, Change loaned the
Company $750,000 and the Company issued a promissory note in the aggregate
principal amount of $750,000 due April 30, 2004 in favor of Change. On November
14, 2003, the merger agreement was amended to increase the amount of the loan to
$1,100,000 and to extend the term of the loan to June 30, 2004. Change funded
the additional $350,000
F-58
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
amount of the loan on December 18, 2003. The note accrues interest at 4% per
annum, is collateralized by all of the assets of the Company and is senior to
all existing indebtedness of the Company (see Note 8).
The Company's existing resources will not be sufficient to support the
commercial introduction of any of its product candidates. The Company will need
to raise additional funds through public or private equity offerings, debt
financings or additional corporate collaboration and licensing arrangements. The
Company does not know whether additional financing will be available when
needed, or on terms favorable to it or its stockholders.
The accompanying financial statements do not include any adjustments
related to the recoverability and classification of assets or the amounts and
classification of liabilities that might be necessary should the Company be
unable to continue its operations as a going concern.
NOTE 3 -- RELATED PARTY TRANSACTIONS:
At December 31, 2002, the Company has a note payable to several of its
preferred stockholders pursuant to a $2,000,000 credit line agreement that
expires in October 2007 and is collateralized by certain intellectual property
of the Company. Interest expense of approximately $118,000, $96,000, $24,000 and
$238,000 was accrued at 6% for the years ended December 31, 2002, 2001 and 2000
and for the period from February 12, 1999 (date of inception) to December 31,
2002, respectively, but was not paid.
Concurrent with the merger (see Note 8), the outstanding balance, including
accrued interest, will be converted into common stock of the Company at a
conversion price of $6 per share.
The Company paid its CEO/President a management fee of $24,000 for each of
the years ended December 31, 2002, 2001 and 2000 and $72,000 for the period from
February 12, 1999 (date of inception) to December 31, 2002. The Company's
CEO/President is also a stockholder and a noteholder of the Company.
NOTE 4 -- INCOME TAXES:
At December 31, 2002, the Company has net operating loss carryforwards
("NOLs") of approximately $3,500,000, which expire through 2022. The deferred
tax asset from the Company's NOLs approximated $1,400,000. The Company has a
deferred tax asset from research and development credits of approximately
$218,000, which expires through 2022. Due to the uncertainties related to the
Company's ability to utilize its deferred tax assets, a valuation allowance for
the full amount of the deferred tax assets of $1,487,000 has been established at
December 31, 2002. There are no other significant permanent or temporary
differences.
The Company had also offset the potential benefits of $880,000, $520,000
and $100,000 from NOLs by equivalent valuation allowances as of December 31,
2001, 2000 and 1999, respectively. As a result of the increases in the valuation
allowance of $520,000, $360,000, $420,000 and $1,487,000 during the years ended
December 31, 2002, 2001 and 2000 and for the period from February 12, 1999 (date
of inception) to December 31, 2002, respectively, there are no income tax
benefits reflected in the accompanying statements of operations to offset
pre-tax losses.
NOTE 5 -- PREFERRED STOCK:
The Articles of Incorporation of the Company, as amended, authorized
1,000,000 shares of $.001 par preferred stock that may be designated in
different series at the discretion of the Board of Directors. As of December 31,
2002, the Board of Directors has designated 147 of such shares as Convertible
Preferred Stock ("Convertible Preferred Stock") and 562,500 of such shares as
Series B Convertible Preferred Stock ("Series B Preferred Stock").
F-59
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
Pursuant to the terms of a private placement during 1999, the Company sold
all of the 147 shares of Convertible Preferred Stock for aggregate consideration
of $500,000 or $3,401 per share. Each share of Convertible Preferred Stock is
entitled to cumulative dividends at the rate of 10% of the liquidation
preference per year; however, such dividend may not be paid unless corresponding
dividends are paid to the holders of the Series B Preferred Stock. In addition,
each share of Convertible Preferred Stock is convertible into 15,000 shares of
the Company's common stock at the option of the holder.
In the event that shares of the Convertible Preferred Stock are not
converted into common stock on or prior to October 15, 2004, the holder of
shares of Convertible Preferred Stock shall be entitled to have the Company
redeem the shares of Convertible Preferred Stock and to receive $3,401 per share
(as adjusted for any share dividends, combinations or subdivision with respect
to such shares of Convertible Preferred Stock) plus all accrued and unpaid
dividends for each share of Convertible Preferred Stock redeemed by the Company.
In addition, this class of stock is preferential to the common stock of the
Company for distributions in liquidation and dissolution. The aggregate
liquidation preference is $500,000. Holders of the Convertible Preferred Stock
are entitled to all voting rights of the common stockholders.
In 2002, the Company executed preferred stock subscription agreements with
certain investors pursuant to which the Company sold 490,754 shares of Series B
Preferred Stock and received gross proceeds of $2,650,000 or $5.40 per share. In
connection with this private placement, the Company incurred expenses of
approximately $37,000. Each share of Series B Preferred Stock is convertible
into one share of common stock, subject to certain antidilution provisions. The
Series B Preferred Stock carries a liquidation preference which entitles the
holder to receive an amount equal to the equity investment prior to
distributions to the holders of the Company's common stock and Convertible
Preferred Stock. The aggregate Series B Preferred Stock liquidation preference
is approximately $2,650,000 or $5.40 per share. In addition, the Series B
Preferred Stock does not have a cumulative dividend. Holders of the Series B
Preferred Stock are entitled to all voting rights of the common stockholders.
NOTE 6 -- STOCK OPTIONS:
During 2001, the Company approved a stock option plan (the "Plan") which
provided for the granting of stock options and restricted stock to employees,
independent contractors, consultants, directors and other individuals. A maximum
of 1,400,000 shares of common stock have been approved for issuance under the
Plan by the Company's Board of Directors.
A summary of the status of the Company's shares subject to options as of
December 31, 2002 and 2001 and changes during the years then ended is presented
below:
2002 2001
-------------------- --------------------
WEIGHTED WEIGHTED
AVERAGE AVERAGE
SHARES OR EXERCISE SHARES OR EXERCISE
PRICE PRICE PRICE PRICE
--------- -------- --------- --------
Outstanding, beginning of year............... 232,000 $ .24
Granted...................................... 25,000 4.32 232,000 $.24
-------- --------
Outstanding, end of year..................... 257,000 $ .64 232,000 $.24
-------- ===== --------
Options exercisable, end of year............. 208,167 167,500
-------- --------
Weighted average fair value of options
granted during the year.................... $ .96 $ .04
======== ========
F-60
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
The following table summarizes information about fixed stock options
outstanding at December 31, 2002:
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
----------------------------------------------- ----------------------------
WEIGHTED AVERAGE
YEARS OF WEIGHTED WEIGHTED
NUMBER REMAINING AVERAGE NUMBER AVERAGE
EXERCISE PRICE OUTSTANDING CONTRACTUAL LIFE EXERCISE PRICE EXERCISABLE EXERCISE PRICE
-------------- ----------- ---------------- -------------- ----------- --------------
$.23-$.25 232,000 3.5 $ .24 183,167 $ .24
$4.32 25,000 4.5 4.32 25,000 4.32
------- -------
$.23-$4.32 257,000 3.6 $ .64 208,167 $ .72
------- --- ===== ------- =====
Since the Company has elected to continue to use the intrinsic value method
pursuant to the provisions of APB 25 in accounting for stock options granted to
employees and the exercise price of all of the options granted to employees has
been equal to or greater than the fair market value at the date of grant, no
earned or unearned compensation cost was recognized in the accompanying
financial statements for stock options granted to employees. The historical
amounts reported in the accompanying statements of operations for the years
ended December 31, 2002 and 2001 and the pro forma amounts computed as if the
Company had elected to recognize costs for stock options granted to employees
based on the fair value of the options at the date of grant using the minimum
value method as prescribed by SFAS 123 are set forth below:
2002 2001 2000
---------- -------- ----------
Net loss, as reported............................. $1,309,631 $870,626 $1,054,579
Deduct total stock-based compensation determined
under fair value -- based method for all
awards.......................................... 23,890
---------- -------- ----------
Net loss, pro forma............................... $1,333,521 $870,626 $1,054,579
========== ======== ==========
For purposes of determining the pro forma and historical fair values of
options granted to employees and non-employees during the years ended December
31, 2002 and 2001 using the minimum value method, Neurologix uses the following
assumptions: (i) risk free interest rate of 4%; (ii) estimated life of five
years, (iii) volatility of 0%, and (iv) dividend yield of 0%.
NOTE 7 -- COMMITMENTS AND CONTINGENCIES:
LICENSE AGREEMENTS:
In September 1999 and April 2001, the Company entered into two license
agreements whereby a university grants to the Company the sole and exclusive
right and license, under the ownership rights of the university, to certain
patent rights and technical information. In conjunction with the agreements, the
Company shall pay the university an annual maintenance fee of $25,000 per
agreement as well as benchmark payments and royalties as defined. The licenses
shall continue for the lives of the patents covered in the agreements. The
Company shall have the right to terminate the agreements at any time upon 90
days written notice to the university.
In December 2001, the Company entered into a license agreement with another
university whereby the university granted to the Company the sole and exclusive
right and license to certain patent rights and technical information for a
period of three years. In conjunction with the agreement, the Company shall pay
the university $50,000 per year in quarterly installments.
The Company is a party to license agreements with another university
whereby the university granted to the Company the sole and exclusive right and
license to certain patent rights and technical information. In conjunction with
the agreements, the Company shall pay the university benchmark payments and
royalties, as
F-61
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
defined. The license shall continue for the lives of the patents covered in the
agreements. The Company shall have the right to terminate the agreements at any
time upon 90 days written notice to the university. In November 2002, the
license agreements were modified under a new license agreement. In connection
with the new agreement, the Company issued 133,583 shares of common stock to the
university in exchange for cancellation of annual maintenance fees and
modification of the royalty fee structure. The common stock was valued at
approximately $577,000 and was initially charged to unearned compensation with
an offsetting credit to additional paid-in capital. The unearned compensation
will be amortized to research and licensing expense over four years, the
estimated benefit period. During the year ended December 31, 2002, approximately
$24,000 was amortized.
In 2002, the Company entered into two license agreements with another
university whereby the university granted to the Company the sole and exclusive
right and license to certain patent rights and technical information. In
conjunction with the agreements, the Company paid the university an initial fee
of $100,000 and $50,000, respectively for each agreement. In addition, the
Company is committed to pay annual maintenance fees of $100,000 and $20,000,
respectively, as well as benchmark payments and royalties, as defined. The
maintenance fees can be applied to royalty and benchmark fees incurred in the
calendar year of payment only. The licenses shall continue for the lives of the
patents covered in the agreements. The Company shall have the right to terminate
the agreements at any time upon 90 days written notice to the university.
In August 2002, the Company entered into a license agreement with two
universities whereby the universities grant to the Company a nonexclusive
license to certain patent rights and technical information. An initial fee of
$20,000 was paid to each of the two universities pursuant to the agreement. In
addition, the Company is committed to pay an annual maintenance fee of $5,000
per year to each of the two universities. In conjunction with the agreement, the
Company shall make payments upon reaching certain milestones, as defined. The
Company shall have the right to terminate the agreement at any time upon 90 days
written notice to the university.
CONSULTING AGREEMENTS:
The Company has consulting agreements with four scientists who comprise of
the Company's Scientific Advisory Board. These agreements provide that the
scientists are engaged by the Company to provide advice and consulting services
in scientific research on human gene therapy in the brain and central nervous
system and to assist the Company in seeking financing and meeting with
prospective investors.
The first agreement, as amended on October 8, 2003, provides for payments
of $74,000 per annum through September 2007. The second agreement, as amended on
October 8, 2003, provides for payments of $124,000 per annum through 2007. The
third and fourth agreements provide for payments of $50,000 and $25,000 per
annum, respectively, through March and April 2003, respectively. Each of the
agreements shall be automatically renewed annually for up to three additional
years unless terminated for cause or upon 30 days written notice to the other
party prior to an annual anniversary date. These consulting agreements are
subject to confidentiality, proprietary information and invention agreements.
Any discoveries and intellectual property obtained through these agreements
related to the research covered under the agreements is to be assigned to the
Company.
OPERATING LEASE AGREEMENT:
In September 2002, the Company entered into an operating lease agreement,
expiring in September 2003, with a university for office space. The Company uses
the space for research and development and related business development.
Approximate future minimum payments are $38,000 for 2003. Rent expense under the
lease was approximately $13,000 for the year ended December 31, 2002.
F-62
NEUROLOGIX, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
NOTE 8 -- SUBSEQUENT EVENTS:
In January 2003, the Company entered into a capital lease agreement for
equipment. The lease term commenced in March 2003 upon completion of the
installation of the equipment. The lease term is for two years and provides for
monthly payments of approximately $1,900. In addition to the monthly payments,
the lease provides for the Company to pay all operating expenses, including
insurance, maintenance, taxes and assessments.
As described in Note 2, on August 13, 2003 the Company entered into the
merger agreement with Change. Under the merger agreement, Subcorp will merge
with and into Neurologix, with Neurologix being the surviving corporation and
becoming a wholly-owned subsidiary of Change. Under the merger agreement, at the
effective time of the Merger, the outstanding shares of Neurologix common stock
and preferred stock will automatically convert into Change common stock. The
actual number of shares of Change common stock to be issued in the Merger is
directly related to Change's Net Cash Assets as of the closing of the Merger. As
of July 31, 2003, Change estimated that its Net Cash Assets at closing would be
approximately $7,139,995. Accordingly, had the Exchange Ratio been determined as
of July 31, 2003, it would have been 70.2127 resulting in an aggregate of
391,275,156 shares of Change common stock being issued to existing Neurologix
stockholders and approximately 32% and 68% of the common stock of the combined
company outstanding after the Merger being held by existing Change stockholders
and existing Neurologix stockholders, respectively. In addition, Neurologix has
outstanding options to purchase an aggregate of 257,000 shares of its common
stock, which, in accordance with the terms of the merger agreement, would
automatically convert into options to purchase an aggregate of 18,044,664 shares
of Change common stock. Since the stockholders of Neurologix will receive the
majority of the voting shares of the combined company, and the board of
directors and management of the combined company will be controlled by members
of the board of directors and management of Neurologix, the Merger will be
accounted for as a reverse acquisition whereby Neurologix will be the acquirer
and Change will be the acquiree for accounting purposes.
The merger agreement further provides for all of the outstanding preferred
stock of the Company to be converted into shares of common stock and for the
note payable with the related party to be converted into shares of common stock
of the Company at the conversion price of $6 per share.
Concurrent with the execution of the merger agreement, Change loaned the
Company $750,000 and the Company issued a promissory note in the aggregate
principal amount of $750,000 due April 30, 2004 in favor of Change. On November
14, 2003, the merger agreement was amended to increase the amount of the loan to
$1,100,000 and to extend the term of the loan to June 30, 2004. Change funded
the additional $350,000 amount of the loan on December 18, 2003. The note
accrues interest at 4% per annum, is collateralized by all of the assets of the
Company and is senior to all existing indebtedness of the Company.
In addition, in August 2003, Neurologix entered into a one year lease
agreement for facilities expiring on August 31, 2004 that provides for annual
rent of $43,620.
* * *
F-63
APPENDIX A
EXECUTION COPY
AGREEMENT AND PLAN OF MERGER
BY AND AMONG
CHANGE TECHNOLOGY PARTNERS, INC.,
CTP/N MERGER CORP.,
AND
NEUROLOGIX, INC.
DATED AS OF AUGUST 13, 2003
TABLE OF CONTENTS
PAGE
----
ARTICLE I DEFINITIONS AND CONSTRUCTION.................................... A-1
1.1 Specific Definitions........................................ A-1
1.2 Additional Definitions...................................... A-4
1.3 Interpretation.............................................. A-5
ARTICLE II THE MERGER..................................................... A-5
2.1 The Merger.................................................. A-5
2.2 Effective Time; Closing..................................... A-5
2.3 Effects of the Merger....................................... A-6
2.4 Certificate of Incorporation and By-laws.................... A-6
2.5 Directors and Officers of Surviving Corporation............. A-6
2.6 Conversion of Securities.................................... A-6
2.7 Exchange of Certificates.................................... A-9
2.8 Delivery of CTP Common Stock to Exchange Agent.............. A-10
2.9 Treatment of Neurologix Stock Options....................... A-10
ARTICLE III REPRESENTATIONS AND WARRANTIES OF NEUROLOGIX.................. A-11
3.1 Organization and Qualification.............................. A-11
3.2 Authority Relative to this Agreement; Enforceability........ A-11
3.3 Conflicts; Consents and Approvals........................... A-11
3.4 Capitalization.............................................. A-12
3.5 No Litigation; Compliance with Laws; Permits................ A-12
3.6 Title to Assets............................................. A-12
3.7 Taxes....................................................... A-14
3.8 Intellectual Property....................................... A-15
3.9 Financial Statements........................................ A-15
3.10 Undisclosed Liabilities..................................... A-15
3.11 Environmental Matters....................................... A-15
3.12 Material Contracts.......................................... A-16
3.13 Insurance................................................... A-16
3.14 Affiliate Transactions...................................... A-16
3.15 Employee Benefit Plans...................................... A-17
3.16 Funded Debt................................................. A-17
3.17 Other Business Names........................................ A-17
3.18 Required Actions............................................ A-17
3.19 FDA Approval................................................ A-18
3.20 No Material Adverse Change.................................. A-18
3.21 Brokerage................................................... A-18
3.22 Full Disclosure............................................. A-18
A-i
PAGE
----
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF CTP AND SUBCORP.............. A-18
4.1 Organization and Qualification.............................. A-18
4.2 Authority Relative to this Agreement; Enforceability........ A-18
4.3 Conflicts; Consents and Approvals........................... A-18
4.4 Capitalization.............................................. A-19
4.5 CTP SEC Documents and Other Public Disclosures.............. A-19
4.6 No Material Adverse Change.................................. A-19
4.7 No Litigation; Compliance with Laws; Permits................ A-20
4.8 Tax Returns................................................. S-20
4.9 Title to Assets............................................. A-21
4.10 No Default.................................................. A-22
4.11 Intellectual Property....................................... A-22
4.12 No Current Operations....................................... A-22
4.13 Undisclosed Liabilities..................................... A-22
4.14 Funded Debt................................................. A-22
4.15 Other Business Names........................................ A-23
4.16 Environmental Matters....................................... A-23
4.17 Material Contracts.......................................... A-23
4.18 Employee Benefit Plans...................................... A-24
4.19 Insurance................................................... A-24
4.20 CTP's Net Cash Assets....................................... A-24
4.21 Brokerage................................................... A-24
4.22 Full Disclosure............................................. A-24
4.23 Former CEO Severance........................................ A-24
4.24 Affiliate Transactions...................................... A-24
ARTICLE V COVENANTS OF THE PARTIES........................................ A-25
5.1 Disclosure Letters; Access and Information.................. A-25
5.2 Affirmative Covenants....................................... A-26
5.3 Negative Covenants.......................................... A-26
5.4 Closing Documents........................................... A-28
5.5 Further Actions............................................. A-28
5.6 Public Announcements........................................ A-28
5.7 Stockholders' Meeting....................................... A-28
5.8 Preparation of the Registration Statement................... A-28
5.9 Affiliates of Neurologix.................................... A-29
5.10 Board of Directors of CTP................................... A-30
5.11 Merger Subsidiary........................................... A-30
5.12 No Solicitation............................................. A-30
5.13 Reorganization Treatment.................................... A-32
5.14 Directors' and Officers' Insurance.......................... A-32
5.15 Stock Option Plan........................................... A-32
5.16 Neurologix Loan............................................. A-33
A-ii
PAGE
----
ARTICLE VI CONDITIONS..................................................... A-33
6.1 Conditions to the Obligations of Each Party................. A-33
6.2 Conditions to CTP's and Subcorp's Obligations............... A-33
6.3 Conditions to Neurologix's Obligations...................... A-34
ARTICLE VII TERMINATION AND AMENDMENT..................................... A-35
7.1 Termination................................................. A-35
7.2 Effect of Termination....................................... A-37
7.3 Amendment................................................... A-37
7.4 Extension; Waiver........................................... A-37
ARTICLE VIII MISCELLANEOUS................................................ A-38
8.1 Notices..................................................... A-38
8.2 Interpretation; Survival of Representations and
Warranties.................................................. A-38
8.3 Counterparts; Telecopied Signatures......................... A-39
8.4 Entire Agreement............................................ A-39
8.5 No Third Party Beneficiaries................................ A-39
8.6 Governing Law............................................... A-39
8.7 Consent to Jurisdiction; Venue; No Trial by Jury............ A-39
8.8 Specific Performance........................................ A-39
8.9 Assignment.................................................. A-39
8.10 Expenses.................................................... A-39
8.11 Severability................................................ A-40
8.12 No Strict Construction...................................... A-40
8.13 Knowledge................................................... A-40
A-iii
AGREEMENT AND PLAN OF MERGER
This Agreement and Plan of Merger (this "Agreement") is made and entered
into as of the 13th day of August, 2003, by and among Change Technology
Partners, Inc., a Delaware corporation ("CTP"), CTP/N Merger Corp., a Delaware
corporation and a wholly-owned subsidiary of CTP ("Subcorp"), and Neurologix,
Inc., a Delaware corporation ("Neurologix").
PRELIMINARY STATEMENTS
A. CTP and Neurologix desire to engage in a transaction consisting of the
merger of Subcorp with and into Neurologix, with Neurologix as the surviving
corporation (the "Merger"). Pursuant to the Merger, each share of Neurologix
Stock issued and outstanding at the Effective Time will be converted into the
right to receive CTP Common Stock, and Neurologix will become a wholly owned
subsidiary of CTP, all as more fully provided herein.
B. The respective boards of directors of Neurologix and CTP have
determined that the Merger is consistent with and in furtherance of the
long-term business strategy of each and that it is in the best interests of the
holders of shares of Neurologix Stock and CTP Common Stock to have a continuing
equity interest in the combined businesses of CTP and Neurologix through the
ownership of CTP Common Stock after the Effective Time.
C. The respective boards of directors of CTP, Subcorp and Neurologix have
determined that the Merger, structured in the manner contemplated herein, is
desirable and in the best interests of their respective stockholders and, by
resolutions duly adopted, have approved and adopted this Agreement.
D. For federal income tax purposes, the Parties intend that the Merger
constitute a "reorganization" within the meaning of Section 368(a) of the
Internal Revenue Code of 1986, as amended (including any successor code), and
the rules and regulations promulgated thereunder (the "Code").
E. Concurrently with the execution of this Agreement, and as a condition
to the willingness of CTP to enter into this Agreement, certain Stockholders and
holders of Neurologix Notes have entered into a Voting Agreement with CTP,
Subcorp and Neurologix dated as of the date hereof, under which, among other
things, those Stockholders have agreed to (i) convert shares of Neurologix Stock
into, and to exchange their interests in the Neurologix Note for, shares of
Neurologix Common Stock prior to the Effective Time, (ii) execute an irrevocable
written consent with respect to all of their shares of Neurologix Stock in favor
of adoption of this Agreement and the Merger, (iii) irrevocably waive any and
all rights to dissent from the Merger and seek appraisal of their Neurologix
Stock, and (iv) take other actions in furtherance of the transactions
contemplated by this Agreement (the "Voting Agreement").
F. Concurrently with execution of this Agreement, CTP shall loan
Neurologix the principal amount of $750,000 secured by a first priority
perfected security interest in all of the assets of Neurologix (the "Loan") in
accordance with the provisions of this Agreement and the related agreements
evidencing the Loan.
NOW, THEREFORE, in consideration of the mutual representations, warranties,
covenants and agreements herein contained, the parties hereto (the "Parties")
hereby represent, warrant, covenant and agree as follows:
ARTICLE I
DEFINITIONS AND CONSTRUCTION
1.1 Specific Definitions. For purposes of this Agreement, the following
terms shall have the following meanings:
"Affiliate" means, with respect to any entity (the "Subject Entity"),
any Person or other entity which controls, is controlled by, or is under
common control with, the Subject Entity, provided, however, that with
respect to the representations and warranties set forth in Article III of
this Agreement (except
A-1
as otherwise specifically provided in such representations and warranties),
"Affiliate" shall not include Palisade Capital Management, LLC or any
related entities. For the purposes of this definition, "control"
(including, with correlative meanings, the terms "controlling," "controlled
by" and "under common control with"), as applied to any Person, means the
possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of that Person, whether through
the ownership of voting securities, by contract or otherwise.
"Amendments" means the amendments to CTP's certificate of
incorporation to (i) increase the number of authorized shares of CTP Common
Stock to 750 million shares, (ii) decrease the par value of CTP Common
Stock to $.001 per share, (iii) change the name of CTP to Neurologix, Inc.;
and (iv) divide CTP's board of directors into 3 classes, with staggered
three-year terms for each class.
"Business Day" means any day except a Saturday, Sunday or other day on
which commercial banks located in New York, New York are not open for the
general transaction of business.
"CTP Common Stock" means the Common Stock, par value $.01 per share,
of CTP.
"CTP Material Adverse Effect" means a material adverse effect on the
financial condition of CTP and its Subsidiaries, taken as a whole;
provided, however, that (x) in no event shall any effect that results from
(a) the public announcement or pendency of the transactions contemplated
hereby or any actions taken in compliance with this Agreement or (b)
changes affecting the United States economy generally constitute a CTP
Material Adverse Effect; and (y) a decrease in the market price of CTP
Common Stock will not constitute a CTP Material Adverse Effect (except with
respect to an effect which, independent of such decrease, would constitute
a CTP Material Adverse Effect).
"CTP Meeting" means the annual or special meeting of CTP's
stockholders called to vote upon the Merger, this Agreement and the
transactions contemplated hereby, the Amendments and the election of
directors contemplated herein.
"CTP's Net Cash Assets" means as of the Closing Date the aggregate
amount of CTP's unencumbered cash and cash equivalents, in excess of (i.e.,
net of) all liabilities (actual and contingent, accrued and unaccrued) and
contractual commitments of CTP and its Subsidiaries, including, but not
limited to, obligations incurred and to be incurred in closing or
terminating operations of all current businesses, terminating all existing
contractual commitments and other obligations; provided, however, that in
calculating CTP's Net Cash Assets there shall be (i) excluded from the
calculation of liabilities (or, if previously paid, there shall be credited
to the amount of cash) up to $500,000 of legal, accounting, Financial
Advisor and other fees and expenses incurred by CTP that are directly
related to the Merger, this Agreement and the Loan and (ii) included in the
calculation of CTP's unencumbered cash and cash equivalents the outstanding
principal amount of the Loan and accrued but unpaid interest thereon. In
determining the amount of any contractual commitments or other accrued
claims, CTP shall not be entitled to any discount from the full contractual
amount of any liability unless it is finally settled or compromised prior
to the Closing Date. To the extent that there are any pending or threatened
litigations or other claims or contingent liabilities at the Closing Date,
the estimated cost to CTP of each such litigation, claim or liability
(including all legal costs and professional fees required to resolve any
such litigation, claim or liability) shall be established, disputed or
modified in accordance with the procedures set forth in Section 2.6.3.
"Exchange Act" means the Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder.
"Exchange Agent" means Continental Stock Transfer or such other Person
or entity reasonably acceptable to CTP as Neurologix shall designate to
serve as the Exchange Agent hereunder.
"Financial Advisor" means BNY Capital Markets, Inc.
"GAAP" means United States generally accepted accounting principles,
consistently applied.
A-2
"Governmental Entity" means any domestic or foreign international,
national, federal, state, provincial or local governmental, regulatory or
administrative authority, agency, commission, court, tribunal, arbitral
body or self-regulated entity.
"Liens" means liens, encumbrances, charges, adverse claims, security
interests, pledges, mortgages, title restrictions and other limitations on
use, other than restrictions on transfer imposed by federal or state
securities laws or under this Agreement and the Voting Agreement.
"Neurologix Common Stock" means the Common Stock, par value $.001 per
share, of Neurologix.
"Neurologix Holder" means any holder of Neurologix Stock or any other
Neurologix security.
"Neurologix Material Adverse Effect" means a material adverse effect
on the business, operations, assets or financial condition of Neurologix;
provided, however, that in no event shall any effect that results from (a)
the public announcement or pendency of the transactions contemplated hereby
or any actions taken in compliance with this Agreement, (b) changes
affecting Neurologix's industry generally or (c) changes affecting the
United States economy generally constitute a Neurologix Material Adverse
Effect.
Neurologix Note" means the 6% Amended and Restated Secured Promissory
Note of Neurologix in the aggregate principal amount of $2.0 million,
payable to Palisade Private Partnership, L.P., Dr. Martin J. Kaplitt and
Clark A. Johnson, due in October 2007.
"Neurologix Series A Preferred" means the Convertible Preferred Stock,
par value $.001 per share, of Neurologix.
"Neurologix Series B Preferred" means the Series B Convertible
Preferred Stock, par value $.001 per share, of Neurologix.
"Neurologix Stock" means, collectively, the Neurologix Common Stock,
the Neurologix Series A Preferred and the Neurologix Series B Preferred.
"Neurologix Stock" shall also include any equity security issued by
Neurologix between the date hereof and the Closing Date that is not
Neurologix Common Stock, Neurologix Series A Preferred or Neurologix Series
B Preferred.
"Neurologix Written Consent" means a valid written consent of
Neurologix's stockholders approving the Merger, this Agreement and the
transactions contemplated hereby.
"Person" means any individual, corporation, partnership, limited
liability company, business trust, sole proprietorship, Governmental
Entity, or other entity.
"SEC" means the Securities and Exchange Commission.
"Securities Act" means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder.
"Stockholder" means a holder of record of shares of Neurologix Stock
immediately prior to the Effective Time. "Stockholders" shall mean all such
holders.
"Subsidiary" when used with reference to a Person, shall mean any
entity (i) the accounts of which would be consolidated with those of such
Person in such Person's financial statements if such financial statements
were prepared in accordance with GAAP or (ii) of which securities or other
ownership interests representing more than 50% of the equity or more than
50% of the ordinary voting power or, in the case of a partnership, more
than 50% of the general partnership interests or more than 50% of the
profits or losses are owned, controlled or held by such Person and/or one
or more subsidiaries of such Person.
"Taxes" means (i) any and all federal, state, provincial, local,
foreign and other taxes, levies, fees, imposts, duties, and similar
governmental charges (including any interest, fines, assessments, penalties
or additions to tax imposed in connection therewith or with respect
thereto) including, without limitation (x) taxes imposed on, or measured
by, income, franchise, profits or gross receipts, and (y) ad valorem,
A-3
value added, capital gains, sales, goods and services, use, real or
personal property, capital stock, license, branch, payroll, estimated
withholding, employment, social security (or similar), unemployment,
compensation, utility, severance, production, excise, stamp, occupation,
premium, windfall profits, transfer and gains taxes, and customs duties,
and (ii) any transferee liability in respect of any items described in
clause (i) above.
"Tax Returns" means any and all reports, returns, declarations, claims
for refund, elections, disclosures, estimates, information reports or
returns or statements required to be supplied to a Governmental Entity in
connection with Taxes, including any schedule or attachment thereto or
amendment thereof.
1.2 Additional Definitions. The following terms are defined in the
following sections of this Agreement:
TERM SECTION
---- -------
Accountants................................................. 2.6.3.5
Agreement................................................... Heading
Allocation.................................................. 2.6.3.3
Certificates................................................ 2.7.1
Certificate of Merger....................................... 2.2
Closing..................................................... 2.2
Closing Date................................................ 2.2
Code........................................................ Preliminary Statements
Competing Transaction....................................... 5.12
CTP......................................................... Heading
CTP Calculation............................................. 2.6.3.4
CTP Disclosure Letter....................................... 5.1
CTP Exchange Option......................................... 2.9
CTP Existing Option......................................... 4.4
CTP In-the-Money Options.................................... 2.6.3
DGCL........................................................ 2.1
Disclosure Letters.......................................... 5.1
Effective Time.............................................. 2.2
Environmental Laws.......................................... 3.11
Exchange Ratio.............................................. 2.6.3
Excluded Shares............................................. 2.6.1
FDA......................................................... 3.19
Former CEO.................................................. 4.24
Intellectual Property....................................... 3.8
IRS......................................................... 3.7.11
Loan........................................................ Preliminary Statements
Material Contracts.......................................... 3.12
Merger...................................................... Preliminary Statements
Neurologix.................................................. Heading
Neurologix Affiliate's Letter............................... 5.9
Neurologix Disclosure Letter................................ 5.1
Neurologix Financial Statements............................. 3.9
Neurologix In-the-Money Options............................. 2.6.3
A-4
TERM SECTION
---- -------
Neurologix Option........................................... 3.4
Neurologix Reaction Notice.................................. 2.6.3.5
New Stock Option Plan....................................... 5.15
Outside Date................................................ 7.1.3
Parties..................................................... Preliminary Statements
Potential Acquiror.......................................... 5.12.1
Product..................................................... 3.19
Prospectus/Proxy Statement.................................. 5.8.1
Registration Statement...................................... 5.8.1
SEC Documents............................................... 4.5
Secretary of State.......................................... 2.2
Subcorp..................................................... Heading
Surviving Corporation....................................... 2.1
Total CTP Existing Shares................................... 2.6.3
Total CTP Stock Consideration............................... 2.6.3
Total Neurologix Existing Shares............................ 2.6.3
Updated Worksheet........................................... 2.6.3.4
Voting Agreement............................................ Preliminary Statements
Worksheet................................................... 2.6.3.3
1.3 Interpretation. Unless otherwise indicated to the contrary herein by
the context or use thereof: (i) the words, "herein," "hereto," "hereof" and
words of similar import refer to this Agreement as a whole and not to any
particular Section or paragraph hereof; (ii) words importing the masculine
gender shall also include the feminine and neutral genders, and vice versa;
(iii) words importing the singular shall also include the plural, and vice
versa; and (iv) the word "including" means "including without limitation."
ARTICLE II
THE MERGER
2.1 The Merger. Upon the terms and subject to the conditions hereof, and
in accordance with the provisions of the Delaware General Corporation Law (the
"DGCL"), Subcorp shall be merged with and into Neurologix at the Effective Time.
As a result of the Merger, the separate corporate existence of Subcorp shall
cease and Neurologix shall continue its corporate existence under the laws of
the State of Delaware. Neurologix, in its capacity as the corporation surviving
the Merger, is hereinafter sometimes referred to as the "Surviving Corporation."
2.2 Effective Time; Closing. Upon completion of the Closing on the
Closing Date, the Parties shall cause the Merger to be consummated by filing
with the Secretary of State of the State of Delaware (the "Secretary of State")
a certificate of merger (the "Certificate of Merger") in such form as is
required by and executed in accordance with Section 251 of the DGCL. The Merger
shall become effective (the "Effective Time") at 12:01 a.m. on the date when the
Certificate of Merger is filed with the Secretary of State or at such later time
and date as shall be agreed upon by CTP and Neurologix and specified in the
Certificate of Merger. Prior to the filing referred to in this Section 2.2, the
closing of the Merger (the "Closing") shall be held at the offices of Lowenstein
Sandler PC, 65 Livingston Avenue, Roseland, New Jersey 07068, or such other
place as the Parties may agree, on a date specified by Neurologix (provided that
such date is, absent CTP's concurrence, no more than five Business Days
following the first date upon which all conditions set forth in Article VI
(other than the conditions which may be satisfied solely by the delivery of
documentation within the control of the Party required to deliver such
documentation) have been satisfied or waived), or at such other date as CTP and
Neurologix may agree, provided that the conditions set forth in Article VI have
been
A-5
satisfied or waived at or prior to such date. The date on which the Closing
takes place is referred to herein as the "Closing Date."
2.3 Effects of the Merger. From and after the Effective Time, the Merger
shall have the effects set forth in Sections 259 through 261 of the DGCL.
2.4 Certificate of Incorporation and By-laws. At the Effective Time, (i)
the certificate of incorporation of Neurologix as in effect immediately prior to
the Effective Time shall be the certificate of incorporation of the Surviving
Corporation, with a new corporate name to be designated by Neurologix and (ii)
the by-laws of Neurologix in effect immediately prior to the Effective Time
shall be the by-laws of the Surviving Corporation, in each case until amended in
accordance with applicable law.
2.5 Directors and Officers of Surviving Corporation. From and after the
Effective Time, the individuals listed on Section 2.5 of the Neurologix
Disclosure Letter shall be the directors and officers of the Surviving
Corporation, in each case until their respective successors are duly elected and
qualified or until their earlier death, resignation or removal in accordance
with the certificate of incorporation and by-laws of the Surviving Corporation
and the DGCL. On or prior to the Closing Date, Subcorp shall deliver to
Neurologix a written resignation, in form and substance satisfactory to
Neurologix, from each officer and director of Subcorp, effective as of the
Effective Time.
2.6 Conversion of Securities. At the Effective Time, by virtue of the
Merger, and without any action on the part of any of the Parties, the securities
of the constituent corporations shall be converted as follows:
2.6.1 Cancellation of Treasury Stock and CTP-Owned Stock. Each share
of Neurologix Stock owned by Neurologix or by CTP that is issued and
outstanding immediately prior to the Effective Time (collectively, the
"Excluded Shares") shall be automatically canceled and shall cease to
exist, and no shares of CTP Common Stock or other consideration shall be
paid in exchange for those Excluded Shares.
2.6.2 Subcorp's Stock. Each share of common stock, par value $.001
per share, of Subcorp issued and outstanding immediately prior to the
Effective Time shall be automatically converted into one fully paid and
nonassessable share of common stock, par value $.001 per share, of the
Surviving Corporation. Such newly issued shares shall thereafter constitute
all of the issued and outstanding capital stock of the Surviving
Corporation, and shall be owned by CTP.
2.6.3 Neurologix Stock. If immediately prior to the Closing, (i)
CTP's Net Cash Assets are at least $7.5 million, and (ii) Neurologix has
not raised cash proceeds between the date hereof and the Closing through
the issuance and sale of additional equity securities, then upon
consummation of the Merger, (x) each share of Neurologix Common Stock,
Neurologix Series A Preferred (on an as-converted to Neurologix Common
Stock basis) and Neurologix Series B Preferred (on an as-converted to
Neurologix Common Stock basis) issued and outstanding immediately prior to
the Effective Time (excluding Excluded Shares and Dissenting Shares) shall
be converted into that number of shares of CTP Common Stock multiplied by
the Exchange Ratio, and (y) the aggregate number of shares of CTP Common
Stock issuable at the Effective Time shall equal the Total CTP Stock
Consideration.
Total CTP Existing Shares multiplied by 2
EXCHANGE RATIO = -----------------------------------------
Total Neurologix Existing Shares
TOTAL CTP STOCK CONSIDERATION = Total Neurologix Existing Shares multiplied
by Exchange Ratio
WHERE:
"Total CTP Existing Shares" means the number of shares of CTP Common Stock
(i) issued and outstanding prior to the Effective Time, (ii) issuable upon
conversion of all CTP convertible securities including shares of CTP Series
A Preferred Stock, and (iii) issuable upon exercise of all CTP Existing
Options with an exercise price per share that is less than or equal to
$0.03, which options, as reflected in the CTP Disclosure Letter, provide
for the purchase of 12,000,000 shares of CTP Common Stock (the "CTP
In-the-Money Options").
A-6
"Total Neurologix Existing Shares" means the number of shares of Neurologix
Common Stock (i) issued and outstanding prior to the Effective Time, (ii)
issuable upon conversion of all Neurologix convertible securities including
shares of Neurologix Series A Preferred and Neurologix Series B Preferred,
(iii) issuable upon exchange of the Neurologix Note as provided in the
Voting Agreement and (iv) issuable upon exercise of all Neurologix Options
with an exercise price per share less than or equal to $0.25, which
options, as reflected in the Neurologix Disclosure Letter, provide for the
purchase of 232,000 shares of Neurologix Common Stock (the "Neurologix
In-the-Money Options"), in each case, excluding all Excluded Shares but
including all Dissenting Shares.
2.6.3.1 At the Effective Time, all shares of Neurologix Stock that
have been converted into the right to receive shares of CTP Common Stock
shall be automatically canceled and shall cease to exist, and the
holders thereof shall cease to have any rights with respect to such
shares, other than the right to receive certificates representing shares
of CTP Common Stock upon surrender of the relevant instrument in
accordance with Section 2.7.
2.6.3.2 Upon consummation of the Merger, each Neurologix Option
outstanding immediately prior to the Effective Time shall be converted
into a CTP Exchange Option pursuant to the provisions of Section 2.9.
2.6.3.3 Annexed to CTP's Disclosure Letter is a worksheet setting
forth a description of the allocation of the Total CTP Stock
Consideration among the Neurologix Holders (the "Allocation") that would
be in effect if the Total CTP Stock Consideration was determined as of
the date hereof based upon CTP's Net Cash Assets at this date (including
a reasonable estimate of all costs and liabilities of all pending
litigations and other claims and contingent liabilities, and an estimate
of the costs required to wind down CTP's business), the number of shares
of CTP Common Stock and CTP Existing Options outstanding at this date,
the number of shares of Neurologix Stock and the number of Neurologix
Options outstanding at this date, and the number of shares of Neurologix
Common Stock issuable upon conversion of the Neurologix Note (the
"Worksheet").
2.6.3.4 At least five Business Days prior to the time set for the
Closing, CTP shall deliver to Neurologix CTP's good faith calculation of
the Allocation (the "CTP Calculation"), which shall (a) be prepared in
accordance with the provisions of Section 2.6.3 or 2.6.4, as applicable,
(b) be reflected in the form of the Worksheet (the "Updated Worksheet"),
(c) include CTP's good faith estimate of CTP's Net Cash Assets as of the
Closing Date, and (d) set forth (i) the calculation of the Total CTP
Stock Consideration, (ii) each of the calculations contemplated by
Section 2.6.3 or 2.6.4, as applicable, and (iii) confirm the number of
shares of CTP Common Stock outstanding and the number of shares of CTP
Common Stock issuable upon the exercise and/or conversion of all CTP
convertible securities including the CTP Series A Preferred Stock and
CTP In-the-Money Options. At least seven Business Days prior to the time
set for the Closing, Neurologix shall deliver to CTP a certificate
setting forth the total number of shares of Neurologix Common Stock then
outstanding and the number of shares of Neurologix Common Stock issuable
upon the exercise and/or conversion of the other Neurologix Stock, the
Neurologix In-the-Money Options and the Neurologix Note then
outstanding, which CTP shall use in preparing the CTP Calculation. In
addition, CTP shall, following the date hereof and through Closing,
apprise Neurologix of (a) any pending or threatened litigations, claims
and other contingent liabilities that were not reflected on the
Worksheet and (b) any event or fact that occurs, or of which CTP becomes
aware, after the date hereof that could reasonably affect the estimate
of any litigation, claim and other contingent liability listed on the
Worksheet.
2.6.3.5 Promptly, but in no event later than two Business Days
after receipt of the CTP Calculation, Neurologix shall deliver to CTP a
notice (the "Neurologix Reaction Notice") specifying whether Neurologix
concurs with the CTP Calculation or disputes any aspect of the CTP
Calculation. To enable Neurologix to evaluate the CTP Calculation, CTP
and its Subsidiaries shall make available to CTP and its representatives
all of the personnel, properties, contracts, books and records, and all
other documents and data of CTP and its Subsidiaries that Neurologix
shall
A-7
reasonably request. In the event that the Neurologix Reaction Notice
indicates that Neurologix concurs with the CTP Calculation, the CTP
Calculation shall be determinative for purposes of determining the
Allocation at Closing. With respect to any liability or obligation of
CTP or its Subsidiaries for which an estimate of the amount thereof is
set forth on the Worksheet, the parties hereto agree that such estimate
shall be the amount of such liability or obligation for purposes of the
CTP Calculation and that Neurologix shall not dispute such estimate
unless (i) the actual amount of such liability or obligation becomes
known after the date hereof, in which case such actual amount shall be
used in the CTP Calculation (ii) any event occurs after the date of this
Agreement as a result of which any party hereto no longer believes that
such estimate is reasonable or (iii) any party hereto becomes aware,
after the date of this Agreement, of any fact (including, without
limitation, any change, modification, or clarification of any fact of
which such party was aware prior to the date of this Agreement) as a
result of which such party no longer believes that such estimate is
reasonable. CTP and Neurologix agree that to the extent the receivable
owing to CTP in connection with CTP's lease for 16 West 19th Street (the
"Glaser Receivable") is not collected by CTP prior to Closing and
provided that Neurologix receives a letter from the lessor reasonably
satisfactory to Neurologix to the effect that the Glaser Receivable will
be paid within a reasonable time after Closing, the Glaser Receivable
shall be included in the calculation of CTP's Net Cash Assets less a
$40,000 reserve. CTP and Neurologix agree that to the extent any other
receivable set forth on the Worksheet is not collected prior to Closing,
such receivable (less a reserve mutually agreed to by CTP and
Neurologix) shall be included in the calculation of CTP's Net Cash
Assets if, and only if, CTP can provide assurance reasonably
satisfactory to Neurologix that such receivable shall be paid within a
reasonable time after Closing. Subject to the preceding three sentences,
in the event that the Neurologix Reaction Notice indicates that
Neurologix disputes any aspect of the CTP Calculation, CTP and
Neurologix shall engage an accountant mutually acceptable to CTP and
Neurologix (the "Accountants") to promptly review the determination of
such aspect of the CTP Calculation and resolve such dispute. In the
event that such disputes cannot be resolved prior to the date set for
the Closing, the date set for the Closing shall be deferred until such
disputes are resolved (but in no event later than the Outside Date). In
the event the dispute relates to an estimate of liability for pending or
threatened litigation, or other claim or contingent liability, the
parties will ask the Accountants to assist them in mediating the
dispute.
2.6.4 Adjustment in Calculation of Exchange Ratio.
If immediately prior to the Closing, CTP's Net Cash Assets are less
than $7.5 million or if Neurologix has raised cash proceeds between the
date hereof and the Closing through the issuance and sale of additional
equity, then, for purposes of this Agreement, the Exchange Ratio shall be
calculated as follows:
Total CTP Existing Shares multiplied by X
EXCHANGE RATIO = -----------------------------------------
Total Neurologix Existing Shares
WHERE "X" IS THE QUOTIENT:
obtained by dividing (x) $15.0 million by (y) the lesser of the (i)
amount of CTP's Net Cash Assets as of the Closing Date or (ii) $7.5
million.
In the event that Neurologix sells any additional equity during the
period between the date hereof and the Closing Date, the net cash
proceeds there from (after all expenses incurred relating thereto) shall
be added to the numerator.
2.6.5 No Fractional Shares. No certificates or scrip representing
fractional shares of CTP Common Stock shall be issued as a result of any
conversion provided for in this Section 2.6. All fractional shares shall be
rounded to the nearest whole number, with .5 rounded up. If more than one
certificate representing shares of Neurologix Stock shall be surrendered
for the account of the same holder, the number of shares of Neurologix
Common Stock for which certificates have been surrendered shall be computed
on the basis of the aggregate number of shares (on an as-converted to
Neurologix Common
A-8
Stock basis) represented by the certificates so surrendered. No cash shall
be paid in lieu of fractional shares.
2.6.6 Anti-Dilution Protection.
2.6.6.1 To the extent not already taken into account in computing
the Exchange Ratio, in the event that, prior to the Effective Time, CTP
shall declare a stock dividend or other distribution payable in shares
of CTP Common Stock or securities convertible into shares of CTP Common
Stock, or effect a stock split, reclassification, recapitalization,
combination or any other comparable change with respect to CTP Common
Stock, the shares of CTP Common Stock to be received by each Stockholder
in the Merger shall be correspondingly adjusted to reflect such
dividend, distribution, stock split, reclassification, recapitalization,
combination or other comparable change.
2.6.6.2 To the extent not already taken into account in computing
the Exchange Ratio, in the event that, prior to the Effective Time,
Neurologix shall declare a stock dividend or other distribution payable
in shares of Neurologix Common Stock or securities convertible into
shares of Neurologix Common Stock, or effect a stock split,
reclassification, recapitalization, combination or any other comparable
change with respect to Neurologix Common Stock, the shares of CTP Common
Stock to be received by each Stockholder in the Merger shall be
correspondingly adjusted to reflect such dividend, distribution, stock
split, reclassification, recapitalization, combination or other
comparable change.
2.6.7 Dissenting Stock. Any holder of shares of Neurologix Stock
shall have the right to appraisal in the manner provided in Section 262
of the DGCL, and if all necessary requirements of the DGCL are met, such
shares shall be entitled to payment of the fair value of such shares in
accordance with the provisions of the DGCL ("Dissenting Stock");
provided, however, that (i) if any holder of Dissenting Stock shall
subsequently withdraw such holder's demand for appraisal of such shares
within sixty days of the Effective Time, or (ii) if any holder fails to
follow the procedures for establishing such holder's entitlement to
appraisal rights as provided in the DGCL, the right to appraisal of such
shares shall be forfeited and such shares shall thereupon be deemed to
have been converted into the right to receive and to have become
exchangeable for, as of the Effective Time, the shares of CTP Common
Stock such holder would have been entitled to receive had such holder
not exercised appraisal rights.
2.6.8 Tax Consequences. It is intended that the Merger shall
constitute a "reorganization" within the meaning of Section 368(a) of
the Code, and that this Agreement shall constitute a "plan of
reorganization" for the purposes of the Code.
2.7 Exchange of Certificates. The following provisions shall apply with
respect to the exchange of certificates pursuant to the Merger:
2.7.1 Procedures. Prior to the Closing, CTP shall enter into an
exchange agency agreement with the Exchange Agent, in form and substance
satisfactory to Neurologix, pursuant to which the Exchange Agent shall
perform the obligations of the Exchange Agent described in this Agreement.
As soon as practicable after the Effective Time, CTP shall mail, or shall
cause the Exchange Agent to mail, to each holder of record of a certificate
or certificates (the "Certificates") which immediately prior to the
Effective Time represented issued and outstanding shares of Neurologix
Stock, a letter of transmittal in customary form (which shall specify that
delivery shall be effected, and risk of loss and title to the Certificates
shall pass, only upon delivery of the Certificates to CTP and shall be in
such form and have such other provisions as Neurologix and CTP may
reasonably specify, including customary waivers and releases of liability
and which shall contain instructions for effecting the surrender of the
Certificates in exchange for certificates representing shares of CTP Common
Stock). Upon surrender of a Certificate for cancellation to the Exchange
Agent, together with a duly executed letter of transmittal, the holder of
such Certificate shall be entitled to receive in exchange therefor (and CTP
shall cause the Exchange Agent to promptly deliver) a certificate
representing that number of whole shares of CTP Common Stock which such
holder has the right to receive pursuant to Section 2.6 rounded to the
nearest whole number. Any
A-9
Certificate so surrendered shall be immediately canceled. No cash shall be
payable in lieu of the issuance of fractional shares. In the event of a
transfer of ownership of shares of Neurologix Stock which is not registered
on the transfer records of Neurologix, a certificate representing the
proper number of whole shares of CTP Common Stock may be issued to such
transferee if the Certificate representing such shares of Neurologix Stock
held by such transferee is presented to the Exchange Agent, accompanied by
all documents required to evidence and effect such transfer and to evidence
that any applicable stock transfer taxes have been paid. Until surrendered
as contemplated by this Section 2.7, each Certificate shall be deemed at
any time after the Effective Time to represent only the right to receive
upon surrender a certificate representing shares of CTP Common Stock.
2.7.2 Stock Transfer Books; Extinction of Stockholder Rights. At the
Effective Time, the stock transfer books of Neurologix shall be closed with
respect to the shares of Neurologix Stock outstanding immediately prior to
the Effective Time. All shares of CTP Common Stock issued upon surrender of
a Certificate in accordance with the terms hereof shall be deemed to have
been issued in full satisfaction of all rights pertaining to that
Certificate and the shares of Neurologix Stock represented thereby, and
there shall be no further registration of transfers on the stock transfer
books of Neurologix of shares of Neurologix Stock outstanding immediately
prior to the Effective Time. If, after the Effective Time, a Certificate is
presented to the Surviving Corporation for any reason, it shall be canceled
and exchanged for certificates representing shares of CTP Common Stock as
provided in this Article II.
2.7.3 Lost Certificates. In the event that any Certificate shall
have been lost, stolen or destroyed, upon the Exchange Agent's receipt of
appropriate evidence as to such loss, theft or destruction and as to the
ownership of such Certificate by the Person claiming such Certificate to be
lost, stolen or destroyed, and the receipt by CTP and the Exchange Agent of
reasonably appropriate and customary indemnification, CTP shall cause the
Exchange Agent to deliver, in exchange for such lost, stolen or destroyed
Certificate, shares of CTP Common Stock deliverable in respect thereof as
determined in accordance with the provisions of this Agreement.
2.8 Delivery of CTP Common Stock to Exchange Agent. At or prior to the
Effective Time, CTP shall deposit with the Exchange Agent, for the benefit of
each Stockholder, for exchange in accordance with this Article II, certificates
representing the shares of CTP Common Stock issuable to each Stockholder
pursuant to Section 2.6 upon conversion of outstanding shares of Neurologix
Stock.
2.9 Treatment of Neurologix Stock Options. Prior to the Effective Time,
CTP and Neurologix shall take all such actions as may be necessary such that at
the Effective Time each unexpired and unexercised Neurologix Option prior to the
Effective Time shall, by virtue of the Merger and without any action by the
holder of such Neurologix Option, be automatically converted at the Effective
Time into an option (an "CTP Exchange Option") to purchase that number of shares
of CTP Common Stock equal to the number of shares of Neurologix Common Stock
covered by such Neurologix Option multiplied by the Exchange Ratio, which number
shall be correspondingly adjusted (to the extent not already taken into account
in computing the Exchange Ratio) to reflect the effect of any adjustment made
pursuant to Section 2.6.4. Each CTP Exchange Option shall have an exercise price
equal to the exercise price which existed under the corresponding Neurologix
Option divided by the Exchange Ratio but in no event less than the par value of
the shares of CTP Common Stock underlying such CTP Exchange Option. With the
exception of the adjustments set forth above and the fact that the CTP Exchange
Options shall be administered by the Compensation Committee of CTP's board of
directors or such other committee as shall be designated from time to time by
such board, the terms and conditions of each CTP Exchange Option shall be
identical to the terms and conditions to which the corresponding Neurologix
Option was subject immediately prior to the Effective Time; provided that with
respect to any Neurologix Option that is an "incentive stock option" within the
meaning of Section 422 of the Code, the foregoing conversion shall be carried
out in a manner satisfying the requirements of Section 424(a) of the Code. In
connection with the issuance of CTP Exchange Options, CTP shall (i) reserve for
issuance the number of shares of CTP Common Stock that will become subject to
CTP Exchange Options pursuant to this Section 2.9 and (ii) register the shares
of CTP Common Stock subject to the CTP Exchange Options on a registration
statement on Form S-8 to the extent that such shares are so registerable.
A-10
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF NEUROLOGIX
Neurologix represents and warrants to CTP and Subcorp as follows:
3.1 Organization and Qualification. Neurologix is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware and has the power and authority to own, lease and operate its
properties and to conduct its business as presently conducted. Neurologix is
duly qualified or licensed to transact business as a foreign corporation and is
in good standing in each jurisdiction in which the conduct of its business or
the ownership, leasing or operation of its property requires such qualification,
except for failures to be so qualified or in good standing which would not,
singly or in the aggregate with all such other failures, have a Neurologix
Material Adverse Effect. Neurologix has no Subsidiaries, and except as set forth
on Section 3.1 of the Neurologix Disclosure Letter, Neurologix does not own,
directly or indirectly, any shares of capital stock of, or any other security or
interest convertible into or exchangeable or exercisable for shares of capital
stock of or other ownership interests in, any other Person.
3.2 Authority Relative to this Agreement; Enforceability. The execution,
delivery and performance of this Agreement are within the corporate power and
authority of Neurologix and have been duly and validly authorized by all
requisite corporate action on the part of Neurologix. This Agreement has been
duly executed and delivered by Neurologix and is a legal, valid and binding
obligation of Neurologix, enforceable against Neurologix in accordance with its
terms, except insofar as its enforcement may be limited by (a) bankruptcy,
insolvency, moratorium or similar laws affecting the enforcement of creditors'
rights generally and (b) equitable principles limiting the availability of
equitable remedies. All persons who executed this Agreement on behalf of
Neurologix have been duly authorized to do so.
3.3 Conflicts; Consents and Approvals. Neither the execution and delivery
of this Agreement by Neurologix nor the consummation of the transactions
contemplated hereby will: (a) conflict with, or result in a breach of any
provision of, Neurologix's certificate of incorporation or by-laws; (b) violate,
or conflict with, or result in a breach of any provision of, or constitute a
default (or an event which, with the giving of notice, the passage of time or
otherwise, would constitute a default) under, or entitle any party (with the
giving of notice, the passage of time or otherwise) to terminate, accelerate,
modify or call a default under, or result in the creation of any Lien upon any
of the properties or assets of Neurologix under, any of the terms, conditions or
provisions of any note, bond, mortgage, indenture, deed of trust, license,
contract, undertaking, agreement, lease or other instrument or obligation to
which Neurologix is a party or by which Neurologix is bound; (c) violate any
order, writ, injunction, decree, statute, rule or regulation applicable to
Neurologix or its properties or assets; or (d) require any action or consent or
approval of, or review by, or registration or filing by Neurologix or any of its
Affiliates with, any third party or any Governmental Entity, other than filing
of the Certificate of Merger and registrations or other actions required under
federal and state securities laws as are contemplated by this Agreement.
3.4 Capitalization. As of the date hereof, the authorized capital stock
of Neurologix consists solely of: (a) 20,000,000 shares of Neurologix Common
Stock and (b) 1,000,000 shares of Neurologix preferred stock, of which 500 of
such shares have been designated as Neurologix Series A Preferred and 562,500 of
such shares have been designated as Neurologix Series B Preferred. As of the
date hereof there are 2,490,583 shares of Neurologix Common Stock issued and
outstanding, 147 shares of Neurologix Series A Preferred issued and outstanding,
which are convertible into 2,205,000 shares of Neurologix Common Stock, and
490,754 shares of Neurologix Series B Preferred issued and outstanding, which
are convertible into 490,754 shares of Neurologix Common Stock, and no shares of
Neurologix Stock were held in Neurologix's treasury. There are no options,
warrants or other securities, rights or agreements outstanding that entitle any
Person to acquire (either currently or upon the passage of time or the
occurrence of any condition or event) any shares of Neurologix Common Stock or
any other security convertible into or exchangeable or exercisable for
Neurologix Common Stock, other than as set forth in the immediately preceding
sentence and except for (x) stock options to purchase 257,000 shares of
Neurologix Common Stock granted by Neurologix to current or former directors,
officers, employees, consultants or representatives of Neurologix or to other
persons with relationships to Neurologix (each, a "Neurologix Option") and (y)
the Neurologix Note which the holders thereof (including
A-11
all Persons having a participatory interest therein) and Neurologix have agreed
will be exchanged, pursuant to the terms of the Voting Agreement, for Neurologix
Common Stock, at a price of $6 per share (383,040 shares if computed at June 30,
2003).
3.5 No Litigation; Compliance with Laws; Permits. There is no (i) action,
suit, claim, proceeding, demand, arbitration, hearing, complaint, examination or
investigation pending or, to the best of Neurologix's knowledge, threatened
against or affecting Neurologix, at law or in equity, or before or by any
federal, state, municipal or other governmental department, commission, board,
bureau, agency or instrumentality, domestic or foreign or any other Governmental
Entity (including, without limitation, any action, suit, claim, proceeding,
demand arbitration, hearing, complaint, examination or investigation against any
director, officer or employee of Neurologix or other person for whom Neurologix
may be liable), (ii) arbitration proceeding relating to Neurologix pending under
collective bargaining agreements or otherwise, or (iii) governmental inquiry
pending or, to the best of Neurologix's knowledge, threatened against or
affecting Neurologix (including without limitation any inquiry as to the
qualification of Neurologix to hold or receive any license or permit), except as
would not have, either individually or in the aggregate, a Neurologix Material
Adverse Effect. Neurologix has complied with all material laws, rules,
regulations and orders applicable to its business, operations, properties,
assets, products and services. Neurologix has all necessary permits, licenses,
grants, consents, approvals and other authorizations required to conduct its
business as now conducted, except such permits, licenses, grants, consents,
approvals and other authorizations that, if not obtained, would have, either
individually or in the aggregate, a Neurologix Material Adverse Effect, and such
permits, licenses, grants, consents, approvals, and other authorizations are in
full force and effect. No suspension or cancellation of any such permit,
license, grant, consent and authorization is pending or, to the best of
Neurologix's knowledge, threatened. No such suspension or cancellation will
result from transactions contemplated by this Agreement.
3.6 Title to Assets. Neurologix has good and marketable title to or a
valid leasehold interest in, or licenses to, its properties and assets and all
such properties and assets owned by Neurologix are free and clear of all Liens,
except for (i) Liens for current taxes not yet due and payable and minor
imperfections of title, if any, not material in nature or amount and not
materially detracting from the value or impairing the use of the property
subject thereto or impairing the operations of Neurologix, (ii) Liens granted to
CTP and the holders of the Neurologix Note and (iii) as set forth on Section 3.6
of the Neurologix Disclosure Letter. Each lease or agreement to which Neurologix
is a party under which it is a lessee of any property, real or personal, is a
valid and existing agreement without any default of Neurologix thereunder and,
to the best of Neurologix's knowledge, without any default thereunder of any
other party thereto. To the best of Neurologix's knowledge, no event has
occurred and is continuing which, with due notice or lapse of time or both,
would constitute a default or event of default by Neurologix under any such
lease or agreement or, to the best of Neurologix's knowledge, by any other party
thereto.
3.7 Taxes. As of the date of this Agreement:
3.7.1 all Tax Returns required to be filed by or with respect to
Neurologix have been properly prepared and timely filed, and all such Tax
Returns (including information provided therewith or with respect to
thereto) are true, complete and correct in all material respects;
3.7.2 Neurologix has paid all Taxes owed by it (whether or not shown
on any Tax Return), and has made adequate provision for any Taxes that are
not yet due and payable, for all taxable periods, or portions thereof,
ending on or before the date hereof;
3.7.3 Neurologix has given or otherwise made available to CTP true,
correct and complete copies of all Tax Returns, examination reports and
statements of deficiencies for taxable periods, or transactions
consummated, for which the applicable statutory periods of limitations have
not expired;
3.7.4 there are no outstanding agreements extending or waiving the
statutory period of limitations applicable to any claim for, or the period
for the collection or assessment or reassessment of, Taxes due from
Neurologix for any taxable period and no request for any such waiver or
extension is currently pending;
A-12
3.7.5 to the knowledge of Neurologix, no audit or other proceeding by
any Governmental Entity is pending or threatened with respect to any Taxes
due from or with respect to Neurologix, no Governmental Entity has given
notice of any intention to assert any deficiency or claim for additional
Taxes against Neurologix, and no claim has been made by any Governmental
Entity in a jurisdiction where Neurologix does not file Tax Returns that it
is or may be subject to taxation by that jurisdiction, and all deficiencies
for Taxes asserted or assessed against Neurologix have been fully and
timely paid, settled or properly reflected in the most recent audited
financial statements;
3.7.6 there are no Liens for Taxes upon the assets or properties of
Neurologix, except for statutory Liens for current Taxes not yet due;
3.7.7 Neurologix has not taken any reporting position on a Tax
Return, which reporting position (i) if not sustained would be reasonably
likely, absent disclosure, to give rise to a penalty for substantial
understatement of federal income Tax under Section 6662 of the Code (or any
similar provision of state, local, or foreign Tax law), and (ii) has not
adequately been disclosed on such Tax Return in accordance with Section
6662(d)(2)(B) of the Code (or any similar provision of state, local, or
foreign Tax law);
3.7.8 Neurologix has withheld (or will withhold) from its employees,
independent contractors, creditors, stockholders and third parties and
timely paid to the appropriate Governmental Entity proper and accurate
amounts in all material respects for all periods ending on or before the
Closing Date in compliance with all Tax withholding and remitting
provisions of applicable laws and have each complied in all material
respects with all Tax information reporting provisions of all applicable
laws;
3.7.9 Neurologix has not constituted a "distributing corporation" or
a "controlled corporation" (within the meaning of Section 355(a)(1)(A) of
the Code) in a distribution of shares qualifying for tax-free treatment
under Section 355 of the Code (i) in the two years prior to the date of
this Agreement or (ii) in a distribution that could otherwise constitute
part of a "plan" or "series of related transactions" (within the meaning of
Section 355(e) of the Code) in conjunction with this acquisition.
3.7.10 Neurologix has not agreed, and is not required to make, any
adjustment under Section 481(a) of the Code, and to the knowledge of
Neurologix, no Governmental Entity has proposed any such adjustment or
change in accounting method;
3.7.11 any adjustment of Taxes of Neurologix made by the Internal
Revenue Service (the "IRS"), which adjustment is required to be reported to
the appropriate state, local, or foreign governmental authorities, has been
so reported;
3.7.12 Neurologix has not executed or entered into a closing
agreement pursuant to Section 7121 of the Code or any similar provision of
state, local or foreign law, and Neurologix is not subject to any private
letter ruling of the IRS or comparable ruling of any other Governmental
Entity;
3.7.13 there is no contract, agreement, plan, or arrangement covering
any person that, individually or collectively, could give rise to the
payment of any amount that would not be deductible by CTP, Subcorp, or
Neurologix by reason of Section 280G of the Code;
3.7.14 Neurologix is not a party to any contract, agreement or other
arrangement which could result in the payment of amounts that could be
nondeductible by reason of Section 162(m) of the Code;
3.7.15 Neurologix has not entered into a transaction that is being
accounted for under the installment method of Section 453 of the Code or
similar provision of state, local or foreign law;
3.7.16 Neurologix has not filed a consent under Section 341(f) of the
Code;
3.7.17 Neurologix is not a party to any lease arrangement involving a
defeasance of rent, interest or principal;
3.7.18 Neurologix is not a direct or indirect beneficiary of a
guarantee of Tax benefits or any other arrangement that has the same
economic effect (including an indemnity from a seller or lessee of
property, or other insurance) with respect to any transaction or Tax
opinion relating to Neurologix;
A-13
3.7.19 Neurologix does not owe any "corporate acquisition
indebtedness" within the meaning of Section 279 of the Code;
3.7.20 Neurologix has never been (i) a "passive foreign investment
company," (ii) a "foreign personal holding company," (iii) a "foreign sales
corporation," (iv) a "foreign investment company," or (v) a person other
than a United States person, each within the meaning of the Code;
3.7.21 Neurologix is not a "personal holding company" within the
meaning of Section 542 of the Code;
3.7.22 Neurologix has no elections in effect for federal income tax
purposes under Sections 108, 168, 338, 441, 472, 1017 or 4977 of the Code
or any other material Tax election; and
3.7.23 Neurologix is not an "investment company" within the meaning
of Section 368(a)(2)(F) of the Code.
3.8 Intellectual Property. Neurologix owns or possesses licenses or other
rights to all patents, patent applications, trademarks, copyrights, know-how,
trade secrets and other intellectual property ("Intellectual Property")
necessary to the conduct of its business as currently conducted by it, free and
clear of any Liens (except as set forth on Section 3.8 of the Neurologix
Disclosure Letter) and without any Neurologix obligation to any person or entity
for royalties, fees or commissions (except pursuant to various licenses,
research, development and consulting agreements which have been provided to
counsel to CTP). Section 3.8 of the Neurologix Disclosure Letter sets forth a
true and complete list of all registrations and issuances of, and applications
for, any Intellectual Property owned or purported to be owned by Neurologix,
setting forth the serial or registration number and name or title of each item
of Intellectual Property. To the best of Neurologix's knowledge, Neurologix's
operations do not infringe upon or conflict with the asserted rights of any
other person under any Intellectual Property. To the best of Neurologix's
knowledge, all such Intellectual Property owned, purported to be owned or
licensed by Neurologix, or which Neurologix otherwise uses, reproduces, prepares
derivative works based upon, distributes, performs, displays, makes, has made,
sells, offers to sell and imports (collectively, "Practices"), is valid and
enforceable and has not been challenged in any judicial or administrative
proceeding. To the best of Neurologix's knowledge, no claim is pending or
threatened against Neurologix to the effect that any such Intellectual Property
owned or licensed by Neurologix, or which Neurologix otherwise Practices, is
invalid or unenforceable by Neurologix. To the best of Neurologix's knowledge,
no Person nor such Person's business or products has infringed, misused,
misappropriated or conflicted with such Intellectual Property owned, purported
to be owned or licensed by Neurologix, or which Neurologix otherwise Practices
or currently is infringing, misusing, misappropriating or conflicting with such
Intellectual Property owned, purported to be owned or licensed by Neurologix, or
which Neurologix otherwise Practices. To the best of Neurologix's knowledge,
Neurologix has made, or is diligently preparing to make, all statutorily
required filings in the United States, if any, to record its interests, and
taken reasonable actions to protect its rights in such Intellectual Property
owned or licensed by Neurologix, or which Neurologix otherwise Practices. Except
as set forth on Section 3.8 of the Neurologix Disclosure Letter, Neurologix is:
(i) diligently preparing to file patent applications in the United States and
all foreign jurisdictions in which Neurologix currently contemplates conducting
business for all inventions which Neurologix owns or with respect to which
Neurologix has the contractual right to control the filing of a patent
application and which Neurologix believes are material to its business within a
sufficient time period to avoid statutory disqualification of any such potential
application; and (ii) diligently prosecuting all patent applications it has
previously filed and which it deems to be material to its business. Except as
set forth on Section 3.8 of the Neurologix Disclosure Letter, each present or
past employee, officer or consultant who developed any part of any product of
Neurologix or any Intellectual Property that is or will be Practiced by
Neurologix has executed an invention assignment agreement with Neurologix
substantially in the form provided to counsel to CTP. It is not necessary for
the business of Neurologix to acquire the rights to Practice any Intellectual
Property owned by any present or past director, officer, employee or consultant
of Neurologix (or Persons Neurologix presently intends to hire), except for such
rights which Neurologix already has acquired. To the knowledge of Neurologix, at
no time during the conception or reduction to practice of any of the
Intellectual Property that is or currently is intended to be Practiced by
Neurologix was any developer,
A-14
inventor or other contributor to such Intellectual Property operating under any
grants from any Governmental Authorities or subject to any employment agreement,
invention, assignment, nondisclosure agreement or other contract with any Person
(other than institutions to which Neurologix is a party to research or license
agreements, copies of which agreements have been delivered to CTP's counsel)
that could adversely affect the rights of Neurologix to such Intellectual
Property. Neurologix is a joint owner, together with Rockefeller University
("RU") and Thomas Jefferson University ("TJU"), and is an exclusive licensee of
RU's and TJU's interest in, the intellectual property contained in United States
provisional patent application No. 60/292,604, filed on May 22,2001, titled
"Transcriptional Regulation of Target Genes" Klauber & Jackson Docket No.
2573-1-001P, and the related non-provisional patent application No. 10/151,702
(publication no. 20020087264 A1), which bears the same title (collectively, the
"MDT IP") subject to an agreement between Neurologix and Medtronic Neurological,
dated as of February 28, 2002. The MDT IP (i) is not necessary to the conduct of
Neurologix's business as currently conducted or its current product strategy,
and (ii) will not be part of Neurologix's Phase I human clinical trials of gene
therapy for the treatment of Parkinson's disease.
3.9 Financial Statements. Attached as Section 3.9 of the Neurologix
Disclosure Letter are the audited balance sheet of Neurologix as of December 31,
2002, and the related audited statements of income, changes in stockholders'
equity and cash flows of Neurologix for the year ended December 31, 2002, each
prepared in accordance with GAAP applied on a consistent basis, and the
unaudited balance sheet of Neurologix as of June 30, 2003 and the related
unaudited statements of income and cash flows for the six months then ended (the
"Neurologix Financial Statements"). The Neurologix Financial Statements fairly
present (subject, in the case of any unaudited interim statements, to normal,
year-end adjustments, none of which will be material) the financial condition of
Neurologix and the results of Neurologix's operations and cash flows as at the
dates and for the periods to which they apply, as the case may be, and such
statements have been prepared in conformity with GAAP.
3.10 Undisclosed Liabilities. Neurologix has no liabilities or
obligations of any kind whatsoever, whether known or unknown, absolute, accrued,
contingent or otherwise, or whether due or to become due, other than those (i)
reflected in the Neurologix Financial Statements including the footnotes
thereto, (ii) that arise under the contracts delivered to CTP's counsel or in
Section 3.10 of the Neurologix Disclosures Letter, (iii) incurred in the
ordinary course of business since June 30, 2003 and which would not have a
Neurologix Material Adverse Effect or (iv) as would not have an impact on
Neurologix's unencumbered cash and cash equivalents in excess of (i.e., net of)
all liabilities (actual and contingent, accrued and unaccrued) and contractual
commitments of Neurologix.
3.11 Environmental Matters. Neurologix has complied in all material
respects with all federal, state or local statutes, ordinances, orders,
judgments, rulings or regulations relating to protection of the environment or
natural resources or to environmental regulation or control (collectively,
"Environmental Laws"). Neurologix, to its knowledge, is not the subject of any
federal, state, local or foreign investigation, and Neurologix has not received
any written notice or claim, or entered into any negotiations or agreements with
any person, relating to any material liability or material remedial action under
any applicable Environmental Laws. Neither Neurologix nor any of its officers,
employees, representatives or agents, nor, to the knowledge of Neurologix, any
other person, has utilized, treated, stored, processed, released, manufactured,
discharged, spilled or otherwise disposed of any odor, pollutant, contaminant or
other substance defined as hazardous or toxic by any Environmental Law, or any
waste or by-products thereof, at any real property or any other facility owned
or leased by Neurologix, in violation of any applicable statutes, regulations,
ordinances or directives of any Governmental Entity or court, except as would
not have a Neurologix Material Adverse Effect.
3.12 Material Contracts. Except as set forth in Section 3.12 of the
Neurologix Disclosure Letter, Neurologix is not a party to or bound by any:
3.12.1 employment agreement (other than those that are terminable by
Neurologix without cost or penalty upon 60 days' or less notice);
3.12.2 operating or capital lease, whether as lessor or lessee, with
respect to any real property;
A-15
3.12.3 contract, whether as licensor or licensee, for the license of
any patent, know-how, trademark, trade name, service mark, copyright or
other intangible asset;
3.12.4 loan or guaranty agreement, indenture or other instrument,
contract or agreement under which any money has been borrowed or loaned or
any note, bond or other evidence of indebtedness has been issued;
3.12.5 mortgage, security agreement, conditional sales contract,
capital lease or similar agreement which effectively creates a lien on any
assets of Neurologix;
3.12.6 contract restricting Neurologix in any material respect from
engaging in business or from competing with any other parties;
3.12.7 plan of reorganization;
3.12.8 partnership, joint venture or similar agreement;
3.12.9 collective bargaining agreement;
3.12.10 "material contract" (as defined in Item 601(b)(10) of
Regulation S-K of the SEC);
3.12.11 contract or commitment (whether written or oral) which
continues for a period of more than six months from the date hereof or
requires payments, in the aggregate, in excess of $50,000;
3.12.12 investment banking or other professional service agreement;
3.12.13 agreement regarding acquisitions or dispositions of a
material portion of Neurologix's assets other than in the ordinary course
of Neurologix's business;
3.12.14 outstanding loan or loan commitment to any person or any
factoring, credit line or subordination agreement; or
3.12.15 any power of attorney outstanding or any contract, commitment
or liability (whether absolute, accrued, contingent or otherwise), as
guarantor, surety, cosigner, endorser, co-maker, indemnitor in respect of
the contract or commitment of any other Person.
All of the foregoing are collectively referred to as "Neurologix Material
Contracts." To the extent Neurologix Material Contracts are evidenced by
documents, true and complete copies thereof (and summaries of oral Neurologix
Material Contracts) have been delivered or made available to CTP. Each
Neurologix Material Contract is in full force and effect. Neurologix and, to the
best of Neurologix's knowledge, each other party thereto have in all material
respects performed all of the obligations required to be performed by them to
date, have received no notice of default and are not in default (with due notice
or lapse of time or both) under any Neurologix Material Contract.
3.13 Insurance. Section 3.13 of the Neurologix Disclosure Letter sets
forth a list of all insurance policies which Neurologix currently has in effect,
and the status of any unpaid claims thereunder. True and correct copies of such
insurance policies have been made available to CTP. All premiums due and payable
under all such policies have been paid, and to Neurologix's knowledge,
Neurologix is in compliance in all material respects with the terms and
conditions of all such policies.
3.14 Affiliate Transactions. Except as set forth on Section 3.14 of the
Neurologix Disclosure Letter, there are no other transactions, agreements,
arrangements or understandings between Neurologix, on the one hand, and any
officer, director, employee, family member of any of the foregoing, or any
Affiliate (including, without limitation, Palisade Capital Management LLC and
its Affiliates) of Neurologix or other persons, on the other hand, that would be
required to be disclosed under Item 404 of Regulation S-K under the Securities
Act of 1933, as amended.
3.15 Employee Benefit Plans. Except as set forth in Section 3.15 of the
Neurologix Disclosure Letter, neither Neurologix nor any of its Affiliates
maintains, sponsors or otherwise has any obligation or liability with respect to
any "employee benefit plan" (as defined in Section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended ("ERISA")) or any other plan,
policy, contract or arrangement (whether
A-16
written or oral), including any plan, policy, contract or arrangement providing
bonuses, stock options, stock purchase rights, deferred compensation, health or
welfare benefits, vacation or sick benefits, or any other employee fringe
benefits (each an "Employee Benefit Plan"), and there exists no circumstances,
whether known or unknown, contingent or otherwise, under which Neurologix could
have any material liability, whether direct or indirect, with respect to any
Employee Benefit Plan that Neurologix or any of its Affiliates maintained,
sponsored or otherwise had any obligation or liability with respect to prior to
the Closing Date. No suit is currently pending, or to Neurologix's knowledge is
being threatened, by any former employee alleging wrongful termination, breach
of an employment agreement, discrimination or any other payments from
Neurologix.
3.16 Funded Debt.
3.16.1 Except as set forth in (i) the balance sheet of Neurologix as
of December 31, 2002 and the footnotes thereto included in the Neurologix
Financial Statements, (ii) the balance sheet of Neurologix as of June 30,
2003 and the footnotes thereto included in the Neurologix Financial
Statements, or (iii) Section 3.16 of the Neurologix Disclosure Letter,
Neurologix does not have any term or funded debt, debt to banks or debt to
Affiliates. No event has occurred which (whether with or without notice,
lapse of time or the happening or occurrence of any other event) would
constitute a default by Neurologix which has not been cured or waived under
any agreement or other instrument relating to any funded debt, bank loan or
debt to Affiliates.
3.16.2 Except as set forth in Section 3.16 of the Neurologix
Disclosure Letter, Neurologix is not a guarantor of the obligations of any
Person.
3.16.3 There are no accrued or declared dividends on any shares of
any of Neurologix's capital stock that have not been paid.
3.17 Other Business Names. Section 3.17 of the Neurologix Disclosure
Letter sets forth each business name or registered trade name currently used by
Neurologix in connection with its business, and each jurisdiction, if any in
which such name is registered.
3.18 Required Actions. Pursuant to the Voting Agreement, a majority of
the holders of each class of the capital stock of Neurologix has committed to
take all action in accordance with the federal securities laws, the DGCL, its
certificate of incorporation and its by-laws necessary to obtain the consent and
approval of its Stockholders to the Merger, this Agreement and the transactions
contemplated hereby. Neurologix's board is recommending to its Stockholders
approval of the Merger and the transactions contemplated by this Agreement and
declaring its advisability.
3.19 FDA Approval. (i) Neurologix has no knowledge that any Governmental
Entity, including, but not limited to, the United States Food and Drug
Administration (the "FDA"), will ultimately prohibit the marketing, sale,
license or use in the United States or any other jurisdiction in which
Neurologix expects to exploit its Intellectual Property of any product proposed
to be developed, produced or marketed by Neurologix, or with third parties
(each, a "Product"), (ii) no Product is on clinical hold and Neurologix does not
have any reason to expect that any Product is reasonably likely to be placed on
clinical hold, (iii) Neurologix has made available to CTP all submissions to the
FDA and the FDA responses (and other material correspondence received from or
submitted to the FDA), including, but not limited to, all FDA warning letters,
regulatory letters and notice of adverse finding letters and the relevant
responses, received by Neurologix or any agent thereof relative to the
development of its Products, (iv) to the knowledge of Neurologix, the FDA has
not prohibited any product or production process from being marketed or used in
the United States which product or process is substantially similar to any
Product in composition, (v) neither Neurologix nor, to the knowledge of
Neurologix, the employees, consultants, contractors, and sub-contractors of
Neurologix, has ever been sanctioned, formally or otherwise, by the FDA, and
(vi) there has not been any suspensions or debarments by the FDA or other
federal departments and state regulatory bodies against Neurologix, or, to the
knowledge of Neurologix, any current or former employee, consultant, contractor
or subcontractor of Neurologix. Neither Neurologix, nor to its knowledge any
officer, employee or agent of
A-17
Neurologix, has knowingly made an untrue statement of a material fact or
fraudulent statement to the FDA or other Governmental Entity.
3.20 No Material Adverse Change. Except as set forth on Section 3.20 of
the Neurologix Disclosure Letter, since December 31, 2002, Neurologix has
conducted its business in the ordinary course consistent with past practice, and
there has not been any material adverse change in the business, financial
condition, prospects, assets or operations of Neurologix.
3.21 Brokerage. No broker or finder has rendered services to Neurologix
or, to the best of Neurologix's knowledge, to any Stockholder in connection with
this Agreement or the transactions contemplated hereby, other than Palisade
Capital Securities, L.L.C. Neurologix has agreed to pay Palisade Capital
Securities, L.L.C. an aggregate of $200,000 at the Effective Time for such
services. Other than as set forth in this Section 3.21, there is no agreement
executed by Neurologix which will obligate Neurologix or any of its successors
or Affiliates to pay any brokerage or finder's fee in the future with respect to
any type of commercial, corporate, financial, acquisition, banking, borrowing or
other business transaction.
3.22 Full Disclosure. No representation or warranty made in this Article
III, and no certification furnished or to be furnished by Neurologix pursuant to
this Agreement, contains or will contain any untrue statement of a material fact
or omits, or will omit, to state a material fact necessary to make the
statements contained herein or therein not misleading.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF CTP AND SUBCORP
CTP and Subcorp represent and warrant to Neurologix as follows:
4.1 Organization and Qualification. Each of CTP and Subcorp is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware and has the power and authority to own, lease and
operate its properties and to conduct its business as now conducted. Each of CTP
and Subcorp is duly qualified or licensed to transact business as a foreign
corporation, and is in good standing in each jurisdiction in which the conduct
of its business or the ownership, leasing or operation of its property requires
such qualification, except for failures to be so qualified or in good standing
which would not, singly or in the aggregate with all such other failures, have a
CTP Material Adverse Effect. CTP has no Subsidiaries (other than Subcorp and
Iguana Studios, Inc., a Delaware corporation which is inactive). CTP has no
interests in any other Person other than inactive subsidiaries with no material
assets or liabilities. Subcorp was formed solely for the purpose of engaging in
the transactions contemplated by this Agreement and has not engaged in any
business activities or conducted any operations other than in connection with
the transactions contemplated by this Agreement.
4.2 Authority Relative to this Agreement; Enforceability. The execution,
delivery and performance of this Agreement are within the corporate power and
authority of CTP and Subcorp and have been duly and validly authorized by all
requisite corporate action on the part of CTP and Subcorp. This Agreement has
been duly executed and delivered by CTP and Subcorp and is a legal, valid and
binding obligation of CTP and Subcorp, enforceable against CTP and Subcorp in
accordance with its terms, except insofar as its enforcement may be limited by
(a) bankruptcy, insolvency, moratorium or similar laws affecting the enforcement
of creditors' rights generally and (b) equitable principles limiting the
availability of equitable remedies. All persons who executed this Agreement on
behalf of CTP and Subcorp have been duly authorized to do so.
4.3 Conflicts; Consents and Approvals. Neither the execution and delivery
of this Agreement by CTP and Subcorp nor the consummation of the transactions
contemplated hereby will: (a) conflict with, or result in a breach of any
provision of, CTP or Subcorp's certificate of incorporation or by-laws; (b)
violate, or conflict with, or result in a breach of any provision of, or
constitute a default (or an event which, with the giving of notice, the passage
of time or otherwise, would constitute a default) under, or entitle any party
(with the giving of notice, the passage of time or otherwise) to terminate,
accelerate, modify or call a default under, or result in the creation of any
Lien upon any of the properties or assets of CTP or Subcorp under, any of the
A-18
terms, conditions or provisions of any note, bond, mortgage, indenture, deed of
trust, license, contract, undertaking, agreement, lease or other instrument or
obligation to which CTP or Subcorp is a party or by which CTP or Subcorp is
bound; (c) violate any order, writ, injunction, decree, statute, rule or
regulation applicable to CTP or Subcorp or their respective properties or
assets; or (d) require any action or consent or approval of, or review by, or
registration or filing by CTP or Subcorp or any of their respective Affiliates
with, any third party or any Governmental Entity, other than the filing of the
Certificate of Merger and registrations or other actions required under federal
and state securities laws as are contemplated by this Agreement.
4.4 Capitalization. As of the date hereof, the authorized capital stock
of CTP consists solely of: (a) 500,000,000 shares of CTP Common Stock, and (b)
5,000,000 shares of CTP preferred stock, of which 500,000 of such shares have
been designated as CTP Series A Preferred Stock and 4,000,000 of such shares
have been designated as CTP Series B Preferred Stock. As of the date hereof,
there are 182,003,920 shares of CTP Common Stock issued and outstanding, 645
shares of CTP Series A Preferred Stock issued and outstanding, which are
convertible into 645 shares of CTP Common Stock, and no shares of CTP Series B
Preferred Stock issued and outstanding. There are no options, warrants or other
securities, rights or agreements outstanding that entitle any person to acquire
(either currently or upon the passage of time or the occurrence of any condition
or event) any shares of CTP Common Stock or any other security convertible into
or exchangeable or exercisable for CTP Common Stock, except for such stock
options to purchase shares of CTP Common Stock granted by CTP to current or
former directors, officers, employees, consultants or representatives of CTP or
to other persons with relationships to CTP (each, a "CTP Existing Option") as
are set forth in the CTP Disclosure Letter. Each outstanding share of CTP Common
Stock is, and all shares of CTP Common Stock to be issued in connection with the
transactions contemplated hereby will be, duly authorized and validly issued,
fully paid and nonassessable, with no personal liability attaching to the
ownership thereof, and each outstanding share of CTP Common Stock has not been,
and all shares of CTP Common Stock to be issued in connection with the
transactions contemplated hereby will not be, issued in violation of any
preemptive or similar rights. As of the date hereof, except as set forth on
Section 4.4 of the CTP Disclosure Letter, CTP did not have, and was not bound
by, any outstanding subscriptions, options, warrants, calls, commitments or
agreements of any character calling for the purchase or issuance of any shares
of CTP Common Stock or any other equity securities of CTP or any securities
representing the right to purchase or otherwise receive any shares of CTP Common
Stock. Section 4.4 of the CTP Disclosure Letter sets forth with respect to each
CTP Existing Option (i) the name of the holder thereof, (ii) its exercise price,
(iii) its expiration date, and (iv) its vesting schedule.
4.5 CTP SEC Documents and Other Public Disclosures. CTP has timely filed
with the SEC all forms, reports, schedules, statements and other documents
required to be filed by it since January 1, 2000 under the Exchange Act (such
documents, as supplemented and amended since the time of filing, collectively,
the "SEC Documents"). The SEC Documents, including any financial statements or
schedules included therein, after giving effect to any amendment or restatement
thereof (a) did not contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they were
made, not misleading, and (b) complied in all material respects with the
applicable requirements of the Exchange Act. CTP has previously provided to
Neurologix's counsel true and complete copies of the SEC Documents filed since
June 30, 2002. The audited consolidated financial statements and unaudited
consolidated interim financial statements of CTP and its consolidated
Subsidiaries included or incorporated by reference in the SEC Documents at the
time (a) filed complied as to form in all material respects with applicable
accounting requirements and with the published rules and regulations of the SEC
with respect thereto, (b) were prepared in accordance with GAAP applied on a
consistent basis during the periods involved (except as may be indicated in the
notes thereto or, in the case of unaudited statements, as permitted by Form 10-Q
of the SEC), and (c) fairly present (subject, in the case of unaudited interim
statements, to normal, year-end adjustments) the consolidated financial position
of CTP and its consolidated Subsidiaries as at the dates thereof and the
consolidated results of their operations and cash flows for the periods then
ended in conformity with GAAP.
4.6 No Material Adverse Change. Except (i) as set forth in the SEC
Documents at least five Business Days prior to the date of this Agreement or on
Section 4.6 of the CTP Disclosure Letter, and (ii) for the
A-19
disposition and/or termination of the business and operations of CTP and its
Subsidiaries, since December 31, 2002, there has not been any material adverse
change in the business, financial condition, prospects, assets or operations of
CTP.
4.7 No Litigation; Compliance with Laws; Permits. Except as set forth in
the SEC Documents at least five Business Days prior to the date of this
Agreement or on Section 4.7 of the CTP Disclosure Letter, there is no (i)
action, suit, claim, proceeding, demand, arbitration, hearing, complaint,
examination or investigation pending or, to the best of the CTP's knowledge,
threatened against or affecting CTP, at law or in equity, or before or by any
federal, state, municipal or other governmental department, commission, board,
bureau, agency or instrumentality, domestic or foreign, or any other
Governmental Entity (including, without limitation, any action, suit, claim,
proceeding, demand, arbitration, hearing complaint, examination or investigation
against any director, officer or employee of CTP or other person for whom CTP
may be liable), (ii) arbitration proceeding relating to CTP pending under
collective bargaining agreements or otherwise, or (iii) governmental inquiry
pending or, to the best of CTP's knowledge, threatened against or affecting CTP
(including without limitation any inquiry as to the qualification of CTP to hold
or receive any license or permit), except as would not have, either individually
or in the aggregate, a CTP Material Adverse Effect. CTP has complied with all
material laws, rules, regulations and orders applicable to its business,
operations, properties, assets, products and services. CTP had all necessary
permits, licenses and other authorizations required to conduct its business as
conducted in the past, except such permits, licenses, grants, consents,
approvals and other authorizations that, if not obtained, would have, either
individually or in the aggregate, a CTP Material Adverse Effect.
4.8 Tax Returns. As of the date of this Agreement:
4.8.1 all Tax Returns required to be filed by or with respect to CTP
have been properly prepared and timely filed, and all such Tax Returns
(including information provided therewith or with respect to thereto) are
true, complete and correct in all material respects;
4.8.2 CTP has fully and timely paid all Taxes owed by them (whether
or not shown on any Tax Return), and have made adequate provision for any
Taxes that are not yet due and payable, for all taxable periods, or
portions thereof, ending on or before the date hereof;
4.8.3 CTP has given or otherwise made available to Neurologix true,
correct and complete copies of all Tax Returns, examination reports and
statements of deficiencies for taxable periods, or transactions
consummated, for which the applicable statutory periods of limitations have
not expired;
4.8.4 there are no outstanding agreements extending or waiving the
statutory period of limitations applicable to any claim for, or the period
for the collection or assessment or reassessment of, Taxes due from CTP or
Subcorp for any taxable period and no request for any such waiver or
extension is currently pending;
4.8.5 no audit or other proceeding by any Governmental Entity is
pending or, to the knowledge of CTP or Subcorp, threatened with respect to
any Taxes due from or with respect to CTP or Subcorp, no Governmental
Entity has given notice of any intention to assert any deficiency or claim
for additional Taxes against CTP or Subcorp, and no claim has been made by
any Governmental Entity in a jurisdiction where CTP or Subcorp do not file
Tax Returns that CTP or Subcorp is or may be subject to taxation by that
jurisdiction, and all deficiencies for Taxes asserted or assessed against
CTP or Subcorp have been fully and timely paid, settled or properly
reflected in the most recent audited financial statements;
4.8.6 there are no Liens for Taxes upon the assets or properties of
CTP or Subcorp, except for statutory Liens for current Taxes not yet due;
4.8.7 CTP has not taken any reporting position on a Tax Return, which
reporting position (i) if not sustained would be reasonably likely, absent
disclosure, to give rise to a penalty for substantial understatement of
federal income Tax under Section 6662 of the Code (or any similar provision
of state, local, or foreign Tax law), and (ii) has not adequately been
disclosed on such Tax Return in accordance with Section 6662(d)(2)(B) of
the Code (or any similar provision of state, local, or foreign Tax law);
A-20
4.8.8 CTP has withheld (or will withhold) from its employees,
independent contractors, creditors, stockholders and third parties and
timely paid to the appropriate Governmental Entity proper and accurate
amounts in all material respects for all periods ending on or before the
Closing Date in compliance with all Tax withholding and remitting
provisions of applicable laws and have each complied in all material
respects with all Tax information reporting provisions of all applicable
laws;
4.8.9 CTP has not constituted a "distributing corporation" or a
"controlled corporation" (within the meaning of Section 355(a)(1)(A) of the
Code) in a distribution of shares qualifying for tax-free treatment under
Section 355 of the Code (i) in the two years prior to the date of this
Agreement or (ii) in a distribution that could otherwise constitute part of
a "plan" or "series of related transactions" (within the meaning of Section
355(e) of the Code) in conjunction with this acquisition.
4.8.10 CTP has not agreed, and is required to make, any adjustment
under Section 481(a) of the Code, and to the knowledge of CTP and Subcorp,
no Governmental Entity has proposed any such adjustment or change in
accounting method;
4.8.11 any adjustment of Taxes of CTP or Subcorp made by the IRS,
which adjustment is required to be reported to the appropriate state,
local, or foreign governmental authorities, has been so reported;
4.8.12 neither CTP nor Subcorp has executed or entered into a closing
agreement pursuant to Section 7121 of the Code or any similar provision of
state, local or foreign law, and neither CTP nor any of its Subsidiaries is
subject to any private letter ruling of the IRS or comparable ruling of any
other Governmental Entity;
4.8.13 there is no contract, agreement, plan, or arrangement covering
any person that, individually or collectively, could give rise to the
payment of any amount that would not be deductible by CTP, Subcorp, or
Neurologix by reason of Section 280G of the Code;
4.8.14 none of CTP and Subcorp is a party to any contract, agreement
or other arrangement which could result in the payment of amounts that
could be nondeductible by reason of Section 162(m) of the Code;
4.8.15 neither CTP nor Subcorp has entered into a transaction that is
being accounted for under the installment method of Section 453 of the Code
or similar provision of state, local or foreign law;
4.8.16 CTP has not filed a consent under Section 341(f) of the Code;
4.8.17 CTP is not a party to any lease arrangement involving a
defeasance of rent, interest or principal;
4.8.18 CTP is not a direct or indirect beneficiary of a guarantee of
Tax benefits or any other arrangement that has the same economic effect
(including an indemnity from a seller or lessee of property, or other
insurance) with respect to any transaction or Tax opinion relating to CTP
and Subcorp;
4.8.19 CTP does not owe any "corporate acquisition indebtedness"
within the meaning of Section 279 of the Code;
4.8.20 CTP has never been (i) a "passive foreign investment company,"
(ii) a "foreign personal holding company," (iii) a "foreign sales
corporation," (iv) a "foreign investment company," or (v) a person other
than a United States person, each within the meaning of the Code;
4.8.21 CTP is not a "personal holding company" within the meaning of
Section 542 of the Code; and
4.8.22 CTP has no elections in effect for federal income tax purposes
under Sections 108, 168, 338, 441, 472, 1017 or 4977 of the Code or any
other material Tax election.
4.9 Title to Assets. CTP and its Subsidiaries have good and marketable
title to or a valid leasehold interest in their respective properties and assets
and all such properties and assets owned by them are free and clear of all
Liens, except (i) for Liens for current taxes not yet due and payable and minor
imperfections of
A-21
title, if any, not material in nature or amount and not materially detracting
from the value or impairing the use of the property subject thereto or impairing
the operations of CTP, and (ii) as set forth on Section 4.9 of the CTP
Disclosure Letter. Each lease or agreement to which CTP or any of its
Subsidiaries is a party under which it is a lessee of any property, real or
personal, is a valid and existing agreement without any default of CTP or any
such Subsidiaries thereunder and, to the best of CTP's knowledge, without any
default thereunder of any other party thereto. To the best of CTP's knowledge,
no event has occurred and is continuing which, with due notice or lapse of time
or both, would constitute a default or event of default by CTP or any of its
Subsidiaries under any such lease or agreement or, to the best of CTP's
knowledge, by any other party thereto.
4.10 No Default. CTP, and to the best of CTP's knowledge, each other
party thereto, have in all material respects performed all the obligations
required to be performed by them to date, have received no notice of default and
are not in default (with due notice or lapse of time or both) under any lease,
agreement or contract now in effect to which CTP is a party.
4.11 Intellectual Property. To the best of CTP's knowledge, no claim is
pending or overtly threatened to the effect that the prior or current operations
of CTP infringe or infringed upon or conflict or conflicted with the asserted
rights of any other person under any patents, patent applications, trademarks,
copyrights, know-how, trade secrets and other intellectual property.
4.12 No Current Operations. Except as set forth on Section 4.12 of the
CTP Disclosure Letter, CTP and its Subsidiaries have no current business
operations. Except as set forth in Section 4.12 of the CTP Disclosure Letter or
the SEC Documents, CTP and its Subsidiaries have (i) disposed (whether by sale,
liquidation or otherwise) of all of their active business operations on or prior
to June 30, 2003 and (ii) neither CTP nor its Subsidiaries have any liabilities
or obligations to the acquirors of such business operations, nor did the terms
of disposition require them to retain any liabilities of such disposed business
operations.
4.13 Undisclosed Liabilities.
4.13.1 As of the date hereof, neither CTP nor any of its Subsidiaries
has any liabilities or obligations of any kind or nature whatsoever,
whether known or unknown, absolute, accrued, contingent or otherwise, or
whether due or to become due, other than those (i) reflected in the most
recent balance sheet, including the footnotes thereto (the "Recent Balance
Sheet"), included in CTP's consolidated financial statements (the "CTP
Financial Statements") contained in the SEC Documents, (ii) contractual
liabilities or liabilities related to litigation or other claims or
contingent liabilities estimated on the Worksheet, (iii) incurred in the
course of disposing of and winding down the Company's existing business
since June 30, 2003 and estimated through Closing on the Worksheet or (iv)
as would not change CTP's Net Cash Assets or the number of shares of CTP
Common Stock outstanding.
4.13.2 As of the Closing Date, neither CTP nor any of its
Subsidiaries has any liabilities or obligations of any kind or nature
whatsoever, whether known or unknown, absolute, accrued, contingent or
otherwise, or whether due or to become due, other than those (i) reflected
in the most Recent Balance Sheet included in CTP's Financial Statements
contained in the SEC Documents, (ii) contractual liabilities or liabilities
related to litigation or other claims or contingent liabilities estimated
on the Updated Worksheet, (iii) incurred in the course of disposing of and
winding down the Company's existing business since June 30, 2003 and
estimated through Closing on the Updated Worksheet or (iv) as would not
change CTP's Net Cash Assets or the number of shares of CTP Common Stock
outstanding.
4.14 Funded Debt.
4.14.1 Except as set forth in (i) the consolidated balance sheet of
CTP and its consolidated Subsidiaries as of December 31, 2002 and the
footnotes thereto set forth in CTP's Annual Report on Form 10-K for the
fiscal year ended December 31, 2002, (ii) the consolidated balance sheet of
CTP and its consolidated Subsidiaries as of June 30, 2003 and the footnotes
thereto set forth in CTP's Quarterly Report on Form 10-Q for the quarter
ended June 30, 2003, or (iii) Section 4.14 of the CTP Disclosure Letter,
none of CTP nor Subcorp has any term or funded debt, debt to banks or debt
to Affiliates. No event has occurred which (whether with or without notice,
lapse of time or the happening or occurrence
A-22
of any other event) would constitute a default by CTP which has not been
cured or waived under any agreement or other instrument relating to any
funded debt, bank loan or debt to Affiliates.
4.14.2 Except as set forth in Section 4.14 of the CTP Disclosure
Letter, neither CTP nor Subcorp is a guarantor of the obligations of any
Person.
4.14.3 There are no accrued or declared dividends on any shares of
any of CTP's capital stock that have not been paid.
4.15 Other Business Names. Neither CTP nor any of its Subsidiaries
currently uses a business name or registered trade name.
4.16 Environmental Matters. CTP has complied in all material respects
with all Environmental Laws. Neither CTP nor Subcorp is, to CTP's knowledge, the
subject of any federal, state, local or foreign investigation, and neither CTP
nor Subcorp has received any written notice or claim, or entered into any
negotiations or agreements with any person, relating to any material liability
or material remedial action under any applicable Environmental Laws. Neither CTP
nor Subcorp, nor any of their respective officers, employees, representatives or
agents, nor, to the knowledge of CTP, any other person, has utilized, treated,
stored, processed, released, manufactured, discharged, spilled or otherwise
disposed of any odor, pollutant, contaminant or other substance defined as
hazardous or toxic by any Environmental Law, or any waste or by-products
thereof, at any real property or any other facility owned or leased by CTP or
Subcorp, in violation of any applicable statutes, regulations, ordinances or
directives of any Governmental Entity or court, except as would not have a CTP
Material Adverse Effect.
4.17 Material Contracts. Except as set forth in the list of material
contracts in Part II, Section 6 of CTP's most recent Form 10-Q or Section 4.17
of the CTP Disclosure Letter, neither CTP nor its Subsidiaries is a party to or
bound by any:
4.17.1 employment agreement (other than those that are terminable by
CTP or any Subsidiary without cost or penalty upon 60 days' or less
notice);
4.17.2 operating or capital lease, whether as lessor or lessee, with
respect to any real property;
4.17.3 contract, whether as licensor or licensee, for the license of
any patent, know-how, trademark, trade name, service mark, copyright or
other intangible asset;
4.17.4 loan or guaranty agreement, indenture or other instrument,
contract or agreement under which any money has been borrowed or loaned or
any note, bond or other evidence of indebtedness has been issued;
4.17.5 mortgage, security agreement, conditional sales contract,
capital lease or similar agreement which effectively creates a lien on any
assets of CTP or its Subsidiaries;
4.17.6 contract restricting CTP or any of its Subsidiaries in any
material respect from engaging in business or from competing with any other
parties;
4.17.7 plan of reorganization;
4.17.8 partnership, joint venture or similar agreement;
4.17.9 collective bargaining agreement;
4.17.10 "material contract" (as defined in Item 601(b)(10) of
Regulation S-K of the SEC);
4.17.11 contract or commitment (whether written or oral) which
continues for a period of more than six months from the date hereof or
requires payments, in the aggregate, in excess of $50,000;
4.17.12 investment banking or other professional service agreement;
4.17.13 agreement regarding acquisitions or dispositions of a
material portion of CTP's assets other than in the ordinary course of CTP's
business;
A-23
4.17.14 outstanding loan or loan commitment to any person or any
factoring, credit line or subordination agreement; or
4.17.15 any power of attorney outstanding or any contract, commitment
or liability (whether absolute, accrued, contingent or otherwise), as
guarantor, surety, cosigner, endorser, co-maker, indemnitor in respect of
the contract or commitment of any other Person.
All of the foregoing are collectively referred to as the "CTP Material
Contracts." To the extent CTP Material Contracts are evidenced by documents,
true and complete copies thereof (and summaries of oral CTP Material Contracts)
have been delivered or made available to Neurologix. Each Material Contract is
in full force and effect. CTP and, to the best of CTP's knowledge, each other
party thereto have in all material respects performed all of the obligations
required to be performed by them to date, have received no notice of default and
are not in default (with due notice or lapse of time or both) under any CTP
Material Contract.
4.18 Employee Benefit Plans. Except as set forth in Section 4.18 of the
CTP Disclosure Letter, neither CTP nor any of its Affiliates maintains, sponsors
or otherwise has any obligation or liability with respect to any Employee
Benefit Plan, and there exists no circumstances, whether known or unknown,
contingent or otherwise, under which CTP could have any material liability,
whether direct or indirect, with respect to any Employee Benefit Plan that CTP
or any of its Affiliates maintained, sponsored or otherwise had any obligation
or liability with respect to prior to the Closing Date. No suit is currently
pending, or to CTP's knowledge is being threatened, by any former employee
alleging wrongful termination, breach of an employment agreement, discrimination
or any other payments from CTP.
4.19 Insurance. Section 4.19 of the CTP Disclosure Letter sets forth a
list of all insurance policies which CTP and Subcorp currently have in effect,
and the status of any unpaid claims thereunder. True and correct copies of such
insurance policies have been made available to Neurologix. All premiums due and
payable under all such policies have been paid, and to CTP's knowledge, CTP and
Subcorp are in compliance in all material respects with the terms and conditions
of all such policies.
4.20 CTP's Net Cash Assets. CTP's Net Cash Assets (assuming for purposes
of such calculation that the Closing Date is the date hereof and that the
estimates of pending litigations and other claims and contingent liabilities and
costs to wind down CTP's business set forth on the Worksheet are reasonable) are
as reflected on the Worksheet.
4.21 Brokerage. No broker or finder has rendered services to CTP or
Subcorp or, to the best of CTP's knowledge, to any stockholder of CTP in
connection with this Agreement or the transactions contemplated hereby. There is
no agreement executed by CTP or Subcorp which will obligate CTP or Subcorp or
any of its successors or Affiliates to pay any brokerage or finder's fee in the
future with respect to any type of commercial, corporate, financial,
acquisition, banking, borrowing or other business transaction.
4.22 Full Disclosure. When taken together with the SEC Documents, no
representation or warranty made in this Article IV, and no certification
furnished or to be furnished by CTP or Subcorp pursuant to this Agreement
contains or will contain any untrue statement of a material fact or omits, or
will omit, to state a material fact necessary to make the statements contained
herein or therein not misleading.
4.23 Former CEO Severance. In exchange for obtaining a release from
William B. Avery, the former chief executive officer of CTP (the "Former CEO"),
of any and all other claims he may have against CTP or its affiliates, CTP shall
not have paid the Former CEO any consideration other than as previously paid or
provided for on the Worksheet.
4.24 Affiliate Transactions. Except as set forth in Section 6 of Part II
of CTP's most recent Form 10-Q or on Section 4.24 of the CTP Disclosure Letter,
there are no other transactions, agreements, arrangements or understandings
between CTP, on the one hand, and any officer, director, employee, family member
of any of the foregoing, or any Affiliate of CTP or other persons, on the other
hand, that would be required to be disclosed under Item 404 of Regulation S-K
under the Securities Act of 1933, as amended.
A-24
ARTICLE V
COVENANTS OF THE PARTIES
5.1 Disclosure Letters; Access and Information. (a) On or prior to the
date hereof, CTP has delivered to Neurologix and Neurologix has delivered to CTP
a letter (respectively, the "CTP Disclosure Letter" and the "Neurologix
Disclosure Letter" and, collectively, the "Disclosure Letters") setting forth,
among other things, items the disclosure of which is necessary or appropriate
either in response to an express disclosure requirement contained in a provision
hereof or as an exception to one or more representations or warranties contained
herein or to one or more of its covenants contained herein; provided that the
mere inclusion of an item in the Disclosure Letters as an exception to a
representation or warranty shall not be deemed an admission by a Party that such
item represents a material exception or fact, event or circumstance or that such
item is reasonably likely to result in a CTP Material Adverse Effect or
Neurologix Material Adverse Effect, as applicable.
(b) Prior to the Closing, Neurologix shall be entitled to make or cause to
be made such reasonable investigation of CTP or Subcorp, and the financial and
legal condition thereof, as Neurologix reasonably deems necessary or advisable,
and CTP and Subcorp shall cooperate with any such investigation. Prior to the
Closing, CTP shall be entitled to make or cause to be made such reasonable
investigation of Neurologix, and the financial and legal condition thereof, as
CTP reasonably deems necessary or advisable, and Neurologix shall cooperate with
any such investigation. In furtherance of the foregoing, but not in limitation
thereof, each of the Parties shall (a) permit the other Parties and their
respective agents and representatives to have reasonable access to its premises,
operating systems, computer systems (hardware and software), computer equipment
and books and records upon reasonable notice during regular business hours, and
(b) use all reasonable commercial efforts to cause its accountants to furnish to
such Party and its accountants access to all work papers relating to any of the
periods covered by the Neurologix Financial Statements, with respect to
Neurologix, or to the financial statements contained in the SEC Documents, with
respect to CTP and its Subsidiaries, subject to the execution by the Party
seeking such disclosure of such reasonable and customary documentation as such
accountants shall request to be executed.
(c) Neither Neurologix nor its representatives shall use any information
provided to it in confidence by CTP or Subcorp for any purpose unrelated to this
Agreement. None of CTP, Subcorp, nor their respective representatives, shall use
any information provided to any of them in confidence by Neurologix for any
purpose unrelated to this Agreement. Except with respect to publicly available
documents, in the event that this Agreement is terminated, (a) CTP and Subcorp
will deliver to Neurologix all documents obtained by them from Neurologix in
confidence or otherwise and any copies thereof in the possession of CTP,
Subcorp, or their respective agents and representatives or, at the option of
Neurologix, CTP and Subcorp shall cause all of such documents and all of such
copies to be destroyed and shall certify the destruction thereof to Neurologix
and (b) Neurologix will deliver to CTP all documents obtained by it from CTP or
Subcorp in confidence or otherwise and any copies thereof in the possession of
Neurologix or its agents and representatives or, at the option of CTP,
Neurologix shall cause all of such documents and all of such copies to be
destroyed and shall certify the destruction thereof to CTP.
(d) Notwithstanding anything herein to the contrary, any Party to this
Agreement (and each employee, representative, or other agent of any Party to
this Agreement) may disclose to any and all Persons, without limitation of any
kind, the tax treatment and tax structure of the transactions contemplated by
this Agreement, and all materials of any kind (including opinions or other tax
analyses) related to such tax treatment and tax structure; provided that this
sentence shall not permit any Person to disclose the name of, or other
information that would identify, any Party to such transactions or to disclose
confidential commercial information regarding such transactions; provided
further that this sentence shall not be effective with respect to any Person
until the earliest of the date of a public announcement (if any) of discussions
relating to any such transaction involving such Person, the date of a public
announcement (if any) of any such transaction involving such Person or the date
of the execution of a definitive agreement to enter into any such transaction
involving such Person, it being understood that there are no limits at any time
on the ability of any Party to consult its own independent tax advisor regarding
the tax treatment or tax structure of the transaction.
A-25
5.2 Affirmative Covenants. Prior to the Closing, except as otherwise
expressly provided herein, the Parties shall (and shall cause each of its
Subsidiaries to):
5.2.1 use reasonable commercial efforts to keep in full force and
effect its corporate existence and all material rights, franchises,
intellectual property rights and goodwill relating or pertaining to its
businesses;
5.2.2 conduct its operations only in the ordinary course of business
consistent with past practice (except in connection with the disposition
and/or termination of the business and operations of CTP and its
Subsidiaries);
5.2.3 maintain its books, accounts and records in accordance with
past practice;
5.2.4 Tax Matters
5.2.4.1 prepare, in the ordinary course of business and consistent
with past practice (except as otherwise required by law), and timely
file all Tax Returns required to be filed by it (or them) on or before
the Closing Date ("Post Signing Returns");
5.2.4.2 fully and timely pay all Taxes due and payable in respect
of such Post Signing Returns that are so filed;
5.2.4.3 properly reserve (and reflect such reserve in its books
and records and financial statements), in accordance with past practice
and in the ordinary course of business, for all Taxes payable by it (or
them) for which no Post Signing Return is due prior to the Closing Date;
5.2.4.4 consult with one another with respect to all material
Post-Signing Returns and deliver drafts of such Post-Signing Returns to
one another no later than ten (10) business days prior to the date
(including extensions) on which such Post-Signing Returns are required
to be filed;
5.2.4.5 promptly notify one another of any material federal,
state, local or foreign income or franchise and any other suit, claim,
action, investigation, proceeding or audit (collectively, "Actions")
pending against or with respect to it (or them) in respect of any Tax
matter, including (without limitation) Tax liabilities and refund
claims, and not settle or compromise any such Tax matter or Action
without the consent of the other Parties;
5.2.4.6 not make or revoke any Tax election or adopt or change a
tax accounting method without consent of the other Parties;
5.2.5 use reasonable commercial efforts to obtain all authorizations,
consents, waivers, approvals or other actions and to make all filings and
applications necessary or desirable to consummate the transactions
contemplated hereby and to cause the conditions to Neurologix's obligation
to close to be satisfied and to cause the conditions to CTP's obligation to
close to be satisfied; and
5.2.6 promptly notify the other Parties in writing if, prior to the
consummation of the Closing, to its knowledge (a) any of the
representations and warranties made by it herein cease to be accurate and
complete in all material respects (except for any representation and
warranty which is qualified hereunder as to materiality, as to which such
notification shall be given if the Party obtains knowledge that such
representation and warranty is inaccurate in any respect) or (b) it fails
to comply with or satisfy any material covenant, condition or agreement to
be complied with or satisfied by it hereunder; provided, however, that the
delivery of any notice pursuant to this Section 5.2.6 shall not limit or
otherwise affect the remedies available hereunder.
5.3 Negative Covenants. Prior to the Closing, except as otherwise
expressly provided herein, the Parties shall not (and shall cause each of its
Subsidiaries to not):
5.3.1 change any method or principle of accounting in a manner that
is inconsistent with past practice (except for any change required by the
SEC or GAAP);
A-26
5.3.2 take any action that would likely result in the representations
and warranties set forth herein (other than representations made as of a
particular date) becoming false or inaccurate in any material respect (or,
as to representations and warranties, which, by their terms, are qualified
as to materiality, becoming false or inaccurate in any respect);
5.3.3 take or omit to be taken any action, or permit any of its
Affiliates to take or to omit to take any action, which would reasonably be
expected to result in a CTP Material Adverse Effect or Neurologix Material
Adverse Effect, as applicable;
5.3.4 consummate the acquisition of any entity (by merger,
combination, purchase of the equity of such entity or purchase of all or
substantially all of the assets of such entity);
5.3.5 enter into any contract or transaction outside the ordinary
course of business consistent with past practice;
5.3.6 (i) issue any security (including any option or warrant) to any
Person, including, without limitation, convertible securities, or incur any
indebtedness to any Person, other than upon stock option exercises, the
conversion of Neurologix Series A Preferred, Neurologix Series B Preferred
and the Neurologix Note as described in Section 2.6 of this Agreement, or
(ii) enter into any contract, understanding or arrangement with respect to
the sale, voting, registration or repurchase of its capital stock, except
in the case of either of the foregoing clauses (i) and (ii), the issuance
and sale for cash of not more than $1 million (net of expenses) of
additional equity securities by Neurologix
5.3.7 other than the adoption of the Amendments by CTP's board of
directors and the approval of the amendments by CTP's shareholders, effect
any change to its certificate of incorporation or by-laws; or
5.3.8 agree or commit to take any action precluded by this Section
5.3.
5.3.9 make, declare or pay any dividend or distribution on, or,
directly or indirectly, redeem, purchase or otherwise acquire, any shares
of its capital stock or any securities convertible or exchangeable into or
exercisable for any shares of its capital stock;
5.3.10 except for increases in salary, wages and benefits of officers
or employees consistent with past practice, in conjunction with new hires,
promotions or other bona fide changes in job status or pursuant to existing
collective bargaining agreements, (i) increase the compensation or benefits
payable or to become payable to its directors, officers or employees, (ii)
pay any compensation or benefits not required by any existing plan or
arrangement (including the granting of stock options, stock appreciation
rights, shares of restricted stock or performance units) or grant any
severance or termination pay to (except pursuant to existing agreements,
plans or policies or as part of the disposition and/or termination of the
business and operations of CTP and its Subsidiaries), or enter into any
employment or severance agreement with, any director, officer or other
employee or (iii) establish, adopt, enter into, amend or take any action to
accelerate rights under any collective bargaining, bonus, profit sharing,
thrift, compensation, stock option, restricted stock, pension, retirement,
savings, welfare, deferred compensation, employment, termination, severance
or other employee benefit plan, agreement, trust, fund, policy or
arrangement for the benefit or welfare of any directors, officers or
current or former employees, except in each case to the extent required by
applicable law;
5.3.11 incur, assume or prepay any long-term indebtedness or incur or
assume any short-term indebtedness (including, in either case, by issuance
of debt securities), other than in the ordinary course of business
consistent with past practice under existing lines of credit;
5.3.12 assume, guarantee, endorse or otherwise become liable or
responsible for the obligations of any other Person;
5.3.13 make any loans, advances or capital contributions to, or
investments in, any other Person except in the ordinary course of business
consistent with past practice or in accordance with the terms of this
Agreement;
5.3.14 make any loans to its directors, officers or shareholders;
A-27
5.3.15 waive, release, assign, settle or compromise any material
rights, claims or litigation except in connection with the disposition
and/or termination of the business and operations of CTP and its
Subsidiaries;
5.3.16 pay, discharge or satisfy any material liabilities, other than
in the ordinary course of business consistent with past practice except in
connection with the disposition and/or termination of the business and
operations of CTP and its Subsidiaries; or
5.3.17 propose, authorize, agree or commit to take any action
precluded by this Section 5.3.
5.4 Closing Documents. Neurologix shall, prior to or on the Closing Date,
execute and deliver, or cause to be executed and delivered, to CTP the documents
or instruments described in Section 6.2. CTP and Subcorp shall, prior to or on
the Closing Date, execute and deliver, or cause to be executed and delivered, to
Neurologix the documents or instruments described in Section 6.3.
5.5 Further Actions. Subject, in the case of CTP, to Section 5.12.1.2
below, each of the Parties agrees to use all reasonable efforts to take, or
cause to be taken, all actions, and to do, or cause to be done, and to assist
and cooperate with the other Parties in doing, all things necessary, proper or
advisable to consummate and make effective, in the most expeditious manner
practicable under the circumstances (after taking into effect all such factors
as shall reasonably effect timing hereunder), the Merger and the other
transactions contemplated by this Agreement, including (A) the obtaining of all
other necessary actions or non-actions, waivers, consents, licenses, permits,
authorizations, orders and approvals from governmental authorities and the
making of all other necessary registrations and filings, (B) the obtaining of
all consents, approvals or waivers from third parties related to or required in
connection with the Merger that are necessary to consummate the Merger and the
transactions contemplated by this Agreement or required to prevent a CTP
Material Adverse Effect or a Neurologix Material Adverse Effect from occurring
prior to or after the Effective Time, (C) the taking of all action necessary to
ensure that the Merger constitutes a reorganization within the meaning of
Section 368(a) of the Code, and (D) the execution and delivery of any additional
instruments necessary to consummate the transactions contemplated by, and to
fully carry out the purposes of, this Agreement. If any "control share
acquisition", "business combination", voting restriction or other form of
takeover statute or regulation (collectively, "Business Combination
Restraint(s)") is or shall become applicable to the transactions contemplated
hereby or any shares of CTP Common Stock to be issued pursuant to the Merger,
each of the Parties, and its board of directors, shall grant such approvals and
take all such actions as are reasonably necessary so that the transactions
contemplated hereby may be consummated as promptly as practical on the terms
contemplated hereby and otherwise act to eliminate the effects of such Business
Combination Restraints on the transactions contemplated hereby, including
without limitation taking all action to ensure that the restrictions of Section
203 of the DGCL will not apply to or affect Palisade Capital Management, LLC and
its Affiliates or any other shareholder of Neurologix if it is deemed an
"interested stockholder" under Section 203 of the DGCL. CTP represents that it
has taken any such actions which were required prior to the execution of this
Agreement.
5.6 Public Announcements. Unless otherwise required by applicable law, no
Party shall make any press release or other public announcement regarding the
Merger or this Agreement without the prior written consent of the other Parties
hereto.
5.7 Stockholders' Meeting. CTP shall take, as promptly as practicable,
all action in accordance with the federal securities laws, the DGCL, its
certificate of incorporation and its by-laws necessary to obtain the consent and
approval of its stockholders to the Merger, this Agreement and the transactions
contemplated hereby, including its board's recommending to its stockholders
approval of the Merger and the transactions contemplated by this Agreement, the
Amendments and the election of CTP's directors as contemplated herein.
5.8 Preparation of the Registration Statement.
5.8.1 CTP shall, as soon as is reasonably practicable, prepare a
prospectus/proxy statement (the "Prospectus/Proxy Statement") to be
included in a registration statement on Form S-4 as promulgated by the SEC
(the "Registration Statement"). Once both Parties consent to the filing of
the Registration
A-28
Statement with the SEC (which consent shall not be unreasonably withheld),
CTP shall file the Registration Statement with the SEC. CTP and Neurologix
shall use all reasonable efforts to have the Registration Statement
declared effective by the SEC as promptly as practicable thereafter and to
maintain the effectiveness of the Registration Statement through the
Effective Time. If, at any time prior to the Effective Time, Neurologix or
CTP shall obtain knowledge of any information contained in or omitted from
the Registration Statement that would require an amendment or supplement to
the Registration Statement or the Prospectus/Proxy Statement, the Party
obtaining such knowledge will so advise the other Party in writing and both
Neurologix and CTP will promptly take such action as shall be required to
amend or supplement the Registration Statement and/or the Prospectus/Proxy
Statement. Neurologix shall promptly furnish to CTP all information
concerning it as may be required for the Prospectus/Proxy Statement and any
supplements or amendments thereto, including without limitation, financial
statements in conformity with all applicable provisions of the Securities
Act and Exchange Act, as the case may be. CTP and Neurologix shall
cooperate in the preparation of the Prospectus/Proxy Statement in a timely
fashion and shall use all reasonable efforts to clear the Registration
Statement with the Staff of the SEC. Promptly after the Registration
Statement is declared effective by the SEC, Neurologix shall use all
reasonable efforts to mail at the earliest practicable date to its
Stockholders the Prospectus/Proxy Statement, which shall include all
information required under applicable law to be furnished to Neurologix's
Stockholders in connection with the Merger and the transactions
contemplated thereby. Promptly after the Registration Statement is declared
effective by the SEC, CTP shall use all reasonable efforts to mail at the
earliest practicable date to its stockholders the Prospectus/Proxy
Statement, which shall include all information required under applicable
law to be furnished to CTP's stockholders in connection with the Merger and
the transactions contemplated thereby, the Amendments and the election of
directors as contemplated herein by Section 5.10.
5.8.2 None of the financial or other information to be supplied by
Neurologix or its representatives for inclusion in the Registration
Statement or the Prospectus/Proxy Statement, including all amendments and
supplements thereto, shall, in the case of the Registration Statement, at
(i) the time the Registration Statement becomes effective, (ii) the Closing
and (iii) the Effective Time, and, in the case of the Prospectus/Proxy
Statement, (iv) on the date or dates the Prospectus/Proxy Statement is
first mailed to CTP's Stockholders, (v) at the date or dates of the CTP
Meeting, (vi) at the Closing, and (vii) at the Effective Time, contain any
untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements
therein not misleading. Neurologix agrees that the financial statements of
Neurologix to be included in the Registration Statement and the
Prospectus/Proxy Statement will comply as to form in all material respects
with the applicable provisions of the Securities Act and the Exchange Act,
as the case may be.
5.8.3 None of the financial or other information supplied by CTP for
inclusion or incorporation by reference in the Registration Statement or in
the Prospectus/Proxy Statement, including all amendments and supplements
thereto, shall, in the case of the Registration Statement, at (i) the time
the Registration Statement becomes effective, (ii) the Closing and (iii)
the Effective Time, and, in the case of the Prospectus/Proxy Statement,
(iv) on the date or dates the Prospectus/Proxy Statement is first mailed to
CTP's stockholders, (v) at the date or dates of the CTP Meeting, (vi) at
the Closing, and (vii) at the Effective Time, contain any untrue statement
of a material fact or omit to state a material fact required to be stated
therein or necessary in order to make the statements therein not
misleading. CTP agrees that the Registration Statement and the
Prospectus/Proxy Statement will (with respect to CTP and Subcorp) comply as
to form in all material respects with the applicable provisions of the
Securities Act and the Exchange Act, as the case may be.
5.9 Affiliates of Neurologix. Within ten business days of the date
hereof, Neurologix shall cause each Person who may be at the Effective Time, or
was on the date hereof, an "affiliate" of Neurologix for purposes of Rule 145
under the Securities Act to execute and deliver to CTP a letter in the form and
substance of the letter annexed hereto as Appendix 5.9 (the "Neurologix
Affiliate's Letter"). Neurologix has provided CTP with a letter specifying all
of the persons or entities who, in Neurologix's opinion, may be deemed to be
"affiliates" of Neurologix under the preceding sentence. The foregoing
notwithstanding, CTP shall be entitled
A-29
to place legends as specified in the Neurologix Affiliate's Letter on the
certificates evidencing any shares of the CTP Common Stock to be received by (i)
any such "affiliate" of Neurologix specified in such letter or (ii) any Person
CTP reasonably identifies (by written notice to Neurologix) as being a Person
who may be deemed an "affiliate" for purposes of Rule 145 under the Securities
Act, and to issue appropriate stop transfer instructions to the transfer agent
for the CTP Common Stock, consistent with the terms of the Neurologix
Affiliate's Letter, regardless of whether such Person has executed the
Neurologix Affiliate's Letter and regardless of whether such Person's name
appears on the letter to be delivered pursuant to the preceding sentence.
5.10 Board of Directors of CTP. On or prior to the Closing Date, CTP
shall deliver to Neurologix a written resignation, in form and substance
reasonably satisfactory to Neurologix, from each officer and director of CTP
(other than no more than two directors to be designated by CTP, referred to as
the "CTP Directors"), effective as of the Effective Time. At the Effective Time,
CTP's board of directors shall consist of the CTP Directors and the five members
of Neurologix's then current board of directors (the "Existing Neurologix
Directors") plus up to two additional members to be designated by Neurologix
(together with the Existing Neurologix Directors, the "Neurologix Designated
Directors"). Following the Effective Time, the board of directors of CTP shall
be free to fix the number of directors from time to time and to nominate, or
have a Nominating Committee nominate, such directors as such board or committee
may choose in its sole discretion. Upon the Closing of the Merger, pursuant to
an election of directors at the CTP Meeting, CTP's board of directors shall be
divided into three classes, as nearly equal in size as is practicable,
designated as Class I, Class II and Class III, respectively. At the first annual
meeting of CTP's stockholders following the dates of the Closing of the Merger,
the term of office of the Class I directors shall expire and Class I directors
shall be elected for a full term of three years. At the second annual meeting of
CTP's stockholders following the Closing of the Merger, the term of office of
the Class II directors shall expire and Class II directors shall be elected for
a full term of three years. At the third annual meeting of stockholders
following the Closing of the Merger, the term of office of the Class III
directors shall expire and Class III directors shall be elected for a full term
of three years. At each succeeding annual meeting of CTP's stockholders,
directors shall be elected for a full term of three years to succeed the
directors of the class whose terms expire at such annual meeting. At the
Effective Time, each of the CTP Directors shall be designated as Class III
directors and each of the Neurologix Designated Directors shall be designated by
Neurologix, in its discretion, as either Class I, Class II or Class III
directors as necessary to make each class of directors as nearly equal as
possible. At the CTP Meeting, CTP's stockholders shall take all action required
by applicable law to ensure that at the Effective Time, CTP's board of directors
will consist of the persons described in this Section 5.10.
5.11 Merger Subsidiary. Prior to the Effective Time, Subcorp shall not
conduct any business or make any investments other than as specifically
contemplated by this Agreement and will not have any assets (other than a
nominal amount of cash paid to Subcorp for the issuance of its stock to CTP) or
any material liabilities.
5.12 No Solicitation.
5.12.1 CTP agrees that, during the term of this Agreement, it shall
not, and it shall cause its directors, officers, employees, agents or
representatives, not to, directly or indirectly, solicit, initiate,
encourage or facilitate, or furnish or disclose non-public information in
furtherance of, any inquiries or the making of any proposal with respect to
any recapitalization, merger, consolidation or other business combination
involving CTP or Subcorp, or acquisition of any capital stock of CTP or
Subcorp or 5% or more of the assets of CTP or any of its Subsidiaries in a
single transaction or a series of related transactions, or any acquisition
by CTP or Subcorp of any material assets or capital stock of any other
Person, or any liquidation of CTP or Subcorp, or any combination of the
foregoing (a "Competing Transaction"), or negotiate, explore or otherwise
engage in discussions with any Person (other than Neurologix and its
directors, officers, employees, agents and representatives) with respect to
any Competing Transaction or enter into any agreement, arrangement or
understanding requiring it to abandon, terminate or fail to consummate the
Merger or any other transaction contemplated by this Agreement. CTP will
immediately cease all existing activities, discussions and negotiations
with any parties conducted heretofore with respect to any proposal for a
Competing Transaction. Notwithstanding the foregoing and anything to the
contrary contained in this Section 5.12.1 or in any other provision of
A-30
this Agreement, CTP and CTP's board of directors may ask questions of,
consider and clarify a proposal from, and conduct a due diligence
investigation of (but not negotiate with or provide any information to,
without Neurologix's prior written consent) any third party making an
unsolicited Competing Transaction (a "Potential Acquirer"), solely for the
purpose of evaluating such Competing Transaction, if CTP's board of
directors or any committee thereof determines, after consultation with
CTP's Financial Advisor and CTP's legal counsel, that (A) such third party
has submitted to CTP a Competing Transaction which has a reasonable
likelihood of resulting in a Superior Proposal (as defined in Section
5.12.1.3), and (B) the failure to participate in such process will
constitute a breach of CTP's board of directors' fiduciary duties under
applicable law. In the event that CTP shall determine to enter into the
process described above, or shall receive any Competing Transaction, it
shall promptly (subject to obligations under any confidentiality agreement)
inform Neurologix in writing of the identity of the Potential Acquirer and
the material terms of such Competing Transaction. If CTP, after
consultation with its Financial Advisor and CTP's legal counsel, determines
that the Competing Transaction is a Superior Proposal, and the failure to
consider such Competing Transaction would constitute a breach of CTP's
board of directors' fiduciary duties under applicable law, then it shall
promptly notify Neurologix of such determination, and CTP and CTP's board
of directors, if CTP has complied with the provisions of this Section
5.12.1, may participate in discussions or negotiations (including, as a
part thereof, making any counterproposal) with the Potential Acquirer. In
the event that CTP shall determine to provide any information to such
Potential Acquirer following its determination that the Competing
Transaction is a Superior Proposal it shall promptly (within two (2)
Business Days) inform Neurologix orally and in writing as to the fact that
information is to be provided. CTP agrees that any non-public information
furnished to a Potential Acquirer will be pursuant to a confidentiality
agreement on terms no less favorable to CTP than the confidentiality
provisions contained in this Agreement. CTP will inform Neurologix promptly
of any related developments, discussions and negotiations with respect to
the Competing Transaction (including the terms and conditions of the
Competing Transaction and any modifications or changes thereto).
5.12.1.1 Subject to Section 5.12.1.2 below, neither CTP's board of
directors nor any committee thereof shall (i) withdraw or modify, or
publicly propose to withdraw or modify, in a manner adverse to
Neurologix, the approval or recommendation by CTP's board of directors
or committee thereof of this Agreement and the Merger, (ii) approve or
recommend, or propose publicly to approve or recommend, any Competing
Transaction or (iii) cause CTP to enter into, approve or recommend, or
propose publicly to approve or recommend, or execute, any letter of
intent, agreement in principle, merger agreement, acquisition agreement,
option agreement or other agreement relating to any Competing
Transaction or agree or propose to agree to do any of the foregoing, or
(iv) submit any Competing Transaction at the CTP Meeting or any other
stockholders meeting for purposes of voting upon approval and adoption
of the Competing Transaction.
5.12.1.2 Notwithstanding Section 5.12.1.1 above, CTP's board of
directors (or any committee thereof) may withdraw or modify its approval
or recommendation of this Agreement or the Merger and approve or
recommend a Competing Transaction, if CTP has complied with the
provisions of this Section 5.12.1 and, in the event that CTP's board of
directors (or any committee thereof) determines in good faith, after
consultation with the Financial Advisor and CTP's legal counsel, that
the Competing Transaction is a Superior Proposal, and that the failure
to take such action would be a breach of CTP's board of directors' or
any such committee's fiduciary duties under applicable law; provided,
however, that prior to taking any such action, the Company shall (A)
notify Neurologix in writing that it intends to enter into an agreement
relating to a Superior Proposal (which notice shall include the most
recent draft of such Superior Proposal), (B) during the two (2) Business
Days following CTP's notice (or such longer period as agreed to by the
parties), CTP shall negotiate in good faith with Neurologix to make such
adjustments in the terms and conditions of such Agreement such that the
Competing Transaction is no longer a Superior Proposal, and CTP's board
of directors (or committee thereof) shall have concluded, after
termination of such time period, that the Competing Transaction giving
rise to CTP's obligations to provide notice hereunder, continues to be a
Superior Proposal, (C) pay the termination fee set forth in Section
7.2.2.2 to Neurologix in full
A-31
and in immediately available funds and (D) deliver written
acknowledgment from CTP and from the other Person to the Competing
Transaction that CTP and such other Person have irrevocably waived any
right to contest such payment.
5.12.1.3 For purposes of this Agreement, a "Superior Proposal"
means any bona fide written proposal (or its most recent amended or
modified terms, if amended or modified) made by a Potential Acquirer to
enter into an Acquisition Proposal, the effect of which would be that
(i) the Company stockholders would beneficially own less than 20% of the
voting stock, common stock and participating stock of the combined or
on-going entity, or (ii) the transaction would result in the sale,
transfer or other disposition of all or substantially all of the assets
of CTP and Subcorp, taken as a whole, and which CTP determines in its
good faith judgment, based on among other things, the advice of the
Financial Advisor, if consummated, would result in a transaction more
favorable to CTP's stockholders from a financial point of view than the
Merger, taking into account all relevant factors (including whether, in
the good faith judgment of CTP's board of directors, after obtaining the
advice of the Financial Advisor, the Potential Acquirer is reasonably
able to finance the transaction, whether such transaction is subject to
any material contingency to which the other party has not demonstrated
its ability to overcome and whether such transaction is reasonably
capable of being completed, and any proposed changes to this Agreement
that may be proposed by Neurologix in response to the Competing
Transaction).
5.12.1.4 During the period from the date of this Agreement through
the Effective Time, CTP shall not terminate, amend, modify or waive any
provision of any confidentiality or standstill agreement (other than any
entered into in the ordinary course of business not in connection with
any possible Competing Transaction) to which it or Subcorp is a party.
5.12.2 Neurologix agrees that, during the term of this Agreement, it
shall not, and it shall cause its directors, officers, employees, agents or
representatives, not to, directly or indirectly, solicit, initiate,
encourage or facilitate, or furnish or disclose non-public information in
furtherance of, any inquiries or the making of any Competing Transaction
involving Neurologix with respect to, or negotiate, explore or otherwise
engage in discussions with any Person (other than CTP and its directors,
officers, employees, agents and representatives) with respect to any such
Competing Transaction or enter into any agreement, arrangement or
understanding requiring it to abandon, terminate or fail to consummate the
Merger or any other transaction contemplated by this Agreement. Neurologix
will immediately cease all existing activities, discussions and
negotiations with any parties conducted heretofore with respect to any
proposal for a Competing Transaction. Notwithstanding the foregoing,
Neurologix shall have the right, in its sole discretion, to raise up to
$1.0 million of additional equity between the date hereof and the Closing
Date.
5.13 Reorganization Treatment. This Agreement is intended to constitute a
"plan of reorganization" within the meaning of Section 1.368-2(g) of the income
tax regulations promulgated under the Code. Each of the Parties shall use its
best efforts to cause the Merger to qualify as a "reorganization" under Section
368(a) of the Code. No Party shall knowingly take any action inconsistent with
the treatment of the Merger as a "reorganization" under Section 368(a) of the
Code.
5.14 Directors' and Officers' Insurance. For a period of six years after
the Closing, CTP shall maintain in effect a policy of directors' and officers'
liability insurance covering all individuals who were directors and officers of
Neurologix immediately prior to the Closing, with coverage limits no less
favorable than those currently in effect. All rights to indemnification now
existing in favor of any such director or officer as provided in the certificate
of incorporation and bylaws of Neurologix in effect on the date of this
Agreement shall survive the Merger and shall continue in full force and effect
for a period of not less than six years after the Closing.
5.15 Stock Option Plan. CTP may establish a new incentive stock option
plan (the "New Stock Option Plan") after Closing, provided that all options
under the plan, if fully exercised, would represent no more than 5% of the total
number of shares of CTP Common Stock outstanding immediately after adoption.
Such New Stock Option Plan shall not be amended or replaced for a period ending
18 months after the Effective Date.
A-32
5.16 Neurologix Loan. On the date hereof, simultaneously with the
execution of this Agreement, CTP shall loan to Neurologix the principal amount
of $750,000 secured by all of the assets of Neurologix. Interest on the unpaid
principal shall accrue at the rate of 4% per year. The outstanding principal
under the Loan and the accrued interest thereon shall be due and payable on
demand at any time after April 30, 2004. In the event that the Merger is
consummated pursuant to this Agreement, the principal amount and accrued
interest on such Loan shall be included in the calculation of CTP's Net Cash
Assets.
ARTICLE VI
CONDITIONS
6.1 Conditions to the Obligations of Each Party. The obligations of
Neurologix, CTP and Subcorp to consummate the Merger shall be subject to the
satisfaction of the following conditions:
6.1.1 No Governmental Entity shall have enacted, issued, promulgated,
enforced or entered any statute, rule, regulation, judgment, decree,
injunction or other order which is in effect, which would prohibit
consummation of the Merger and the transactions contemplated by this
Agreement.
6.1.2 There shall not be pending any legal proceeding by any
Governmental Entity or other third party (i) challenging or seeking to
restrain or prohibit the consummation of the Merger or any of the other
transactions contemplated by this Agreement, (ii) seeking to prohibit or
limit the ownership or operation by Neurologix, CTP or Subcorp of, or to
compel Neurologix, CTP or Subcorp to dispose of or hold separate, any
material portion of the business or assets of Neurologix, CTP or any
Subsidiary of CTP, as a result of the Merger or any of the other
transactions contemplated by this Agreement, or (iii) seeking to impose
limitations on the ability of CTP to acquire or hold, or exercise full
rights of ownership of, any shares of capital stock of the Surviving
Corporation, including the right to vote such capital stock on all matters
properly presented to the stockholders of the Surviving Corporation.
6.1.3 The Merger, this Agreement and the transactions contemplated
hereby, the Amendments and the election of directors contemplated herein
shall have been approved and adopted by CTP's stockholders in the manner
required by any applicable law.
6.1.4 The SEC shall have declared the Registration Statement
effective under the Securities Act, and no stop order or similar
restraining order suspending the effectiveness of the Registration
Statement shall be in effect and no proceedings for such purpose shall be
pending before or threatened by the SEC or any state securities
administrator.
6.1.5 All consents, approvals and action of any Governmental Entity
required to permit the consummation of the Merger and the other
transactions contemplated by this Agreement (other than the filing of the
Certificate of Merger with the Secretary of State of the State of Delaware)
shall have been obtained or made.
6.2 Conditions to CTP's and Subcorp's Obligations. The obligations of CTP
and Subcorp to consummate the transactions contemplated by this Agreement shall
be subject to the fulfillment prior to or at Closing of each of the following
conditions:
6.2.1 The representations and warranties of Neurologix set forth in
Article III shall be true and correct in all material respects (other than
representations and warranties which are qualified as to materiality, which
representations and warranties shall be true in all respects) on the date
hereof and on and as of the Closing Date as though made on and as of the
Closing Date (except for representations and warranties made as of a
specified date, which shall be measured only as of such specified date).
6.2.2 Neurologix shall have performed in all material respects each
obligation and agreement and shall have complied in all material respects
with each covenant to be performed and complied with by it under this
Agreement at or prior to the Closing.
6.2.3 Since December 31, 2002, there shall not have occurred any act,
event, change, occurrence, circumstance, development or omission resulting
in a Neurologix Material Adverse Effect, nor any loss or
A-33
damage to the assets of Neurologix, whether or not insured, which
materially affects the ability of Neurologix to conduct it businesses. CTP
shall have received a certificate (executed by an officer of Neurologix on
behalf of Neurologix to its best knowledge), dated the Closing Date, to the
foregoing effect.
6.2.4 All material authorizations, consents, waivers, approvals or
other actions required in connection with the execution, delivery and
performance of this Agreement by Neurologix and the consummation by
Neurologix of the transactions contemplated hereby shall have been obtained
and shall be in full force and effect. Neurologix shall have obtained any
authorizations, consents, waivers, approvals or other actions required to
prevent a material breach or default by Neurologix under any material
contract to which Neurologix is a party or for the continuation of any
material agreement to which Neurologix is a party.
6.2.5 The aggregate number of shares of Dissenting Stock shall not
exceed 5% of the aggregate number of shares of Neurologix Common Stock and
Neurologix Series B Preferred outstanding on the Closing Date.
6.2.6 Prior to or at the Closing, Neurologix shall have delivered the
following closing documents, in form and substance reasonably acceptable to
CTP (which acceptance shall not be unreasonably withheld):
6.2.6.1 a certificate of an officer of Neurologix, dated the
Closing Date, to the effect that (1) the person signing such certificate
is familiar with this Agreement and (2) to the best of each such
person's knowledge, the conditions specified in Section 6.2.1 and 6.2.2
have been satisfied;
6.2.6.2 a certificate of the Secretary or Assistant Secretary of
Neurologix, dated the Closing Date, as to the incumbency of any officer
of Neurologix executing this Agreement;
6.2.6.3 a certified copy of the resolutions of Neurologix's board
of directors authorizing the execution, delivery and consummation of
this Agreement and the transactions contemplated hereby and the
resolutions of the stockholders of Neurologix approving the Merger, this
Agreement and the transactions contemplated hereby;
6.2.6.4 good standing certificates with respect to Neurologix from
such jurisdictions as CTP shall reasonably designate; and
6.2.6.5 such other closing documents as CTP shall reasonably
request.
6.3 Conditions to Neurologix's Obligations. The obligations of Neurologix
to consummate the transactions contemplated by this Agreement shall be subject
to the fulfillment prior to or at Closing of each of the following conditions:
6.3.1 The representations and warranties of CTP and Subcorp set forth
in Article IV shall be true and correct in all material respects (other
than representations and warranties which are qualified as to materiality,
which representations and warranties shall be true in all respects) on the
date hereof and on and as of the Closing Date as though made on and as of
the Closing Date (except for representations and warranties made as of a
specified date, which shall be measured only as of such specified date).
6.3.2 CTP and Subcorp shall have performed in all material respects
each obligation and agreement and shall have complied in all material
respects with each covenant to be performed and complied with by CTP and
Subcorp under this Agreement at or prior to the Closing.
6.3.3 Since December 31, 2002, there shall not have occurred any act,
event or omission resulting in a CTP Material Adverse Effect. Neurologix
shall have received a certificate (executed by an officer of CTP on behalf
of CTP to its best knowledge), dated the Closing Date, to the foregoing
effect.
6.3.4 Prior to or at the Closing, Neurologix shall have received the
written resignations (in form and substance reasonably satisfactory to
Neurologix) of each of the directors and officers of CTP and Subcorp,
except for the CTP Directors, effective as of the Closing, as contemplated
herein.
A-34
6.3.5 All material authorizations, consents, waivers, approvals or
other actions required in connection with the execution, delivery and
performance of this Agreement by CTP and Subcorp and the consummation by
CTP and Subcorp of the transactions contemplated hereby shall have been
obtained and shall be in full force and effect. CTP and Subcorp shall have
obtained any authorizations, consents, waivers, approvals or other actions
required to prevent a material breach or default by CTP and Subcorp under
any material contract to which CTP or Subcorp is a party or for the
continuation of any material agreement to which CTP or Subcorp is a party.
6.3.6 CTP's Net Cash Assets as of the Closing shall be at least $6.5
million, and Neurologix shall have received a certificate from CTP's chief
executive officer stating the amount of CTP's Net Cash Assets as of the
Closing.
6.3.7 CTP shall have terminated any and all of its Employee Benefit
Plans.
6.3.8 Prior to or at the Closing, CTP shall have delivered the
following closing documents, in form and substance reasonably acceptable to
Neurologix (which acceptance shall not be unreasonably withheld):
6.3.8.1 a certificate of the President or a Vice President of CTP,
dated the Closing Date, to the effect that (1) the Person signing such
certificate is familiar with this Agreement and (2) to the best of such
person's knowledge, the conditions specified in Sections 6.3.1 and 6.3.2
have been satisfied;
6.3.8.2 a certificate of the Secretary or Assistant Secretary of
each of CTP and Subcorp, dated the Closing Date, as to the incumbency of
any officer of CTP and Subcorp executing this Agreement;
6.3.8.3 a certified copy of the resolutions of CTP's board of
directors authorizing the execution, delivery and consummation of this
Agreement and the transactions contemplated hereby and the resolutions
of the stockholders of CTP approving the Merger, this Agreement and the
transactions contemplated hereby, the Amendments and the election of
directors contemplated herein;
6.3.8.4 a certified copy of the resolutions of Subcorp's board of
directors authorizing the execution, delivery and consummation of this
Agreement and the transactions contemplated hereby; and
6.3.8.5 such other closing documents as Neurologix shall
reasonably request.
ARTICLE VII
TERMINATION AND AMENDMENT
7.1 Termination. This Agreement may be terminated and the Merger may be
abandoned at any time prior to the Effective Time (notwithstanding any approval
of this Agreement by Neurologix's or CTP's stockholders):
7.1.1 by mutual written consent of CTP and Neurologix;
7.1.2 by either CTP or Neurologix if there shall be any law or
regulation that, as supported by the written opinion of legal counsel,
makes consummation of the Merger illegal or otherwise prohibited, or if any
judgment, injunction, order or decree of a Governmental Entity enjoining
CTP or Neurologix from consummating the Merger shall have been entered and
such judgment, injunction, order or decree shall have become final and
nonappealable;
7.1.3 by either CTP or Neurologix if the Merger shall not have been
consummated on or before December 19, 2003 (the "Outside Date"); provided,
however, that the right to terminate this Agreement under this Section
7.1.3 shall not be available to any Party whose failure or whose
Affiliate's failure to
A-35
perform any material covenant or obligation under this Agreement has been
the cause of or resulted in the failure of the Merger to occur on or before
such date;
7.1.4 by CTP or Neurologix if, at or before the completion of the
Closing, it shall have discovered that any representation or warranty made
in this Agreement for its benefit, or in any certificate, exhibit or
document furnished to it pursuant to this Agreement, is untrue in any
material respect and, but only if, the failure to be true in any material
respect (i) would give rise to failure of condition set forth in 6.2.1 or
6.3.1, and (ii) would reasonably be expected to prevent CTP or Neurologix,
respectively, from obtaining the material portion of the benefits intended
by the Parties to be derived by CTP or Neurologix, as applicable, from this
Agreement and the transactions contemplated hereby (other than
representations and warranties which are qualified as to materiality, which
representations and warranties will give rise to a right of termination if
untrue in any respect and, but only if, the failure to be true in any
respect would reasonably be expected to prevent CTP or Neurologix,
respectively, from obtaining the material portion of the benefits intended
by the Parties to be derived by CTP or Neurologix, as applicable, from this
Agreement and the transactions contemplated hereby); provided, however,
that in order to terminate this Agreement under this Section 7.1.4, the
terminating Party shall, upon discovery of such a breach or default, give
written notice thereof to the breaching or defaulting Party and the latter
shall fail to cure the breach or default by the earlier of thirty (30)
calendar days after receipt of such notice or the day immediately prior to
the Outside Date;
7.1.5 by CTP if (i) Neurologix shall have defaulted in the
performance of any material obligation under this Agreement, but only if,
the default would reasonably be expected to prevent CTP from obtaining the
material portion of the benefits intended by the Parties to be derived by
CTP from this Agreement and the transactions contemplated hereby or (ii)
any party (other than CTP or Subcorp) shall have defaulted in the
performance of any material obligation under the Voting Agreement such that
Neurologix cannot represent that it has requisite shareholder approval for
the Merger; provided, however, that in order to terminate this Agreement
under this Section 7.1.5, CTP shall, upon discovery of such a breach or
default, give written notice thereof to Neurologix and Neurologix shall
fail to cure the breach or default by the earlier of thirty (30) calendar
days after receipt of such notice or the day immediately prior to the
Outside Date;
7.1.6 by Neurologix if CTP shall have defaulted in the performance of
any material obligation under this Agreement and, but only if, the default
would reasonably be expected to prevent Neurologix from obtaining the
material portion of the benefits intended by the Parties to be derived by
Neurologix from this Agreement and the transactions contemplated hereby;
provided, however, that in order to terminate this Agreement under this
Section 7.1.6, Neurologix shall, upon discovery of such a breach or
default, give written notice thereof to CTP and CTP shall fail to cure the
breach or default by the earlier of thirty (30) calendar days after receipt
of such notice or the day immediately prior to the Outside Date;
7.1.7 by CTP if any authorization, consent, waiver or approval
required for the consummation of the transactions contemplated hereby shall
require the divestiture or cessation of any of the present material
business or operations conducted by Neurologix or shall impose any other
condition or requirement, which divestiture, cessation, condition or
requirement would constitute a Neurologix Material Adverse Effect upon
consummation of the transactions contemplated by this Agreement;
7.1.8 by CTP, in the event that any of the conditions to its
obligations set forth in Article VI have not been satisfied or waived by
the Outside Date or in the event that any such condition cannot possibly be
satisfied prior to the Outside Date;
7.1.9 by Neurologix, in the event that any of the conditions to its
obligations set forth in Article VI have not been satisfied or waived by
the Outside Date or in the event that any such condition cannot possibly be
satisfied prior to the Outside Date; or
7.1.10 by CTP or Neurologix if (i) at the CTP Meeting (including any
adjournment or postponement thereof) the requisite vote of CTP's
stockholders to approve the Merger, this Agreement and the transactions
contemplated hereby, the Amendments and the election of directors
contemplated
A-36
herein shall not have been obtained or (ii) CTP's board of directors
withdraws its recommendation to its stockholders to approve the Merger,
this Agreement and the transactions contemplated hereby.
7.2 Effect of Termination.
7.2.1 In the event of the termination of this Agreement pursuant to
Section 7.1, this Agreement, except for any provisions relating to the
confidentiality obligations of the Parties to each other and the provisions
of this Section 7.2 and Section 8.10, shall become void and have no effect
without any liability on the part of any Party or its directors, officers
or stockholders. Notwithstanding the foregoing, nothing in this Section 7.2
shall relieve any Party to this Agreement of liability for a material
breach of any provision of this Agreement and provided, further, however,
that if it shall be judicially determined that termination of this
Agreement was caused by an intentional breach of this Agreement, then, in
addition to other remedies at law or equity for breach of this Agreement,
the Party so found to have intentionally breached this Agreement shall
indemnify and hold harmless the other Parties for their respective fees and
expenses of their counsel, accountants, financial advisors and other
expenses incident to the negotiation, preparation and execution of this
Agreement and the preparation, filing and mailing of the Registration
Statement and Prospectus/Proxy Statement ("Costs").
7.2.2 CTP agrees as follows:
7.2.2.1 If Neurologix or CTP terminates this Agreement pursuant to
Section 7.1.10(i), then upon such termination CTP will pay to Neurologix
$225,000 in cash by wire transfer in immediately available funds to an
account designated by Neurologix. Notwithstanding the foregoing
sentence, if within 120 days after such termination, CTP acquires or
offers, makes a proposal or agrees to acquire in any manner, whether
directly or indirectly, any business or company (including, but not
limited to, the assets, capital stock or ownership interests thereof)
then Neurologix shall be entitled to the amount set forth in 7.2.2.2 in
lieu of the payment that Neurologix would otherwise be entitled to
receive pursuant to the preceding sentence.
7.2.2.2 If Neurologix or CTP terminates this Agreement pursuant to
Section 5.12.1 or pursuant to Section 7.1.10(ii) upon CTP's board of
director's withdrawal of its recommendation, then upon such termination
or withdrawal of its recommendation, CTP will pay to Neurologix an
amount equal to $750,000 in cash by wire transfer in immediately
available funds to an account designated by Neurologix. CTP shall be
entitled to offset against such payment the aggregate amount of the
unpaid principal of the Loan.
7.2.3 Notwithstanding anything in this Agreement to the contrary, in
the event that this Agreement is terminated such that Neurologix would be
entitled to receive from CTP either or both of the payments provided for in
Section 7.2.2.1 and Section 7.2.2.2, Neurologix shall be entitled to
receive from CTP only the payment provided for in Section 7.2.2.2.
7.3 Amendment. This Agreement may be amended by the Parties, by action
taken or authorized by their respective boards of directors, at any time prior
to the Effective Time, so long as no amendment which by law requires stockholder
approval shall be made without such further approval. Notwithstanding the
foregoing, this Agreement may not be amended except by an instrument in writing
signed on behalf of each of the Parties.
7.4 Extension; Waiver. At any time prior to the Effective Time, CTP (with
respect to Neurologix) and Neurologix (with respect to CTP and Subcorp) by
action taken or authorized by their respective boards of directors, may, to the
extent legally allowed, (a) extend the time for the performance of any of the
obligations or other acts of such Party, (b) waive any inaccuracies in the
representations and warranties contained herein or in any document delivered
pursuant hereto and (c) waive compliance with any of the agreements or
conditions contained herein. Any agreement on the part of a Party to any such
extension or waiver shall be valid only if set forth in a written instrument
signed on behalf of such Party.
A-37
ARTICLE VIII
MISCELLANEOUS
8.1 Notices. All notices or other communications required or permitted
hereunder shall be in writing and shall be delivered personally, by telecopy, by
overnight courier or sent by certified or registered mail, postage prepaid, and
shall be deemed given when so delivered personally, or when so received by
facsimile or courier, or if mailed, three calendar days after the date of
mailing, as follows (or at such other address for a Party as shall be specified
by like notice):
if to CTP or Subcorp:
Change Technology Partners, Inc.
537 Steamboat Road
Greenwich, CT 06830
203.661.6942
203.661.1331 (facsimile)
Attention: Michael Gleason, Chairman and Chief Executive Officer
with a copy (which shall not constitute notice) to:
Paul, Weiss, Rifkind, Wharton & Garrison LLP
1285 Avenue of the Americas
New York, NY 10019-6064
212.373.3000
212.757.3990 (facsimile)
Attention: James H. Schwab, Esq.
if to Neurologix:
Neurologix, Inc.
One Bridge Plaza
Fort Lee, NJ 07024
201.585.7733 x 11
201.585.9798 (facsimile)
Attention: Mark Hoffman, Secretary
with a copy (which shall not constitute notice) to:
Lowenstein Sandler PC
65 Livingston Avenue
Roseland, NJ 07068
973.597.2500
973.597.2400 (facsimile)
Attention: Alan Wovsaniker, Esq.
8.2 Interpretation; Survival of Representations and Warranties. Any
statute, regulation, or other law defined or referred to herein (or in any
agreement or instrument that is referred to herein) means such statute,
regulation or other law as, from time to time, may be amended, modified or
supplemented, including (in the case of statutes) by succession of comparable
successor statutes. References to a person also refer to its predecessors and
permitted successors and assigns. When a reference is made in this Agreement to
an Article or Section, such reference shall be to an Article or Section of this
Agreement unless otherwise indicated. The headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement. The representations and warranties provided
for in this Agreement shall not survive the Closing.
A-38
8.3 Counterparts; Telecopied Signatures. This Agreement may be executed
in counterparts, which together shall constitute one and the same Agreement. The
Parties may execute more than one copy of the Agreement, each of which shall
constitute an original. A signed signature page telecopied by one Party to
another Party shall be deemed to constitute an original.
8.4 Entire Agreement. This Agreement (including the appendices, documents
and other instruments referred to herein) constitutes the entire agreement among
the Parties and supersedes all prior agreements and understandings, arrangements
or representations by or among the Parties, written and oral, with respect to
the subject matter hereof and thereof.
8.5 No Third Party Beneficiaries. Nothing in this Agreement, express or
implied, is intended or shall be construed to create any third party
beneficiaries other than the directors and officers of Neurologix prior to the
Closing with respect to Section 5.15 of this Agreement.
8.6 Governing Law. Except to the extent that the laws of the jurisdiction
of organization of any Party, or any other jurisdiction, are mandatorily
applicable to the Merger or to matters arising under or in connection with this
Agreement, this Agreement shall be governed by the laws of the State of Delaware
without regard to conflicts of laws principles. All actions and proceedings
arising out of or relating to this Agreement shall be heard and determined in
any state or federal court sitting in the State of Delaware.
8.7 Consent to Jurisdiction; Venue; No Trial by Jury. Each of the Parties
irrevocably submits to the exclusive jurisdiction of the state and federal
courts located in the State of Delaware, for the purpose of any action or
proceeding arising out of or relating to this Agreement, and each of the Parties
irrevocably agrees that all claims in respect to such action or proceeding shall
be heard and determined exclusively in any Delaware state or federal court. Each
of Parties agrees that a final judgment in any action or proceeding shall be
conclusive and may be enforced in other jurisdictions by suit on the judgment or
in any other manner provided by law. Each of the Parties irrevocably consents to
the service of any summons and complaint and any other process in any action or
proceeding relating to the Merger, on behalf of itself or its property, by the
delivery of copies of such process to such Party in the same manner as notice is
to be provided pursuant to Section 8.1. Nothing in this Section 8.7 shall affect
the right of any Party hereto to serve legal process in any other manner
permitted by law. Each Party acknowledges and agrees that any controversy which
may arise under this Agreement is likely to involve complicated and difficult
issues, and therefore each Party hereby irrevocably and unconditionally waives
any right such Party may have to a trial by jury in respect to any litigation
directly or indirectly arising out of or relating to this Agreement or the
transactions contemplated by this Agreement. Each Party certifies and
acknowledges that (i) no representative, agent or attorney of any other Party
has represented, expressly or otherwise, that such other Party would not, in the
event of litigation, seek to enforce the foregoing waiver, (ii) each such Party
understands and has considered the implications of this waiver, (iii) each such
Party makes this waiver voluntarily, and (iv) each such Party has been induced
to enter into this Agreement by, among other things, the waivers and
certifications in this Section 8.7.
8.8 Specific Performance. The Parties agree that irreparable damage would
occur in the event that any of the provisions of this Agreement were not
performed in accordance with their specific terms or were otherwise breached. It
is accordingly agreed that, in addition to any other remedy to which they are
entitled at law or in equity, the Parties will be entitled to an injunction or
injunctions to prevent breaches of this Agreement and to enforce specifically
the terms and provisions hereof.
8.9 Assignment. Neither this Agreement nor any of the rights, interests
or obligations hereunder shall be assigned by any of the Parties (whether by
operation of law or otherwise) without the prior written consent of the other
Parties. Subject to the preceding sentence, this Agreement shall be binding
upon, inure to the benefit of and be enforceable by the Parties and their
respective successors and assigns.
8.10 Expenses. Upon consummation of the Merger, CTP shall pay all
transaction expenses (including legal and accounting fees and disbursements)
incurred by CTP, Subcorp and Neurologix relating to the Merger, this Agreement
and the transactions contemplated hereby. In the event the Merger is not
consummated, subject to the provisions of Section 7.2, all costs and expenses
incurred in connection with this Agreement and the transactions contemplated
hereby shall be paid by the Party incurring such expenses,
A-39
except that those reasonable out-of-pocket expenses incurred in connection with
the preparation, filing, printing and mailing of the Registration Statement and
the Prospectus/Proxy Statement (including all filing fees related thereto) shall
be paid by CTP.
8.11 Severability. The invalidity of any portion hereof shall not affect
the validity, force or effect of the remaining portions hereof. If it is ever
held that any restriction hereunder is too broad to permit enforcement of such
restriction to its fullest extent, such restriction shall be enforced to the
maximum extent permitted by law.
8.12 No Strict Construction. Each of CTP, Subcorp and Neurologix
acknowledges that this Agreement has been prepared jointly by the Parties and
that there shall not be a presumption that ambiguities shall be construed
against any Party.
8.13 Knowledge. Any representation made herein which is qualified by the
knowledge of, or notice given to, Neurologix shall refer to the actual knowledge
of, or notice actually given to, any of the executive officers of Neurologix,
after reasonable inquiry by such executive officers. Any representation made
herein which is qualified by the knowledge of, or notice given to, CTP shall
refer to the actual knowledge of, or notice actually given to, any of the
executive officers of CTP, after reasonable inquiry by such executive officers.
(Signature Page Follows)
A-40
IN WITNESS WHEREOF, CTP, Subcorp and Neurologix have signed this Agreement
and Plan of Merger as of the date first written above.
CHANGE TECHNOLOGY PARTNERS, INC.
By: /s/ MICHAEL GLEASON
------------------------------------
Name: Michael Gleason
Title: Chairman and Chief Executive
Officer
CTP/N MERGER CORP.
By: /s/ MICHAEL GLEASON
------------------------------------
Name: Michael Gleason
Title: Chief Executive Officer
NEUROLOGIX, INC.
By: /s/ MARTIN J. KAPLITT
------------------------------------
Name: Martin J. Kaplitt
Title: President
A-41
APPENDIX B
EXECUTION COPY
AMENDMENT NO. 1 TO
AGREEMENT AND PLAN OF MERGER
This Amendment No. 1 to Agreement and Plan of Merger (this "Amendment") is
made and entered into as of the 14th day of November, 2003, by and among Change
Technology Partners, Inc., a Delaware corporation ("CTP"), CTP/N Merger Corp., a
Delaware corporation and a wholly-owned subsidiary of CTP ("Subcorp"), and
Neurologix, Inc., a Delaware corporation ("Neurologix").
PRELIMINARY STATEMENTS
A. Each of CTP, Subcorp and Neurologix is a party to an Agreement and Plan
of Merger, dated as of August 13, 2003 (the "Merger Agreement").
B. CTP, Subcorp and Neurologix wish to amend certain provisions of the
Merger Agreement.
AGREEMENT
NOW, THEREFORE, in consideration of the premises and other good and
valuable consideration, the parties hereto hereby agree as follows:
1. Definitions. All capitalized terms used herein but not otherwise
defined herein shall have the meanings given to them in the Merger Agreement, as
such meanings may have been amended by this Amendment.
2. Amendment of the Merger Agreement. The Merger Agreement hereby is
amended as follows:
(a) All references throughout the Merger Agreement to the "Agreement"
shall refer to the Merger Agreement as amended by this Amendment.
(b) Preliminary Statement F hereby is amended and restated in its
entirety as follows:
"F. On August 13, 2003, CTP loaned to Neurologix the principal
amount of $750,000 secured by a first priority perfected security
interest in all of the assets of Neurologix (the "Original Loan") in
accordance with the then-existing provisions of this Agreement and terms
of the Senior Secured Promissory Note, dated as of August 13, 2003,
issued by Neurologix (the "Note"), the Security Agreement, dated as of
August 13, 2003, between Neurologix and CTP (the "Security Agreement"),
and the Subordination and Intercreditor Agreement, dated as of August
13, 2003, among Neurologix, CTP, Palisade Private Partnership, L.P., Dr.
Martin J. Kaplitt and Clark A. Johnson (together with the Note and the
Security Agreement, the "Original Loan Documents")."
(c) Immediately after Preliminary Statement F the following new
Preliminary Statement G shall be added:
"G. CTP and Neurologix desire to amend the terms of the Original
Loan such that, upon the request of Neurologix at anytime after December
1, 2003, CTP shall loan to Neurologix an additional principal amount of
$350,000 secured by a first priority perfected security interest in all
of the assets of Neurologix (as the Original Loan is so amended, the
"Loan"). All references throughout this Agreement to the "Loan" shall
refer to the Loan as so amended.
(d) The definition of "CTP's Net Cash Assets" in Section 1.1 hereby is
amended by replacing the reference therein to "$500,000" with "$600,000."
(e) To the extent that the consent of any of the parties to the Merger
Agreement is necessary to prevent either Neurologix's or CTP's execution
of, or consummation of the transactions contemplated by,
B-1
this Amendment from constituting a breach of Section 5.3 of the Merger
Agreement, this Amendment shall be deemed to constitute such consent.
(f) Section 5.16 hereby is amended and restated to read in its
entirety as follows:
"Upon the request of Neurologix at anytime after December 1, 2003, CTP
shall loan to Neurologix, within two business days after it receives such
request, the principal amount of $350,000 secured by all of the assets of
Neurologix, which principal amount is in addition to the $750,000 that CTP
loaned to Neurologix on August 13, 2003, pursuant to the then existing
provisions of this Agreement and the terms of the Original Loan Documents.
Interest on the outstanding unpaid principal amount of the Loan shall
accrue at the rate of 4% per year. The outstanding unpaid principal amount
of the Loan and the accrued and unpaid interest thereon shall be due and
payable on demand at any time after June 30, 2004. In the event that the
Merger is consummated pursuant to this Agreement, the outstanding unpaid
principal amount and accrued and unpaid interest on such Loan shall be
included in the calculation of CTP's Net Cash Assets."
(g) Section 6.3.7 hereby is amended to add the following immediately
before the end thereof:
", other than its 2000 Stock Option Plan"
(h) Section 7.1.3 hereby is amended by replacing the reference therein
to "December 19, 2003" with "February 15, 2004."
(i) Section 7.2.2.2 hereby is amended by replacing the reference
therein to "$750,000" with "$1,100,000."
3. Authority of Neurologix Relative to this Agreement;
Consents. Neurologix represents and warrants to CTP and Subcorp as follows:
(a) The execution, delivery and performance of the Merger Agreement
and this Amendment are within the corporate power and authority of
Neurologix and have been duly authorized by all corporate action on the
part of Neurologix. In addition, neither the execution and delivery of this
Amendment by Neurologix nor Neurologix's consummation of the transactions
contemplated hereby will (i) require any consent or approval which has not
already been obtained, and (ii) conflict with, or result in a breach of any
provision of Neurologix's certificate of incorporation, bylaws or other
organizational documents.
4. Authority of CTP and Subcorp Relative to this Agreement; Consents. CTP
and Subcorp represent and warrant to Neurologix as follows:
(a) The execution, delivery and performance of the Merger Agreement
and this Amendment are within the corporate power and authority of CTP and
Subcorp and have been duly authorized by all corporate action on the part
of CTP and Subcorp. In addition, neither the execution and delivery of this
Amendment by CTP and Subcorp nor their consummation of the transactions
contemplated hereby will (i) require any consent or approval which has not
already been obtained (other than the approval of the stockholders of CTP),
and (ii) conflict with, or result in a breach of any provision of CTP or
Subcorp's certificate of incorporation, bylaws or other organizational
documents.
5. Effect of Amendment. This Amendment shall not constitute a waiver,
amendment or modification of any other provision of the Merger Agreement not
expressly referred to herein and shall not be construed as a waiver or consent
to any further or future action on the part of the parties hereto. Except as
amended or modified hereby, the Merger Agreement shall remain in full force and
effect in accordance with its original terms.
6. Governing Law. Except to the extent that the laws of the jurisdiction
of organization of any party hereto, or any other jurisdiction, are mandatorily
applicable to the Merger or to matters arising under or in connection with the
Merger Agreement, this Amendment shall be governed by the laws of the State of
Delaware without regard to conflicts of laws principles. All actions and
proceedings arising out of or relating to this Amendment shall be heard and
determined in any state or federal court sitting in the State of Delaware.
B-2
7. Counterparts; Telecopied Signatures. This Amendment may be executed in
counterparts, which together shall constitute one and the same agreement. The
parties hereto may execute more than one copy of this Amendment, each of which
shall constitute an original. A signed signature page telecopied by one party to
another party shall be deemed to constitute an original.
(Signature Page Follows)
B-3
IN WITNESS WHEREOF, CTP, Subcorp and Neurologix have signed this Amendment
No. 1 to Agreement and Plan of Merger as of the date first written above.
CHANGE TECHNOLOGY PARTNERS, INC.
By: /s/ MICHAEL GLEASON
------------------------------------
Name: Michael Gleason
Title: Chairman and Chief Executive
Officer
CTP/N MERGER CORP.
By: /s/ MICHAEL GLEASON
------------------------------------
Name: Michael Gleason
Title: Chief Executive Officer
NEUROLOGIX, INC.
By: /s/ MARTIN J. KAPLITT
------------------------------------
Name: Martin J. Kaplitt
Title: President
B-4
APPENDIX C
EXECUTION COPY
VOTING AGREEMENT
THIS VOTING AGREEMENT, is made as of August 13, 2003 (this "Agreement"), by
and among CTP/N Merger Corp., a Delaware corporation ("MergerCo"), the persons
listed on Exhibit A hereto (collectively, the "Securityholders" and each a
"Securityholder"), Change Technology Partners, Inc., a Delaware corporation and
the parent corporation of MergerCo ("CTP"), and Neurologix, Inc., a Delaware
corporation ("Target").
PRELIMINARY STATEMENTS
WHEREAS, as of the date hereof each Securityholder owns (beneficially and
of record) the number of shares of (i) Target common stock, par value $.001 per
share (the "Target Common Stock"), (ii) Target convertible preferred stock, par
value $.001 per share (the "Target Series A Preferred"), and (iii) Target Series
B convertible preferred stock, par value $.001 per share (the "Target Series B
Preferred" and, together with the Target Common Stock and the Target Series A
Preferred, the "Target Stock"), in each case, set forth opposite such
Securityholder's name on Exhibit B hereto (all such securities and any shares of
capital stock of Target hereafter acquired by the Securityholders prior to the
termination of this Agreement are collectively referred to herein as the
"Shares");
WHEREAS, as of the date hereof each Securityholder owns (beneficially) the
principal amount of, or participatory interest in, the 6% secured promissory
note of Neurologix due in October 2007 (the "Neurologix Note" and, together with
the Shares, the "Securities") set forth opposite such Securityholder's name on
Exhibit B hereto;
WHEREAS, CTP, MergerCo and Target are entering into an Agreement and Plan
of Merger, dated as of the date hereof (as the same may be amended from time to
time, the "Merger Agreement"), which provides, upon the terms and subject to the
conditions thereof, for the merger of MergerCo with and into Target (the
"Merger") with Target being the Surviving Corporation (the "Surviving
Corporation");
WHEREAS, each of the Securityholders desires, immediately prior to the
consummation of the Merger, to (i) convert all of the shares of Target Series A
Preferred and Target Series B Preferred that such Securityholder owns into
Target Common Stock in accordance with their terms (all such shares of Target
Common Stock to be issued upon conversion are referred to collectively as the
"Target Conversion Common Shares") and (ii) exchange the principal amount of, or
participatory interest in, the Neurologix Note, that such Securityholder holds
for the number of whole shares of Target Common Stock, which shall not exceed an
aggregate of 400,000 shares of Target Common Stock, determined by dividing (x)
the sum of (a), the product of the outstanding unpaid principal amount of the
Neurologix Note as of the date of the exchange multiplied by such
Securityholder's percentage participatory interest in the Neurologix Note (such
portion of the principal amount, the "Securityholder's Portion") plus (b) the
amount of accrued and unpaid interest on the Securityholder's Portion as of the
date of the exchange by (y) $6.00 (all such shares of Target Common Stock to be
issued upon exchange are referred to collectively as the "Target Exchange Common
Shares" and together with the Target Conversion Common Shares, the "Target
Common Shares");
WHEREAS, the Securityholders desire that, in connection with the Merger,
the Target Common Shares, as well as all other shares of Target Common Stock
that the Securityholders hold, be converted into shares of common stock, par
value $.001 per share ("New Common"), of CTP as provided in the Merger
Agreement; and
WHEREAS, as a condition to the willingness of CTP and MergerCo to enter
into the Merger Agreement and consummate the transactions contemplated therein,
CTP and MergerCo have requested that each
C-1
Securityholder agree, and, in order to induce CTP and MergerCo to enter into the
Merger Agreement each such Securityholder is willing to agree, to vote the
Shares pursuant to the terms and conditions hereof;
NOW, THEREFORE, in consideration of the premises and of the mutual
agreements and covenants set forth herein and in the Merger Agreement, and other
good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:
ARTICLE I
REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS
Each Securityholder hereby severally represents and warrants to CTP,
MergerCo and Target as follows:
SECTION 1.01 Due Authority. (a) Such Securityholder has full power,
corporate or otherwise, and authority to execute and deliver this Agreement and
to perform such Securityholder's obligations hereunder. This Agreement has been
duly executed and delivered by or on behalf of such Securityholder and, assuming
its due authorization, execution and delivery by MergerCo and Target,
constitutes a legal, valid and binding obligation of such Securityholder,
enforceable against such Securityholder in accordance with its terms, except to
the extent that enforceability may be limited by bankruptcy, insolvency,
moratorium, reorganization and other laws affecting the enforcement of
creditors' rights generally and by general principles of equity.
(b) There is no beneficiary or holder of a voting trust certificate or
other interest of any trust of which such Securityholder is a trustee, or other
person or entity whose consent is required for the execution and delivery of
this Agreement by such Securityholder or the consummation by such Securityholder
of the transactions contemplated hereby.
SECTION 1.02 No Conflict; Consents. (a) The execution and delivery of
this Agreement by such Securityholder do not, and the performance by such
Securityholder of such Securityholder's obligations under this Agreement and the
compliance by such Securityholder with any provisions hereof do not and will
not, (i) conflict with or violate any law, statute, rule, regulation, order,
writ, judgment or decree applicable to such Securityholder or such
Securityholder's Securities, (ii) conflict with or violate the Securityholder's
charter, bylaws, partnership agreement or other organizational documents, if
applicable, or (iii) result in any breach of or constitute a default (or an
event that with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment, acceleration or
cancellation of, or result in the creation of a lien or encumbrance on any of
such Securityholder's Securities pursuant to, any note, bond, mortgage,
indenture, contract, agreement, lease, license, permit, franchise or other
instrument or obligation to which such Securityholder is a party or by which
such Securityholder or such Securityholder's Securities are bound.
(b) The execution and delivery of this Agreement by such Securityholder do
not, and the performance of this Agreement by such Securityholder will not,
require any consent, approval, authorization or permit of, or filing with or
notification to, any governmental or regulatory authority except for applicable
requirements, if any, of the Securities Exchange Act of 1934, as amended, and
except where the failure to obtain such consents, approvals, authorizations or
permits, or to make such filings or notifications, will not prevent or delay the
performance by such Securityholder of his or her obligations under this
Agreement in any material respect.
SECTION 1.03 Title to Securities. (a) The Securities set forth opposite
such Securityholder's name on Exhibit B hereto constitute all of the securities
of Target that are owned by such Securityholder. Such Securityholder is the
record and beneficial owner of all of such Securityholder's shares of Target
Stock and has such interest in the Neurologix Note as is set forth opposite such
Securityholder's name on Exhibit B hereto. As of the date hereof, (i) the
aggregate number of outstanding shares of Target Common Stock held by the
Securityholders represents approximately 86.1% of the aggregate number of
outstanding shares of Target Common Stock held by all of Target's stockholders,
(ii) the aggregate number of outstanding shares of Target Series A Preferred
held by the Securityholders represents 100% of the aggregate number of
outstanding shares of Target Series A Preferred held by all of Target's
stockholders, (iii) the aggregate number of outstanding shares of Target Series
B Preferred held by the Securityholders represents approxi-
C-2
mately 79.2% of the aggregate number of outstanding shares of Target Series B
Preferred held by all of Target's stockholders, and (iv) the aggregate number of
outstanding shares of Target Common Stock, Target Series A Preferred (on an
as-converted to Target Common Stock basis) and Target Series B Preferred (on an
as-converted to Target Common Stock basis) held by the Securityholders
represents approximately 91.4% of the aggregate number of outstanding shares of
Target Common Stock, Target Series A Preferred (on an as-converted to Target
Common Stock basis) and Target Series B Preferred (on an as-converted to Target
Common Stock basis) held by all of Target's stockholders. Such Securityholder
has, and such Securityholder will have as of the Closing Date, good and
marketable title to such Securities, free and clear of all security interests,
claims, liens, pledges, options, encumbrances, charges, agreements, voting
trusts, proxies and other arrangements or restrictions whatsoever
("Encumbrances").
(b) Such Securityholder has, and during the Voting Term (as defined below)
will have, the sole voting power with respect to the matters set forth in
Article IV hereof with respect to all of the Shares held by such Securityholder,
with no restrictions on such rights, subject to applicable laws and the terms of
this Agreement.
SECTION 1.04 No Prior Voting Agreements. Such Securityholder's Shares and
the certificates representing such Shares are now, and at all times during the
Voting Term hereof will be, held by such Securityholder free and clear of all
proxies, voting trusts and voting agreements, understandings or arrangements
providing for any right on the part of any person other than such Securityholder
to vote such Shares except any such understandings arising under this Agreement.
SECTION 1.05 Acknowledgment of Reliance. Such Securityholder understands
and acknowledges that CTP and MergerCo are entering into the Merger Agreement in
reliance upon such Securityholder's execution and delivery of this Agreement.
ARTICLE II
REPRESENTATIONS AND WARRANTIES OF CTP AND MERGERCO
Each of CTP and MergerCo (each a "CTP Party") hereby represents and
warrants to the Securityholders and Target as follows:
SECTION 2.01 Due Authority. Such CTP Party has full power, corporate or
otherwise, and authority to execute and deliver this Agreement and to perform
such CTP Party's obligations hereunder. This Agreement has been duly executed
and delivered by or on behalf of such CTP Party and, assuming its due
authorization, execution and delivery by the other CTP Party, the
Securityholders and Target, constitutes a legal, valid and binding obligation of
such CTP Party, enforceable against such CTP Party in accordance with its terms,
except to the extent that enforceability may be limited by bankruptcy,
insolvency, moratorium, reorganization and other laws affecting the enforcement
of creditors' rights generally and by general principles of equity.
SECTION 2.02 No Conflict; Consents. (a) The execution and delivery of
this Agreement by such CTP Party do not, and the performance by such CTP Party
of such CTP Party's obligations under this Agreement and the compliance by such
CTP Party with any provisions hereof do not and will not, (i) conflict with or
violate any law, statute, rule, regulation, order, writ, judgment or decree
applicable to such CTP Party, (ii) conflict with or violate such CTP Party's
charter, bylaws, partnership agreement or other organizational documents, if
applicable, or (iii) result in any breach of or constitute a default (or an
event that with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment, acceleration or
cancellation of any note, bond, mortgage, indenture, contract, agreement, lease,
license, permit, franchise or other instrument or obligation to which such CTP
Party is a party.
(b) The execution and delivery of this Agreement by such CTP Party do not,
and the performance of this Agreement by such CTP Party will not, require any
consent, approval, authorization or permit of, or filing with or notification
to, any governmental or regulatory authority.
C-3
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF TARGET
Target hereby represents and warrants to CTP, the Securityholders and
MergerCo as follows:
SECTION 3.01 Due Authority. Target has full power, corporate or
otherwise, and authority to execute and deliver this Agreement and to perform
Target's obligations hereunder. This Agreement has been duly executed and
delivered by or on behalf of Target and, assuming its due authorization,
execution and delivery by the Securityholders and MergerCo, constitutes a legal,
valid and binding obligation of Target, enforceable against Target in accordance
with its terms, except to the extent that enforceability may be limited by
bankruptcy, insolvency, moratorium, reorganization and other laws affecting the
enforcement of creditors' rights generally and by general principles of equity.
SECTION 3.02 No Conflict; Consents. (a) The execution and delivery of
this Agreement by Target do not, and the performance by Target of Target's
obligations under this Agreement and the compliance by Target with any
provisions hereof do not and will not, (i) conflict with or violate any law,
statute, rule, regulation, order, writ, judgment or decree applicable to Target,
(ii) conflict with or violate Target's charter or bylaws, or (iii) result in any
breach of or constitute a default (or an event that with notice or lapse of time
or both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of any note, bond,
mortgage, indenture, contract, agreement, lease, license, permit, franchise or
other instrument or obligation to which Target is a party.
(b) The execution and delivery of this Agreement by Target do not, and the
performance of this Agreement by Target will not, require any consent, approval,
authorization or permit of, or filing with or notification to, any governmental
or regulatory authority except where the failure to obtain such consents,
approvals, authorizations or permits, or to make such filings or notifications,
could not reasonably be expected to prevent or delay the performance by Target
of its obligations under this Agreement in any material respect.
SECTION 3.03 Valid Issuance. The (a) Target Exchange Common Shares, when
issued in compliance with the provisions of this Agreement and the Merger
Agreement for the consideration expressed herein, and (b) Target Conversion
Common Shares will, when issued in each case, be validly issued, fully paid and
nonassessable and will be free of any liens or encumbrances other than
restrictions on transfer under this Agreement and applicable state and federal
securities laws.
SECTION 3.04 Stockholder Written Consent. Upon Target's receipt of the
Stockholder Written Consent (as defined below) from the Securityholders and
executed thereby, Target's stockholders will have taken all action required of
them to approve the Merger, the Merger Agreement and the transactions
contemplated thereby for purposes of the federal securities laws, the DGCL,
Target's certificate of incorporation and Target's by-laws.
ARTICLE IV
COVENANTS OF THE PARTIES
SECTION 4.01 Transfer of Shares. During the Voting Term, each
Securityholder shall not hereafter (a) sell, tender, transfer, pledge, encumber,
assign or otherwise dispose of any of such Securityholder's Securities, (b)
deposit such Securityholder's Shares into a voting trust or enter into a voting
agreement or arrangement with respect to such Shares or grant any proxy or power
of attorney with respect thereto, (c) enter into any contract, option or other
arrangement or undertaking with respect to the direct or indirect sale,
transfer, pledge, encumbrance, assignment or other disposition of any of
securities of Target, or (d) take any action that would make any representation
or warranty of such Securityholder contained herein untrue or incorrect in any
material respect or have the effect of preventing or disabling, in whole or in
part, such Securityholder from performing such Securityholder's obligations
under this Agreement; provided, however, that nothing in this Agreement shall
prevent any Securityholder from selling, tendering, transferring, pledging,
encumbering, assigning or otherwise disposing of any of such Securityholder's
securities of Target to any other Securityholder who remains bound by this
Agreement.
C-4
SECTION 4.02 Voting of Shares. (a) Each Securityholder, by this
Agreement, does hereby agree, during and for the Voting Term, to vote all of
such Securityholder's Shares at every meeting of the stockholders of Target or
any adjournment thereof or in connection with any written consent of Target's
stockholders, (i) in favor of the adoption of the Merger Agreement and approval
of the Merger and the other transactions contemplated by the Merger Agreement
and (ii) in favor of any other matter necessary for consummation of the
transactions contemplated by the Merger Agreement which is considered at any
such meeting of stockholders or in such consent, and in connection therewith to
execute any documents that are necessary or appropriate in order to effectuate
the foregoing. Without limiting the foregoing and in accordance therewith, each
Securityholder agrees to execute and deliver to Target, concurrently with the
execution of this Agreement, a written consent substantially in the form
attached hereto as Exhibit D (the "Stockholder Written Consent").
(b) For the purposes of this Agreement, "Voting Term" means the period from
the execution of this Agreement until the earlier of (i) the date of any
termination of the Merger Agreement pursuant to the terms thereof or (ii) the
Effective Time.
(c) Each Securityholder agrees that such Securityholder will not enter into
any agreement or understanding with any person or entity or take any action
during the Voting Term that will permit any person or entity to vote or act by
written consent or give instructions to vote or so act with respect to any of
such Securityholder's Shares in any manner inconsistent with the terms of this
Section 4.02.
SECTION 4.03 Certain Events. Each Securityholder agrees that, during the
Voting Term, this Agreement and the obligations hereunder shall attach to such
Securityholder's Shares and shall be binding upon any person or entity to which
legal or beneficial ownership of such Shares shall pass, whether by operation of
law or otherwise, including without limitation, if applicable, such
Securityholder's heirs, guardians, administrators, successors or assigns.
SECTION 4.04 Conversion and Exchange of Securities. (a) Each
Securityholder agrees that immediately prior to the Effective Time, such
Securityholder shall (a) convert all of the shares of Target Series A Preferred
and Target Series B Preferred that such Securityholder holds (collectively, the
"Rollover Shares") into such number of shares of Target Common Stock as such
Rollover Shares, by their terms, are then convertible (as indicated on Exhibit C
hereto).
(b) Target and each of the Noteholders (as defined below) agrees that
immediately prior to the Effective Time, such Noteholder shall exchange all of
such Noteholder's interest in the Neurologix Note (regardless whether such
interest (i) arises under the any of the Credit Documents (as defined below) and
(ii) relates to any right to receive any payment or other consideration in
respect of unpaid principal, accrued and unpaid interest thereon, or any other
obligation or liability of Target under the Credit Documents) for such whole
number of Target Exchange Common Shares as is determined by dividing (x) the sum
of (a) the product of the outstanding unpaid principal amount of the Neurologix
Note as of the date of the exchange multiplied by such Securityholder's Portion,
plus (b) the amount of the accrued and unpaid interest on the Securityholder's
Portion as of the date of the exchange by (y) $6.00. Each of the Securityholders
having such an interest in the Neurologix Note (Palisade Private Partnership,
L.P. ("Palisade"), Clark A. Johnson ("Johnson"), and Martin J. Kaplitt
("Kaplitt")) is referred to individually as a "Noteholder." The Noteholders
agree that, notwithstanding any other provision of this Agreement to the
contrary, in no event shall Target be required or obligated to issue more than
400,000 Target Exchange Common Shares in the aggregate to the Noteholders in
consideration of their exchange of the Neurologix Note. Target agrees that, upon
the tender to Target of the Neurologix Note for cancellation by the holder
thereof, Target shall, immediately prior to the Effective Time and in accordance
with the terms of this Agreement and the Merger Agreement, issue to the
Noteholders all of the Target Exchange Common Shares.
SECTION 4.05 Termination of Credit Documents. Target and each of the
Noteholders agrees that (a) upon the exchange of the Neurologix Note and the
issuance of the Target Exchange Common Shares as provided in Section 4.04, each
of the Credit Documents and all of such parties respective rights and
obligations thereunder shall be terminated effective as of the closing date of
the Merger, (b) the Credit Documents shall be of no further force or effect. For
purposes of this Agreement, the term "Credit
C-5
Documents" means each of the following agreements or instruments: (i) the
Neurologix Note, (ii) the Credit Line Agreement, dated as of November 1, 1999,
between Target and Palisade, (iii) the Participation Agreement between Palisade
and Johnson with respect to the Neurologix Note and (iv) the Participation
Agreement between Palisade and Kaplitt with respect to the Neurologix Note and
(c) such Noteholder shall forthwith deliver to Target UCC-3 termination
statements terminating the Noteholder's security interest under the Credit
Documents and any other agreement granting the Noteholder a security interest in
any of Target's assets, which agreement was executed and delivered in connection
with the Credit Documents (as each such agreement or Credit Document may have
heretofore been amended, modified or supplemented), and the security interest
granted by the Credit Documents or such other agreement shall become null and
void and of no further force and effect.
SECTION 4.06 Waiver of Appraisal Rights. Each Securityholder hereby
waives, with respect to all of such Securityholder's Shares (including, without
limitation, the Target Common Shares whether acquired prior to or after date of
the Stockholder Written Consent) and to the fullest extent permitted by
applicable law, all appraisal or other rights to which such Securityholder may
be entitled under Section 262 of the Delaware General Corporation Law in
connection with the Merger. This waiver shall be binding upon all of such
Securityholder's heirs, representatives, executors, successors and assigns, as
applicable.
SECTION 4.07 Stop Transfer. (a) Each Securityholder agrees with, and
covenants to, CTP and MergerCo that such Securityholder shall not request that
Target register the transfer (book-entry or otherwise) of any certificate or
instrument representing any of such Securityholder's Securities, unless such
transfer is made in compliance with this Agreement. Each Securityholder agrees
that such Securityholder will surrender to Target, within fifteen Business Days
after the date hereof, the certificates and instruments representing such
Securities, and Target will place a legend in substantially the following form
on such certificates and instruments (as well as on all other Shares issuable to
the Securityholder after the date hereof) in addition to any other legend
required thereof:
THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO TRANSFER,
VOTING AND OTHER RESTRICTIONS PURSUANT TO A VOTING AGREEMENT, DATED AS OF
AUGUST 13, 2003, BY AND AMONG NEUROLOGIX, INC. (THE "COMPANY"), THE HOLDER
HEREOF, AND OTHER PARTIES THERETO (AS AMENDED FROM TIME TO TIME, THE
"VOTING AGREEMENT"). THE COMPANY WILL FURNISH A COPY OF SUCH VOTING
AGREEMENT TO THE HOLDER OF THIS CERTIFICATE WITHOUT CHARGE UPON WRITTEN
REQUEST TO THE COMPANY AT ITS PRINCIPAL PLACE OF BUSINESS.
Target shall notify its transfer agent of the provisions set forth in this
Section 4.07 and instruct its transfer agent not to permit any transfer of
Securities except in compliance with the terms hereof, and each Securityholder
agrees to provide such documentation and to do such other things as may be
required to give effect to such provisions with respect to such Securities.
SECTION 4.08 Target agrees that it shall not issue any shares with respect
to any new class or series of capital stock authorized after the date hereof
unless the prospective holders of such shares become party to this Agreement or
a enter into a similar written agreement for the benefit of CTP, MergerCo and
Target.
ARTICLE V
GENERAL PROVISIONS
SECTION 5.01 Severability. Any provision of this Agreement that is
prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without
invalidating the remaining provisions hereof but shall be interpreted as if it
were written so as to be enforceable to the maximum extent permitted by
applicable law, and any such prohibition or unenforceability in any jurisdiction
shall not invalidate or render unenforceable such provision in any other
jurisdiction. To the extent permitted by applicable law, the parties hereby
waive any provision of law which renders any provision hereof prohibited or
unenforceable in any respect.
C-6
SECTION 5.02 Entire Agreement. This Agreement, those documents expressly
referred to herein, the Merger Agreement, and the other documents dated as of
the date hereof, contain the sole and entire agreement among the parties hereto
with respect to the subject matter hereof and supersede all prior discussions
and agreements between the parties with respect to the subject matter hereof.
SECTION 5.03 Amendments. This Agreement may not be modified, amended,
waived; altered or supplemented, except upon the execution and delivery of a
written agreement executed by the parties hereto; provided, however, that CTP
and MergerCo may in writing waive or consent to a modification of any provision
of this Agreement with respect to any Securityholder without the agreement of
any other party hereto.
SECTION 5.04 Termination. This Agreement shall terminate upon the earlier
to occur of the (a) the consummation of the Merger and (b) the termination of
the Merger Agreement.
SECTION 5.05 Assignment. This Agreement shall not be assigned by
operation of law or otherwise, except in accordance with Section 4.01.
SECTION 5.06 Parties in Interest. This Agreement shall be binding upon
and inure solely to the benefit of each party hereto and its heirs, successors
and assigns and nothing in this Agreement, express or implied, is intended to or
shall confer upon any other person any right, benefit or remedy of any nature
whatsoever under or by reason of this Agreement.
SECTION 5.07 Specific Performance. The parties hereto agree that
irreparable damage would occur in the event that any provision of this Agreement
was not performed in accordance with the terms hereof or was otherwise breached.
It is accordingly agreed that the parties shall be entitled to specific relief
hereunder, including, without limitation, an injunction or injunctions to
prevent and enjoin breaches of the provisions of this Agreement and to enforce
specifically the terms and provisions hereof, in any court of the United States
or any state having jurisdiction, this being in addition to any other remedy to
which they may be entitled at law or in equity. Any requirements for the
securing or posting of any bond with respect to any such remedy are hereby
waived.
SECTION 5.08 Choice of Law; Consent to Jurisdiction. This Agreement and
any and all matters arising directly or indirectly herefrom ("Agreement
Matters") shall be governed by and construed and enforced in accordance with the
internal laws of the State of Delaware applicable to agreements made and to be
performed entirely in such state, without giving effect to the conflict of law
principles thereof. Each of the parties hereto hereby (i) irrevocably consents
and submits to the sole exclusive jurisdiction of the United States District
Court for the District of Delaware and any state court in the State of Delaware
(and of the appropriate appellate courts from any of the foregoing) in
connection with any suit, arbitration, mediation, action or other proceeding
(each a "Proceeding") directly or indirectly arising out of or relating to any
Agreement Matter; provided that a party to this Agreement shall be entitled to
enforce an order or judgment of such a court in any United States or foreign
court having jurisdiction over the other party hereto, (ii) irrevocably waives,
to the fullest extent permitted by law, any objection that it may now or
hereafter have to the laying of the venue of any such Proceeding in any such
court or that any such Proceeding which is brought in any such court has been
brought in an inconvenient forum, (iii) waives, to the fullest extent permitted
by law, any immunity from jurisdiction of any such court or from any legal
process therein, and (iv) agrees that service of any summons, complaint, notice
or other process relating to such Proceeding may be effected in the manner
provided for the giving of notice hereunder.
SECTION 5.09 Counterparts. This Agreement may be executed in two or more
counterparts, each of which will be deemed an original, but all of which will
constitute one and the same instrument and shall become effective when one or
more counterparts have been signed by each of the parties and delivered to the
other parties.
SECTION 5.10 Definitions. Terms used in this Agreement but not otherwise
defined herein shall have the respective meanings set forth in the Merger
Agreement.
SECTION 5.11 No Agreement Until Executed. Irrespective of negotiations
among the parties or the exchanging of drafts of this Agreement, this Agreement
shall not constitute or be deemed to evidence a
C-7
contract, agreement, arrangement or understanding among the parties hereto
unless and until this Agreement is executed by the parties hereto.
SECTION 5.12 Exculpation. No Securityholder shall have any liability or
obligation whatsoever under or by reason of this Agreement because of a breach
by any other Securityholder of its obligations, representations or warranties
hereunder or thereunder.
SECTION 5.13 Directors and Officers. Notwithstanding anything herein to
the contrary, the covenants and agreements set forth herein shall not prevent
any of the Securityholders who are serving on Target's board of directors or who
are officers of Target from taking any action, subject to the applicable
provisions of the Merger Agreement, while acting in such capacity as a director
or officer of Target.
SECTION 5.14 Notices. All notices or other communications required or
permitted hereunder shall be in writing and shall be delivered personally, by
telecopy, by overnight courier or sent by certified or registered mail, postage
prepaid, and shall be deemed given when so delivered personally, or when so
received by facsimile or courier, or if mailed, three calendar days after the
date of mailing, as follows (or at such other address for a party as shall be
specified by like notice):
If to CTP or MergerCo, to:
Change Technology Partners, Inc.
537 Steamboat Road
Greenwich, CT 06830
(203) 661-6942
(203) 661-1331
Attention: Michael Gleason, Chairman and Chief Executive Officer
with a copy to (which shall not constitute notice):
Paul, Weiss, Rifkind, Wharton & Garrison LLP
1285 Avenue of the Americas
New York, New York 10019-6064
(212) 373-3000
(212) 757-3990
Attention: James H. Schwab, Esq.
If to Target, to:
Neurologix, Inc. c/o
Palisade Capital Management, L.L.C.
One Bridge Plaza
Fort Lee, NJ 07024
Attention: Mark Hoffman
Facsimile: (201) 585-9798
with a copy to (which shall not constitute notice):
Lowenstein Sandler PC
65 Livingston Avenue
Roseland, New Jersey 07068-1791
Attention: Alan Wovsaniker, Esq.
Facsimile: (973) 597-2400
and if to any of the Securityholders, at the address or facsimile transmission
number specified below its name on the signature pages hereto (or, in the case
of persons who subsequently become parties hereto, at their last addresses or
facsimile transmission numbers shown on the record books of Target). Any Person
who becomes a Securityholder shall provide its address and facsimile number to
Target, which shall promptly provide such information to each of the other
Securityholders.
(Remainder of page intentionally left blank; signature pages follow)
C-8
IN WITNESS WHEREOF, the parties have duly executed this Voting Agreement as
of the date first written above.
"TARGET"
NEUROLOGIX, INC.
By: /s/ MARTIN J. KAPLITT
------------------------------------
Name: Martin J. Kaplitt
Title: President
"CTP"
CHANGE TECHNOLOGY PARTNERS, INC.
By: /s/ MICHAEL GLEASON
------------------------------------
Name: Michael Gleason
Title: Chairman and Chief
Executive Officer
"MERGERCO"
CTP/N MERGER CORP.
By: /s/ MICHAEL GLEASON
------------------------------------
Name: Michael Gleason
Title: Chief Executive Officer
(SIGNATURE PAGE TO VOTING AGREEMENT)
C-9
"STOCKHOLDERS"
AUCKLAND TECHNOLOGY ENABLING
CORPORATION
By: /s/ MATHEW DURING
------------------------------------
Name: Mathew During, on behalf
of
Mr. Warwick Greenwood, Trustee
and Director
Title:
Address for Notice:
P.O. Box 10-359
Wellington, New Zealand
Facsimile:
--------------------------------------
ZENITH PARTNERS
By: /s/ MARTIN J. KAPLITT
------------------------------------
Name: Martin J. Kaplitt
Title:
Address for Notice:
--------------------------------------
--------------------------------------
--------------------------------------
Facsimile:
--------------------------------------
(SIGNATURE PAGE TO VOTING AGREEMENT)
C-10
PALISADE PRIVATE PARTNERSHIP, L.P.
By: Palisade Private Holdings, LLC,
General Partner
By: /s/ MARK HOFFMAN
------------------------------------
Name: Mark Hoffman
Title: Member
Address for Notice:
One Bridge Plaza
Fort Lee, NJ 07024
Facsimile:
--------------------------------------
CLARK A. JOHNSON
/s/ CLARK A. JOHNSON
--------------------------------------
Name: Clark A. Johnson
Address for Notice:
--------------------------------------
--------------------------------------
--------------------------------------
Facsimile:
--------------------------------------
(SIGNATURE PAGE TO VOTING AGREEMENT)
C-11
MARTIN J. KAPLITT KEOGH-PROFIT SHARING
By: /s/ MARTIN J. KAPLITT
----------------------------------
Name: Martin J. Kaplitt
Title:
Address for Notice:
--------------------------------------
--------------------------------------
--------------------------------------
Facsimile:
--------------------------------------
MARTIN J. KAPLITT
/s/ MARTIN J. KAPLITT
--------------------------------------
Name: Martin J. Kaplitt
Address for Notice:
--------------------------------------
--------------------------------------
--------------------------------------
Facsimile:
--------------------------------------
(SIGNATURE PAGE TO VOTING AGREEMENT)
C-12
MEDTRONIC INTERNATIONAL, LTD.
By: /s/ GARY L. ELLIS
----------------------------------
Name: Gary L. Ellis
Title: V.P. Corporate Controller &
Treasurer
Address for Notice:
710 Medtronic Parkway
MS LC 460
Minneapolis, MN 55432
Facsimile:
(SIGNATURE PAGE TO VOTING AGREEMENT)
C-13
EXHIBIT A
SECURITYHOLDERS
Auckland Technology Enabling Corporation
Zenith Partners
Palisade Private Partnership, L.P.
Clark A. Johnson
Martin J. Kaplitt Keogh-Profit Sharing
Medtronic International, Ltd.
Martin J. Kaplitt
C-14
EXHIBIT B
SECURITYHOLDERS' OWNERSHIP OF SECURITIES
TARGET TARGET TARGET
SECURITYHOLDER COMMON STOCK SERIES A PREFERRED SERIES B PREFERRED NEUROLOGIX NOTE
-------------- ------------------- ------------------- ------------------- ---------------
(PERCENTAGE
(OWNED BENEFICIALLY (OWNED BENEFICIALLY (OWNED BENEFICIALLY PARTICIPATORY
AND OF RECORD) AND OF RECORD) AND OF RECORD) INTEREST)*
Auckland Technology Enabling
Corporation.................. 1,312,500
Zenith Partners................ 832,500
Palisade Private Partnership,
L.P.......................... 138.768 9,260 94.4%
Clark A. Johnson............... 5.880 55,560 4.0%
Martin J. Kaplitt Keogh-Profit
Sharing...................... 2.352
Medtronic International,
Ltd. ........................ 324,074
Martin Kaplitt................. 1.6%
--------- ------- ------- -----
TOTALS......................... 2,145,000 147.000 388,894 100.0%
========= ======= ======= =====
---------------
* The Neurologix Note is owned of record by Palisade Private Partnership, L.P.
C-15
EXHIBIT C
ROLLOVER SHARES AND TARGET CONVERSION COMMON SHARES
TARGET SERIES A PREFERRED TARGET SERIES B PREFERRED
---------------------------------- ----------------------------------
SHARES OF TARGET SHARES OF TARGET
TARGET COMMON STOCK TARGET COMMON STOCK
SERIES A SHARES RECEIVABLE UPON SERIES B SHARES RECEIVABLE UPON
SECURITYHOLDER OUTSTANDING CONVERSION OUTSTANDING CONVERSION
-------------- --------------- ---------------- --------------- ----------------
Auckland Technology Enabling
Corporation.......................
Zenith Partners.....................
Palisade Private Partnership,
L.P............................... 138.768 2,081,520 9,260 9,260
Clark A. Johnson.................... 5.880 88,200 55,560 55,560
Martin J. Kaplitt Keogh-Profit
Sharing........................... 2.352 35,280
Medtronic International, Ltd. ...... 324,074 324,074
Martin Kaplitt......................
------- --------- ------- -------
TOTALS.............................. 147.000 2,205,000 388,894 388,894
======= ========= ======= =======
C-16
EXHIBIT D
ACTION BY WRITTEN CONSENT OF THE STOCKHOLDERS OF
NEUROLOGIX
August 13, 2003
In accordance with Section 228(a) of the General Corporation Law of
Delaware and Article II, Section 12 of the Bylaws of Neurologix, Inc., a
Delaware corporation (the "Company"), the undersigned, constituting stockholders
holding a majority of the outstanding shares of capital stock of the Company
voting together as a single class, a majority of the outstanding shares of each
series of Preferred Stock of the Company and a majority of the outstanding
shares of Common Stock of the Company, hereby take the following actions and
adopt the following resolutions by written consent, with respect to all of the
shares of the Company's capital stock held by the undersigned, effective as of
the date first written above:
APPROVAL OF MERGER AND RELATED TRANSACTIONS
NOW, THEREFORE, BE IT RESOLVED that the Agreement and Plan of Merger, by
and among the Company, CTP/N Merger Corp., a Delaware corporation("MergerCo"),
and Change Technology Partners, Inc., a Delaware corporation and the parent
corporation of MergerCo ("CTP") (the "Merger Agreement"), in the form attached
hereto, whereby, among other things, (i) MergerCo shall merge with and into the
Company, with the Company being the surviving corporation (the "Merger"), and
(ii) all of the Company's shares of capital stock outstanding immediately prior
to the Merger shall upon consummation of the Merger be converted into shares of
CTP's common stock, par value $.001 per share, in accordance with the terms of
the Merger Agreement, hereby is approved and adopted.
RESOLVED FURTHER that all of the transactions contemplated by the Merger
Agreement, including, without limitation, the Merger, hereby are approved and
adopted.
(REMAINDER OF PAGE INTENTIONALLY LEFT BLANK; SIGNATURE PAGES FOLLOW.)
C-17
IN WITNESS WHEREOF, the undersigned have caused this Action by Written
Consent to be executed as of the date first written above. This written consent
may be executed in any number of counterparts, each of which shall constitute an
original and all of which together shall constitute one action
AUCKLAND TECHNOLOGY ENABLING
CORPORATION
By:
------------------------------------
Name:
Title:
ZENITH PARTNERS
By:
------------------------------------
Name: Martin J. Kaplitt
Title:
PALISADE PRIVATE PARTNERSHIP, L.P.
BY: PALISADE PRIVATE HOLDINGS, LLC,
GENERAL PARTNER
By:
------------------------------------
Name: Mark Hoffman
Title: Member
MARTIN J. KAPLITT KEOGH-PROFIT SHARING
By:
------------------------------------
Name: Martin J. Kaplitt
Title:
(SIGNATURE PAGE TO ACTION BY WRITTEN CONSENT)
C-18
MEDTRONIC INTERNATIONAL, LTD.
By:
------------------------------------
Name:
Title:
CLARK A. JOHNSON
--------------------------------------
Name: Clark A. Johnson
MARTIN J. KAPLITT
--------------------------------------
Name: Martin J. Kaplitt
(SIGNATURE PAGE TO ACTION BY WRITTEN CONSENT)
C-19
APPENDIX D
BNY CAPITAL MARKETS, INC.
MERCHANT BANKING GROUP
445 PARK AVENUE,
NEW YORK, NEW YORK 10022
August 11, 2003
Board of Directors
Change Technology Partners, Inc.
537 Steamboat Road, 2nd Floor
Greenwich, CT 06830
Gentlemen:
We understand that Change Technology Partners, Inc. ("CTP" or the
"Company") and Neurologix, Inc. ("Neurologix") are contemplating entering into
an Agreement and Plan of Merger (the "Merger Agreement"), whereby a wholly owned
subsidiary of CTP ("Subcorp") shall be merged into and with Neurologix, with
Neurologix surviving the merger as a wholly owned subsidiary of the Company (the
"Proposed Transaction"). Pursuant to the Merger Agreement, if, immediately prior
to the closing of the Proposed Transaction, CTP's net cash assets (as determined
in accordance with the Merger Agreement, "Net Cash Assets") are at least $7.5
million, and Neurologix has not raised any additional cash proceeds between the
date hereof and the consummation of the Proposed Transaction through the
issuance and sale of additional equity securities, then each issued and
outstanding share of: (i) common stock, par value $0.001 per share, of
Neurologix ("Neurologix Common Stock"); and (ii) Series B Preferred Stock, par
value $0.001 per share, of Neurologix ("Neurologix Series B Preferred Stock" and
together with the Neurologix Common Stock, the "Neurologix Stock"), shall be
converted into the right to receive shares of CTP's common stock, par value
$0.01 per share ("CTP Common Stock") equal to the number of shares of Neurologix
Stock multiplied by the Exchange Ratio, calculated as follows: CTP's total
shares outstanding including CTP Common Stock, CTP Series A Preferred Stock, par
value $0.10 per share (the "CTP Series A Preferred Stock") and CTP's
in-the-money options ("CTP In-the-Money Options" and together with CTP Series A
Preferred Stock and CTP Common Stock, "Total CTP Existing Shares") multiplied by
two, all divided by the total shares of Neurologix Stock and the Neurologix
shares issuable upon exercise of all in-the-money options (the "Neurologix
In-the-Money Options" and together with Neurologix Stock, "Total Neurologix
Existing Shares") (the "Exchange Ratio"). The Neurologix In-the-Money Options
shall be converted into an option to purchase the number of shares of CTP Common
Stock equal to the number of shares of Neurologix stock covered by such
Neurologix In-the-Money Options multiplied by the Exchange Ratio.
If, immediately prior to the closing of the Proposed Transaction, CTP's Net
Cash Assets are less than $7.5 million, or if Neurologix has raised additional
cash proceeds between the date hereof and the consummation of the Proposed
Transaction through the issuance and sale of additional equity securities, then
the Exchange Ratio will be adjusted as follows: Total CTP Existing Shares
multiplied by the quotient obtained by dividing $15.0 million plus the net cash
proceeds (after all expenses incurred relating thereto) from the sale of
additional equity by Neurologix, by the lesser of CTP's Net Cash Assets or $7.5
million, all divided by Total Neurologix Existing Shares. The terms and
conditions of the Proposed Transaction are more fully set forth in the Merger
Agreement.
We further understand that concurrently with the execution of the Merger
Agreement and as a condition to the willingness of CTP to enter into the Merger
Agreement, certain holders of Neurologix Stock and Neurologix's 6% Amended and
Restated Secured Promissory Note in the aggregate principal amount of $2.0
million and due October 2007 (the "Neurologix Note") have entered into a voting
agreement with CTP, Subcorp and Neurologix, under which, among other things,
they have agreed to: (i) convert shares of
D-1
BNY CAPITAL MARKETS, INC.
August 11, 2003
Page 2
Neurologix Stock into, and to exchange their interests in the Neurologix Note
for, shares of Neurologix Stock prior to the consummation of the Proposed
Transaction, (ii) execute an irrevocable written consent with respect to all of
their shares of Neurologix in favor of adoption of the Merger Agreement, (iii)
irrevocably waive any and all rights to dissent from the merger and seek
appraisal of their Neurologix Stock, and (iv) take other actions in furtherance
of the transactions contemplated by the Merger Agreement (the "Voting
Agreement"). In addition, concurrently with the execution of the Merger
Agreement, CTP shall loan Neurologix the principal amount of $750,000 secured by
a first priority perfected security interest in all of the assets of Neurologix
(the "Loan").
You have asked for our opinion as to whether the Proposed Transaction is
fair from a financial point of view to each of the Series A Preferred
Stockholders (as defined below) and the Common Stockholders (as defined below).
We have not been requested to opine as to, and our opinion does not in any
manner address, the Company's underlying business decision to proceed with or
effect the Proposed Transaction.
For the purpose of this opinion, "Series A Preferred Stockholders" shall
mean all holders of the CTP Series A Preferred Stock (the "Series A Preferred
Stockholders"), and "Common Stockholders" shall mean all holders of CTP Common
Stock (the "Common Stockholders").
For purposes of the opinion set forth herein, we have:
(i) reviewed the Merger Agreement, the Voting Agreement and the Loan;
(ii) reviewed and analyzed certain internal financial statements,
including audited historical and unaudited interim statements, and other
financial and operating data concerning CTP and Neurologix, as well as
projections prepared by the management of Neurologix;
(iii) discussed the past and current operations and financial
condition as well as the prospects of CTP and Neurologix with senior
executives and consultants of CTP and Neurologix;
(iv) reviewed CTP's Annual Reports on Form 10-K for the years ended
December 31, 2000 through 2002, its Quarterly Report on Form 10-Q for the
quarter ended March 31, 2003, its Reports on Form 8-K dated June 18, 2003,
and June 30, 2003, and its Certificate of Incorporation;
(v) reviewed the reported prices and trading activity of CTP Common
Stock from March 28, 2000, to present;
(vi) reviewed publicly available information for certain
publicly-traded companies selected for comparative purposes;
(vii) considered traditional valuation methodologies, including but
not limited to publicly-traded companies selected for comparative purposes,
recent industry merger and acquisition transactions, recent industry
venture capital transactions and discounted cash flow analyses; and
(viii) performed such other analyses and considered such other
factors as we have deemed relevant and appropriate.
In arriving at our opinion, we have assumed and relied upon the accuracy
and completeness of the financial and other information used by us, without
assuming any responsibility for independent verification of such information,
and have further relied upon the assurances of management of CTP and Neurologix
that they are not aware of any facts or circumstances that would make such
information inaccurate or misleading in any material respect. With respect to
the financial projections, upon advice of the Company and Neurologix, we have
assumed that such projections have been reasonably prepared on bases reflecting
the best currently available estimates and judgments of the future financial
performance of CTP and Neurologix. We have assumed that the Proposed Transaction
will be consummated in accordance with the terms of the Merger Agreement without
any limitations, restrictions, conditions, amendments or modifications,
regulatory or
D-2
BNY CAPITAL MARKETS, INC.
August 11, 2003
Page 3
otherwise, that collectively would have a material adverse effect on CTP or
Neurologix. Our opinion is necessarily based on economic, market and other
conditions as in effect on, and the information made available to us as of, the
date hereof.
We do not express any opinion as to the price or range of prices at which
the shares of CTP Common Stock may trade subsequent to the announcement of the
Proposed Transaction or as to the price or range of prices at which the shares
of CTP Common Stock may trade subsequent to the consummation of the Proposed
Transaction.
BNY Capital Markets, Inc. ("BNYCMI") is a nationally recognized investment
banking firm and is acting as exclusive financial advisor to the Board of
Directors of CTP to the extent set forth in the letter agreement between BNYCMI
and the Company dated July 30, 2003 (the "Engagement Letter"), and will receive
a fee for its services. In addition, the Company has agreed to indemnify BNYCMI
for certain liabilities that may arise out of the rendering of this opinion.
BNYMCI is a wholly owned subsidiary of The Bank of New York Company, Inc.
("BNYCo."). In the ordinary course of business, affiliates of BNYCo. may from
time to time trade in the securities of CTP for the accounts of investment funds
under their management and for the accounts of their customers and, accordingly,
may at any time hold a long or short position in such securities.
This letter is for the information of the Board of Directors of CTP and may
be used in the manner and to the extent set forth in the Engagement Letter. This
letter may not be used for any other purpose without our prior written consent.
Based on and subject to the foregoing, BNYCMI is of the opinion on the date
hereof that the Proposed Transaction is fair from a financial point of view to
each of the Series A Preferred Stockholders and the Common Stockholders.
Very truly yours,
/s/ BNY CAPITAL MARKETS, INC.
--------------------------------------
BNY Capital Markets, Inc.
D-3
APPENDIX E
8 DEL.C. SEC. 262
DELAWARE CODE ANNOTATED
TITLE 8. CORPORATIONS
CHAPTER 1. GENERAL CORPORATION LAW
SUBCHAPTER IX. MERGER, CONSOLIDATION OR CONVERSION
sec. 262 Appraisal rights.
(a) Any stockholder of a corporation of this State who holds shares of
stock on the date of the making of a demand pursuant to subsection (d) of this
section with respect to such shares, who continuously holds such shares through
the effective date of the merger or consolidation, who has otherwise complied
with subsection (d) of this section and who has neither voted in favor of the
merger or consolidation nor consented thereto in writing pursuant to sec. 228 of
this title shall be entitled to an appraisal by the Court of Chancery of the
fair value of the stockholder's shares of stock under the circumstances
described in subsections (b) and (c) of this section. As used in this section,
the word "stockholder" means a holder of record of stock in a stock corporation
and also a member of record of a nonstock corporation; the words "stock" and
"share" mean and include what is ordinarily meant by those words and also
membership or membership interest of a member of a nonstock corporation; and the
words "depository receipt" mean a receipt or other instrument issued by a
depository representing an interest in one or more shares, or fractions thereof,
solely of stock of a corporation, which stock is deposited with the depository.
(b) Appraisal rights shall be available for the shares of any class or
series of stock of a constituent corporation in a merger or consolidation to be
effected pursuant to sec. 251 (other than a merger effected pursuant to sec.
251(g) of this title), sec. 252, sec. 254, sec. 257, sec. 258, sec. 263 or sec.
264 of this title:
(1) Provided, however, that no appraisal rights under this section
shall be available for the shares of any class or series of stock, which
stock, or depository receipts in respect thereof, at the record date fixed
to determine the stockholders entitled to receive notice of and to vote at
the meeting of stockholders to act upon the agreement of merger or
consolidation, were either (i) listed on a national securities exchange or
designated as a national market system security on an interdealer quotation
system by the National Association of Securities Dealers, Inc. or (ii) held
of record by more than 2,000 holders; and further provided that no
appraisal rights shall be available for any shares of stock of the
constituent corporation surviving a merger if the merger did not require
for its approval the vote of the stockholders of the surviving corporation
as provided in subsection (f) of sec. 251 of this title.
(2) Notwithstanding paragraph (1) of this subsection, appraisal rights
under this section shall be available for the shares of any class or series
of stock of a constituent corporation if the holders thereof are required
by the terms of an agreement of merger or consolidation pursuant to
sec.sec. 251, 252, 254, 257, 258, 263 and 264 of this title to accept for
such stock anything except:
a. Shares of stock of the corporation surviving or resulting from
such merger or consolidation, or depository receipts in respect thereof;
b. Shares of stock of any other corporation, or depository
receipts in respect thereof, which shares of stock (or depository
receipts in respect thereof) or depository receipts at the effective
date of the merger or consolidation will be either listed on a national
securities exchange or designated as a national market system security
on an interdealer quotation system by the National Association of
Securities Dealers, Inc. or held of record by more than 2,000 holders;
c. Cash in lieu of fractional shares or fractional depository
receipts described in the foregoing subparagraphs a. and b. of this
paragraph; or
E-1
d. Any combination of the shares of stock, depository receipts and
cash in lieu of fractional shares or fractional depository receipts
described in the foregoing subparagraphs a., b. and c. of this
paragraph.
(3) In the event all of the stock of a subsidiary Delaware corporation
party to a merger effected under sec. 253 of this title is not owned by the
parent corporation immediately prior to the merger, appraisal rights shall
be available for the shares of the subsidiary Delaware corporation.
(c) Any corporation may provide in its certificate of incorporation that
appraisal rights under this section shall be available for the shares of any
class or series of its stock as a result of an amendment to its certificate of
incorporation, any merger or consolidation in which the corporation is a
constituent corporation or the sale of all or substantially all of the assets of
the corporation. If the certificate of incorporation contains such a provision,
the procedures of this section, including those set forth in subsections (d) and
(e) of this section, shall apply as nearly as is practicable.
(d) Appraisal rights shall be perfected as follows:
(1) If a proposed merger or consolidation for which appraisal rights
are provided under this section is to be submitted for approval at a
meeting of stockholders, the corporation, not less than 20 days prior to
the meeting, shall notify each of its stockholders who was such on the
record date for such meeting with respect to shares for which appraisal
rights are available pursuant to subsection (b) or (c) hereof that
appraisal rights are available for any or all of the shares of the
constituent corporations, and shall include in such notice a copy of this
section. Each stockholder electing to demand the appraisal of such
stockholder's shares shall deliver to the corporation, before the taking of
the vote on the merger or consolidation, a written demand for appraisal of
such stockholder's shares. Such demand will be sufficient if it reasonably
informs the corporation of the identity of the stockholder and that the
stockholder intends thereby to demand the appraisal of such stockholder's
shares. A proxy or vote against the merger or consolidation shall not
constitute such a demand. A stockholder electing to take such action must
do so by a separate written demand as herein provided. Within 10 days after
the effective date of such merger or consolidation, the surviving or
resulting corporation shall notify each stockholder of each constituent
corporation who has complied with this subsection and has not voted in
favor of or consented to the merger or consolidation of the date that the
merger or consolidation has become effective; or
(2) If the merger or consolidation was approved pursuant to sec. 228
or sec. 253 of this title, then either a constituent corporation before the
effective date of the merger or consolidation or the surviving or resulting
corporation within 10 days thereafter shall notify each of the holders of
any class or series of stock of such constituent corporation who are
entitled to appraisal rights of the approval of the merger or consolidation
and that appraisal rights are available for any or all shares of such class
or series of stock of such constituent corporation, and shall include in
such notice a copy of this section. Such notice may, and, if given on or
after the effective date of the merger or consolidation, shall, also notify
such stockholders of the effective date of the merger or consolidation. Any
stockholder entitled to appraisal rights may, within 20 days after the date
of mailing of such notice, demand in writing from the surviving or
resulting corporation the appraisal of such holder's shares. Such demand
will be sufficient if it reasonably informs the corporation of the identity
of the stockholder and that the stockholder intends thereby to demand the
appraisal of such holder's shares. If such notice did not notify
stockholders of the effective date of the merger or consolidation, either
(i) each such constituent corporation shall send a second notice before the
effective date of the merger or consolidation notifying each of the holders
of any class or series of stock of such constituent corporation that are
entitled to appraisal rights of the effective date of the merger or
consolidation or (ii) the surviving or resulting corporation shall send
such a second notice to all such holders on or within 10 days after such
effective date; provided, however, that if such second notice is sent more
than 20 days following the sending of the first notice, such second notice
need only be sent to each stockholder who is entitled to appraisal rights
and who has demanded appraisal of such holder's shares in accordance with
this subsection. An affidavit of the secretary or assistant secretary or of
the transfer agent of the corporation that is required to give either
notice that such notice has been given shall, in the absence of fraud, be
prima facie evidence of the facts stated therein. For purposes of
E-2
determining the stockholders entitled to receive either notice, each
constituent corporation may fix, in advance, a record date that shall be
not more than 10 days prior to the date the notice is given, provided, that
if the notice is given on or after the effective date of the merger or
consolidation, the record date shall be such effective date. If no record
date is fixed and the notice is given prior to the effective date, the
record date shall be the close of business on the day next preceding the
day on which the notice is given.
(e) Within 120 days after the effective date of the merger or
consolidation, the surviving or resulting corporation or any stockholder who has
complied with subsections (a) and (d) hereof and who is otherwise entitled to
appraisal rights, may file a petition in the Court of Chancery demanding a
determination of the value of the stock of all such stockholders.
Notwithstanding the foregoing, at any time within 60 days after the effective
date of the merger or consolidation, any stockholder shall have the right to
withdraw such stockholder's demand for appraisal and to accept the terms offered
upon the merger or consolidation. Within 120 days after the effective date of
the merger or consolidation, any stockholder who has complied with the
requirements of subsections (a) and (d) hereof, upon written request, shall be
entitled to receive from the corporation surviving the merger or resulting from
the consolidation a statement setting forth the aggregate number of shares not
voted in favor of the merger or consolidation and with respect to which demands
for appraisal have been received and the aggregate number of holders of such
shares. Such written statement shall be mailed to the stockholder within 10 days
after such stockholder's written request for such a statement is received by the
surviving or resulting corporation or within 10 days after expiration of the
period for delivery of demands for appraisal under subsection (d) hereof,
whichever is later.
(f) Upon the filing of any such petition by a stockholder, service of a
copy thereof shall be made upon the surviving or resulting corporation, which
shall within 20 days after such service file in the office of the Register in
Chancery in which the petition was filed a duly verified list containing the
names and addresses of all stockholders who have demanded payment for their
shares and with whom agreements as to the value of their shares have not been
reached by the surviving or resulting corporation. If the petition shall be
filed by the surviving or resulting corporation, the petition shall be
accompanied by such a duly verified list. The Register in Chancery, if so
ordered by the Court, shall give notice of the time and place fixed for the
hearing of such petition by registered or certified mail to the surviving or
resulting corporation and to the stockholders shown on the list at the addresses
therein stated. Such notice shall also be given by 1 or more publications at
least 1 week before the day of the hearing, in a newspaper of general
circulation published in the City of Wilmington, Delaware or such publication as
the Court deems advisable. The forms of the notices by mail and by publication
shall be approved by the Court, and the costs thereof shall be borne by the
surviving or resulting corporation.
(g) At the hearing on such petition, the Court shall determine the
stockholders who have complied with this section and who have become entitled to
appraisal rights. The Court may require the stockholders who have demanded an
appraisal for their shares and who hold stock represented by certificates to
submit their certificates of stock to the Register in Chancery for notation
thereon of the pendency of the appraisal proceedings; and if any stockholder
fails to comply with such direction, the Court may dismiss the proceedings as to
such stockholder.
(h) After determining the stockholders entitled to an appraisal, the Court
shall appraise the shares, determining their fair value exclusive of any element
of value arising from the accomplishment or expectation of the merger or
consolidation, together with a fair rate of interest, if any, to be paid upon
the amount determined to be the fair value. In determining such fair value, the
Court shall take into account all relevant factors. In determining the fair rate
of interest, the Court may consider all relevant factors, including the rate of
interest which the surviving or resulting corporation would have had to pay to
borrow money during the pendency of the proceeding. Upon application by the
surviving or resulting corporation or by any stockholder entitled to participate
in the appraisal proceeding, the Court may, in its discretion, permit discovery
or other pretrial proceedings and may proceed to trial upon the appraisal prior
to the final determination of the stockholder entitled to an appraisal. Any
stockholder whose name appears on the list filed by the surviving or resulting
corporation pursuant to subsection (f) of this section and who has submitted
such stockholder's certificates of stock to the Register in Chancery, if such is
required, may participate fully in all proceedings until it is finally
determined that such stockholder is not entitled to appraisal rights under this
section.
E-3
(i) The Court shall direct the payment of the fair value of the shares,
together with interest, if any, by the surviving or resulting corporation to the
stockholders entitled thereto. Interest may be simple or compound, as the Court
may direct. Payment shall be so made to each such stockholder, in the case of
holders of uncertificated stock forthwith, and the case of holders of shares
represented by certificates upon the surrender to the corporation of the
certificates representing such stock. The Court's decree may be enforced as
other decrees in the Court of Chancery may be enforced, whether such surviving
or resulting corporation be a corporation of this State or of any state.
(j) The costs of the proceeding may be determined by the Court and taxed
upon the parties as the Court deems equitable in the circumstances. Upon
application of a stockholder, the Court may order all or a portion of the
expenses incurred by any stockholder in connection with the appraisal
proceeding, including, without limitation, reasonable attorney's fees and the
fees and expenses of experts, to be charged pro rata against the value of all
the shares entitled to an appraisal.
(k) From and after the effective date of the merger or consolidation, no
stockholder who has demanded appraisal rights as provided in subsection (d) of
this section shall be entitled to vote such stock for any purpose or to receive
payment of dividends or other distributions on the stock (except dividends or
other distributions payable to stockholders of record at a date which is prior
to the effective date of the merger or consolidation); provided, however, that
if no petition for an appraisal shall be filed within the time provided in
subsection (e) of this section, or if such stockholder shall deliver to the
surviving or resulting corporation a written withdrawal of such stockholder's
demand for an appraisal and an acceptance of the merger or consolidation, either
within 60 days after the effective date of the merger or consolidation as
provided in subsection (e) of this section or thereafter with the written
approval of the corporation, then the right of such stockholder to an appraisal
shall cease. Notwithstanding the foregoing, no appraisal proceeding in the Court
of Chancery shall be dismissed as to any stockholder without the approval of the
Court, and such approval may be conditioned upon such terms as the Court deems
just.
(l) The shares of the surviving or resulting corporation to which the
shares of such objecting stockholders would have been converted had they
assented to the merger or consolidation shall have the status of authorized and
unissued shares of the surviving or resulting corporation.
E-4
APPENDIX F
CHANGE TECHNOLOGY PARTNERS, INC.
PROXY SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON
FEBRUARY 9, 2004 AT 10:00 A.M. LOCAL TIME AT 537 STEAMBOAT ROAD,
GREENWICH, CONNECTICUT 06830.
The undersigned hereby appoints Michael Gleason and Rodd Evonsky, and each
of them, with full power of substitution, proxies to represent the undersigned
at the special meeting of stockholders of Change Technology Partners, Inc.
("Change") to be held February 9, 2004 and at any adjournments or postponements
of the special meeting to vote all of the shares of stock which the undersigned
would be entitled to vote, with all powers the undersigned would possess if
personally present, as follows.
The board of directors recommends that you vote FOR the following
proposals:
1. The approval and adoption of the merger agreement between Change, CTP/N
Merger Corp., Change's wholly owned subsidiary and Neurologix, Inc.
[ ] FOR [ ] AGAINST [ ] ABSTAIN
2. The approval of amendments to the certificate of incorporation of
Change, as provided in the merger agreement, which amendments provide for (i)
increasing the number of authorized shares of Change common stock from
500,000,000 shares to 750,000,000 shares, (ii) decreasing the par value of
Change common stock from $0.01 to $0.001 per share, (iii) changing the name of
Change to "Neurologix, Inc." and (iv) increasing the size of and dividing the
Change board of directors into three classes, with staggered three-year terms
for each class.
[ ] FOR [ ] AGAINST [ ] ABSTAIN
3. In their discretion to act upon such other business as may properly
come before the meeting and any adjournments or postponements of such meeting.
[ ] FOR [ ] AGAINST [ ] ABSTAIN
APPROVAL OF PROPOSALS 1 AND 2 ABOVE IS A CONDITION TO THE CLOSING OF THE
MERGER. THEREFORE, IF YOU VOTE AGAINST EITHER OF THESE PROPOSALS, IT WOULD HAVE
THE EFFECT OF A VOTE AGAINST THE OTHER PROPOSAL AND THE MERGER.
THE BOARD OF DIRECTORS OF CHANGE TECHNOLOGY PARTNERS, INC.
RECOMMENDS A VOTE FOR THE PROPOSALS.
F-1
The proxy holders will vote the shares represented by this proxy in the
manner indicated on the reverse side hereof. UNLESS A CONTRARY DIRECTION IS
INDICATED, THE PROXY HOLDERS WILL VOTE FOR APPROVAL OF EACH OF THE STATED
PROPOSALS AND AT THE DISCRETION OF THE PROXY HOLDERS AS TO ANY OTHER MATTER
RELATED TO THE PROPOSALS THAT MAY PROPERLY COME BEFORE THE FIRST PART OF THE
SPECIAL MEETING.
The undersigned hereby acknowledges notification of the special meeting and
receipt of the proxy statement dated January 13, 2004, relating to the special
meeting.
Signature
Dated , 2004
In case of joint owners, each joint
owner must sign, if signing for a
corporation or partnership as an
agent, attorney or fiduciary, indicate
the capacity in which you are signing.
PLEASE MARK, DATE AND SIGN YOUR NAME AS IT APPEARS ON
THIS CARD AND RETURN IT IN THE ENCLOSED ENVELOPE.
F-2